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A b s t r a c t
Coronary heart disease (CHD) is a common m ulti-factoria l disease. It is influenced 
by dietary factors, and inflamm atory markers appear to predict outcomes. The dietary 
intake o f patients at coronary risk and controls was assessed by food frequency 
questionnaire. D ietary macro- and m icronutrient intake was related to plasma 
antibody titres to heat shock proteins.
Dyslipidaemic patients (n=238) were recruited from  the L ip id  C linics o f a local NHS 
hospital, Guildford. Demographic features, including the prevalence o f CHD risk 
factors such as hypertension and obesity, were typical o f a L ip id  C lin ic population. 
Controls (n=189) were recruited from  hospital and university employees.
The dyslipidaemic patients were found to have a significantly higher dietary intake o f 
protein (p<0.05), starch (p<0.05), fibre (p<0.05), total fat (p<0.05), selenium 
(p<0.05), zinc (p<0.01) and a higher dietary zinc/ copper ratio, compared to controls. 
These patients also had significantly higher serum copper (p<0.001), 
copper/caeruloplasmin ratio (p<0.01) and selenium (p<0.05) concentrations and lower 
GPx (p<0.001) and zinc/ copper ratio ( p < 0 . 0 5 )  than controls. Serum selenium 
concentrations decreased w ith  accumulating features o f the metabolic syndrome 
w ith in  the dyslipidaemic subjects (/K0.05).
Among dyslipidaemia; obesity and the presence o f the metabolic syndrome 
contributed significantly to serum C-reactive protein (CRP) concentrations. CRP 
concentrations increased w ith  accumulating features o f the metabolic syndrome
( p < 0.01).
Although antibody titres to Hsp-60, -65 and -70 were higher in  the dyslipidaemic 
patients ( p < 0.02), little  o f the variation in  antibody titres could be explained by 
classical CHD risk factors. D ietary total fat (p<0.01), vitam in E (p<0.05) and C
(p<0.01) were major determinants o f  titres to Hsp-60, dietary vitamin C (p<0.01), and 
vitamin E (p<0.05) were major determinants o f  titres to Hsp-65 (p<0.01), and dietary 
total fat was a determinant o f  titres to Hsp-70 (p<0.05). Treatment o f  dyslipidaemic 
patients with statins reduced titres to Hsp-60 (p<0.05), -65 (p<0.01) and -70 (p<0.01), 
and was also associated with a reduction in serum zinc (p<0.05), copper (/K0.01), 
caeruloplasmin (/K0.05) and CRP (P<0.05).
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CHAPTER 1
I n t r o d u c t i o n
Coronary heart disease (CHD) remains the leading cause of mortality and morbidity 
in Western societies including in the British Isles, causing more than 125000 deaths 
per annum (Hartwell and Henry, 2003). The manifestations of CHD include angina 
pectoris, myocardial infarction (MI), and sudden cardiac death.
1.1 Atherosclerosis
In most cases atherosclerosis is the underlying cause of vascular disease including 
heart disease and stroke (Lusis, 2000).
It is believed that endothelial injury is the earliest change in the artery wall and that 
this precedes the formation of lesions of atherosclerosis (Figure 1.1). Endothelial 
dysfunction is associated with increased leucocyte adhesion and increased endothelial 
permeability to lipoproteins and other plasma constituents. This is followed by the 
accumulation of a mixed leukocyte population within the subendothelial space (Ross, 
1999). The earliest macroscopically recognisable atherosclerotic lesions are fatty 
streaks (Figure 1.2). They consist o f lipid-laden monocytes and macrophages (foam 
cells) together with T lymphocytes (Ross, 1999).
1 . I n t r o d u c t i o n
Figure 1.1 Endothelial dysfunction (Ross, 1999). Figure 1.2 Fatty-streak formation (Ross, 1999). 
Progression to intermediate and then advanced lesions is characterised by the 
formation of a fibrous cap overlying a lipid-rich core (Figure 1.3). Rupture of this 
fibrous cap or ulceration of the fibrous plaque can rapidly lead to thrombosis and
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usually occurs at sites of inflammation and thinning of the fibrous cap that covers the 
advanced lesion (Figure 1.4). Thinning of the fibrous cap is apparently due to the 
continuing influx and activation of macrophages, which release metalloproteinases 
and other proteolytic enzymes at these sites. These enzymes cause degradation of the 
matrix and can result in thrombus formation and subsequent occlusion of the artery 
(Ross, 1999).
Figure 1.3 Advanced, complicated lesion Figure 1.4 Unstable fibrous plaques
Formation (Ross, 1999). (Ross, 1999).
1.1.1 Endothelial dysfunction
Normal vascular homeostasis provides for adequate end-organ perfusion through the 
continuous control of vascular tone, blood flow, and constitutive inhibition of 
thrombosis. The endothelium, with its intercellular tight junction complexes, 
functions as a selectively permeable barrier between blood and tissues and is an 
important and critical component in vascular homeostasis (Keaney, Jr., 2000). The 
normal endothelial functions compose regulations of platelet aggregation, leukocyte 
adhesion with the vessel, smooth muscle cell proliferation, and most importantly, the 
control of vascular tone by secretion of various substances such as endothelium- 
derived relaxing factor [nitric oxide (NO)], prostacylin, endothelin, and adhesion 
molecules (Vane et al., 1990).
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In animal models that develop atherosclerosis, such as animal models of 
hypercholesterolaemia, the endothelium continues to elaborate NO, but its biological 
activity appears to be compromised (Minor et al., 1990). It is also less able to respond 
to vasodilators such as acetylcholine (Anderson et al., 1994; Matz et al., 1994; 
Stewart-Lee et al., 1994). The latter is likely to be partly due to interaction of NO with 
other molecular species, such as superoxide radicals (Anderson et al., 1994; Stewart- 
Lee et al., 1994). These interactions not only neutralise the protective effects o f NO, 
but also generate products, such as peroxynitrite, that may be cytotoxic. These 
changes in the properties o f endothelium have given rise to the concept o f endothelial 
dysfunction (Ferns and Lamb, 2001).
It has been reported that antioxidants such as vitamin E (Anderson et al., 1994; 
Stewart-Lee et al., 1995) and probucol (Anderson et al., 1995) may prevent or reverse 
the endothelial dysfunction. However, the benefits o f vitamin E supplementation on 
endothelial function in humans are still a subject o f debate (Mottram et al., 1999; 
Simons et al., 1999). The inhibition of endothelial cell apoptosis by vitamin C 
treatment of chronic heart failure patients and of endothelial cells in vitro provides 
evidence of the functional benefit o f vitamin C supplementation on endothelial 
function (Rossig et al., 2001).
1.1.2 Factors predisposing to endothelial dysfunction
Because a high plasma concentration of cholesterol, in particular low-density 
lipoprotein (LDL) cholesterol, is one o f the principal risk factors for atherosclerosis, 
atherogenesis has been considered by many to consist largely of the accumulation of 
lipids within the artery wall; however, it is much more than this (Ross, 1999).
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As part o f their original ‘response to injury’ hypothesis, Ross and Glomset proposed 
that endothelial denudation was the first step in atherosclerosis (Ross and Glomset, 
1973). The original hypothesis focused on the role of platelets as a possible source of  
growth factors, and their interaction with damaged artery wall. Over the years, this 
hypothesis was modified in line with contemporary evidence (Ross, 1986; Ross, 
1993; Ross, 1999). The most recent version of this hypothesis emphasizes endothelial 
dysfunction rather than denudation because platelets do not appear to be involved until 
rather late in the disease process (Ross, 1993). Possible causes o f endothelial 
dysfunction leading to atherosclerosis include elevated levels o f potentially toxic 
modified LDL (e.g. oxidised LDL); free radical induced injury arising from, for 
example, cigarette smoking; hemodynamic stress associated with hypertension; 
elevated plasma homocysteine concentrations; infectious microorganisms such as 
herpes viruses or Chlamydia pneumoniae; and combinations o f these (Ross, 1993; 
Ross, 1999).
The emergence of the ‘ lipid oxidation’ hypothesis provided an explanation for the 
formation of lipid-laden, macrophage-derived foam cells (Steinberg, 1997). Normally, 
the LDL receptor mediates the uptake o f cholesterol by cells, and in the presence of 
high cellular levels o f cholesterol, the LDL receptor is downregulated, limiting 
cholesterol accumulation (Brown and Goldstein, 1979). However, the uptake of 
oxidatively modified LDL takes place via ‘ scavenger receptors’ , and this mechanism 
is not regulated by cellular cholesterol content (Brown and Goldstein, 1979). This 
hypothesis can explain the putative effect o f antioxidants such as vitamin E. Recent 
epidemiological data (Riemersma et al., 1991; Rimm et al., 1993) and some 
intervention trials (Stephens et al., 1996) supported this hypothesis. However, the
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benefits o f antioxidants in coronary and stroke prevention remain unclear (GISSI,
1999; Yusuf et al., 2000). I
i
j
I
j
1.2 Epidemiology of CHD
j
CHD is a multifactorial disease, and is due to genetic and environmental j
determinants. Coronary risk factors are variables that have been shown to predict
coronary events in prospective studies. These may be categorised as established j
(accepted) or classical risk factors and emerging risk factors for which further i
]
evidence is required. |
i
Age, gender, genetic factors and personal and family history o f cardiovascular disease I
j
are non-modifiable risk factors for CHD (Assmann et al., 1999). Among the 
established modifiable risk factors are lipid profile, hypertension, smoking, obesity, 
and clotting factors. Several other novel risk factors have recently been identified.
These include homocysteine and autoantibodies such as those directed against ox­
LDL (Inoue et al., 2001), and anti-Hsps antibody titres (Xu et al., 1993), leucocyte 
count (Sweetnam et al., 1997), markers of inflammation (C-reactive protein (CRP) 
and IL-6), and cell stress (Hsp-65). These are listed in Table 1.1,
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T a b le  1 .1  C H D  R is k  F a c to r s
C H D  r is k  fa c to rs R e fe r e n c e s
Non-modifiable CHD risk factors
Age*
Gender*
Personal and family history o f CHD* 
Genetic factors
Modifiable CHD risk factors
Lipid related 
Hypercholesterolaemia*
*HDL cholesterol*
fTriglycerides*
tLipoprotein(a)
Clottins factors 
fFibrinogen 
Coagulation factor VIIc
Inflammatory markers 
C-reactive protein 
Interleukin-6 (IL-6)
Tumour necrosis factor-a (TNF-a) 
Serum amyloid A  (SAA)
Erythrocyte sedimentation rate (ESR)
Leucocyte count
Leptin
Auto-immune markers
Anti-ox-LDL
Anti-Hsps
Rheumatoid arthritis
Metabolic disease 
Hypertension*
Diabetes* 
tHomocysteine 
Renal disease (Urate)
Lifee style 
Cigarette smoking*
Obesity*
Physical inactivity*
(Assmami et al., 1999) 
(Jensen et al., 1990) 
(Assmann et al., 1999)
(Flier and Mantzoros, 2001)
(Assmann et al., 1998; Neaton and 
Wentworth, 1992)
(Gordon et al., 1989)
(Hokanson and Austin, 1996)
(Rnopp, 2002)
(Graham et al., 1997; Nygard et al., 1997) 
(Kelleher, 1992)
(Berk et al., 1990)
(Harris et al., 1999) 
(Barath et al., 1990) 
(Yamada et al., 1996) 
(Andresdottir et al., 2003) 
(Sweetnam et al., 1997) 
(Wallace et al., 2001)
(Inoue et al., 2001)
(Xu et al., 1993)
(Justice and Carmthers, 2004)
(Staessen et al., 1998) 
(Koskinen et al., 1992) 
(Majors et al., 1997) 
(Puddu et al., 2001)
(Bolego et al., 2002) 
(Brochu et al., 2000) 
(Miller et al., 1997)
The accepted coronary risk factors are marked * and the rest are emerging coronary 
risk factors.
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The relationship between abnormalities in lipid metabolism and atherosclerosis is well 
described (Assmann et al., 1998).
Absorption of lipid in the diet
There is a complex system for absorbing and transporting lipids around the body 
because lipids are hydrophobic. In the gut lumen, they are partially hydrolysed by 
pancreatic lipase. They then form into micelles (an emulsion o f hydrolysed fat) with 
the help of bile acids secreted by the liver (Knopp, 2002).
The epithelial cells o f the duodenum and proximal jejunum absorb non-esterified fatty 
acids and monoglycerides, which are immediately re-esterified into triglycerides 
within the entrocyte. Dietary cholesterol is hydrolysed by pancreatic enzymes and 
then absorbed by the small intestine (Figure 1.5) (Burtis and Ashwood, 1999).
Within the enterocyte, these insoluble lipids are incorporated into a lipoprotein 
particle, termed the chylomicron by combining cholesterol (both free and//esterified), 
triglycerides, phospholipids and proteins (called apolipoproteins, mostly just B48). 
These particles are secreted into the lymphatic system and then enter the systemic 
circulation via the thoracic duct that delivers lipids to the various parts of the body 
(Table 1.2) (Knopp, 2002).
1 .2 .1  P la s m a  l i p i d  a n d  l i p o p r o t e i n  m e t a b o l is m
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Figure 1.5 Lipoprotein metabolisms 
exogenous
D i e t a r y  f a t
I
Diacyl glycerol cholesterol 
Entrocyte
Apo B48-
Chylomicron 
LPL
Free fatty acids
Chylomicron remnant
Liver
LDL =  Low density lipoproteins; IDL =  Intermediated density lipoprpteins 
VLDL =  Very low density lipoproteins; HDL =  High density lipoproteins 
LPL =  Lipoprotein lipase; CETP =  Cholesteryl ester transfer protein
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T a b le  1 .2  C la s s i i f c a t io n  a n d  fu n c t io n  o f  a p o l ip o p r o te in s
Apolipoprotein Lipoprotein Function
A I HDL LCAT activation
A l l HDL ?
B 48 Chylomicron Ligand for remnant receptor
B 100 VLDL, LDL Ligand for LDL receptor
C II VLDL, LDL LPL
C III VLDL, LDL LPL
E VLDL, LDL Ligand for remnant receptor
(a) Lp(a) ?
LDL =  Low density lipoproteins 
VLDL =  Very low density lipoproteins 
HDL =  High density lipoproteins 
LPL =  Lipoprotein lipase
1 0
Chylomicrons are the first lipoproteins that form after uptake of dietary lipids and 
their major function is to deliver dietary triglycerides to the tissue. These triglyceride- 
rich complexes are initially secreted into the intestinal lymphatic system, and then 
transported along the thoracic duct and into the blood stream. As chylomicrons have a 
half-life o f only a few minutes, they only appear after a meal and are normally 
removed rapidly and absent in the fasting state (Burtis and Ashwood, 1999).
The lipoprotein lipase enzyme, which is present in the microvascular endothelium is 
activated by an apolipoprotein in the chylomicrons (apo C II), hydrolysing the 
triglycerides to fatty acids that can be absorbed by the tissues themselves to produce 
energy. When the chylomicrons become totally depleted o f triglycerides they are 
called ‘chylomicron remnants’ (Burtis and Ashwood, 1999).
The very low density lipoprotein (VLDL) is another major carrier o f triglycerides, 
even when triglyceride from the diet is not available, and is secreted by the liver. Its 
triglyceride is removed in the tissues by lipoprotein lipase in exactly the same as way 
in chylomicrons (Burtis and Ashwood, 1999).
LDL cholesterol
The remnants of VLDL cholesterol are called intermediate density lipoprotein (IDL). 
Normally the liver removes some of the IDL, but most o f it is modified further to give 
rise to low density lipoprotein (LDL). Several large intervention trials have shown 
that lowering LDL cholesterol levels is associated with a reduced risk o f CHD 
(Collins et al., 2003; Downs et al., 1998; Lewis et al., 1998).
LDL, which may be modified by oxidation, glycation (in diabetes), aggregation, 
association with proteoglycans, or incorporation into immune complexes (Steinberg, 
1997; Navab et al., 1996), is a major cause of injury to the endothelium and
Chylomicrons and VLDL cholesterol
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underlying smooth muscle (Navab et al., 1996; Griendling and Alexander, 1997). 
When LDL particles become trapped in an artery, they can undergo progressive 
oxidation and be internalised by macrophages by means of the scavenger receptors on 
the surfaces of these cells (Han et al., 1997). The internalisation leads to the formation 
of lipid peroxides and facilitates the accumulation of cholesterol esters, resulting in the 
formation of foam cells (Han et al., 1997).
HDL cholesterol
High density lipoprotein (HDL) is thought to be involved in reverse cholesterol 
transport (Thompson, 1999). Also, HDL cholesterol has antioxidant properties and 
may attenuate oxidative stress on LDL cholesterol (Mackness et al., 2004). The 
antioxidant activity o f HDL is thought to be largely due to paraoxonase (PON) 1 
activating, which is an enzyme with a molecular mass of 43 KDa (354 amino acids) 
and in serum is exclusively located on HDL (Mackness et al., 2002). Therefore, high 
levels o f HDL cholesterol are associated with reduction in the development of CHD 
through the accumulation o f too much cholesterol (Knopp, 2002). HDL cholesterol is 
a stronger predictor o f atherosclerosis in women than in men (Gordon et al., 1989). 
Data from Framingham Study suggest that a 0.03 mmol/L increase in HDL 
cholesterol levels is associated with a 3%  decrease in the incidence o f CHD in women 
compared with a 2%  decrease in men (Gordon et al., 1989).
Triglycerides
Elevated plasma triglyceride concentrations are a significant risk factor for CHD in 
both sexes, but more so for women (Hokanson and Austin, 1996; Knopp et al., 1994). 
It has been reported that plasma triglyceride concentrations account for 16% of the 
variation in the severity o f atherosclerosis in women (Reardon et al., 1985). In
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addition, the only lipoprotein parameter that has a significant effect on atherosclerosis 
severity scores in women is the plasma triglyceride level, whereas the significant risk 
factor for men is elevated LDL (Reardon et al., 1985).
An increase in the number of small dense LDL particles may originate from a defect 
in the metabolism of triglyceride-rich lipoproteins (Griffin, 1999). One mechanism 
may involve the overproduction and increased residence time o f large triglyceride- 
rich VLDL in the postprandial phase, a situation thought to arise through pathways of 
insulin resistance (Griffm, 1999).
1.2.2 Dyslipidaemia
Dyslipidaemia may be primary (genetic), or due to secondary conditions such as 
alcohol excess, diabetes and hypothyroidism. The major primary hyperlipidaemia is 
classified for clinical purposes as ( 1 ) hypercholesterolaemia (polygenic or familial); 
(2) combined hyperlipidemia; or (3) hypertriglyceridemia.
Initially, dyslipidaemia is usually initially managed by conservative measures 
(correction of obesity, a lipid-lowering diet, and treatment o f underlying causes); drug 
treatment is instituted only if conservative measures fail to achieve the lipid target 
value. Dietary intervention alone does not always allow patients with CHD to achieve 
the recommended blood cholesterol levels, even if dietary fat is dramatically reduced. 
The lowering of LDL cholesterol reduces total mortality and the incidence of fatal and 
nonfatal MI in both primary and secondary prevention (Spratt, 2004; Evans et al., 
2004). Beyond 85 years, a high plasma cholesterol concentration may be associated 
with increased life expectancy possibly because o f the spurious fact that undiagnosed 
cancers and infections can lower total serum cholesterol levels. The effects of
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cholesterol-lowering therapy have yet to be assessed in this age group (Aquilani et al., 
1999; Assmann et a !, 1999).
1.2.3 Gender and CHD risk
Premenopausal women are relatively protected from CHD compared with men, but 
this protection will rapidly disappear with increasing age and with the onset of 
menopause (Bello and Mosca, 2004), Although traditional CHD risk factors are the 
same for men and women, there are gender-specific differences in prevalence rates 
and relative risks associated with specific risk factors (Bello and Mosca, 2004).
The relative risk o f CHD associated with diabetes mellitus type II vary in the reports 
from 3 to 7 in women, compared with 2 to 3 in men. It is unclear why diabetic women 
are more susceptible to CHD than men (Hu et al., 2001).
Before the menopause, LDL cholesterol levels are lower in women than in men, but 
post menopausal, levels increase and become higher in women than in men (Jensen et 
al., 1990). The increase perimenopausally is partly because o f advancing age and 
partly because of the loss o f oestrogen (NCEP, 2001).
Effects of oestrogens on lipid metabolism
The effects o f oestrogens on lipid metabolism are shown in figure 1.6, which 
illustrates that oestrogens increase the rate of lipoprotein transport at every step except 
hepatic uptake o f HDL. An increase in triglycerides, a decrease in LDL cholesterol 
levels, and an increase in HDL cholesterol levels are the net results (Knopp, 2002). 
Alterations in lipid metabolism, because of the decrease in oestrogen production, are 
thought to account for a substantial proportion of the increased CHD risk seen in 
postmenopausal women (Kannel and Wilson, 1995).
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F ig u r e  1 .6  T h e  e ffe c ts  o f  o e s t r o g e n  o n  l ip o p r o t e in  m e ta b o l is m  ( K n o p p ,  2 0 0 2 )
B/E =  LDL receptor that recognizes apolipoprotein B or E
CA =  cholic acid
CDA =  chenodeoxycholic acid
Choi =  cholesterol
DC =  deoxycholate
FC — free cholesterol that is taken up from cell walls by HDL3
HTGL =  hepatic triglyceride lipase, which changes inverse to HDL concentrations
LPL =  lipoprotein lipase
LTP =  lipid transfer protein, which exchanges cholesterol on HDL for triglyceride on 
VLDL and LDL
VLDL =  very-low-density lipoprotein 
? =  steps about which there is uncertainty
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Obesity, defined as a body mass index (BMI) above 30, is recognised as a major 
world health problem (British Nutrition Foundation Task Force, 1999). There is 
archaeological evidence o f obesity dating back to the Stone Age, but it has never been 
so common as it is today and across such a large proportion o f the world. The 
frequency of obesity in Britain has tripled over the last 20 years. One in five adults is 
obese and nearly two-thirds of men and over half o f women are overweight or obese 
(BMI >25kg/m2) in the U K  (James et ak, 2004).
North Americans are among the most obese population group in the world. There are 
at least two possible explanations for the high prevalence o f obesity in the USA. First, 
the lack o f exercise due to high ownership of automobiles and sedimentary lifestyle. 
Second, there may be differences in quantity or quality of dietary intake (Kopeman, 
1998).
Several studies have reported a high prevalence of obesity among in subjects with 
established CHD (Brochu et al., 2000), and in this group it is associated with a high 
occurrence of CHD morbidity and mortality (Garrison et al., 1996). The distribution 
of fat in the body appears to be important: high levels o f visceral fat confers a 
relatively higher risk o f CHD compared with high levels o f accumulation of 
peripheral fat (Vague et al., 1983), even in a lean population (de Portugal et al., 1997). 
This is probably due to differences in metabolism associated with these different 
forms of fat accumulation (Sailer, 1998).
The risks of CHD associated with obesity are likely to be conferred by several 
mechanisms. For example central obesity is associated with raised peripheral vascular 
resistance, lower cardiac output, a vasoconstrictor response to psychosocial stress 
(Jem et al., 1992), and higher serum caeruloplasmin levels (Cignarelli et al., 1996).
1 .2 .4  O b e s i t y
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Central obesity is a coronary risk factor, which is independent of, but exacerbated by, 
the severity of general obesity. Several non-modifiable factors such as age, gender, 
and menopause as well as some modifiable factors such as smoking, physical 
inactivity, hypertension, type II diabetes mellitus, dyslipidaemia, alcohol intake, 
hyperhomocystinaemia, elevated Lipoprotein (a) levels and factors that increase 
thrombogenesis are positively associated with abdominal fat deposition (Alexander, 
2001; Emery et al., 1993). Obesity may be associated with endothelial dysfunction 
(Alexander, 2001) due to the release of inflammatory cytokines such as IL-6  from 
adipocytes (Yudkin et al., 2000). In central obesity, there is also an increase in cortisol 
and a decrease in both growth hormone and sex steroids. These hormonal changes 
may be induced by lifestyle factors such as stress, cigarette smoking and a high 
alcohol intake (British Nutrition Foundation Task Force, 1999).
The strong and consistent relationship observed between body weight and blood 
pressure develops early in life, and obesity in adult life is a good predictor of 
hypertension. Obesity is a relatively weak independent risk factor for CHD but it is 
closely associated with several other coronary risk factors such as HDL and 
triglycerides (Shaper, 1996).
The mechanisms by which obesity causes ill health and early death are becoming 
clearer. Excessive body fat (especially intra-abdominal fat) is associated with 
decreased sensitivity o f tissues to the action of insulin (Bjomtorp, 1996). This leads to 
an increased liability to impaired glucose tolerance and type II diabetes mellitus, and 
also to raised blood lipids and blood pressure, which are important risk factors for 
CHD (Bjomtorp, 1996; British Nutrition Foundation Task Force, 1999). Obesity is 
influenced by genetic, behavioural and nutritional factors (Seedorf and Assmann, 
2001). Weight reduction significantly improves semm lipid parameters, blood
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pressure, and fasting blood glucose values. Successful weight reduction requires the 
support o f the physician, a calorie-restricted diet, and a suitable exercise program 
(Assmami et al., 1998; Assmann et al., 1999). Effective treatment approaches are 
available for most overweight or obese individuals but a major challenge is to enable 
these individuals to engage in these programs (Anderson and Konz, 2001).
1.2.4.X Anthropometric measurements
There is growing interest in the measurement of body composition, in particular the 
assessment of fat mass, because BMI does not predict risk very well in metabolic 
syndrome or central obesity. The gold-standard methods for measuring body fat 
content such as underwater weighing (U W W ), magnetic resonance imaging (MRI), 
total body potassium (TBK), and dual energy X-ray absorptiometry (DEXA) are 
expensive and are not used routinely. Consequently, a number o f surrogate 
anthropometric measures, which are indirect measures of body fat and fat-free mass, 
have been adopted, including the measurement of body mass index, waist-hip ratio, 
skinfold thickness and bioelectrical impedance analysis (British Nutrition Foundation 
Task Force, 1999).
Body weight and height
Body weight and height are the simplest measurements and are, therefore, well suited 
to large-scale prospective studies. Height and weight are highly reproducible 
measurements, although in the short term, weight can have considerable physiological 
variation associated with gastric emptying and state o f hydration (Williams et ah,
1997). Body weight is a poor predictor of CHD. Some studies have reported no 
difference in the body weight o f CHD patients compared to subjects free of the 
disease, others found the body weight o f subjects with CHD to be slightly greater, and
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one found the body weight of cardiac patients to be less than controls (Williams et al.,
1997).
Height is associated with CHD in prospective studies with long-term and shorter-term 
follow-up periods and in case-control designs (Williams et al., 1997). One possible 
biological mechanism is that taller individuals have larger coronary arteries than 
shorter individuals and, thefore, have a lessened risk of occlusion (Palmer et al., 
1990).
Body mass index (BMI) or Quetelet's index 
BMI can be calculated using this equation:
BMI =  Weight (kg) +  Height (m)2 
It measures body weight corrected for height, but cannot distinguish between 
excessive weight arising from adiposity, muscularity, or oedema (James et al., 2004). 
Yoneda et al. (1998) found a positive correlation between BMI and the prevalence of 
several coronary risk factors including hypertension, hyperlipidaemia, glucose 
intolerance and hyperuricaemia (Yoneda et al., 1998). It has been reported that both 
underweight and obese subjects are at increased risk o f morbidity and mortality, and 
BMI can classify individuals as underweight or obese (Yoneda et al., 1998). Schulte 
et al. (1999) have shown a graded and continuous positive interaction in both men and 
women between BMI, age and serum total cholesterol, LDL, and both systolic and 
diastolic blood pressure (Schulte et al., 1999). Serum triglycerides increased with 
BMI in both sexes and with age in women, but decreased in the older age groups of 
overweight and obese men. Though fasting blood glucose increased with age and BMI 
in both sexes, the increase was more marked in women (Schulte et al., 1999).
In a review by Williams et al. (1997), BMI was generally shown not to be a strong 
predictor of CHD. Indeed case-control designs have consistently failed to show a
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relationship between BMI and CHD. Inconsistent results from prospective studies, 
however, are difficult to interpret. To further confuse the situation, the BMI has been 
examined in relation to different CHD end-points and adjusted for different 
confounding variables. Explaining the inconsistent results on the basis o f length of 
follow-up is also not straightforward (Williams et al., 1997). Evidence from the 
Framingham Study shows a strong ’independent' association between BMI and CHD 
(Williams et al., 1997).
Waist/Hip Ratio (WHR)
There are possible associations between the waist/hip ratio and risk factors for insulin 
resistance, atherosclerosis and diabetes (Tichet et al., 1993). Abdominal (visceral) 
obesity is more closely associated with type II diabetes than CHD, while an increased 
W HR without visceral obesity may be more closely linked to CHD than type II 
diabetes (Bjomtorp, 1992). The measurement of W HR is a simple, clinically useful 
indicator of body fat distribution (Folsom et al., 1994).
1.2.4.2 Bioelectrical Impedance Analysis (BIA)
The BMI, WHR, skin fold thickness measures are operator dependent and subject to 
marked day-to day variation. Bioelectrical impedance measurement devices have 
recently become widely available, and their use in clinics and by patients is increasing. 
A  tiny current is passed via electrodes between hands and feet, and the impedance of  
the body is related to the relative amounts of fat versus electrically conducting tissue 
between the electrodes. Proper detector electrode placement, accurate measurement of  
the subject's height and weight are crucial for accurate and reproducible BIA  
measurements (National Institutes of Health, 1996). BIA values are affected by several 
variables including body position, hydration, consumption o f food and beverages,
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ambient air and skin temperature, recent physical activity, and conductance o f the 
examining table. Reliable BIA requires standardization and control o f these variables 
(National Institutes of Health, 1996).
BIA has been reported to be a useful technique for assessing body composition in 
healthy individuals, the elderly, and in those with chronic conditions such as mild-to- 
moderate obesity, diabetes mellitus, and other medical conditions in which major 
disturbances of water distribution are not prominent (National Institutes of Health, 
1996). BIA is a useful clinical method for measuring change in body composition in 
obesity (Kushner et al., 1990; National Institutes of Health, 1996). However it is not 
reliable in severe obesity, because the composition of one or more body compartments 
of the very-obese subjects (e.g. >  50%  body fat) may simply be different from that of 
less-obese subjects. Therefore, a different equation is needed for calculating fat 
percentage (Gray et al., 1989). BIA may provide a more accurate measure of adiposity 
than skinfold thickness measurement and may be more easily standardised, although 
measurements of skinfold thickness and girths may provide additional useful 
information on body fat patterning (National Institutes of Health, 1996).
Several bioelectrical impedance analysers are available commercially including tetra- 
polar, hand-held, stand-on, and the ’home' use machines. It is claimed that tetrapolar 
machines give an assessment of 'whole-body' fat and that stand-on and hand-held BIA  
machines only probably measure adiposity in the lower and upper part o f the body 
respectively. All o f these devices are indirect measures o f body fat. Jebb et al. (2000) 
have shown that the accuracy o f ‘Bodystat’ (tetrapolar machines) and ‘Tanka’ (stand- 
on machines) relative to the reference method was very similar. The equations applied 
in the 'home' use machine is not as accurate as it does not adjust for age, which 
improves any prediction equation (Jebb et al., 2000).
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A  study by Heitman (Heitmann, 1990) developed a multiple regression equation using 
BIA, which correlated better with fat measured by total body water and total body 
potassium than equivalent equations using either skinfolds or weight- height indices. 
By comparison with gold standard methods such as total body potassium, the best 
equations are as below:
F =  0.819W - (0.279H2/R)~ 0.231H +  0.077A +  14.941 (for women)
F =  0 .7 55W - (0.279H2 /R)- 0.231H +  0.077A +  14.941 (for men)
Where F= fat (kg), W=weight (kg), H=height (cm), R=impedance (ohms) and A  =age 
(years) (Garrow et al., 2000).
Low frequencies are primarily conducted by extra cellular water, but high frequencies 
penetrate the cell membranes and are modified by both intra- and extra-cellular water 
(i.e. total body water), while single-frequency impedance measurement at 50 kHz 
detects extra-cellular water plus an unknown amount of intracellular water (Garrow et 
al., 2000).
Measurement error in assessing anthropometric indices
Errors in measurement are unavoidable. Possible errors are o f two sorts; those that are 
associated with: (1) repeated measures giving the same value (unreliability, 
imprecision, analytical bias, undependability); and (2) observer error, which is the 
most common measurement errore (inaccuracy, bias); (3) biological variations 
(Ulijaszek and Kerr, 1999). It is possible to measure weight and height with greatest 
precision and accuracy. Waist and hip circumference show strong between-observer 
differences, and should, where possible, be carried out by one observer (Ulijaszek and 
Kerr, 1999). Skinfold thickness can be associated with large measurement error that 
makes interpretation problematic (Ulijaszek and Kerr, 1999).
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It is claimed that BIA machines are "whole-body" measurements but they are in fact 
heavily biased to the limbs, especially the arms. The arm contributes approximately 4 
percent o f body weight but accounts for 45 percent of "whole-body" resistance, in 
contrast to the trunk, which contributes about 45 percent of body weight but accounts 
for 10 percent of "whole-body" resistance (Jebb et al., 2000).
1.2.5 Physical inactivity
More than half o f the adult population is sedentary or inactive (Assmann et al., 1999; 
Miller et al., 1997). Epidemiological studies indicate that a physically inactive life­
style is associated with twice the risk of developing CHD, whereas aerobic exercise 
reduces this risk (Assmann et al., 1999; Miller et al., 1997). This relationship is 
independent of other risk factors (Assmann et al., 1999; Miller et al., 1997). Those 
who exercise regularly have less body fat, a higher HDL cholesterol level, lower LDL 
cholesterol and triglyceride levels, greater insulin sensitivity, and lower blood glucose 
and systolic and diastolic blood pressure (Assmann et al., 1999; Miller et al., 1997).
1.2.6 Diabetes mellitus
The diagnostic criteria for diabetes mellitus type II were developed by the NDDG  
(National Diabetes Data Group, 1979) and the W HO (World Health Organisation, 
1985). Later, the A D A  (American Diabetes Association, 1997), in response to the 
inconvenience, variability and nonphysiological nature of the oral glucose tolerance 
test, recommended abandoning its routine use in favour of lowering the diagnostic cut 
off value for fasting plasma glucose to >7 mmol/L, which seemed to better predict the 
risk of developing macrovascular complications (Engelgau et al., 1997; McCance et
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al., 1994). In 1999 the W HO included this recommendation in its new diagnostic 
criteria (World Health Organization, 1999).
After the discovery that one fraction of haemoglobin in red blood cells (glycated 
haemoglobin, or HbAic) is elevated in the presence of prolonged hyperglycaemia, the 
Aic fraction of haemoglobin became the main tool for monitoring metabolic control in 
persons with diabetes mellitus (UKPDS, 1998). More recently, it was suggested, when 
fasting blood glucose is inconclusive (6.1-7 mmol/L), an HbAic value more than 3 
standard deviations above the mean (>5.94%) is useful in suggesting a likely 
diagnosis o f diabetes and identifying patients who require treatment (Jimeno et al., 
2004). Further studies need to be done before the HbAic can be used diagnostically. 
The prevalence of type II diabetes in Western societies is approximately 5-6%  and 
hence it affects approximately 1.4 million individuals in the U K  (Amos et al., 1997). 
In 1997, it was estimated that approximately 124 million people worldwide have 
diabetes mellitus, o f these 97%  have type II diabetes. By the year 2010 the projected 
number of people with diabetes is estimated to be 221 million (Amos et al., 1997). 
Cardiovascular complications account for much of the increased risk o f death in 
patients with diabetes. People with type II diabetes have a risk of CHD 2 -4  times 
greater than the general population (Koskinen et al., 1992). Heart disease is the most 
common cause of diabetes-related deaths (Koskinen et al., 1992). In these patients, 
heart disease occurs earlier, “ the absolute risks of CHD are approximately equal in 
both sexes in patients with diabetes”  (Wingard and Barrett-Connor, 1995) and is fatal 
approximately 2-4 times more frequently than in adults who do not have diabetes. 
There is also a two- to fourfold greater risk for stroke, hypertension and dyslipidaemia 
among diabetics (Wingard and Barrett-Connor, 1995).
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Patients with diabetes who develop CHD have a worse prognosis than patients who do 
not have diabetes (Haffner, 1998). Mortality associated with CHD is much higher for 
patients with diabetes, and the risk of a first MI among diabetics is comparable to that 
of patients with a past history o f MI but who do not have diabetes (Haffner, 1998). 
“ The relative risk o f death related to ischaemic heart disease in women with diabetes 
was shown to be nearly twice that o f men with diabetes” (Barrett-Connor et al., 1991). 
Control o f blood glucose, even the intensive level o f control achieved in the UK  
Prospective Diabetes Study (UKPDS), did not significantly reduce the frequency of  
diabetes-related MI (UKPDS, 1998). Tight glycaemic control by itself is not sufficient 
to control diabetic dyslipidaemia and a significant proportion of diabetic subjects will 
require lipid-lowering treatment (Stem et al., 1992). Available data imply that factors 
other than blood glucose are responsible for the increased CHD risk in patients with 
diabetes. For example, diabetics have been shown to have low levels o f HDL, high 
small dense LDL particles, increased levels o f clotting factors (Gottlieb, 2003; 
Gmndy et al., 1999a), and increased postprandial free fatty acid flux and total 
apoliprotein B and liporotein(a) (Smaoui et al., 2004; Lamarche et al., 1997).
The impact o f LDL levels in these patients is indicated by recent sub-group analysis 
data from the HPS (Collins et al., 2003), 4S (Haffner et al., 1999) and WOSCOPS 
trial’ s (Streja et al., 2002). Diabetic patients manifest several alterations in 
coagulation mechanisms including increased fibrinogen levels (Imperatore et al.,
1998), increased plasminogen activator inhibitor-1 (Byberg et al., 1998), and various 
platelet abnormalities (Trovati and Anfossi, 1998). Hyperglycaemia also contributes 
to accelerated arterial stiffening by increasing formation of advanced glycation end- 
products (AGEs), which alter vessel wall stmcture and function (Liu et al., 2003; 
Vlassara and Palace, 2002; Santana et al., 2003).
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Several epidemiological studies have demonstrated an almost linear relationship 
between smoking and CHD mortality and morbidity, particularly in postmenopausal 
women who have a lack o f natural estrogen protection (Bolego et al., 2002), the risk 
being more than two fold and most pronounced in younger women (Landmark, 2001). 
Smoking not only accelerates the process of atherosclerosis but also predisposes to 
early acute complications including death. The effects o f smoking on CHD risk are 
complex and include hypercoagulability, reduced tissue oxygen delivery, 
catecholamine release, and coronary vasoconstriction (Adnot, 1998). The 
atherogencity o f smoking seems to be related to several adverse effects on endothelial 
function, vascular tone, haemostasis, lipid profile and inflammatory cells (Adnot,
1998).
There is evidence that smokers have increased oxidative stress (high serum 
thiobarbituric acid-reactive substances and low serum ascorbic acid) and an impaired 
oxidant defence system (Kim et al., 2002). The oxidative damage observed in smokers 
can be related to the direct effects of oxidants in cigarette smoke and the 
consequences o f lower antioxidant nutrition status associated with smoking (Kim et 
al., 2002).
Smoking also affects lipoprotein metabolism and is associated with lower HDL 
cholesterol and higher fasting triglyceride. These correlations were affected by 
adjusting for BMI, due to the lower mean BMI of smokers (Hughes et al., 1998). 
Cigarette smoking is associated with increased lipase activity including lipoprotein 
lipase and hepatic lipase (Blache et al., 1992), which is associated with HDL 
cholesterol metabolism (Fievet and Fruchart, 1991). Smoking is also associated with 
increased insulin-resistance and an increased risk of developing type II diabetes
1 .2 .7  C i g a r e t t e  S m o k i n g
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mellitus (Landmark, 2001). More recently the risks of passive smoking have emerged 
(Haustein, 2000).
1.2.8 Hyperhomocysteinaemia
Homocysteine is a sulphur containing amino acid. It is not present in food, but formed 
by the body as an intermediary product of the metabolism of methionine and cysteine. 
High levels of plasma homocysteine are toxic to the endothelium (Hajjar, 1993). 
Hyperhomocysteinaemia is a prothrombotic condition (Hajjar, 1993). It is also 
associated with increased collagen synthesis (Majors et al., 1997) and decreased 
bioavailability of nitric oxide (Upchurch et al., 1997).
However, the elevation o f plasma homocysteine may not be an independent CHD risk 
factor, because its levels are related to renal function, smoking, fibrinogen, and CRP, 
which are themselves associated with an increased incidence o f CHD. It has been 
argued that plasma homocysteine levels should be measured in patients with a history 
of premature CHD and/or stroke in the absence of other risk factors (Assmann et al.,
1999).
Daily supplementation with 200 pg folic acid lowers homocysteine levels by 
approximately 4 pmol/L (Boushey et al., 1995). Other studies showed that 200 pg 
folic acid lowered homocysteine levels in healthy older adults by 14% (van Oort et 
al., 2003).
1.2.9 Hypertension
Arterial hypertension (systolic blood pressure > 1 4 0  mm Hg and/or diastolic blood 
pressure <90) is a risk factor for CHD, stroke and other cardiovascular diseases. Its 
treatment reduces the incidence of CHD by 14% within 5 years; the benefit occurs in 
both mild and severe hypertension and at all ages up to 75 years. The goal for blood 
pressure reduction is a systolic pressure of 140 mm Hg or less and a diastolic pressure
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of 90 mmHg or less. Isolated systolic hypertension is a cardiovascular risk factor, 
especially in the elderly, and should also be treated (Savage et al., 1998; Staessen et 
al., 1998).
Antihypertensive drugs include p-blockers, angiotensin-converting enzyme (ACE) 
inhibitors or angiotensin II subtype 1 (ATi) receptor, calcium channel blockers, 
diuretics and a-blockers. They influence the neurohumoral cardiovascular system and 
the concentration o f hormones involved in blood pressure regulation (Seifarth et al., 
2002).
1.2.10 Thrombogenic Risk Factors
Thrombogenic factors increase the risk of acute coronary occlusion and may play a 
causal role. Lifestyle is important in the management of these factors and includes 
smoking cessation, reduction of weight, a low intake of saturated fat, and an increased 
consumption of polyunsaturated fatty acids (co-6 and co-3). Weight reduction and some 
fibrate drugs lower plasma fibrinogen (Assmann et al., 1999).
1.2.11 Coronary risk assessment (PROCAM )
The prospective cardiovascular Munster (PROCAM) study was initiated in 1979 and 
followed up at least for 8 years in order to examine cardiovascular risk factors and 
cardiovascular events including MI. Examination at entry comprised a standardized 
case history, measurement of blood pressure and anthropometric data, a resting 
electrocardiogram, and measurement of more than 20 laboratory parameters in a 
fasting blood sample. Using a multiple logistic function analysis, an algorithm for the 
assessment of the global risk, was derived from the data. The observed incidence of 
CHD was found to rise sharply as the global risk increased, thus permitting the use of  
this algorithm in clinical practice for the assessment of the individual risk of MI 
(Assmann et al., 1998).
2 8
The inclusion of risk factors such as lipoprotein (a) and coagulation factors may 
improve the predictive value o f this algorithm. Furthermore it is expected that the 
exploration of genetic defects will strongly increase the predictive value and precise 
determination of individual risk (Assmann et al., 1999; Assmann et al., 2002).
1.3 Metabolic syndrome
Reaven first described the combination of metabolic disturbance succinctly in 1988 as 
Syndrome X ; it included a combination of insulin resistance, dyslipidaemia, and 
hypertension (Reaven, 1994). In 1989, Kaplan added abdominal obesity to the above 
list o f disturbances and Haffner renamed it the “Insulin Resistance Syndrome” 
(Barnard et al., 1998; Roth et ah, 2002). In 2001, the Adult Treatment Panel III (ATP 
III) recognized the importance of the "constellation of lipid and non-lipid risk factors 
of metabolic origin," as CHD risk factors, and has designated this cluster of 
abnormalities as "the Metabolic Syndrome". ATP III has indicated, "This syndrome is 
closely linked to insulin resistance" (Lee, 2001) and commonly predisposes to CHD 
(Lee, 2001).
Table 1.3 lists the criteria the ATP III stipulated be used in the identification of the 
metabolic syndrome, and 1 out of 4 adults living in the United States merits this 
diagnosis (Ford et al., 2002). Each single component of the cluster increases the 
cardiovascular risk, but the combination o f factors appear to have a synergistic effect 
on CHD (Bosello and Zamboni, 2000).
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Table 1.3 ATP III Criteria for Identification o f the Metabolic Syndrome (Ford et al., 
2002)__________________________________________________________________________________
Abdominal obesity (waist circumference) 
Men 
Women
> 102cm (40in) 
>88 cm (3 5 in)
Triglycerides >150 mg/dL (1.7 mmol/L)
HDL cholesterol 
Men <40 mg/dL (1 mmol/L)
Women <50 mg/dL (1.3 mmol/L)
Blood pressure; systolic>130/ diastolic>85 mm Hg
Fasting glucose > 1 1 0  mg/dL (6. lmmol/L)
A  diagnosis o f the Metabolic Syndrome should be made when 3 or more of the risk
determinants shown above are present
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1.3.1 Pathophysiology of metabolic syndrome
Five mechanisms have been proposed as possible contributors to the development of  
metabolic syndrome.
1. Genetic abnormalities in the insulin action cascade (Flier and Mantzoros, 
2001)
2. Fetal malnutrition (Barker et al., 1989)
3. Increased visceral adiposity (Busetto, 2001)
4. Physical inactivity (Miller et al., 1997)
5. Many gene abnormalities that cluster together (Lebovitz, 2001)
1.3.1.1 Genetic abnormalities as a contributor to metabolic syndrome
Single genetic disorders account for a very small number of rare syndromes in which 
insulin action is severely impaired (Flier and Mantzoros, 2001). They include one 
type o f metabolic syndrome characterised by extreme resistance to the action of 
exogenous or endogenous insulin on glucose metabolism, acanthosis nigricans and 
hyperandrogenism (Lebovitz, 2001). Mutations of the insulin receptor have been 
shown in several o f these patients. Leprechaunism and Rabson-Mendenhall Syndrome 
are examples of severe insulin resistance associated with defects in growth and 
development. Several o f these patients have been shown to have mutations in the 
insulin receptor gene (Lebovitz, 2001).
1.3.1.2 Fetal malnutrition as a contributor to metabolic syndrome
Barker and colleagues have reported that men who had had the lowest birth weights 
and weight at one year old had the highest death rates from ischaemic heart disease 
(Barker et al., 1989). In attempt to understand the factors responsible for this finding,
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they subsequently undertake a study in China in which they showed that after 
correction for gender and current BMI, low birth weight was associated with elevated 
plasma glucose, insulin and triglycerides as well as higher blood pressures (Mi et al.,
2000).
It is hypothised that fetal malnutrition leads to changes in central nervous system 
regulation of metabolism to create more metabolically efficient pathways. The 
imprinting within the central nervous system affects metabolism throughout adult life. 
When exposed to excess calories and reduced physical activity in adult life, the 
individuals exposed to fetal malnutrition are proposed to be susceptible to obesity and 
the development of the metabolic syndrome (Lebovitz, 2001).
Phillips et al. (1998) showed that adults who had low birth weight have elevated 
fasting plasma cortisol levels as evidence for the possibility o f such a mechanism 
(Phillips et al., 1998). The cortisol levels were correlated with systolic blood pressure, 
plasma glucose levels -fasting and 2 hours after an oral glucose load, plasma 
triglyceride levels and insulin resistance as assessed by the homeostasis model 
assessment (HOMA) model, which should reflect, in principle, insulin action on both 
the liver and the periphery. It was suggested that fetal malnutrition causes intrauterine 
programming of the hypothalamic-pituitary-adrenal axis (Phillips et al., 1998).
1.3.1.3 Visceral obesity as a contributor to metabolic syndrome
Experimental and epidemiological evidence has established an association between 
visceral obesity and other features o f the metabolic syndrome. The association may be 
due to an excessive supply o f free fatty acids to the liver, derived from the high 
lipolytic activity o f omental fat (Busetto, 2001).
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Results of the Quebec Cardiovascular Study have shown that the cluster of metabolic 
disturbances observed among subjects with visceral obesity (hyperinsulinaemia, 
hyperapolipoprotein B and small, dense LDL particles) are associated with a 20-fold 
increase in the risk o f CHD (Lamarche et al., 1998). Despres (2001) found that the 
simultaneous presence o f an elevated waist girth combined with moderate 
hypertriglyceridaemia (hypertriglyceridaemic waist) could adequately identify a large 
proportion (approximately 80%) o f carriers of the above triad o f atherogenic 
metabolic abnormalities (hyperinsulinaemia, hyperapolipoprotein B and small, dense 
LDL particles) (Despres, 2001). In addition, obesity is the predominant factor 
contributing to insulin resistance, although other factors play a role (Grundy, 2000). 
Figure 1.6 shows one mechanism, proposed by Lebovitz (2001), by which an increase 
in visceral adipose tissue could lead to the development of insulin resistance and the 
metabolic syndrome. An increase in visceral adipose tissue would lead to a decreased 
release of adiponectin levels and an increased release of products o f adipose tissue 
metabolism including free fatty acids (FFA), TNF-a, resistin, and probably leptin. 
Visceral adipose tissue is more important with respect to FFA metabolism than other 
adipose tissue of the body, because o f its high rate of lipolysis and a rapid turnover of 
FFAs (Lebovitz, 2001).
The liver is exposed to high levels o f FFAs and triglycerides in the presence of 
visceral obesity. This leads to increase in VLDL particle synthesis and hepatic insulin 
resistance. A  large amount o f FFAs are released into the peripheral circulation by the 
liver. They contribute to the development of insulin resistance in skeletal muscle 
either directly or through increasing muscle triglyceride accumulation (Figure 1.7) 
(Lebovitz, 2001).
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Figure 1.7 A  proposed mechanism by which an increase in visceral adiposity leads to 
metabolic syndrome (Lebovitz, 2001)
TNF-a =  Tumour necrosis factor-a 
VLDL =  Very low density lipoproteins 
PAI-1 =  Plasminogen activator inhibitors 1
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Insulin resistance is defined clinically as a reduced ability o f exogenous or 
endogenous insulin to increase glucose uptake and utilization in an individual. Several 
mechanisms have been proposed as possible causes underlying the development of 
insulin resistance and the insulin resistance syndrome (Lebovitz, 2001).
Insulin resistance increases the risk of developing the abnormalities listed in Table
1.4. Not all insulin-resistant individuals develop the entire cluster o f these 
abnormalities, nor is their appearance confined to insulin-resistant individuals. On the 
other hand, the presence o f any one of them indicates that the individual may be 
insulin resistant and increases the possibility that the other abnormalities may also be 
present (Reaven, 2002).
Leyva et al. (1998) have shown that a high plasma leptin may be a component of a
\
metabolic syndrome. They have demonstrated that interindividual variations in plasma 
leptin concentrations were strongly related to the components o f a metabolic 
syndrome. The statistical strength of the relationship between plasma leptin and both 
fasting and postglucose insulin concentrations suggests that the insulin-leptin axis 
may be important in the coordination of the metabolic disturbances that constitute this 
syndrome (Leyva et al., 1998).
Insulin resistance is suspected in patients with a history of diabetes type II in first- 
degree relatives; patients with a personal history of gestational diabetes, polycystic 
ovary syndrome or impaired glucose tolerance; and obese patients, particularly those 
with abdominal obesity (Rao, 2001). Losing weight, increasing physical activity, 
cessation of smoking and managing dyslipidaemia is the most effective way to reduce 
CHD in patients with the metabolic syndrome (Bosello and Zamboni, 2000; Steinmetz 
et al., 2001).
1 .3 .2  I n s u l i n  r e s is t a n c e
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Table 1.4 Abnormalities associated with insulin resistance/hyperinsulinaemia
(Reaven, 2002)__________________________________________________________________________
Some degree o f glucose intolerance
Impaired fasting glucose 
Impaired glucose tolerance 
Type II diabetes 
Abnormal uric acid metabolism
t  Plasma uric acid concentration 
4 Renal uric acid clearance 
Dyslipidaemia
fTriglycerides
4HDL-C
4 LDL-particle diameter 
t  Postprandial lipaemia 
Haemodynamic
f  Sympathetic nervous system activity 
t  Renal sodium retention
t  Blood pressure (^50%  of patients with hypertension are insulin resistant) 
Haemostatic
t  Plasminogen activator inhibitor-1 
f  Fibrinogen 
Endothelial dysfunction
f  Mononuclear cell adhesion
t  Plasma concentration o f cellular adhesion molecules 
t  Plasma concentration of asymmetric dimethyl arginine 
4 Endothelial-dependent vasodilatation
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Epidemiological and experimental studies have shown that several nutrients may 
affect CHD risk factors (Table 1.5) (Mann, 2002). There is also good evidence that 
dietary advice to patients with CHD as one of the cheapest way can reduce mortality 
and morbidity as well as modify risk factors (Hooper, 2001).
1.4.1 Fatty acids
Dietary fatty acids may be saturated (no double bond), monounsaturated (MUFA) 
(with a single double bond) or polyunsaturated fatty acid (PUFA) (several double 
bonds). Unsaturated fatty acids may be of two district geometric configurations, 
termed Cis- or trans-, dependent on the relative positions of the two hydrogen atoms 
attached to the carbon atoms forming the double bond. These atoms are on the same 
side (Cis) or the opposite side (trans) o f the molecule (Figure 1.8) (Roche, 1999).
1 .4  D i e t  a n d  C H D
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T a b le  1 .5  E f f e c t s  o f  n u t r ie n ts  a n d  s e le c te d  fo o d s  o n  c o r o n a r y  r is k  fa c to r s
Nutrients Risk factors References
Saturated fatty acids tL D L
t  thrombogenesis
(Bonanome and Grundy, 1988) 
(Hoak, 1997)
Linoleic acid 
(moderate quantities)
tL D L
I h d l
(Mann, 2002)
n-3 fatty acids 
(from fish oil)
^Triglycerides 
tPlatelet aggregation
t  thrombogenesis
(Griffin, 2001)
(Lichtenstein and Chobanian, 
1990)
(Assmann et al., 1999)
Oleic acid Might tH D L, tL D L (Khor, 2004)
Trans unsaturated 
fatty acids
tL D L , tH D L (Lichtenstein et al., 1999)
Total fat tHaemostatic factors, 
especially factor VII
(Mezzano et al., 2001)
Antioxidant nutrients tL D L  oxidation (Kushi et al., 1996)
Non-starch 
polysaccharides 
(especially soluble)
tL D L
thyperglycaemia
(Mann, 2002)
Folate, vitamin B12, 
riboflavin, folic acid 
supplements or 
fortification
tHomocysteine (Ubbink, 1997)
Sodium tBlood pressure (Rrauss et al., 2000)
Fruits and vegetables tBlood pressure (Krauss et al., 2000)
Low fat dairy products tBlood pressure (Hooper et al., 2001)
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Epidemiological studies and controlled trial data indicate that variations in the relative 
amounts of saturated, monounsaturated and polyunsaturated dietary fats influence the 
risk o f CHD in part by influencing lipid metabolism (Katan et al., 1997). Saturated 
fatty acids appear to increase the risk of CHD, whereas unsaturated fatty acids have 
been shown to protect against CHD. It was demonstrated that the trans form of 
unsaturated fatty acids appear to increase the risk of CHD, similar to saturated fatty 
acids (Grundy et al., 1999b; Katan et al., 1997).
Monounsaturated fatty acids
The major M UFA in the diet is oleic acid. It has been demonstrated that, when 
substituted for dietary saturated fatty acids, MUFAs have a hypocholesterolaemic 
effect (Lichtenstein et al., 1993; Wardlaw and Snook, 1990). In animal studies, 
MUFAs enhanced LDL apo B clearance compared to saturated fatty acids (Brousseau 
et al., 1993). MUFAs appeal* to lower LDL and raise HDL-cholesterol (Brousseau et 
al., 1993; Mensink and Katan, 1992; Valsta et al., 1992).
Polyunsaturated fatty acids
Dietary PUFAs are subclassified as n-6 and n-3, indicating the location of the carbon 
forming to the first double bond from the omega end of the chain (Schaefer, 2002). 
The major n-6 fatty acid in the diet is a-linoleic acid, which is an essential fatty acid 
(Schaefer, 2002). It serves as the precursor for arachidonic acid, which has important 
biological effects in the body (Schaefer, 2002). Linoleic acid has a 
hypocholesterolaemic effect when substituted for dietary saturated fatty acids, 
reducing both LDL-C and HDL-C concentrations (Nelson et al., 1997). However, 
dietary arachidonic acid has little or no effect on plasma lipoprotein concentrations 
(Nelson et al., 1997).
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Long-chain n-3 fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA) (20:5n-3) and 
docosahexaenoic acid (DHA) (22:6n-3), are associated with decreased triglyceride 
levels in hypertriglyceridaemic patients and decreased risk o f developing CHD 
(Lichtenstein, 2003). Their effects are dose-dependent and persistent (Roche, 1999). 
This effect o f n-3 PUFAs underlies their capacity to reduce the concentration of small, 
dense LDL. Much o f this effect arises from their ability to inhibit the synthesis of 
triglycerides in the liver, which decreases the rate of synthesis o f VLD L and leads to 
the production of smaller and more dense VLDL particles (Griffin, 2001).
A  high intake o f n-3 PUFAs is associated with reduced platelet aggregation, altered 
immune function and a reduction in blood pressure (Lichtenstein and Chobanian, 
1990; Meydani et al., 1993). The EPA and DHA, but not a-linolenic acids seem to 
stabilize the myocardium electrically, resulting in reduced susceptibility to ventricular 
arrhythmias, thereby reducing the risk of sudden death. These fatty acids also have 
potent anti-inflammatory effects, the effects on immune response appear to be related 
to eicosapentaenoic acid intake but not docosahexaenoic acid (Khor, 2004), and may 
also be anti-thrombotic and anti-atherogenic. The use of n-3 PUFA should be 
considerate as part o f a comprehensive secondary prevention strategy post MI (GISSI, 
1999; Lee and Lip, 2003; von Schacky, 2004).
The n-3 PUFAs are more potent than the n-6 PUFA in regulating the activation of 
peroxisome proliferator-activated receptors a  (PPAR-a) (Clarke, 2001). In general, 
PPAR-a activation leads to the induction of several genes encoding proteins involved 
in lipid transport, oxidation, and thermgenesis (Kliewer et al., 1997). Clearly, PPAR- 
a  is emerging as a pivotal player in both fatty acid and glucose metabolism. Its 
regulation by PUFA, particularly n-3 PUFA, may offer an explanation for both the
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reported benefits o f these fatty acids in protecting individuals from developing type II 
diabetes (Clarke, 2001).
1.4.2 Carbohydrates
The various dietary carbohydrates are digested and absorbed at different rates in the 
human small intestine because of their differences in chemical compositions and 
physical structures. Therefore, they give rise to different blood glucose and insulin 
responses (Leeds, 2002). The different chemical forms o f carbohydrates include 
sugars, oligosaccharides, starches, and nonstarch polysaccharides (Leeds, 2002). 
Jenkins et al. (1981) were the first to establish an index designed to describe the effect 
of any one carbohydrate food on the area under the blood glucose curve (Jenkins et 
al., 1981). This was used to attribute a “ glycaemic index”  (GI), and was initially 
reported against standards o f white bread. However, oral glucose is becoming the 
standard because o f the differences in white bread preparation, and therefore the blood 
glucose response in different countries (Leeds, 2002).
Carbohydrates with a high GI affect the clearance of triglyceride postprandially. This 
is in part due to an overproduction o f triglyceride and triglyceride-rich lipoproteins 
(Parks and Hellerstein, 2000). In cross-sectional studies a significant negative 
correlation between serum HDL-C and dietary GI have been reported (Ford and Liu, 
2001; Frost et al., 1999).
Reduction of average dietary GI values have been shown to be associated with an 
increased insulin stimulated glucose uptake after 4 weeks of dietary treatment and to 
improve some markers of cardiovascular risk (Hotamisligil et al., 1995). Low GI diets 
have been shown to be associated with lower plasma fatty acids concentrations 
(Wolever et al., 1995; Wolever and Mehling, 2003), which may suppress production
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or release of signalling hormones from adipose tissue, which in turn may reduce LDL- 
C and increase HDL-C (Frayn et al., 1996; Frost et al., 1998).
1.4.3 B vitamins
It has been shown that plasma concentrations of folate, vitamin B12 and B6 are 
inversely associated with plasma total homocysteine levels (Ubbink, 1997). O f these 
three vitamins, folate is the most powerful homocysteine lowering agent and vitamins 
B12 and B6 as supplements have been shown to amplify the homocysteine-lowering 
effect o f folic acid (Ubbihk, 1997).
Several intervention trials have been found that B vitamin supplements can affect 
coronary risk factors. Treatment with a combination of folic acid, vitamin B12, and 
pyridoxine was found to significantly reduce plasma homocysteine levels (Schnyder 
et al., 2002). B vitamin supplementation has also reported to reduce the rate of  
restenosis following coronary angioplasty (Schnyder et al., 2001) and decreases the 
incidence of major adverse events after percutaneous coronary intervention (Schnyder 
et al., 2001; Schnyder et al., 2002).
1.5 Inflammation in atherosclerosis
Atherosclerotic lesions contain macrophages at all stages of their development (Ross, 
1993). This evidence led to the notion that atherosclerosis is a chronic inflammatory 
disease (Metzler et al., 1998). Serum levels o f several markers of inflammation have 
been investigated as predictors o f cardiovascular events. Some of the most commonly 
measured inflammatory markers, such as CRP, fibrinogen, and serum amyloid A, 
originate in the liver, and their production is stimulated by systemic cytokines such as 
IL-1[3, IL-6, and TNFa. These cytokines are produced at several extrahepatic sites 
including the heart, arterial wall, extravascular macrophages, and adipose tissue.
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These tissues are also potential sources of other inflammatory markers, which are 
shown in figure 1.9 (Rader, 2000).
Figure 1.9 Sources of inflammatory markers and cytokines (Rader, 2000)
Tumor necrosis factor a
Lipoprotein-associated phospholipase A 2 
Secretory phospholipase A 2
Liver
C-reactive protein 
Fibrinogen 
Serum amyloid A
ICAM-1 =  Intercellular adhesion molecule 1 
VCAM -1 =  Vascular-cell adhesion molecule 1
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C- reactive protein (CRP) is an acute phase reactant. It consists o f five identical, non­
glycosylated peptide subunits linked to form a cyclic polymer (Pepys, 1981). The 
relationship between serum CRP concentrations and cardiovascular events provides 
one form of evidence linking the inflammatory response and risk o f vascular disease 
(Patrick and Uzick, 2001). However, Levinson et al. (2004) have recently questioned 
the predictive value of high-sensitivity CRP for CHD. They argue that serum CRP is 
likely to lead to errors estimating risk and that their measurement is economically 
unjustified (Levinson et al., 2004). It is perhaps too early to abandon the use of hs- 
CRP for estimating coronary risk. Its predictive value may be improved with 
combining it with other measurement of inflammation, or by repeated measures, in 
specific category o f subjects. It may not be economic at the present time, but much 
cheaper automated methods are being introduced.
CRP immunoreactivity has been demonstrated in vulnerable and ruptured plaque 
(Lagrand et al., 1997). Whether this is locally expressed or absorbed from the blood 
stream is not yet clear. The possible mechanisms for direct involvement of CRP in 
atherosclerosis and thrombosis include complement activation through binding to 
damaged cell membranes (Lagrand et al., 1999) with subsequent induction of tissue 
factor production by monocytes (Cermak et al., 1993).
Elevated levels o f CRP have been associated with increased risk of cardiovascular 
disease, MI, and coronary artery disease deaths among individuals with angina 
pectoris (Berk et al., 1990; Ford and Giles, 2000). Levels o f CRP can rise to 100-fold 
over normal levels within 24-48 hours after an acute inflammatory stimulus. 
However, in the absence of trauma or acute infection, it is clear that inter-individual 
variations in CRP levels are stable over long periods of time (Ridker et al., 1999). A
1 .5 .1  C - r e a c t i v e  p r o t e in s
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doubling o f risk for ischaemic stroke in hypertensives (Ridker et al., 1998; 
Schaumberg et al., 1999), and for peripheral arterial disease (Ridker et al., 1998) has 
been demonstrated in subjects with raised levels o f CRP. A  positive association 
between elevated levels o f CRP and smoking, BMI, chronic asymptomatic infections, 
and increased age have been previously reported (Mendall et al., 1996).
Several large-scale prospective studies have demonstrated that CRP is a strong 
independent predictor o f future MI and stroke (Ridker, 2001). One prospective study 
compared CRP with other markers of vascular risk (figure 1.10) (Ridker et al., 2000). 
Serum CRP was found to be the single strongest predictor o f risk (RR 4.4 for the 
highest versus lowest quartile) (Ridker et al., 2000). Because agents such as aspirin 
and statins have anti-inflammatory effects, measurement o f serum CRP may allow 
patients to be identified who may benefit from treatment in primary prevention 
(Ridker, 2001).
Figure 1.10 Direct comparison o f magnitude of relative risk o f future cardiovascular 
events associated with CRP, cholesterol levels, lipoprotein (a), and homocysteine 
among apparently healthy women. For consistency, relative risks and 95%  Cl are
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shown for individuals in the top versus bottom quartile for each factor (taken from 
Ridker et al., 2000).
1.5.2 Interleukin-6 (IL-6)
11-6 is a proinflammatory cytokine, which regulates humoral and cellular responses 
and plays a central role in inflammation and tissue injury (reviewed by Saadeddin et 
al., 2002). Many vascular cells including endothelium, smooth muscle cells, 
macrophages and adipocytes express IL-6 (Lotz, 1993).
IL-6 has the potential to play a key role in the development o f CHD through a number 
of different mechanisms. IL-6 increases basal glucose uptake, alters insulin 
sensitivity, increases the express of adhesion molecules by the endothelium and 
increases the hepatic release of fibrinogen (Yudkin et al., 1999). Both IL-6 and TNF- 
a  inhibit lipoprotein lipase and stimulate lipolysis (Greenberg et al., 1992; 
Hardardottir et al., 1994; Van Snick, 1990). High levels o f IL-6 are found in human 
atherosclerotic plaques, and several studies have found a direct relationship between 
serum IL-6 levels and CHD (Rus et al., 1996). IL-6 levels appear to be predictive of  
future CHD and non CHD mortality in the elderly (Harris et al., 1999).
1.5.3 Tumour necrosis factor-a (TNF-a)
TNF-a was recognised as a cytokine with multiple biological capacities (Saadeddin et 
al., 2002). Monocytes and macrophages are the main source o f TNF-a, but other cells 
such as T-lymphocytes, natural killer cells, smooth muscle cells, endothelial cells and 
some tumour cells also produce TNF-a (Saadeddin et al., 2002).
TNF-a is a primary proinflammatory cytokine, detected in human atherosclerotic 
plaques and increased in plasma after MI (Saadeddin et al., 2002). TNF-a plays 
important roles in the regulation o f acute phase proteins such as factor VIII (Baumann
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and Gauldie, 1994). Therefore, TNF-a may be expected to have a role in the 
pathogenesis o f CHD (Barath et al., 1990).
1.5.4 Serum Amyloid A  (SAA)
SAA proteins are a family o f inflammatory apoproteins. They are major acute phase 
reactants that are produced in response to various insults, mainly by the liver (Malle et 
al., 1993). During inflammation, their serum concentrations can rise as much as 1000- 
fold (Benditt et al., 1962; Gabay and Kushner, 1999). They rapidly bind to HDL-C 
after their synthesis and may play a role in modifying cholesterol transport during 
inflammatory conditions (Malle and De Beer, 1996).
SAA has been shown to be present in human atherosclerotic plaque (Yamada et al., 
1996) and has been found to be increased in serum of patients with CHD. The exact 
role of SAA in atherogenesis has not been fully defined. Serum concentrations of 
SAA usually parallel those of CRP although it has been reported that SA A  is a more 
sensitive marker o f inflammatory disease (Malle and De Beer, 1996). At the present, 
assays for serum SA A  are not widely available (Ridker et al., 2000; Saadeddin et al., 
2002).
1.5.5 Fibrinogen
Fibrinogen is a key coagulation factor, and an acute phase reactant exclusively 
synthesised by the liver (Gabay and Kushner, 1999). Fibrinogen plays a central role in 
thrombosis and strongly affects haemostasis, serum viscosity and platelet aggregation, 
because fibrinogen is the substrate for the enzyme thrombin and the precursor of 
fibrin (Koenig and Ernst, 1992). Several coronary risk factors including age, smoking 
habit, levels o f physical activity and blood pressure are associated with increased 
plasma fibrinogen (Ernst and Resch, 1993). An association between plasma
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fibrinogen and increased risk o f CHD was found among healthy and high-risk 
individuals e.g. (Folsom et al., 1997; Meade et al., 1993).
1.6 Heat shock protein (Hsp) and atherosclerosis
Cells respond to a variety o f environmental stresses by rapidly expressing a family of 
proteins called the heat shock proteins (Hsp) (Morimoto, 1993; Udelsman et al., 
1993). Potential risk factors for atherosclerosis such as infections, ox-LDL, oxidative 
stress, hypertension, and biomechanical stress, stimulate Hsp over-expression in the 
endoplasmic reticulum of macrophages, and smooth muscle cells (Xu, 2002). This 
response is highly conserved through evolution, and is seen in bacteria to humans 
(Soltys and Gupta, 1996; Xu et al., 1994).
Hsps have been categorized into several protein families, according to their molecular 
weight from: HsplO, small Hsps, Hsp40, Hsp60, Hsp70, Hsp90, and HsplOO (Table 
1.6) (Hartl and Hayer-Hartl, 2002).
The primary physiological function of some Hsps (e.g. 60kDa and 70 kDa families) is 
as molecular chaperones. They bind to immature or partially denatured proteins, 
helping them to fold into their native conformation and regain their functional activity 
(Becker and Craig, 1994; Snoeckx et al., 2001; Soltys and Gupta, 1996). Molecular 
chaperones have been defined as a class o f proteins that mediate the correct folding of 
other proteins, but do not take part in the final assembly o f new structures (Ellis and 
van der Vies, 1991). Human Hsp production in the arterial wall is essential for cell 
protection against unfavourable conditions (Udelsman et al., 1993), such as 
haemodynamic stress, free radical exposure, and cytokine stimulation (Ferreira and 
Carlos, 2002).
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Table 1.6 Summary o f  the nomenclature, location and function o f the major Hsp families (Lamb et al., 
2003)
Family Organism Location Functions
Hsp100 E. coli Cytosol Role in stress tolerance; helps the solubilisation o f  heat- 
inactivated proteins from insoluble aggregates.
S. cerevisiae Cytosol
Hsp90 E. coli Cytosol Role in signal transduction (e.g. integration with steroid 
hormone receptors, tyrosine kinases, serine/threonine 
kinases); refolds and maintains proteins in vitro; 
autoregulation o f  the heat shock response; role in cell 
cycle and proliferation.
S. cerevisiae Cytosol
Mammals Cytosol
ER
Hsp70 E. coli Cytosol Roles in lambda phage replication; autoregulation o f  the 
heat shock response; integration with nascent chain 
polypeptides; functions in interorganellar transport; roles 
in signal transduction; refolds and maintains denatured 
proteins in vitro; role in cell cycle and proliferation; 
antiapoptotic activity; potential antigen-presenting 
molecule in tumour cells.
S. cerevisiae Cytosol
ER
Mitochondria
Mammals Cytosol/nucleus
ER
Mitochondria
Hsp60 E. coli Cytosol Refolds and prevents aggregation o f  denatured proteins 
in vitro; may facilitate protein degradation by acting as a 
cofactor in proteolytic system; role in the assembly o f  
bacteriophages and Rubisco (an abundant protein in the 
chloroplast).
S. cerevisiae Mitochondria
Plants Chloroplasts
Mammals Mitochondria
Hsp40 E. coli Cytosol Essential cochaperone activity with H sp70 proteins to 
enhance rate o f  adenosine triphosphatease activity and 
substrate release.
S. cerevisiae 
Mammals
Cytosol/nucleus
Small Hsp E. coli Cytosol Suppresses aggregation and heat inactivation o f  proteins 
in vitro; confers thermotolerance through stabilization o f  
microfilaments; antiapoptotic activity.
S. cerevisiae Cytosol
Mammals Cytosol
E. coli, Escherichia coli; S. cerevisiae, Saccharomyces cerevisiae; ER, endoplasmic reticulum.
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Due to their high degree o f sequence homology with human Hsp, the immune 
response against microbial Hsp carries the risk of eliciting an autoimmune response. 
Elevated plasma levels o f antibody against Hsps have been found to be associated 
with diseases like rheumatoid arthritis (Sato et al., 1996), diabetes mellitus (Feige and 
van Eden, 1996), systemic sclerosis (Danieli et al., 1992), rejection o f transplanted 
organs (Trieb et al., 1996) and atherosclerosis (Wick et al., 1995; Wick et al., 1997).
1.6.1 Hsp expression in atherosclerotic lesions
Berberian et al. (1990) first reported the increased expression o f Hsp70 in human and 
rabbit arteries and its distribution in relation to necrosis and lipid accumulation, and 
its expression by vascular smooth muscle cells and macrophages, in human 
atherosclerotic plaques (Berberian et al., 1990). Several experiments have shown that 
there is a constitutional expression of endoplasmic reticulum Hsp in vascular 
endothelium, which can be significantly raised by exposing endothelial cells to a 
variety o f stresses, including thermic stress, shear stress (that mimics haemodynamic 
stress) and chemical stress including exposure to oxidized LDL (Hochleitner et al., 
2000; Mayr et al., 1999). This expression increases with higher levels o f stress, in a 
dose dependent fashion (Snoeckx et al., 2001).
1.6.2 Soluble Hsps
Xu et al. (2002) have shown that plasma soluble Hsp-60 (sHsp-60) levels were 
significantly elevated in subjects with established carotid atherosclerosis, were 
correlated with intima-media thickness, and were independent of age, sex, and other 
risk factors. Interestingly, sHsp-60 concentrations were correlated with anti-LPS, anti- 
Chlamydia, and anti-Hsp-60 antibodies, markers of inflammation, and chronic
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infections. Affinity chromatography and Western blot analysis confirmed the 
molecular weight of sHsp-60, i.e., 60 kDa (Xu et al., 2000). Because the antibodies 
used for sHsp-60 measurement reacted with both human and bacterial Hsp-60, it is 
unknown whether these 60-kDa bands on Western blots were derived from human or 
bacteria-derived Hsp60. Nevertheless, these data provide the first evidence of a 
relationship between sHsp-60 and atherosclerosis, suggesting a role for sHsp-60 in the 
development of atherosclerosis (Xu, 2002).
Where and how sHsps are released into the blood is currently unknown. As several 
types o f tissues express Hsps and high levels in response to stress, there are several 
possibilities.
1. Infectious agents may be the major factor contributing to sHsp-60 release from the 
organisms and from human cells (Beatty et al., 1994).
2. The sHsps could be released from the dying cells o f tissues during chronic 
inflammation and from atheroma, in as much as earlier studies have shown the 
occurrence o f cell death within atheroma (Dybdahl et al., 2002; Mayr and Xu,
2001).
3. Surface-expressed Hsps in cells undergoing apoptosis may be released into blood 
via the formation o f microparticles. sHsps may be present in the microparticles 
(Mallat et al., 1999).
Therefore, sHsp release into the circulation could be the result o f different pathways.
1.6.3 Hsp as target antigens and inflammatory response
It has been shown that antibodies against Hsp can induce lysis o f human endothelial 
cells in culture (Schett et al., 1995), but only if these cells have been previously 
subjected to stress. These stressed cells express much more intracellular and cell
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surface-bound Hsp, and are therefore more able to bind antibodies to Hsp. Cell lysis 
may subsequently be mediated by complement or by antibody dependent cell 
cytotoxicity (ADCC). There is also some evidence for the presence o f specific T cells 
directed against Hsp epitopes and, in some studies, it has been possible to show direct 
T cell cytotoxicity against Hsp-expressing cells. Other studies have demonstrated the 
presence, within human atherosclerotic plaques, o f T lymphocytes that are reactive to 
Chlamydia pneumoniae Hsp, and this response may involve autoimmunity (Mosorin 
et al., 2000).
In addition to the possibility o f molecular mimicry, Hsp-60 also has direct biological 
effects that may be pro-atherogenic including induction of vascular adhesion molecule 
and proinflammatory cytokines (TNF-a and IL-6) expression, and modulation of the 
expression of matrix metalloproteinases in macrophages (Kol et al., 1999). Kel et al. 
have elegantly shown that bacterial and human Hsp-60 could both act to promote 
macrophage, endothelial cell, and smooth muscle cell activation, further supporting 
the link between Hsp-60/Hsp-65 and atherosclerosis (Kol et al., 1998; Kol et al.,
1999).
1.6.4 Hsp can induce atherosclerosis experimentally
Mori et al. studied whether immunization with human Hsp-60 could lead to 
atherosclerosis in mice. They attempted to induce atherosclerosis in C57BL/6NJcl 
mice by immunization with human Hsp-60 whilst they were fed a high-cholesterol 
diet. The size of fatty streak lesions was significantly enhanced in mice immunized 
with human Hsp-60 fed a high-cholesterol diet compared with non-immunized mice 
(Mori et al., 2000). George et al. showed that immunization o f mice with recombinant
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Hsp-65 or with heat-killed, Hsp-rich Mycobacterium tuberculosis (BCG) could lead to 
accelerated fatty streak formation (George et al., 1999).
1.6.5 Ox-LDL and free radicals induce Hsp expression
Ox-LDL is believed to be crucial in the development of atherosclerosis. It has been 
reported that ox-LDL triggers the expression of Hsps (e.g. Hsp-23 and Hsp-32) in 
mouse peritoneal macrophages in vitro (Yamaguchi et al., 1993), Hsp-60 in 
monocytes/macrophages (Frostegard et al., 1996), and Hsp-70 in human endothelial 
(Zhu et al., 1994) and smooth muscle cells (Zhu et al., 1995). Additionally, Zhu et al. 
(1996) reported that ox-LDL induced Hsp-70 expression by proliferating endothelial 
cells, indicating that those cells, present in lesion-prone areas, are more sensitive to 
ox-LDL than are quiescent cells (Zhu et al., 1996).
Stimulation of cell apoptosis and proliferation by free radicals is thought to be a 
critical step in atherosclerotic lesion formation. The potential role o f oxidative stress 
in the induction o f Hsps has been reported (Lee and Corry, 1998). Treatment of 
endothelial cells with H2O2 has been shown to increased Hsp-70 mRNA levels (Jomot 
et al., 1991). Nuclear runoff transcription data and kinetics o f mRNA decay have 
indicated that the observed increase in Hsp-70 mRNA levels in ^(V treated  cells is 
mainly due to a transcriptional induction (Madamanchi et al., 2001).
1.6.6 Epidemiological evidence for the role of anti-Hsps in atherosclerosis
In a study o f 750 subjects 45 to 74 years old over a 5-year observation period, Xu et 
al. (1999) showed that Hsp-65 antibody titres in subjects with severe atherosclerosis 
predicted 5-year mortality (Xu et al., 1999). Hsp-65 antibody titres were significantly 
higher in subjects with progressive carotid atherosclerosis and correlated with
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intima/media thickness (Xu et al., 1999). Multiple linear regression analysis showed 
that these associations were independent of age, gender, and other risk factors (Xu et 
al., 1999). Subgroup analyses revealed a preferential association of Hsp-65 antibody 
titers with advanced lesions. Other risk factors neither confounded nor modified this 
association (Pockley et al., 2000).
Other authors have identified elevated Hsp-60 antibody levels in patients with 
borderline hypertension and an association between early atherosclerosis and Hsp-60 
antibody levels (Pockley et al., 2000).
Elevated levels of circulating antibody to the mycobacterial 65-kDa heat shock 
proteins have been reported in carotid atherosclerosis and CHD (Pockley et al., 2000). 
In addition, many other groups have confirmed the elevated levels of Hsp antibodies 
in CHD, MI, stroke, hypertension, and restenosis after angioplasty (Table 1.7a-b) (Xu,
2002).
In the current model for the role of Hsps in atherogenesis, all risk factors, e.g. 
infections, biomechanical stress, ox-LDL, and free radicals, directly stimulate cells of 
the arterial wall and/or other tissues to express high levels of Hsps. The physiological 
function of these Hsps is to protect cells against apoptosis. However, cell death leads 
to the release of intracellular Hsps into intercellular spaces as sHsps. Macrophages 
present Hsp-related antigens to T and B cells, which produce potentially damaging 
autoantibodies against Hsps (Xu, 2002).
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Table 1.7a Summary of case/control studies on Hsp antiDodies
First Author & 
Reference
Cases/Controls
(n)
Disease Anti-Hsps Odds Ratio & 
P*
(Gruber et al., 
1996)
107/90 Vascular
diseases**
Hsp-65 P0.001
(Hoppichler et al., 
1996)
203/76 CHD, MI Hsp-65 P<0.05
(Mukherjee et al., 
1996)
28/12 CHD, PTCA Hsp-65 PO.036
(Frostegard et al., 
1997)
66/67 Hypertension Hsp-65 P=0.034
(Chan et al., 
1999)
61/21 Peripheral AS Hsp-70 P=0.0037
(Zhu et al., 2001) 274/91 CAD Hsp-60 1.86
(1.13-3.04)
(Burian et al., 
2001)
276/129 CAD Hsp-60 2.6(1.3-5.0)
(Gromadzka et 
al., 2001)
180/64 Carotid
ischaemia
Hsp-65/70 PO.OOOl
(Prohaszka et al., 
2001)
424/321 CHD Hsp-60 P0.007
(Ciervo et al., 
2002)
179/100 CHD Hsp-60 PO.05
(Huittinen et al., 
2002)
239/239 CHD Hsp-60 2.0(1.1-3.6)
*P values are shown when odds ratios were not provided in the articles.
** Patients with systemic vacuities and systemic lupus erythematosus (SLE)
AS indicates atherosclerosis; CHD, coronary heart disease; CAD, coronary artery 
disease; MI, myocardial infarction; PTCA, percutaneous transluminal coronary 
angioplasty (Xu, 2002).
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Table 1.7b Summary of cohort studies on Hsp antibodies
First Author & 
Reference
Cohort
(n)
Disease Anti-Hsps Odds Ratio & 
P*
(Xu et al., 1993) 867 Carotid AS Hsp-65 1.52
(1.09-2.02)
(Bimie et al., 
1998)
136 CHD Hsp-65 P=0.012
(Prohaszka et al., 
1999)
74 CHD Hsp-60 P=0<0001
(Xu et al., 1999) 750 Carotid AS Hsp-65 1.42
(1.02-1.98)
*P values are shown when odds ratios were not provided in the articles. 
AS indicates atherosclerosis; CHD, coronary heart disease (Xu, 2002).
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Trace element status has been investigated as a possible contributory factor to 
atherosclerosis. There is evidence that free radicals play an important role in CHD. 
Protective mechanisms such as the action of the antioxidant enzymes, glutathione 
peroxidase, superoxide dismutase, and catalyse may play a role in atherogenesis. 
Trace elements such as zinc, copper and selenium are of particular interest because 
they are essential components of these enzymes but are also possibly implicated in 
lipid oxidation (Craig et al., 1995; Ferns et al., 2000b; Rayman, 2000; Singh, 1992a).
1.7.1 Copper and caeruloplasmin
Copper is an essential nutritional element. It is required for normal cell metabolism 
and is present in all human cells and tissues. The recommended daily intake is 2-3 
mg, but many Western diets contain considerably less than this. Approximately 50- 
70% of dietary copper is absorbed. Foods with the highest copper content include 
wheat germ, pulse, nuts and liver. Caeruloplasmin is the major copper-containing 
plasma protein. It is an acute phase reactant protein synthesised in the liver and 
present in human plasma. A major difficulty in interpreting many of the studies 
relating serum copper to atherosclerosis is the fact that plasma caeruloplasmin levels 
are often elevated in the presence of acute or chronic inflammatory disease (Singh, 
1992b). Copper absorption, and its plasma and tissue levels, are affected by age, 
oestrogen status and sex (Singh, 1992b). Plasma copper levels are particularly high in 
women on oral contraceptives (Milne and Johnson, 1993).
Copper deficiency is associated with elevated serum cholesterol concentrations and 
impaired endothelium-dependent arterial relaxation that may result in hypertension 
(Ferns et al., 1997). Copper deficiency has been shown to cause an increased
1.7 Trace element metabolism and C H D
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accumulation of arterial lipid peroxides, possibly due to decreased CuZnSOD activity 
(Ferns et al., 1997). There is accumulating evidence that LDL modification is 
important in the early phases of atherogenesis. Copper is very effective in catalysing 
this modification in vitro, although the mechanisms by which this occurs are still 
obscure (Esterbauer et al., 1992).
A positive association between serum copper levels and CHD has been described 
previously. Klevay (1975) proposed the hypothesis that an imbalance in zinc/copper 
metabolism predisposes to CHD (Klevay, 1975). According to this hypothesis, dietary 
copper deficiency, either alone or in association with a high zinc intake, leads to 
hypercholaesterolemia and development of atherosclerosis (Klevay, 1975). Because 
of the effects of copper on the cellular elements of the arterial wall, leukocyte and 
platelet function and lipoprotein metabolism, it clearly has the potential to play an 
important role in atherogenesis in man (Ferns et al., 1997).
Epidemiological studies have suggested that high levels of copper may promote 
atherosclerosis, although some of these data are difficult to interpret and are not 
entirely consistent (Ferns et al., 2000b).
Caeruloplasmin is an independent risk factor for CHD, and also is an antioxidant 
protein (Atanasiu et al., 1998). Increased serum caeruloplasmin concentrations have 
been reported as a predictor of acute MI (Manttari et al., 1994; Reunanen et al., 1992), 
and serum levels of caeruloplasmin were positively correlated with severity of 
coronary atherosclerosis (Mori et al., 1995).
Several studies have shown an association between serum caeruloplasmin 
concentrations and classical coronary risk factors (Cignarelli et al., 1996; Craig et al., 
1995). There was a positive association of copper and caeruloplasmin concentrations 
with lipid peroxide, total cholesterol, and triglycerides (Craig et al., 1995). An
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association between caeruloplasmin and intra-abdominal fat thickness has also been 
reported (Cignarelli et al., 1996). Elevated serum concentrations of caeruloplasmin in 
type I and type II diabetes mellitus as well as in subjects with metabolic syndrome 
have been reported (Daimon et al., 1998; Kim et al., 2002; Smith et al., 1988). 
Caeruloplasmin can function as a pro-oxidant and can oxidatively modify LDL 
cholesterol in vitro (Ehrenwald et al., 1994). On the other hand, caeruloplasmin is one 
of the major physiological inhibitors of lipid peroxidation (Atanasiu et al., 1998). It 
has ferroxidase activity, which inhibits the ferrous ion-dependent formation of 
hydroxyl radicals and lipid peroxidation. Caeruloplasmin also acts as a scavenger of 
superoxide radicals (Kim et al., 2002). It has been reported that various coronary risk 
factors such as hypertension, hyperlipidaemia, diabetes mellitus, metabolic syndrome 
and haemodynamic shear stress lead to the generation of oxidative stress in the 
vascular cells, leading to endothelial dysfunction and atherosclerosis. Therefore, 
elevated serum caeruloplasmin concentrations could be a defence mechanism against 
increased oxidative stress (Kim et al., 2002).
1.7.2 Zinc
Zinc has a wide range of biological functions and is a component of more than 70 
mammalian enzymes. It participates in carbohydrate, lipid, protein, and nucleic acid 
synthesis and degradation. Zinc also plays a structural role in non-enzymic proteins 
such as insulin and growth hormone. Over the age of 15 years, the reference nutrient 
intake (RNI) for males is 9.5 mg/day and for females 7.0 mg/day (Garrow et al.,
2000). Approximately 30% of the British population have recently been reported to 
have a zinc intake below the reference nutrient intake (RNI), but few people were 
found to have an intake below the lower reference nutrient intake (LRNI) (Garrow et
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al., 2000). In the average UK diet zinc is principally derived from meat and meat 
products (40%), cereal foods (22%), milk and milk products (16%), vegetables and 
potatoes (9%) (Garrow et al., 2000). Zinc is not an antioxidant in the same sense as, 
for example, vitamin E. However, zinc could conceivably limit oxidant-induced 
damage in other ways (Thomas, 2001).
As zinc is essential for many enzymes involved in human metabolism and plays a role 
in the biosynthesis and storage of insulin in the p-cells (Zargar et al., 2002), zinc 
deficiency may predispose to glucose intolerance, diabetes mellitus, insulin resistance, 
atherosclerosis and coronary artery disease (Roth and Kirchgessner, 1991). A 
decrease in serum zinc levels has been reported after acute M I with a concomitant 
increase in serum copper (Jain and Mohan, 1991). As zinc is an important constituent 
of various matrix metalloproteinases, the fall in serum zinc levels could be due to the 
large amount of zinc needed by the myocardial tissue to participate in the process of 
repair. However, variation in serum zinc could also be explained by acute phase 
response. Both hypotheses involve an increase of zinc uptake by tissue. This increase 
could be reflected in serum, by changes in protein zinc-binding capacities (mainly 
albumin-bound) (Amaud et al., 1994).
Taneja et al. (1996) have reported that higher hair zinc concentrations are present in 
subjects who are obese compared to subjects with normal BMI. On the other hand 
(Taneja et al., 1996), Atkinson et al. (1978) have reported significantly lower serum 
zinc concentrations and higher copper concentrations in obese subjects than in the 
lean control subjects (Atkinson et al., 1978). The hair zinc concentrations and Zn/Cu 
ratio in survivors of M I was significantly higher in comparison with controls 
(Bialkowska et al., 1987). Regarding zincuria following MI, there is not any date 
available.
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Circulating leptin concentrations have been reported to be low in zinc deficiency in 
both rats and humans. This appears to be due to both a decrease in the amount of body 
fat present in zinc deficiency and decrease in the amount of leptin produced per gram 
of adipose tissue (Shay and Mangian, 2000). Lukasiak et al. (1998) and Falkiewicz et 
al. (2000) reported lower zinc levels in patients with metabolic syndrome than 
controls, as assessed by the analysis of hair trace element content (Falkiewicz et al., 
2000; Lukasiak et al, 1998). They believed that it might be one of the risk (or 
aetiological) factors leading to the development of metabolic syndrome, although 
these findings may also be a consequence of the metabolic syndrome (Falkiewicz et 
al., 2000; Lukasiak et al., 1998).
1.7.3 Selenium and glutathione peroxidase
The essential trace mineral, selenium, is of fundamental importance to human health 
(Rayman, 1997). In the human diet, it is largely obtained from bread and cereals, fish, 
poultry, and meat. It is a key component of a number of functional selenoproteins 
required for normal health. The antioxidant enzyme glutathione peroxidase (GPx) is 
the best known of these. This catalyses the breakdown of hydrogen peroxide and 
organic hydroperoxides (Rayman, 1997).
Lipid hydroperoxides impair membrane structure and function (Rayman et al., 1996) 
and enhance thrombotic potential by decreasing the production of prostacyclin whilst 
increasing the production of thromboxane, and hence GPx protects against these 
pathological processes (Rayman et al., 1996).
The ability of GPx to combat the oxidative modification of lipids theoretically 
supported the beneficial role of selenium against cardiovascular disease. The evidence 
from case-control and prospective studies for an association between low selenium
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status and cardiovascular disease remains controversial. Moor et al. (1984) reported 
an inverse relationship between serum selenium concentrations and severity of 
coronary atherosclerosis in patients examined by coronary arteriography (Moore et 
al., 1984).
In some studies there has been a reported increased risk of cardiovascular disease in 
populations with low selenium (<45pg/L). The mechanisms by which selenium may 
be protective against atherosclerosis include increased resistance of LDL against 
oxidative modification, modulation of prostaglandin synthesis and platelet 
aggregation, and protection against toxic heavy metals such as mercury, high intake of 
which increases the risk of CHD by promoting lipid peroxidation (Neve, 1996; 
Rayman, 2000; Salonen et al., 1995b).
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Free radicals are generated constantly in the human body during normal biological 
processes. Additional quantities of oxidants may be generated in response to external 
stressors, such as cigarette smoke and air pollution. If  the generation of free radicals is 
more than the body’s ability to inactive them, a condition of oxidative stress develops. 
Hence, oxidative stress is an imbalance between pro-oxidant factors and antioxidant 
defences, which can damage cells by a variety of mechanisms. Free radicals and 
oxidative stress play a role in the causation of a wide range of chronic and 
degenerative disease including cardiovascular disease (Aruoma et al., 1991). 
Antioxidants are substances, which can delay or inhibit the damaging effects of 
oxidants. Biological fluids contain enzymatic antioxidants and non-enzymatic 
antioxidants.
1. Enzymatic antioxidants include SOD, catalase, methionine sulphoxide reductase 
and GPx.
2. Non-enzymatic antioxidants include uric acid, bilirubin, albumin, vitamins C, E, p 
carotene, lycopene, ubiquinol and ubiquinone (Sies, 1991).
1.8.1 Vitamin E
Vitamin E is a major lipid-soluble antioxidant present in cellular membranes. The 
term vitamin E describes a group of the tocopherols (a,p,x,§) and tocotrienols 
(a,p,x,5), which share similar biological activities, but have different potencies 
(Figure 1.11) (Kamal-Eldin and Appelqvist, 1996).
1.8 Antioxidants and C H D
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T o c o p h e r o l
T o c o t r ie n o l
1.8.1.1 Possible mechanisms of vitamin E protection
It has been demonstrated that dietary supplementation with vitamin E can inhibit the 
oxidation of LDL (Princen et al., 1992; Reaven et al., 1993). Not all antioxidants 
share vitamin E’s ability to inhibit the oxidation of LDL. For example, no consistent 
effects of supplementation with (3 carotene on LDL oxidation have been reported 
(Gaziano et al., 1995; Princen et al., 1992; Reaven et al., 1993).
At least part of the beneficial effects of vitamin E against CHD may be due to 
decrease in platelet aggregability (Reaven et al., 1993). This effect of vitamin E on 
platelets might be particularly beneficial in patients with existing vascular disease, 
low dietary antioxidant intakes, or platelet hyperaggregability, a condition in which 
platelets are unusually sticky (Gaziano et al., 1995).
Vitamin E and/or vitamin C may also have a beneficial acute effect on vascular 
endothelial function. A high-fat meal transiently reduces endothelial function for up to 
4 hours in healthy, normocholesterolemic subjects, probably through the accumulation 
of triglyceride-rich lipoproteins (Vogel et al., 1997). Pre-treatment with antioxidant 
vitamins C (lOOOmg) and E (800 IU) blocks the advese effect of high-fat meal on 
endothelial function and restores the normal responsiveness of endothelium (Plotnick 
et al., 1997).
1.8.1.2 Animal studies
Most of the more recent work in animal models has supported the hypothesis that 
vitamin E supplementation can prevent or slow the development of atherosclerosis, 
although the results of early animal experiments were equivocal (Smith and 
Kummerow, 1989; Verlangieri and Bush, 1992).
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The ability of a-tocopherol supplementation to prevent cardiovascular events has been 
tested in several prospective clinical trials and their results are summarised in table 
1.8. These studies include -^Tocopherol fi-Carotene (ATBC) (Rapola et al., 1996); 
Cambridge Heart Antioxidant Study (CHAOS) (Stephens et al., 1996); Gruppo 
Italiano per lo Studio della Supervienza nellTnfarto miocardico (GISSI) (GISSI,
1999); Heart Outcomes Prevention Evaluation (HOPE) (Yusuf et al., 2000); 
Secondary Prevention with Antioxidants of Cardiovascular disease in End-stage renal 
disease (SPACE) (Boaz et al., 2000), Antioxidant Supplementation in Atherosclerosis 
Prevention (ASAP) (Salonen et al., 2000), and Heart Protection study (HPS, 2002). 
The short description of the trials shows that each one has its inherent problems and 
that the trials are not easily compared. Taken together, the results are inconsistent. To 
properly interpret the results, the major differences between the studies must be 
considered such as selection of individuals, age, the mode of intake of vitamin E and 
dosage and chemical form of vitamin E (Table 1.8) (Brigelius-Flohe et al., 2002).
The following reasons could explain why these studies do not support the antioxidants 
hypothesis:
1. A lack of power to detect associations between antioxidants intake and CHD risk
2. Misclassification of antioxidant intake
3. Unsatisfactory control for potential confounding factors
4. An inability to investigate subpopulations
5. The habitual diet of subjects in the study may not have been low for the 
antioxidants under study
6. Not all antioxidants have an equivalent protective effect within the plaque
1.8.1.3 Prospective clinical trials
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7. Oxidation may only be involved at an early stage of atherosclerosis and it may be 
too late to reverse it
8. Antioxidants may be unable to access the necrotic core of the plaque, or even if 
they do they may not be effective in preventing lipid oxidation.
9. Some methodological factors may have masked associations or caused artificial 
associations (Knelct et al., 2004);
a) Possible changes in dietary habits during the study
b) Lack of or limited information on particular dietary (eg, iron) and lifestyle factors
c) Adjustment for certain nutrients may have caused overadjustment
d) Methodological issues related to the dietary questionnaire and to the estimation of 
nutrient intakes may have affected the results
e) The oxidative balance between prooxidants and antioxidants may affect 
antioxidant efficiency (Block et al., 2002; Van Hoydonck et al., 2002). Because 
polyunsaturated fatty acids are sensitive to oxidation and may increase the 
formation of free radicals, the intake of polyunsaturated fatty acids may modify 
the associations between antioxidant vitamins and CHD risk (Kardinaal et al., 
1995).
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It has been reported that vitamin E supplementation in patients with existing CHD 
may have a beneficial effect in preventing new M I and delaying the progression of 
arterial damage. It is unclear whether vitamin E is of any benefit in delaying or 
preventing restenosis in patients who have undergone coronary angioplasty (Hodis et 
al., 1995; Stephens et al., 1996). It has been suggested that antioxidants including 
vitamin E may be of value in limiting the oxidative damage to the heart muscle that 
occurs during ischaemia-reperfusion. There is as yet no conclusive evidence that 
vitamin E can help to counteract ischaemia-reperfusion injury in humans.
1.8.2 Vitamin C
Vitamin C is a water-soluble antioxidant that is considered superior to other water- 
soluble antioxidants in protecting lipoproteins in plasma from oxidative damage in 
vitro (Frei, 1991). Vitamin C also protects endogenous lipid-soluble antioxidants from 
oxidative damage as well as influencing the production of prostacyclin, nitric oxide 
and the catabolism of cholesterol (Taddei et al., 1998). Vitamin C is also necessary for 
hydroxylation reactions involved in the synthesis of collagen and other important 
biochemical reactions (Frei, 1991). Simon et al (2001) have shown that low serum 
ascorbic acid concentration was weakly associated with an increased risk of fatal 
CHD and significantly associated with an increased risk for all-cause mortality (Frei, 
1991; Simon et al., 2001).
1.8.3 Antioxidants as pro-oxidants
In some circumstances, vitamin E and vitamin C act as pro-oxidants. This prooxidant 
effect has been widely proposed for explaining the failure of antioxidant vitamins to
1.8.1.4 Studies in patients with existing CHD
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prevent CHD in clinical trials (Landmesser and Harrison, 2001; Meagher et al., 2001; 
Neuzil et al., 2001).
As a chain breaking antioxidant within the lipoprotein, vitamin E reacts with a lipid 
peroxyl radical in a single electron reaction resulting in a vitamin E radical (Figure
I.12). This breaks the chain reaction of lipid peroxidation. If  the vitamin E radical 
reacts with a second peroxyl radical or with another vitamin E radical, the reaction 
comes to termination (Kamal-Eldin and Appelqvist, 1996). Alternatively, studies in 
vitro, ex vivo and with liposomes indicate that vitamin E may act as a prooxidant that 
facilitates rather than terminates lipid peroxidation (Neuzil et al., 1997; Neuzil et al., 
2001). This prooxidant effect occurs more readily under conditions of:
10. Low free radical flux when relatively few aqueous radicals are colliding with the 
lipoprotein (Neuzil et al., 1997).
I I .  The presence of transition metals. Especially, when the metals are in low 
concentrations relative to the concentration of vitamin (Santanam and 
Parthasarathy, 1995), and when the concentration of vitamin E in the lipoprotein is 
very low or the initial level of hydroperoxides in the lipid is high (Kamal-Eldin 
and Appelqvist, 1996).
Vitamin C at low concentrations can also undergo a one-electron reaction to form an 
ascorbyl radical (Figure 1.12). It has been shown that, in the presence of transition 
metals, vitamin C can readily switch from an antioxidant to a prooxidant (Buettner 
and Jurkiewicz, 1996; Frei, 1991). Buettner and Jurkiewicz reported that high 
concentrations of transition metals will increase pro-oxidation by vitamin C (Buettner 
and Jurkiewicz, 1996). Other small water-soluble antioxidants behave similarly in 
vitro (Abudu et al., 2004).
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Figure 1.12 Supplemental co-antioxidant recycling of vitamin E and vitamin C. Under 
normal conditions and in blood, potentially toxic vitamin E and vitamin C radicals can 
be depleted by cellular recycling mechanisms, as illustrated. Species within the 
arterial wall spaces may not have adequate access to these mechanisms. As a result, 
prooxidative conditions may be encouraged. As illustrated, under these conditions, the 
introduction of additional vitamin E or vitamin C may lead to an increase in radical 
production due to tocopherol-mediated peroxidation and transition metal catalysis. 
Asc, ascorbic acid; LOOH, lipid peroxide; LOO', lipid peroxyl radical (Abudu et al., 
2004).
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1.9 Management of dyslipidaemia
1.9.1 Dietary advice
Eating sufficient essential nutrients, together with energy intake in balance with 
energy expenditure, is essential to maintain health and to prevent or delay the 
development of CHD. The consumption of at least 2 fish servings per week is 
recommended because of increasing evidence for the cardiovascular benefits of 
omega-3 PUFA in fish (Krauss et al., 2000).
The American Heart Association strongly recommends the consumption of at least 5 
servings per day of a wide variety of fruits and vegetables. Most fruits and vegetables 
have a high content of antioxidants and fibre, and are relatively low in calories, and 
hence they have a high nutrient density (Joshipura et al., 1999). They also have high 
water content and hence a low energy density, which assist in weight control (Rolls et 
al., 1999).
The consumption of at least 6 seivings per day of a variety of grain products, 
including whole grains, is recommended. Grain products provide complex 
carbohydrates, vitamins, minerals and fibre. Similar to fruits and vegetables, high 
intakes of grain products and fiber have been associated with decreased risk of CHD 
(Assmann et al., 1999; Pietinen et al., 1996). Foods high in starches (polysaccharides) 
such as bread, pasta, cereal and potatoes are recommended over sugar (mono- and 
disaccharides) (Jacobs, Jr. et al., 1998; Pietinen et al., 1997). Dietary fibre may 
promote satiety by slowing gastric emptying and helping to control caloric intake and 
body weight (Anderson et al., 1994).
The major emphasis for weight loss should be on avoidance of excess total energy 
intake and regular physical activity. The American Heart Association guidelines 
recommend fat intake < 30% of total energy intake with limitation of dietary saturated
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fat to < 10% of energy and cholesterol to <300 mg/d. The specific dietary intake of an 
individual should be based on these serum lipid levels and whether the individual has 
existing coronary risk factors (Bray and Popkin, 1998; Krauss et al., 2000; Lissner 
and Heitmann, 1995).
The consumption of vegetables, fruits, low-fat dairy products, salt intake < 6g/day and 
no more than 2 units alcohol per day for men and 1 unit for women has a major 
benefit on blood pressure (Krauss et al., 2000).
1.9.2 Drug treatment
In reality the final decision for treatment of dyslipidaemia can only be made after 
assessing the risks and benefits. Age, the presence or absence of CHD and the level of 
cholesterol or triglyceride must obviously all be taken into account.
To bring some form of simplification into their classification, lipid-lowering drugs 
can be divided into two groups:
B) Drugs that lower serum cholesterol mainly
HMG-CoA reductase inhibitors: e.g. simvastatin and pravastatin
Statins are effective lipid-lowering agents and widely used in the management of
coronary risk. They block cholesterol synthesis being competitive inhibitors of 3-
hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase, an enzyme crucial for
cholesterol synthesis (Aquilani et al., 1999). Several primary and secondary
prevention trials have demonstrated their efficacy in reducing LDL cholesterol
(Collins et al., 2003; The Scandinavian Simvastatin Survival Study (4S), 1994), and
their success in reducing coronary events (Collins et al., 2003; The Scandinavian
Simvastatin Survival Study (4S), 1994). However a debate has ensued as to whether
the benefits of statin therapy are entirely due to their cholesterol-lowering properties,
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or whether other ’pleiotropic' effects also have a role (Collins et al., 2003; Davignon 
and Laaksonen, 1999).
Several studies have demonstrated that statins have anti-inflammatory properties, 
reducing the inflammatory cell content and cytokine expression by plaque cells 
(Davignon and Laaksonen, 1999; Shimizu et al., 2003). A number of studies have also 
demonstrated that statin reduces levels of serum CRP, and it appears that this is a dose 
dependent effect (Ilian et al., 2004; Leibovitz et al., 2004; Sommeijer et al., 2004). 
Other investigators have reported that statins have anti-oxidant properties, protecting 
LDL from being oxidized and hence preventing the deleterious effects of oxidatively- 
modified LDL (Pereira et al., 2004; Kowalski et al., 2004). By doing so, statins may 
reduce the immune response to oxidatively-modified LDL. However there have also 
been reports of direct immunomodulatory effects of statins including an effect on 
lymphocyte function (Raggatt and Partridge, 2002b) and decrease CD40 expression in 
vascular cells in vitro and in vivo (Mulhaupt et al., 2003). They also act as direct 
inhibitors of induction of MHC-II expression by interferon-6 (IFN-5) and thus as 
repressors of MHC-II-mediated T-cell activation (Kwak et al., 2000).
Statins appear to restore or improve endothelial function through their effects on the 
bioavailability of nitric oxide; thereby promoting re-endothelialization, reducing 
oxidative stress, and inhibiting inflammatory responses (Wolfrum et al., 2003).
Statin therapy improves cardiac function, neurohormonal imbalance, and symptoms 
associated with idiopathic dilated cardiomyopathy irrespective of serum cholesterol 
levels or atherosclerotic heart disease (Node et al., 2003).
Ezetimibe
Ezetimibe is the first drug that specifically blocks absorption of intestinal cholesterol. 
This action effectively reduces plasma LDL-C levels, because intestinal absoiption
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may account for up to 50% of the cholesterol found in the circulating lipoproteins 
(Sudhop and von Bergmann, 2002). Ezetimibe inhibits as much as 54% of all 
intestinal cholesterol absorption without affecting uptake of triglycerides or lipid- 
soluble vitamins (Sudhop and von Bergmann, 2002).
Coadministration of ezetimibe and a statin reduces both intestinal cholesterol 
absorption and hepatic cholesterol synthesis, resulting in a significant reduction of the 
plasma LDL-C level (Denke, 2003). The coadministration of ezetimibe (10 mg/d) and 
simvastatin (10 mg/d) has been shown to reduce LDL-C as effectively as monotherapy 
with simvastatin (80 mg/d) and has been well tolerated (Davidson et al., 2002).
Bile acid exchange resins: e.g. cholestyramine and colestipol
These drugs reduce LDL cholesterol by up to 30%, increase HDL cholesterol slightly 
and decrease triglyceride a little.
The mechanism of their action is that they bind with bile salts in the gut and prevent 
bile salt from being reabsorbed.
Probucol
Probucol reduces LDL cholesterol by up to 15%, but unfortunately it can also reduce 
HDL cholesterol, thus limitating its usefulness. The mechanism of action is unclear, 
but it may lead to catabolism of LDL by being somehow incorporated into the central 
lipid core of lipoproteins (Godfrey and Shepherd, 1990).
C) Drugs that lower both cholesterol and triglyceride
Fibric acid derivatives: e.g. clofibrate, bezafibrate, fenofibrate and gemfibrozil 
Fibrates decrease both the levels of cholesterol and triglyceride and increase the level 
of HDL. These drugs increase the activity of the enzyme lipoprotein lipase leading to 
an increase in the breakdown of triglyceride. Fibrates may also reduce cholesterol 
synthesis through a non-specific inhibition of HMG-CoA reductase.
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Fibrates activate peroxisome proliferator activated receptor- a (PPAR-a). This 
changes the transcription of genes involved in lipid metabolism, increasing HDL and 
reducing triglycerides (Fruchart et al., 1999). Newer fibrates, such as fenofibrate, have 
been shown to reduce LDL and the proportion of small, dense LDL particles 
(Lemieux et al., 2002).
Nicotinic acid derivatives: e.g. nicotinic acid, nicofuranose, acipimox 
These drugs are potentially very effective drugs at reducing both cholesterol and 
triglyceride, but their level of side effects is significant at truly therapeutic doses. 
Acipimox may have reduced this problem. They have a number of effects including 
inhibiting the release of fatty acids from adipose tissue and hormone-sensitive lipase 
(Godfrey and Shepherd, 1990).
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C H A P T E R  2
A i m s
I. It is proposed that traditional coronary risk factors including features of 
metabolic syndrome are associated with an abnormality of trace element 
metabolism and vitamin E status. Trace elements such as zinc, copper and 
selenium are of particular interest because they are essential components of the 
enzymes, which have a potential protective role in CHD such as antioxidant 
enzymes, glutathione peroxides, superoxide dismutase, and catalase, but are 
also possibly implicated in lipid oxidation (Craig et al., 1995; Ferns et al., 
2000b; Rayman, 2000; Singh, 1992c).
II. There is a heightened state of inflammation and autoimmunity in subjects with 
traditional coronary risk factors including features of the metabolic syndrome 
that is associated with a) elevated levels of CRP and b) raised antibody titres 
to heat shock proteins.
Atherosclerotic lesions contain macrophages at all stages of their development 
(Ross, 1993). This and other evidence has led to the notion that atherosclerosis 
is a chronic inflammatory disease (Metzler et al., 1998).
To our knowledge, there have been no studies evaluating the association 
between antibody titres to Hsps and individual coronary risk factors or features 
of metabolic syndrome. The measurements of serum hs-CRP would not only 
allow us to confirm recent data from others on serum hs-CRP and features of 
metabolic syndrome, but also allow us to better interpret some of our other 
data such as serum copper and caeruloplasmin in our subjects.
2. Aims
2.1 Hypotheses
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2.2.1 General aims
• To evaluate established, novel, and putative serum coronary risk markers in 
patients with traditional coronary risk factors including features of metabolic 
syndrome, comparing these subjects with healthy controls.
• To evaluate the effects of diet and statin therapy on these coronary risk factors.
2.2.2 Specific aims
In patients with traditional coronary risk factors including features of the metabolic
syndrome and control subjects:
I. To investigate the antibody titres to heat shock proteins (i.e. Hsp60, Hsp65, 
and Hsp70).
II. To investigate the serum trace element status (i.e. zinc, copper and selenium).
III. To assay serum vitamin E concentrations.
IV. To investigate the dietary intake of macro and micronutrients by food 
frequency questionnaire in patients with traditional coronary risk factors 
including features of the metabolic syndrome and control subjects.
V. To evaluate the effects of reported macro and micronutrients intake on trace 
element status, anti-Hsps titres and vitamin E concentrations.
VI. To evaluate the effects of statin treatment on trace element status, anti-Hsps 
titres and vitamin E concentrations.
2.2 Aims
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C H A P T E R  3
M a t e r i a l s  a n d  M e t h o d s
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3.1 Anthropometric measurements
3.1.1 Body Mass Index (BMI)
All subjects had height in centimetres measured without shoes and weight in 
kilograms measured wearing light clothes on a stand-on bioelectrical impedance 
analyser (BIA) (see appendix-1 for details of the equipment). BMI was calculated by 
the formula: BMI = weight (kg)/height (m)2.
3.1.2 Waist/Hip Ratio (WHR)
Subjects stood comfortably, feet 25-30 cm apart and the waist measurement was taken 
midway between the lower margin of the last rib and the crest of ileum, in the 
horizontal plane. Subjects were asked to breath normally, and to breath out gently at 
the time of the measurement to prevent them from contracting their muscles or from 
holding their breath. The hip circumference measurement was taken at the point 
yielding the maximum circumference over the buttocks. The readings were taken to 
the nearest millimetre (Bjomtorp, 1992).
3.1.3 Body fat percentage (%BF)
Percent body fat was estimated using a bioelectrical impedance analyser (BIA). 
Bioelectrical impedance measurement devices have recently become widely available. 
These devices are thought to provide an objective and reliable measure of body fat 
(Schulte et al., 1999), and their use in clinics and by patients is increasing. There are 
few data on the precision of these instruments, and the biological factors that affect 
the measurement of bio-impedance (Frisancho and Flegel, 1982).
Fifteen healthy men and fifteen healthy women were recruited from the School of 
Biomedical and Molecular Sciences, the University of Surrey (Table 3.1).
3. Materials and Methods
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Table 3.1 Characteristics of the subjects in the evaluation
Male (n=15) Female (n=15)
Age (years) 36.07±2.48 32.93+2.88
Height (cm) 171.60+1.74 160.5311.32
Weight (kg) 73.62±3.16 61.3512.65
Body fat (%) (Stand-on device) 19.0111.63 26.8612.06
BMI (kg/ms) 24.9810.98 24.6711.10
Waist/hip ratio 0.87+0.01 0.7710.01
Values expressed as Mean ± SEM
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Bioelectrical impedance measurements were made using the Tanita-305 stand-on 
body-fat analyser (Tanita Corp., Tokyo, Japan) and the Roman hand-held body-fat 
analyser (Bodystat-1500, Bodystat Ltd, Isle of Man, UK). Measurements were made 
four times during the working day; at baseline, after consumption of a meal 
(sandwich), after drinking a glass of water and following gentle physical activity 
(climbing stairs). At each time point, these measurements were repeated three times 
using each device. These investigations were repeated on three separate days to 
determine variation with time.
The precision of both instruments was good (CV was <1%), and in both cases 
percentage body fat was significantly higher in women (p<0.05). Although there was
ft
a good correlation between values obtained by the two devices (R > 0.8, /K0.0001), 
the hand-held device gave results that were consistently higher than the stand-on 
device in both men and women (p<0.05, Table 3.2).
The body fat estimates using either device were strongly related to BMI in both men 
and women (R2 > 0.8, /K0.0001). However the association with waist/ hip ratio was 
weak [0.16<R2 <0.31, in males (p<0.05) and females (p>0.05)].
Both machines were sensitive to physiological factors. With the hand-held device 
body fat estimates were affected significantly by consumption of food or beverage (by 
up to 2.6%, /K0.05). With the stand-on device, there was a significant decrease in 
body fat estimation after exercise (by up to 1.9%,/K0.05) (Table 3.2).
Both instruments assessed for measuring body fat by biojmpedance showed good 
precision. However, they appear to be sensitive to physiological factors, such as 
exercise and food intake with an effect of up to 2.6% on the % body fat estimation. 
The values obtained were also consistently higher for the hand-held machine in both 
men and women (/K0.0001). Hence we concluded that these measurements should be
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made under constant conditions, preferably fasted, before exercise and the same 
device should be used for any follow up. However, BIA had bias towards the limbs. 
We use the BIA for estimating adiposity, because they have a good precision (CV% 
<1%), cheap and rapid.
Table 3.2 Percentage body fat measurements in fifteen male and female subjects using 
two different BIA machines, during the morning and then after exercise, drinking and 
food
Machine Gender Baseline After Exercise After Drink After Food
STAND-
ON
Male 19.01 ±1.67 18.88 ± 1.64* 18.97 ±1.64 19.19 ± 1.60
Female 27.20 ± 2.07 26.75 ±2.12* 26.67 ± 2.05* 26.83 ± 2.02
HAND­
HELD
Male 20.78 ± 1.57 20.91 ±1.56 21.04 ± 1.59* .21.32 ± 1.59*
Female 27.52 ± 1.75 27.61 ± 1.74 27.94 ±1.74* 28.06 ± 1.76*
Values expressed as Mean ± SEM. * = p<0.05 comparison between baseline and after 
exercise, drink or food by using paired t-test.
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3.1.4 Blood pressure
Blood pressure was measured in patients and healthy controls at the Clinical 
Investigation Unit at the Royal Surrey County Hospital, Guildford using an automated 
sphygmomanometer (see appendix 1 for details of equipment).
3.1.5 Blood samples
Ten ml of venous blood was drawn into a 5 ml EDTA tube (BD Biosciences) for 
plasma and into a 5 ml plain tube (BD Biosciences) for serum from all subjects. The 
blood samples were centrifuged at 1000 X g for 15 minutes at 4°C. After separation, 
both serum and plasma were aliquoted and frozen at -80°C.
3.2 Standard blood measurements
3.2.1 Fasting plasma glucose
Plasma glucose concentrations were measured routinely on a Bayer ADVIA 1650 
auto-analyser using the Hexokinase (II) method. The principle of the procedure is that 
ATP phosphorylates glucose in the presence of hexokinase (HK). The glucose-6- 
phosphate that forms is oxidised in the presence of glucose-6-phosphate 
dehydrogenase causing the reduction of NAD to NADH. The absorbance of NADH is 
measured as an endpoint reaction at 340 nm (Tietz, 1995).
ATP, HK Glucose-6-phosphate dehydrogenase
The sample was added to reagent 1, which contained the buffer, adenosine 
triphosphate (ATP), and NAD. Absorbance readings of the sample in reagent 1 were 
taken and were used to correct for interfering substances in the sample. Reagent 2 was
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added, which initiated the conversion of glucose to Glucose-6-phosphate (G6P), the 
generation of NADH at the change in absorbance at 340 nm. The difference between 
the absorbance in reagent 1 and reagent 2 was proportional to the glucose 
concentration (Tietz, 1995).
The within assay and between assay precision were 1 %, and 2.1 % respectively.
3.2.2 Fasting lipids
3.2.2.1 Triglycerides
Triglycerides were measured routinely using a method based on the Fossati three-step 
enzymatic reaction with a Trinder endpoint. This single-reagent procedure quantitated 
the total triglycerides including the mono and diglycerides and the free glycerol 
fractions (Fossati and Prencipe, 1982; Trinder, 1969).
The principles of the procedure are that the triglycerides are converted to glycerol and 
free fatty acids by lipoprotein lipase. The glycerol is then converted to glycerol-3- 
phosphate by glycerol kinase, which then, in the presence of glycerol-3-phosphate- 
oxidase, forms dihydroxyacetone and hydrogen peroxide. A coloured complex is 
formed from hydrogen peroxide, 4-aminophenazone and 4-chlorophenol under the 
catalytic influence of peroxidase. The absorbance of the complex is measured as an 
endpoint reaction at 505 nm (Tietz, 1995).
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Lipase
Triglyceride + 3 H20  [ Glycerol + 3 fatty acid
Glycerol kinase
Glycerol + ATP [ glycerol 3-phosphate + ADP
Glycerol 3-phosphate oxidaseLdas
oGlycerol 3-phosphate + 0 2 [ dihydroxyacetone + H20 2
Peroxidase
H20 2 + phenol + 4-aminophenazone j- quinoneimine dye + 2H2Q
The within assay and between assay precision were 1.1 %, and 1.7 % respectively.
3.2.2.2 Cholesterol
The routine cholesterol method used was based on an enzymatic procedure of Trinder 
(Trinder, 1969). The principles of the procedure are that the cholesterol esters are 
hydrolysed by cholesterol esterase to cholesterol and free fatty acids. The cholesterol 
is converted to cholesterol-3-one by cholesterol oxidase in the presence of oxygen, 
with the formation of hydrogen peroxide. A coloured complex is formed from 
hydrogen peroxide, 4-aminophenazone and phenol under the catalytic influence of 
peroxidase. The absorbance of the complex is measured as an endpoint reaction at 505 
nm (Trinder, 1969; National Cholesterol Education Program, 1988).
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Cholesteryl ester hydrolase
Cholesteryl ester + H 20  ^ Cholesterol + fatty acid
Cholesterol oxidase
Cholesterol + 0 2 [ Cholesterol-3-one + H2Q2
Peroxidase
H20 2 + phenol + 4-aminophenazone [ quinoneimine dye + 2H20
The within assay and between assay precision were 1 %, and 1.8% respectively.
3.2.2.3 HDL-cholesterol
The HDL II cholesterol method measured HDL cholesterol in serum without prior 
separation, based on a procedure developed by Izawa et al. (Izawa et al., 1997). 
Cholesterol from non-HDL particles is released and eliminated in the first step of the 
reaction. Cholesterol in HDL particles is subsequently released in the second step by a 
detergent in the reagent made from buffer 100 mmol/L (pH 7.0), 4-amino antipyrine 4 
mmol/L, peroxidase >4KU/L, and sodium azide 0.09% (w/v), and the HDL 
cholesterol was measured by a Trinder endpoint (Trinder, 1969).
The within assay and between assay precision were 0.6 %, and 2.4 % respectively.
3.2.2.4 LDL-cholesterol
TUT- was calculated from the value of total cholesterol, HDL-cholesterol and 
triglyceride using the Friedwald formula equation (Friedwald et al., 1972) (This 
calculation cannot be used for triglyceride > 4mmol/L, because the equation deviates 
from the values obtained by ultracentrifugation):
LDL-cholesterol = Total cholesterol - [Triglyceride/2.2 + HDL-cholesterol]
3.2.3 Serum high sensitivity CRP
The method measures CRP in human serum by a latex-enhanced 
immunoturbidimetric assay on the AD VIA® 1650 chemistry system. It is based on the
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principle that the analyte concentration is a function of the intensity of scattered light 
caused by the latex aggregates. The latex particles coated with CRP rapidly link 
together in the presence of CRP antibody solution to form aggregates (Claus et al., 
1976).
The CRP latex reagent is a suspension of uniform polystyrene latex particles coated 
with anti-CRP antibody. When serum containing CRP is mixed with the latex reagent, 
agglutination takes place resulting in an increase in the turbidity. This turbidity can be 
measured at 550 nm. The CRP concentration in serum is determined from a 
calibration curve that is obtained using commercial calibrators (Claus et al., 1976). 
The CV% for both within assay and between assay were <1 %. The linearity of this 
assay confirmed the amount of serum CRP concentration up to 160 mg/L.
Limitation of serum CRP evaluation
There are several limitations of serum CRP measurements, which require 
consideration: (1) inflammatory markers are non-specific, increase with trauma or 
acute infection, and have been reported to predict total mortality as well as 
cardiovascular events. Although the subjects having overt inflammatory disorders 
were excluded from the present study, the influence of minor inflammatory conditions 
may not have been completely eliminated. (2) The utility of serum CRP evaluation 
across different ethnic groups is unknown. (3) Although the data relating serum CRP 
to CHD risk in healthy populations are consistent, this does not mean the association 
will held in patients at CHD risk (Ridker et al., 2000). A sensitive, reliable assay for 
circulating IL-6 and CRP levels is now available. In contrast to results for cytokines 
such as IL-6, no circadian variation appears to exist for serum CRP (Ewart et al.,
2001). Thus clinical testing for serum CRP can be accomplished without regard for 
time of day.
/
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Each patient and control subject gave informed written consent to participate in the 
study, which had previously been given approval by the South-West Surrey Research 
Ethics Committee (EC35/02) and The Surrey University’s Advisory Committee on 
Ethics (AEC/2002/26/SBLS).
Dyslipidaemic patients
Two hundred and thirty-seven patients were recruited from the Lipid clinics at the 
Royal Surrey County Hospital. The sample size of our study has been calculated by 
using a nomogram using a p value of <0.05 with a power of between 80% and 90% as 
described by Altman (Altman DG, 1982). These patients were chosen because they 
had high frequency of traditional coronary risk factors including obesity (35%), type 2 
diabetes (18%), hypertension (79%) and positive smoking habit (18%) in the patient 
group, which are typical of a Lipid Clinic population.
None of patients and healthy subjects has given detailed dietary advice. However, the 
patients have routinely received general dietary advice. These advices include 
encouraging the patients to eat at least 5 portions fruits and vegetables per day, 2 
portions fish per week, and reduce their dietary fat as much as possible.
The lists and percentage of patients who were taking drugs include: statins (75%), 
fibrates (74%), nicotinic acid derivatives (2%), bile acid resins (10%), diuretics 
(13%), beta blockers (20%), calcium channel blockers (12%), ACE inhibitors (17%), 
vasodilators (1%), metformin (12%), gliclizide (9%), aspirin (39%), thyroxin (9%), 
allopurinol (5%), hormone replace therapy (9%), vitamins and minerals (22%), fish 
oil (13%), and garlic (6%). Taking vitamin and mineral supplementats did not differ 
between patients and controls.
3.3 Subjects
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Table 3.3 Clinical characteristics of patients and controls
Patients
n (%) 
237
Obese (Body mass index >30) 82 (35%)
Diabetes type 2 (Fasting blood glucose >7 mmol/L) 42 (18%)
Duration of treatment for diabetes (months) 13 (0-51)
Established coronary heart disease 55 (23%)
Unstable angina 9 (4%)
Myocardial Infarction (MI) 15 (6%)
Coronary Artery Bypass Graft (CABG) 10 (4%)
Angioplasty 13 (6%)
Angioplasty or CABG after M I 8 (3%)
Hypertension 186 (79%)
High BP (SBP>160 mmHg or DBP>100 mmHg)* 76 (32%)
Duration of treatment for hypertension (months) 7.5 (0-72)
Moderate BP (SBP 130-160 mmHg or DBP 85-100 mmHg) 110(46%)
Duration of treatment for hypertension (months) 0.0 (0-46)
Hypertriglyceridaemia (Serum triglycerides >1.8 mmol/L) 176 (74%)
Hypercholesterolaemia (Serum total cholesterol >5.2 mmol/L) 216 (92%)
Duration of statin therapy (months) 9.0 (0-43)
Duration of fibrate therapy (months) 0.0 (0-16)
Calculated 10-year coronary risk >30% 42 (18%)
(Calculated using the PROCAM algorithm (Assmann et al., 2002)) 
Calculated 10-year coronary risk between 20 and 30% 54 (23%)
Metabolic syndrome
(as defined using NCEP-ATP III criteria (NCEP, 2001)) 142 (60%)
Controls 189
Normal subjects 135 (71%)
Excluded subjects 54 (29%)
Obese 33 (18%)
Metabolic syndrome 9 (4%)
Taking medications 12 (5%)
Values are expressed as median and interquartile range for duration of treatment, 
* Systolic and Diastolic Blood Pressure; SBP and DBP
92
Eighty-two of the patients were obese (with a BMI>30); forty-two were diabetic (as 
defined by a fasting plasma glucose >7mmol/L); 55 had established coronary heart 
disease (CHD), and 186 were hypertensive. Of the latter, 76 had a systolic blood 
pressure (SBP) > 160mm.Hg or a diastolic blood pressure (DBP) >100 mmHg (high 
BP). One hundred and ten patients had a SBP between 130 and 160 mmHg or a DBP 
between 85 and 100 mmHg (moderate BP). One hundred and seventy six patients 
were hypertriglyceridaemic (with serum triglycerides >1.8 mmol/L) and 216 patients 
were hypercholesterolaemic (serum total cholesterol >5.2 mmol/L). Forty-two of the 
patients had calculated 10-year coronary risk (calculated using the PROCAM 
algorithm (Assmann et al., 2002)) >30%, 54 had calculated 10-year risk of between 
20%-30%. One hundred and forty two patients had metabolic syndrome as defined 
using ATP III criteria (NCEP, 2001).
Patients with a history of established CHD included 9 with unstable angina, 15 who 
had a history of a myocardial infarction (MI), which were diagnosed by cardiologist 
based on changing in electrocardiogram (ECG) and heart enzymes, 10 with a history 
of coronary artery bypass graft (CABG), 13 of angioplasty. Fifteen additional patients 
had CABG after M I and 5 had angioplasty after M I (Table 3.3).
Control subjects
One hundred and eighty-nine apparently healthy controls were recruited from 
amongst employees at the University of Surrey and the Royal Surrey County Hospital, 
Guildford. These subjects were chosen because they lived in the same area of the 
patients, and also they did not have any CHD, diabetes mellitus, and hypertension. Of 
these control subjects, 33 were obese, 9 had metabolic syndrome, and 12 were on 
medication. These 54 controls were excluded from the analysis comparing patients 
and controls.
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As would be expected for patients attending such a clinic, serum fasting triglycerides, 
blood glucose, total- and LDL-cholesterol were significantly higher than for controls. 
Anthropometric indices including waist, waist-hip ratio, BMI, and % body fat were 
also higher in the patients compared to the healthy controls (Table 3.4). Although 
current smoking habit did not differ between patients and control groups, a greater 
proportion of the patients were former smokers (Table 3.4). The mean age of the 
patient group was approximately 6.5 years older than controls (p<0.001), and this 
group had a higher proportion of males (60 % compared with 50 %).
Table 3.5 shows the comparison between obese and non-obese healthy subjects. For 
this comparison the control subjects who were on medication (n=12) or had metabolic 
syndrome (n=9) were excluded.
3.4 Demographic and anthropometric characteristics of the subject groups
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Table 3.4 Clinical and biochemical characterisation of dyslipidaemic patients 
and controls  _____
Group Patients Controls P. Value
n 238 135 —
Age (years)
Mean 55.2+0.86 48.9+1.26 <0.001
Median 57 (46-66) 50 (41-58) <0.001
Male/Female (%) 142/95 (60) 67/68 (50) 0.14
Smoking Habit
Current n (%) 43 (18) 23 (17) 0.90
Former n (%) 84 (35)** 25 (19) <0.001
Body Mass Index (ICg/m2)
Mean 29.1+0.33 24.3+0.25* <0.001
Median 28.2 (25.6-32) 24.5 (22-26.6) <0.001
% Body Fat
Mean 32.5+0.53*** 26.6+0.63*** <0.001
Median 31.7 (26.5-38.3) 26.3 (21.7-31.4) <0.001
Waist circumference 98.1+0.83*** 85.7+0.90*** <0.001
(cm)
Waist: Hip Ratio 0.93+0.01*** 0.86+0.01*** <0.001
Systolic Blood 146.7+1.32 125.2+1.38 <0.001
Pressure (mmHg)
Diastolic Blood 82.1+0.77** 74.7+0.79 <0.001
Pressure (mmHg)
Total cholesterol 7.38+0.12 5.41+0.09 <0.001
(mmol/L)
HDL-cholesterol 1.27+0.03*** 1.70+0.04*** <0.001
(mmol/L)
Triglycerides 2.61 (1.71-4.5)* 1.06 (0.86-1.39)* <0.001
(mmol/L)
Fasting Blood 5.92+0.10 4.99+0.04 <0.001
Glucose (mmol/L)
Values are expressed as mean ± SEM, or median and interquartile range. 
Categorical data were compared by Fisher’s exact tests. Between groups 
comparisons were assessed by Mann-Whitney test for non-normal distribution 
data (serum Triglycerides) and by one-way ANOVA for normally distributed 
data.
*=/K0.05, **=/><0.01, ***=/i<0.001 comparing male and female subjects.
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Table 3.5 Clinical and biochemical characterisation of obese and non-obese subjects 
in the control group_____________________________________________
Group Obese Non-Obese P. Value
n 33 135 —
Age (years) 
Mean 51.29±2.20 48.87±1.26 <0.001
Median 51 (42.8-58) 50 (42-58) <0.001
Male: Female ratio 19/15 (56%) 67/68 (50%) 0.58
Smoking Habit
Current no. (%) 6(18) 23 (17) 1.00
Former no. (%) 16 (48) 25 (19) <0.01
Bodv Mass Index (Kg/m2)
Mean 32.84±0.67 24.29±0.25 <0.001
Median 32.1 (30.3-34.4) 24.5 (22-26.6) <0.001
% Bodv Fat 
Mean 31.09±0.79 26.56±0.63 <0.001
Median 34.5(27.3-41.7) 26.3 (10.1-44.5) <0.001
Waist circumstance 107.25±2.28 85.72+0.90 <0.001
(cm)
Waist: Hip Ratio 0.95+0.02 0.86±0.01 <0.001
Systolic Blood 137.71+3.31 125.22±138 <0.001
Pressure (mmHg) 
Diastolic Blood 81.94+1.73 74.73±0.79 <0.001
Pressure (mmHg) 
Total cholesterol 5.62±0.16 5.41+0.09 0.28
(mmol/L)
HDL-cholesterol 1.43±0.05 1.70±0.04 <0.01
(mmol/L)
Triglycerides 1.63 (1.71-4.5) 1.06 (0.86-1.39) <0.001
(mmol/L) 
Fasting Blood 5.45±0.15 4.97±0.04 <0.001
Glucose (mmol/L) 
Calculated 10 year 
Coronary Risk (%) 9.18±0.1.17 5.99+0.42 <0.01
Values are expressed as mean ± SEM, or median and interquartile range. 
Categorical data were compared by Fisher’s exact tests. Between groups 
comparisons were assessed by Mann-Whitney test for non-normal distribution 
data (serum Triglycerides) and by one-way ANOVA for normally distributed 
data.
96
3.5 Special analytical biochemical methods
3.6.1 Plasma anti-Hsps titres by ELISA
Plasma antibody titres against Hsps were measured using ELISA assays (Xu et al., 
1993). Microtitre plates (Nunc Maxisorp, Nunc) were coated with lOng per well 
recombinant human Hsp-60, Hsp-65 or Hsp-70 dissolved in 100 pi phosphate 
buffered saline (PBS) incubated for 18 hours at 4°C under humidified conditions 
(Figure 3.1, part 1). The wells were washed 3 times in wash buffer (PBS containing
0.05% Tween-20). Non-specific binding was reduced by blocking each well with 
Superblock® blocking buffer in PBS (Pierce& Warriner, Chester, Cheshire, UK) for 1 
hour at 37°C. Wells were washed 3 times with wash buffer. Plasma was diluted 1:15 
with PBT (PBS containing 0.1% Tween-20 and 1% bovine serum albumin) and lOOpl 
added to the coated wells in quadruple and incubated for 30 min at 37°C (Figure 3.1, 
part 2). After washing, peroxidase conjugated-goat anti-human IgG (Sigma Sigma- 
Aldrich, INC., USA) was added to the wells diluted 1:100 with PBT (Figure 3.1, part 
3). One hundered pi of o-phenylenediamine substrate (0.04%), (dissolved in 0.05M 
citrate/0.1M phosphate buffer pH 5 containing lOpl H20 2 per 25ml), was added per 
well and plates incubated at room temperature for 5 min. The reaction was terminated 
by adding 50pl 3M HC1 per well (Figure 3.1, part 4). Optical density at 492nm was 
measured using a Labsystems iEMS Reader MF microtitre plate reader with Genesis 2 
software (Life Sciences, Basingstoke, Hampshire, UK) (see appendix 1 for details of 
equipment and appendix 2 for suppliers of reagents).
Precision of plasma anti-Hsps titres
The plasma Hsp60 antibody titres were measured in replicate wells of a single 96-well 
plate for within assay precision, and 20 samples were assessed on 20 different plates
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for reproducibility between assays. The within assay and between assay precision was 
3.5% and 6.3% respectively.
Figure 3.1 ENZYME LINKED IMMUNOSORBENT ASSAY
Peroxidase-conj ugated 
Detector Antibody
Substrate
C oloured
Product
1 2  3 4
1. Microtitre plates were coated with 1 Ong recombinant human Hsps in PBS per well 
and incubated for 18 hours at 4°C under humidified conditions.
2. Plasma was diluted 1:15 with PBT and lOOpl added to each well and then 
incubated for 30 min at 37°C to allow the binding of endogenous anti-Hsp IgG to 
the bound Hsp antigens.
3. Peroxidase-conjugated goat anti-human IgG, the secondary antibody was added, 
which binds to the endogenous anti-Hsp IgG.
4. O-phenylenediamine (0.04%) in phosphate buffer was added to each well and 
incubated at room temperature for 5 min to give a coloured product. The reaction 
was terminated by adding 50pl 3M HC1 and the absorbance at 492nm measured in 
a plate reader.
98
Serum zinc and copper concentrations were determined by flame atomic absorption 
spectrometry (AAS). In order to make measurements by AAS, it is necessary to 
produce a population of ground state atoms as efficiently as possible and to pass 
resonance radiation of the element to be measured through the population of atoms. In 
an ideal system the light-measuring component of the system should only measure at 
the wavelength being absorbed, as any other radiation detected will decrease the 
sensitivity of the measurement (Taylor, 1997). Figure 3.2 shows the layout of a basic 
flame atomic absorption spectrometer.
3.6.2 Serum zinc and copper concentrations
Figure 3.2 Basic flame spectrometer (Taylor, 1997)
Light emitted from a line source and having a characteristic wavelength for the 
element being determined passes through the flame into which has been sprayed a fine 
aerosol of the sample solution. The region of the spectrum to be measured is selected 
by a monochromator. The isolated spectral line falls on the photomultiplier, the 
detector, and the output is amplified and sent to a readout device (Taylor, 1997). 
Serum samples were diluted 1 in 5 with water and at this dilution interference of the 
signal by the serum matrix was reduced. Samples were compared, with standards 
prepared in water. This method was developed at the Trace Element laboratory at the 
Robens Institute (see appendix 1 for details of equipment and appendix 2 for suppliers 
of reagents).
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The setting of the spectrophotometer for copper and zinc are shown below:
Copper Zinc
Wavelength 324.7 nm 213.9 nm
Band pass 0.5 nm 0.5 nm
Lamp current 5 mA 7 mA
Chart speed 20 mm/min 20 mm/min
Chart range 20 mV 20 mV
To prepare calibration standards, 654 pi of the zinc stock standard and 637 pi of the 
copper stock standard were diluted to 100 ml with reverse osmosis/ deionised 
(RO/DI) water in a 100 ml acid washed "aged" volumetric flask. A standard curve 
was prepared as shown in the table below:
Concentration (pmol/L) Volume working standard 
(ml)
Volume distilled water 
(ml)
5 0.5 9.5
10 1.0 9.0
20 2.0 8.0
30 3.0 7.0
40 4.0 6.0
The standard samples, patient samples, and quality control specimens were diluted,
0.5 ml with 2.0 ml RO/DI water and mixed well. Each solution was aspirated in turn, 
starting and finishing with the set of standards. The peak heights were measured and 
the concentrations of zinc and copper in the test specimens were derived from the 
standard curves. Figures 3.3 and 3.4 represent one of the standard curves for serum 
zinc and copper respectively.
100
Figure 3.3 Standard curve of serum zinc concentrations
Zinc (micromol/L)
Figure 3.4 Standard curve of serum copper concentrations
Copper (micromol/L)
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Control samples containing low, medium, and high concentrations of zinc and copper 
were measured ten times for reproducibility within assay, and on 10 different days for 
between assay precision. For both within and between assay reproducibility, the 
coefficient of variation (CV%) was calculated (Table 3.6).
Precision o f serum zinc and copper concentrations
Table 3.6 CV% of zinc and copper concentrations within and between assays
Zinc Copper
Low Medium High Low Medium High
Within assay 4.2% 1.9% 0.9% 3.1% 3.2% 1.4%
Between assay 5.3% 4.7% 1.9% 4.2% 5.4% 1.9%
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Both immunochemical and enzymatic methods are used to determine serum 
caeruloplasmin, which is a copper-carrying oxidase. Caeruloplasmin is the major 
copper serum protein; approximately 95% of copper found in serum is present as 
caeruloplasmin. It has six or seven copper atoms per molecule, of which one is 
loosely bound. Most laboratories use immunochemical detection methods. However, 
these techniques do not differentiate between caeruloplasmin and apocaeruloplasmin; 
apocaeruloplasmin being the copper-free precursor molecule. Thus, an enzymatic 
method was chosen for our study.
Principle of the enzymatic method
Caeruloplasmin catalyses the oxidation of p-phenylenediamine (PPD) to yield a 
coloured product at pH 5.4. The rate of formation of the coloured oxidation product is 
proportional to the concentration of serum caeruloplasmin if an appropriate correction 
is made for nonenzymatic oxidation of PPD. Therefore, simultaneous assays are 
carried out with and without sodium azide, which inhibits the enzymatic oxidation of 
PPD. The difference between the results of the two assays is proportional to the 
caeruloplasmin concentration. The PPD-oxidase reaction is subject to a lag phase, 
owing to oxidation of serum ascorbic acid. To avoid this potential source of error, 
timing of the reaction is delayed until after the completion of the lag phase 
(Sunderman, Jr. andNomoto, 1970).
p-phenylenediamine (Reduced form) p-phenylenediamine (Oxidized form)
3.6.3 Serum caeruloplasmin measurement
103
In our study, serum caeruloplasmin was determined as ferroxidase activity using a 
modification of the method of Sunderman and Nomoto (Sunderman, Jr. and Nomoto, 
1970). Briefly 10 pL of serum was added to 200 pL of 0.1M acetate buffer (pH 5.2), 
and 100 pL of PPD in 8 wells of a 96-well plate. Samples were incubated at 37°C and 
the reaction terminated in 4 wells after 5 minutes and the remaining wells after 35 
minutes by adding 5 pL of sodium azide (1.5M). The absorbance was measured at 
525 nm in an iEMS MF plate reader. The caeruloplasmin concentration was 
calculated using the formula: caeruloplasmin concentration (g/L) = 0.752 (Ar-Ab), 
where Ar was the absorbance after 35 minutes (sample reaction) and Ab was the 
absorbance after 5 minutes (sample background). If  caeruloplasmin assay is precise 
(reproducible), then comparisons between groups may be valid. But absolute 
concentrations appear to be inaccurate because of a calibration anomaly.
Precision of serum caeruloplasmin concentrations
The serum caeruloplasmin concentrations were measured in replicate wells of a single 
96-well plate for within assay precision, and 20 samples were assessed on 20 different 
plates on different days for reproducibility between assays. The within assay precision 
was 2.5% and between assay precision was 3.6%.
3.6.4 Serum selenium concentrations
Serum selenium concentrations were determined by electrothermal AAS with Zeeman 
background correction using a palladium chloride chemical modifier (Campillo et al.,
2000). Diluted serum was introduced using an autosampler into the graphite-fumace. 
The instrument was temperature programmed to dry, ash, and atomise the samples at 
controlled rates. The spectrophotometer setting were as follows; atomic number = 34, 
lamp current (max) -11 mA, wavelength =196 nm, mode-multi, resample no.2,
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precision-on, peak area-off, concentration-off, band pass 0.5 nm, background 
correction-on, and uncoated graphite tube (see appendix 1 for details of equipment 
and appendix 2 for suppliers of reagents).
Ascorbic acid reducing agent was made up for each run in a 50mL centrifuge tube by 
combining the following reagents:
1. 0.2642g ascorbic acid
2. 25mL distilled water
3. 50pL Anti-foam B
4. 50pL Triton X -100
This ascorbic acid reducing solution was mixed for 15 minutes on a roller mixer at 
room temperature. The following solutions were pipetted into each sampling cup:
1. 50pL of each sample or standard
2. 50pL of distilled water
3. lOOpL of palladium chloride matrix modifier (Sigma Chemical C. UK)
4. lOOpL of ascorbic acid reducing agent (Sigma Chemical C. UK)
A standard curve was drawn and each reading was compared with this standard curve. 
Figure 3.5 represents one of the standard curves for serum selenium.
Precision of serum selenium concentrations
T estimate the precision of the assy the concentrations of selenium, serum control 
material was measured 20 times on the same ran for within assay precision, and 10 
times on different days for between run precision. The within assay and between 
assay precision was 3.7% and 4.3% respectively.
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Figure 3.5 Standard curve for serum selenium concentrations
Absorption
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Serum glutathione peroxidase (GPx) was measured using a modification of the 
method of Paglia and Valentine (Paglia and Valentine, 1967). Briefly 10 pL of serum, 
standard (0.1-0.3 U/mL purified glutathione peroxidase) or water (blank) were added 
in quadruplicate to a 96-well plate. 290 pL of 0.1 M phosphate buffer containing; 
5mmol/L EDTA, 200pmol/L sodium azide, lU/mL glutathione reductase,
0.86mmol/L NADPH, 2 mmol/L reduced glutathione, and 7.8 pmol/L /-butyl 
hydroperoxide; was added to each well. The reagents were mixed and the absorbance 
at 340 nm measured continuously for 5 minutes in an iEMS MF plate reader.
Precision of serum Glutathione peroxidase
The serum GPx concentrations were measured in replicate wells of a single 96-well 
plate for within assay precision, and 20 samples were assessed on 20 different plates 
for reproducibility between assays. The within assay precision was 3.2% and between 
assay precision was 4.5%.
3.6.5 Glutathione peroxidase assay
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Serum a-tocopherol was determined by HPLC (Ferns et a!, 2000a). Briefly, 200 pL 
internal standard (10 pg/ml 5-tocopherol in isopropyl alcohol) was added to 200 pL 
serum and vortex mixed. Aqueous ammonium sulphate (3.9 M) was added (200 pL) 
and the solution was again vortex mixed. After centrifugation (1000 g for 5 minutes), 
50 pL of supernatant was used for analysis using a Prodigy 50 pm ODS2 (50 x 4.6 
mm) column (Phenomenex Ltd, Macclesfield, Cheshire, UK) with methanol as 
mobile phase, and UV-detection at 294 nm. At a flow rate of 1.0 ml/minute, the 
retention time for internal standard and Vitamin E were 6.6 and 8.7 minutes 
respectively. Vitamin E standard, internal standard (5-tocopherol) and quality control 
material were obtained from BioRad Laboratories Ltd, Hemel Hempstead, UK.
Figure 3.6 represents typical chromatogram.
Precision of serum vitamin E assay
The serum low and high vitamin E control material concentrations were measured 15 
times each within the same analytical batch for intra-assay precision, and on 10 
different days each for inter-assay precision. Precision was expressed as Percent 
Coefficient of Variation (CV %). The intra-assay precision was 4.6%, and 3.9% for 
low and high vitamin E control material concentrations respectively. The inter-assay 
precision was 7.6%, and 6.9% for low and high control vitamin E material 
concentrations respectively.
3.6.6 Serum vitamin E
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Figure 3.6 Chromatogram of vitamin E obtained by HPLC
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There are many ways of estimating dietary intake. None is perfect, and each has 
advantages and disadvantages. The choice of which method to use depends on the 
purpose for which it is required, and will also be constrained by practical issues such 
as cost and available facilities.
3.7.1 Methods for assessment of usual dietary intake
3.7.1.1 Dietary history
Dietary history is used to assess usual diet over the recent past, and was first 
suggested by Turner (1940). This method was later modified by Burke (1947) who 
introduced a three-part assessment: an in-depth interview to estimate the usual 
consumption of foods (24-hour recall); a crosscheck frequency list; and a 3-day 
dietary record. In practice, the three components are rarely used together, although 
recent data suggests that multiple assessments can improve the accuracy of 
classification of subjects according to their level of nutrient intake since a 
nutritionist/dietician is required and the interview can often take 1-2 hours to 
complete (Ocke and Kaaks, 1997).
The advantage of this technique is the quantity of information about eating habits that 
can be obtained from a single interview. However, this method is very dependent 
upon the skill of the interviewer to obtain an objective picture of usual diet, and is 
expensive since an expert nutritionist/dietician is required and the interview can often 
take 1-2 hours to complete (Garrow et al., 2000).
3.7.1.2 Twenty-four-hours recall
Twenty-four-hours recall method is originally attributed to Wiehl (1942) and was 
designed to define and quantify food and drink consumed over exactly 24 hours by a 
trained interviewer using standard forms and visual references. The advantage of this
3.7 Assessment of dietary intake
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technique is that it is quick to administer (10-15 minutes), and only short term recall is 
required (Garrow et al., 2000).
However, this method cannot be used to classify a subject according to their usual 
level of intake due to the large day to day variation. Therefore, 24-hours recall data 
are best suited to estimating the average intake in groups of people (Garrow et al., 
2000).
3.7.1.3 Weighed inventory
The weighed inventory is one of the most widely used techniques. This method 
requires the individual to record a detailed description of the types and amount of 
foods and beverages consumed, meal-by-meal, over a prescribed period of time using 
a set of scales and a food record diary. The time period is usually 3-4 days although a 
4-days weighed record appear to be the minimum for recording an individual’s dietary 
intake accurately (Bingham, 1987).
The accuracy of the measurement of portion sizes and the ability to vary the length of 
the record are the main advantages of this technique. This method was thought to 
provide a reasonably unbiased measure of diet against which the validity of other 
techniques could be assessed. Nowadays many researchers suggest that this technique 
is subject to bias and itself requires an external reference measure to assess the 
validity of dietary measurements in individuals. The main problem of weighed 
inventory relates to underreporting of consumption by a proportion of subjects. This 
leads to an underestimate of average group intakes, as well as a misclassification of 
some individuals (Garrow et al., 2000).
3.7.1.4 Food frequency questionnaire (FFQ)
FFQs assess usual long-term dietary intake and are designed to rank subjects into 
quantiles of dietary intake. Foods are listed in a questionnaire format or a multiple-
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response grid, and subjects attempt to estimate how often each food is consumed. This 
technique is inexpensive and provides a rapid estimate of usual intake (Barrett- 
Connor, 1991). The questionnaire can be either self-administered or completed by an 
interviewer, which may be more accurate, but increases the cost of using this method 
(Caan et al., 1999).
The main problems related to FFQ are:
1. The accuracy of the assessment depends on the number of foods in the list. 
About 5000 food items are available, but a typical FFQ lists 150 or so food 
items (Thomas, 2001).
2. A FFQ requires an ability to think abstractly to complete it, and some 
individuals find this easier that others (Field et al., 1999).
3. The accuracy of the FFQ is dependent on an evaluation of portion size, like all 
unweighted assessment techniques (Thomas, 2001).
4. People may be tempted to give the answers, which they think are correct or 
desirable, e.g. more fruit and vegetable and less chocolates than is really the 
case (Thomas, 2001).
5. There is a relationship between frequency of food intake and total food (and 
energy) intake. This can lead to distortions, particularly if FFQ data are used to 
assess the degree of dietary balance or healthiness (Thomas, 2001).
3.7.2 Adjustment for total energy intake in epidemiological analysis
In epidemiological studies, total energy intake requires specific consideration in the 
analysis of diet for three important reasons. Firstly, the level of total energy intake is 
often related to disease risk because of associations between physical activity or body 
size and the probability of disease. In theory, differences in disease incidence may
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also be related to metabolic efficiency and therefore to total energy intake; secondly, 
differences in total energy intake will produce variations in the intake of specific 
nutrients which are not related to dietary composition, but merely due to the fact that 
most nutrients, particularly macronutrients, are positively correlated with total energy 
intake. Variations, which appear may therefore be irrelevant; thirdly, extraneous 
variation in nutrient intake resulting from variation in total energy intake that is 
unrelated to disease risk may weaken associations. Thus, adjustment for total energy 
intake is usually appropriate in epidemiological studies to control for confounding, 
reduce extraneous variation, and predict the effect of dietary interventions (reviewed 
by Willett et al 1997) (Willett et al., 1997).
In the present study, usual dietary intake (over the previous 12 months) was assessed 
using a FFQ, which was previously developed and validated against 7-day weighed 
records (New et al., 2004). The relationship between reported antioxidant intake and 
biochemical measures of antioxidant status and the short and long-term 
reproducibility of the FFQ have been previously reported (New et al., 2004). Subjects 
were given instructions on how to fill out the FFQ during the initial interview and 
completed FFQs were checked for inaccuracies and inconsistencies at subsequent 
interviews. A full copy of this FFQ can be seen in Appendix 7.
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Physical activity levels were assessed using the James and Schofield human energy 
requirements equations (James and Schofield, 1990). Estimations of energy 
requirements can be assessed as three components;
1. Basal metabolic rate (BMR), which is the rate of energy expenditure under 
standardized conditions of immobility. Simple equations for calculation BMR 
from the body weight of different age and gender groups are available 
(Schofield, 1985). Table 3.7 shows the equations for calculating ‘basal’ energy 
needs as identified from the 1985 FAO/WHO/UNU report (FAO/WHO/UNU, 
1985).
2. Thermic responses to food ingestion (TR), which is the use of energy in 
digesting, absorbing, storing and disposing of the ingested nutrients.
3. Physical activity level (PAL).
The TR may be incorporated into the PAL, estimate to provide only two components, 
and the PAL may then be expressed as a multiple of the BMR (James and Schofield, 
1990).
Three major processes have been used to simplify the energy patterns for assessing 
the energy requirements of an individual or population (James and Schofield, 1990).
1. Simplification of energetics, which related to the energy used by people of any 
age/size to their basal metabolic rate.
2. Simplification of timing of activities. Three stages, which have been 
developed to provide a detailed, integrated hourly or an overall daily activity 
pattern.
3. Simplification of activity description. This used the process of describing 
different activity patterns, for example, occupational or leisure activities.
3.8 Assessment of physical activity level
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The energy cost of an activity by individual is calculated using physical activity ratio 
(PAR). It is defined as the actual energy cost of an activity, minute by minute as a 
multiple of the cost of BMR per minute. It is accepted however that individuals pause 
in their work/activity. Thus allowance is made for this by calculating the Integrated 
Energy Index (IEI). These values are therefore slightly lower than the PAR as they 
indicate that a person is active for 60% of the time, with rest periods for 
approximately 40%. For inactive and moderately active the individual is estimated to 
have rest periods 25% of the time. Table 3.8 shows the average for IEIs at different 
activity levels.
Physical activity levels can then be calculated as the total energy required for a 
twenty-four hour period (total energy expenditure TEE) as a ratio of the BMR over 
the twenty-four hour period. Table 3.9 gives an example of the average daily desirable 
activity allowances of adults expressed as PAL values (James and Schofield, 1990). 
The FFQ and physical activity questionnaire used for the present study were 
developed and used extensively by the Aberdeen University Department of Nutrition. 
The questions on physical activity based on the James and Schofield equations were 
selected from those used in the Scottish Heart Health Study (SHHS)/MONICA 
questionnaire (Bolton-Smith et al., 1992). Questions were divided into time spent on 
activities during work (including housework), during non-work time, and in bed 
(resting in bed and sleep). Questions on activities when working, during non-working 
time and time spent in bed are shown in appendix 3. Integrated Energy Index (IEI) 
and an example of the calculations undertaken to assess the total energy expenditure 
and PAL are shown in table 3.10. Questions were also included on time spent walking 
and cycling each day, and the number of times a week when the individual was 
physically active for at least twenty minutes during which time they became short of
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breath and sweated. Time for questionnaire completion was estimated to be 20-30 
minutes.
Past physical activity levels were categorised as follows:
Question 7a) Level of walking a day: Inactive - < 1 hour/day or none at all; Moderate 
-  between 1-2 hours/day; Active -> 2hours/day.
Question 7b) Strenuous physical activity: Inactive - < 1 times/week; Moderate -  1-2 
time/weelc; Active - > 2 times/ week.
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Table 3.7 Equations fo r calculating ‘basal’ energy needs (F A O /W H O /U N U , 1985) 
B M R  for adolescents and adults (M J/day)
Adolescents
(1 0 -1 7 + )
A du lts
18-29+
30-59+
>60
M ales
0 .0 7 3 2 W * +  2.72
0 .0640 W  + 2.84  
0.0485 W  + 3.67  
0.0565 W  + 2.04
Fem ales
0.0510 W  +  3.12
0.0615 W  + 2.08  
0.0364  W  +  3.47
0.0439 W  +  2 .49
* W  is the average w eight (kg)
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Table 3.8 Integrated Energy Index ( IE I)  for m en and wom en at d ifferent activity
levels (Schofield, 1985)___________________________ __________________________________
M ales______________________________ Fem ales
A c tiv ity  level
In ac tive  (0 .7 5 x 1 .5 4 )+ (0 .2 5 x l .4 )= 1 .51
M o d e ra te  (0 .7 5 x 2 .8 )+ (0 .2 5 x l.5 4 )= 2 .4 9
A ctive  (0 .60x6 .2 )+ (0 .40x  1.5 4 )= 4 .3 4
(0 .7 5 x1 .6 8 )+ (0 .2 5 x l .4 )= 1 .61 
(0 .75x2 .8 )+ (0 .2 5 x l .68)=2.52  
(0 .6 0 x 6 .2 )+ (0 .4 0 x l .68)=4 .39
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Table 3.9 Average daily  desirable activity allowances o f  adults expressed as a 
physical activity level value (James and Schofield, 1990)_____________________________
M a le Fem ale
T y p e  w o rk
L ig h t 1.55 1.56
M o d e ra te 1.78 1.64
H eavy 2.10 1.82
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Statistical analyses w ere carried out using the statistical package M in itab  Release 13 
(M in itab  Inc., 3081 Enterprise D rive , State College, P A 1 6 08 1 - 3008, U S A ). 
Quantitative data were assessed for norm ality  using the Kolm ogorov-Sm im ov tests. 
N orm ally  distributed data w ere analysed using one-way analysis o f  variance. N on- 
norm ally distributed data (non log-transformed data) were analysed using the non- 
parametric K ruskal-W allis  test. A lso, non-norm ally distributed data w ere normalised 
using log-transformed and these log-transformed data were analysed using one-way 
analysis o f  variance. W h ile  the statistical results o f  both log-transformed data and non 
log-transformed data are sim ilar, this more supports our findings.
Post-hoc tests (F isher’s m ethod) were used after using one-way analysis o f  variance.
A  two-sided P value o f  <0.05 was considered statistically significant.
Values were expressed as mean and standard error o f  mean (S E M ) or, in  the case o f  
non-norm ally distributed data, as median and inter-quartile range ( IQ R ).
Categorical data (such as smoking habit) were analysed using Fisher’s exact or chi- 
square tests.
M u ltip le  regression was earned out to investigate the relationship between the anti- 
Hsp titres, trace element status, v itam in E  and CRP concentrations and possible 
coronary risk factors and individual components o f  the metabolic syndrome. Stepwise 
regression was used w ith  antibody titres to Hsps and C R P concentration, in turn as 
dependent variables and a set o f  independent variables. These variables included, 
depending upon the sub-category: age, sex, diabetes m ellitus (D M ), metabolic 
syndrome, obesity, hyper-triglyceridaem ia, smoking, hypertension, history o f  C H D , 
accumulation features o f  M S , and drug therapy for dyslipidaem ic patients, and
3.9 Statistical analysis
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systolic and diastolic blood pressure, waist measurements, B M I,  W H R , fasting blood 
glucose, triglycerides and H D L  levels for metabolic syndrome group.
The stepwise approach used the M in itab  default value o f  p=0.15 as the criterion to 
include or exclude a variable from  the model. The results o f  the m ultip le  regression 
analyses were assessed b y  looking at the fit o f  the m odel, the proportion o f  the 
variability  in  the dependent variable explained (R 2) the size and statistical significance 
o f any terms included in the model, the pattern o f  residuals and the im pact o f  possible 
outliers and points w ith  high leverage.
The non-norm ally distributed data such as high-sensitivity CR P concentrations were 
logarithm ically transformed. Analysis o f  covariance (A N C O V A ) was used to assess 
difference o f  biochem ical markers and nutrient intakes after adjustment o f  important 
confounding effect e.g. age, sex, B M I  and smoking status.
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CHAPTER 4
D i e t  i n  r e l a t i o n  t o  
c o r o n a r y  r i s k  f a c t o r s
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M a n y  foods and nutrients influence C H D  risk (M ann, 2002). D ie tary  advice to patients 
w ith  C H D  m od ify  individual risk factors and reduce m ortality  and m orb id ity  (Hooper, 
2001). The association between dietary fat and risk o f  C H D  is a subject o f  debate, 
especially the quantity and the quality o f  dietary fats both relate to C H D  risk. A  positive 
association between total fat and saturated fat intake and risk o f  C H D  was found in  
some studies (Boniface and Te fft, 2002; Esrey et al., 1996), whereas others have 
reported no association (H u  et al., 1997; Pietinen et al., 1997). B oth positive and 
negative association between monounsaturated fat intake and risk o f  C H D  have been 
reported (Esrey et al., 1996; H u  et al., 1997) and some investigators did not find that 
monounsaturated fat intake was associated w ith  C H D  risk (K rom hout and de Lezenne, 
1984; Pietinen et al., 1997). Polyunsaturated fat intake has been reported to be inversely 
associated w ith  risk o f  C H D  in  tw o studies (Goldbourt et al., 1993; H u  et al., 1997), 
whereas others have reported no association (Krom hout and de Lezenne, 1984; Pietinen  
e ta l., 1997).
There are three possible confounding factors that m ay contribute to the discrepancies 
observed:
1. Differences in expressing dietary fat intake and incomplete adjustment for intake 
o f  total energy and other types o f  fat m ay lead to potential confounding and 
differences in  the interpretations o f  the risk estimates.
2. The gender-related difference in  the association between dietary fat and risk o f  
C H D  (Jakobsen et al., 2004), and greater importance o f  postprandial 
hypertriglyceridem ia on the relative C H D  m ortality among w om en than among 
men (Jakobsen et al., 2004; Stensvold et al., 1993).
4. Dietary intake in relation to coronary risk factors
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3. The age o f  the subjects in  the different studies, because older subjects m aybe  less 
vulnerable to dietary factors (Jakobsen et al., 2004).
A  high intake o f  n-3 P U FA s is associated w ith  reduced platelet aggregation, altered 
immune function and a reduction in blood pressure (Lichtenstein and Chobanian, 
1990; M eydani et al., 1993).
Although the n-3 P U FA s have been reported to be more potent than the n -6  P U F A  in  
regulating the activation o f  peroxisome proliferator-activated receptors-a (P P A R -a )  
(C larke, 2001; M anco et al., 2004), other studies do not support these findings 
(Yaqoob, 2004; X u  et al., 2001). In  general, P P A R -a  activation leads to the induction 
o f several genes encoding proteins involved in  lip id  transport, oxidation, and 
thermogenesis (K lie w e r et al., 1997). C learly, P P A R -a  is emerging as a pivotal player 
in  both fatty acid and glucose metabolism (C larke, 2001). Its regulation b y  P U F A , 
particularly n-3 P U F A , m ay offer an explanation for both the reported benefits o f  
these fatty acids in  protecting individuals from  developing type I I  diabetes (Delarue et 
al., 2004; Storlien et al., 1987).
Reduction o f  average dietary glycaemic index (G I)  values has been shown to be 
associated w ith  an increased insulin stimulated glucose uptake after 4  weeks o f  
dietary treatment and to im prove some markers o f  cardiovascular risk (H otam islig il et 
al., 1995). L o w  G I diets have been shown to be associated w ith  low er plasma fatty  
acids concentrations, w hich m ay suppress production or release o f  signalling 
hormones from  adipose tissue, w hich in turn m ay reduce L D L -C  and increase H D L -C  
(Frayn et al., 1996; Frost et al., 1998).
Trace elements status m ay be o f  important in  determining C H D  risk because these 
elements are essential components o f  enzymes that m ay be protective against oxidative  
damage. O n the other hand, transitional elements such as copper also have ability  to
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catalyse lip id  oxidations, which m ay promote atherogenesis (Ferns et al., 2000b; 
K levay, 1975; Raym an, 2000). K le v ay  (1975) has suggested that an imbalance in  
dietary zinc/copper m ay predispose to C H D  in  his zinc/copper hypothesis (K levay, 
1975).
For these reasons, w e have investigated whether conditions associated w ith  increased 
coronary risk are also associated w ith  differences in  dietary intake o f  macro- and 
micronutrients including zinc/copper ratio in dyslipidaemic patients and healthy 
subjects.
4.1 D ie ta ry  in ta k e  in  hea lth y  subjects
4.1.1 Physio logical v a r ia tio n  in  d ie ta ry  in take
Differences in dietary intake with gender and age
Am ong the 189 control subjects, 95 subjects were males and 94 w ere females. M a le  
and female subjects did not d iffer w ith  respect to age, smoking status, B M I,  systolic 
blood pressure, and serum total cholesterol (p>0.05). H ow ever, m ale subjects had 
significantly higher waist/hip ratio, diastolic blood pressure, serum triglycerides, and 
total cholesterol: H D L  ratio, and low er serum H D L-cholesterol than fem ale subjects 
(for more details refer to appendix 4).
M a le  subjects had a significantly higher dietary intake o f  protein, energy, zinc, 
zinc/copper ratio, magnesium, phosphorus, and calcium and a low er dietary intake o f  
carotenes compared w ith  fem ale subjects (Tab le 4 .1). In  an analysis o f  covariance the 
difference in  dietary intake on m acro- and micronutrients in  dyslipidaemic patients 
compared w ith  controls was no longer significant when dietary energy intake was 
used as a covariate (p >0 .05).
N o  significant correlations between age and dietary intake in  healthy subjects were  
observed.
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Table 4.1 Comparison of daily macro- and micronutrients intake in healthy male and
female subjects_____________ _________________________________________
M a c ro n u trie n ts
M a le Fem ale P. V a lu e
Protein (g) 85.64 ± 2 .2 8 77.49 ± 2.42 0.02
Total Fat (g) 74.27 ± 2.62 67.82 ± 2 .3 8 0.07
C H O  (g) 277 .0  ± 10.2 265.9 ± 1 0 .2 0.45
Energy (M J ) 10.98 ± 0 .3 9 9.31 ± 0 .2 9 0.001
Starch (g) 118.76 ± 4 .1 2 108.18 ± 3 .8 9 0.14
Sugar (g) 156.11 ± 5 .2 3 153.14 ± 4 .2 1 0.79
Fibre (g) 18.09 ± 0 .7 7 17.63 ± 0 .7 1 0.65
F a t
Saturated fat (g) 29 .39  ± 1.26 26.98 ± 1 .0 3 0.14
Monounsaturated fat (g ) 26.83 ± 0.99 24.28 ± 0.90 0.06
Polyunsaturated fat (g) 10.27 ± 0 .3 4 9.50 ± 0.34 0.11
Cholesterol (m g) 402.8  ± 1 1 .3 377.1 ± 11.2 0.17
T ra c e  elements
Zinc (m g) 9.93 ± 0.29 9.03 ± 0.28 0.03
Copper (m g) 1.63 ± 0 .0 6 1.64 +  0.07 0.86
Zinc/Copper ratio 6.42 ± 0.20 5.88 ± 0 .1 8 0.04
Protein/Zinc 8.65 ± 0 .1 3 8.68 ± 0 .1 5 0.87
Selenium (pg) 92.45 ±  4.48 82.19 +  4 .14 0.13
A ntiox idan ts
V itam in  E  (m g) 6.09 ± 0.22 6.05 ± 0.22 0.82
V itam in  C (m g) 39.57 +  3.46 40.69 +  3.72 0.83
Carotene (pg) 1820.2 ± 8 8 .6 2151.7 ± 9 7 .9 0.01
O thers
Fe (m g) 16.22 ± 0 .6 6 14.62 ± 0.60 0.07
Folate (pg) 276.0  ± 9.79 260.28 ±  8.22 0.22
M g  (m g) 422.5 ±  16.6 345.1 ± 1 1 .0 <0.001
Phosphorus (m g) 1701.9 ± 5 1 .7 1489.2 +  43.6 0.002
K  (m g) 4224 ± 146 3851 ± 1 3 1 0.06
Ca (m g) 1221.7 ± 4 2 .1 1094.2 ± 3 5 .3 0.02
V itam in  D  (pg ) 4 .22  ± 0.24 4.44  ± 0.27 0.54 '
Values are expressed as M ean  ±  S E M . O ne-w ay A N O V A  used for comparison 
between m ale and fem ale healthy subjects.
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Smolcing
Am ong the 189 control subjects, 123 subjects had never smoked and 66 were current 
or ex-smokers including 32 current smokers and 34 ex-smokers (fo r m ore details refer 
to appendix 5). N e ither current, ex-smokers nor non-smokers differed w ith  respect to 
gender, weight, B M I,  SBP, D B P , fasting blood glucose, serum total cholesterol, H D L -  
cholesterol, and total cholesterol: HD L-cholestero l ratio (p>0.05). How ever, smokers 
had significantly higher waist circumference, waist hip ratio, and serum triglycerides 
and were older than non-sm oking subjects (p<0.05). Smokers had a significantly  
higher dietary intake o f  cholesterol and low er dietary intake o f  sugar compared w ith  
non-smoking healthy subjects (Tab le 4.2).
4.1.2 Pathophysiological conditions and their association with dietary intake
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Table 4.2 Association between smoking habit and macro- and micronutrient dietary 
intake in  healthy subjects________________________________________________________________
M a c ro n u trie n ts
S m oker N on -sm oker P. V a lu e
Proteins (g) 8 5 .2 1 + 3 .1 3 79.22 ± 1 .9 8 0.09
Total Fat (g) 73 .76  ± 3 .1 6 ' 69.27 ± 2 .1 3 0.23
C H O (g ) 258.78 ±  9.48 277.50  ± 9 .8 3 0.22
Energy (M J ) 10.59 ± 0 .4 0 9.82 ± 0 .3 1 0.14
Starch (g) 118.91 ± 5 .5 7 110.05 ± 4 .1 4 0.15
Sugar (g) 138.91 ± 7 .1 8 162.91 ± 7 .5 8 0.04
Fibre (g) 16.83 ± 0 .7 0 19.15 ± 0 .6 9 0.31
F a t
Saturated fat (g) 29.93 ± 1 .5 1 27.14 ± 0 .9 3 0.10
Monounsaturated fat (g ) 26.91 ± 1 .2 7 24.71 ± 0.78 0.12
Polyunsaturated fat (g) 10.18 ± 0 .4 5 9.69 ± 0.29 0.33
Cholesterol (m g) 417.2  ± 14.6 377.4 ± 9.25 0.02
T ra c e  elements
Zinc (m g) 9.69 ± 0.36 9 .32 ± 0.25 0.39
Copper (m g) 1.59 ± 0 .0 8 1.66 ± 0.06 0.46
Zinc/Copper ratio 6 .46 ± 0.24 5.96 ± 0 .1 6 0.07
Protein/Zinc 8.91 ± 0 .1 8 8.54 ± 0 .1 1 0.08
Selenium (pg) 87.09 ± 4.76 87.09 ± 3 .9 5 0.12
A ntiox idan ts
V itam in  E  (m g) 5.98 ± 0.28 6.08 ± 0 .1 9 0.77
V itam in  C (m g) 35.70 ± 3 .9 9 42.51 ± 3 .2 7 0.21
Carotene (pg ) 1977.0 ± 1 2 2 2014.3 ± 8 1 .8 0.79
O thers
Fe (m g) 16.53 ± 0 .8 1 14.75 ± 0.52 0.06
Folate (pg ) 267.83 ± 8.98 267.47 ± 8.47 0.98
M g  (m g) 391.5 ± 1 8 .0 375.6 ± 1 2 .3 0.46
Phosphorus (m g) 1631.3 ± 6 0 .7 1565.4 ± 4 1 .9 0.37
K  (m g) 3 9 8 8 ± 167 4043 ± 123 0.79
Ca (m g) 1196.2 ± 4 7 .2 1131.1 ± 3 3 .9 0.26
V itam in  D  (pg) 4 .60  ± 0.34 4.20 ± 0 .2 1 0.30
Values are ’ expressed as M ean  ± S E M . O ne-w ay A N O V A  used for comparison 
between smokers and non-smoker healthy subjects.
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Am ong 189 control subjects, 33 were obese w ith  a B M I> 3 0 . These comprised 19 
males and 14 females, 58 were over w eight w ith  B M I between 25 and 30 (36 males 
and 22 females), and 78 w ere o f  a norm al w eight w ith  B M I less than 25 (31 males and 
47 females). Obese and non-obese subjects did not d iffer w ith  respect to gender, 
present smoking status, and serum total cholesterol (p>0.05). H ow ever, obese subjects 
had significantly higher measures o f  adiposity (B M I, % body fat, waist circumstance, 
and waist hip ratio), higher systolic and diastolic blood pressure, higher serum 
triglycerides and fasting blood glucose, a high proportion o f  ex-smokers, and a high  
calculated 10 year coronary risk, and low er H D L-cholesterol than non-obese subjects. 
Obese subjects w ere also significantly older than non-obese subjects (Tab le 3.3). 
D ietary intake o f  carotene was significantly lower in obese subjects compared w ith  
healthy subjects o f  norm al w eight (Tab le 4 .3).
Obesity
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Table 4.3 Association between BMI and macro- and micronutrient dietary intake in
healthy subjects ________________________________________________
M a c ro n u trle n ts
Proteins (g) 
Total Fat (g) 
C H O  (g)
Energy (M J )  
Starch (g)
Sugar (g)
Fibre (g)
T ra c e  elements
Zinc (m g)
Copper (m g) 
Zinc/Copper ratio  
Protein/Zinc  
Selenium (pg)
A ntiox idan ts
V itam in  E  (m g) 
V itam in  C  (m g) 
Carotene (pg)
O thers
Fe (m g)
Folate (pg)
M g  (m g) 
Phosphorus (m g) 
K  (m g)
Ca (m g)
V itam in  D  (pg)
Obese
86.09 ± 4.93  
73.49 ± 4 .9 6
253.4  ± 1 6 .1
9.61 ± 0 .5 3  
113.46 ± 8 .0 4
138.60 ± 1 1 .4
17.60 ± 1.42
9.75 ± 0.50  
1.55 +  0.12
6.78 ±  0.38  
8.86 +  0.22
87.09 ± 7 .1 5
6 .40  ± 0.47
33.92 ± 5 .3 3
1864.0 ± 1 8 6
14.92 ± 1 .0 4
263.3 ± 15.3
357.6 ± 2 1 .6
1584.7 ± 8 5 .4  
3850 ± 2 2 6  
1117.5 ± 6 7 .3
5.29 ± 0.61
O verw eig h t
78.85 +  2.78
65.28 ± 2 .7 5
265.5 ± 12.5 
10.04 ± 0 .4 7  
104.45 ± 6 .1 3  
160.70 ± 1 1 .0  
17.47 ± 0 .9 1
25.70 ± 0 .1 .1 5  
23.53 ± 1 .0 4  
9.21 ± 0 .4 1  
376.9 ± 1 1 .8
9 .04+  0.36  
1.59 ± 0 .0 9
6 .00 +  0.21
8.78 ± 0 .1 8
87.09 ± 5.27
5.62 ± 0 .2 4
44.63 ± 4.24
1916.8 +  98.3
14.96 ± 0.78
266.7 ± 1 1 .5
377.1 ± 2 0 .0
1572.8 +  65.1 
4151 ± 2 0 3
1177.7 ± 5 1 .5  
3.95 ± 0.29
N o rm a l w eight
81.43 ± 2 .3 5
73.79 ± 2.52
280.5 ±  10.5
10.29 ± 0 .3 3  
118.97 ± 4 .4 4  
155.30 ± 7 .5 3  
19.15 ± 0 .7 0
29 .64  ± 1 .2 0  
26 .32  ± 0.99  
10.21 ± 0 .3 3  
390.9  ± 1 1 .5
9.63 ± 0.28  
1.69 ± 0 .0 6
6.01 ± 0 .1 9
8.53 ± 0 .1 4  
69.27  ± 4 .3 0
6.23 ± 0.22
39.09  ± 3 .8 5
2104.0  ± 102*
15.79 ± 0 .6 4
269.6  ± 8.77
391.4  ± 1 3 .4
1599.8 ± 4 5 .8  
3992 ± 1 2 1
1148.2 ± 3 7 .1  
4.31 ± 0 .2 3
F a t
Saturated fat (g ) 28 .47  ± 2 .24
Monounsaturated fat (g )26.97  +  1.78 
Polyunsaturated fat (g )10.16  ± 0.67  
Cholesterol (m g) 422.3 ± 2 3 .3
Values are expressed as M ean  ± S E M . O ne-w ay A N O V A  used for comparison 
between obese, over w eight and norm al w eight healthy subjects; *p<0.05.
Subjects w ith  B M I  greater than 30, between 25 and 30, and less than 25 defined as 
obese, over weight, and norm al w eight respectively (B ritish N utrition  Foundation  
Task Force, 1999).
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4.2 D ie ta ry  in ta k e  in  conditions re lated  to C H D
4.2.1 D ie ta ry  in ta k e  and  C H D  ris k  factors
D ietary  intake o f  m acro- and micronutrients were compared between patients w ith  
dyslipidaemia and control subjects. Macronutrient intakes included protein, total fat, 
carbohydrate, energy, starch, sugar and fibre. Total fat was further subclassified into 
cholesterol, saturated, and mono and polyunsaturated fat. M icronutrients included 
dietary trace elements such as zinc, copper, zinc/copper ratio, and selenium, and 
dietary antioxidants comprised vitam in E, v itam in C  and carotene.
Dietary intake of macronutrients
Overall, the dyslipidaemic patients had a significantly higher reported dietary intake 
o f  protein (p <0 .05 ), starch (p <0 .05), fibre (/K 0 .0 5 ), and total fat (p<0 .05 ) compared 
w ith  control subjects (Tab le  4 .4 ). N o  significant differences w ere observed for dietary 
intake o f  total carbohydrate, sugar, and energy between patients and controls, nor 
between subgroups o f  patients. There were small, though statistically significant 
differences in  the dietary intake o f  macronutrients between sub-categories o f  the 
dyslipidaemic patients, segmented on the basis o f  several classical coronary risk 
factors (Tables 4.5a-b and 4 .6 - 4 .8).
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Table 4.4 Comparison of dietary macro- and micronutrient intake between dyslipidaemic
patients and control subjects_____________________________________________
M a c ro n u trie n ts
Patients C ontro ls P. V a lu e
Proteins (g) 8 7 .6 0 +  1.87 80.91 +  1.99 0.02
Total Fat (g) 76.76 +  1.61 71.53 +  2.01 0.04
C H O (g ) 282.59  ± 8.63 276.17 +  9.08 N S
Energy (M J ) 10.02 +  0.26 10.26 +  0.3 N S
Starch (g) 132.40 +  4 .12 1 1 1 .1 1 + 3 .8 9 <0.001
Sugar (g) 145.35 +  5.92 160.84 +  7.16 N S
Fibre (g) 21 .50  +  0.71 18.69 +  0.63 0.005
F a t
Saturated fat (g ) 29.36 +  0.88 28.22 ± 0.64 N S
Monounsaturated fat (g) 27.73 +  0.62 25.65 ± 0.78 0.04
Polyunsaturated fat (g ) 10.57 +  0.22 10.02 ± 0.28 N S
Cholesterol (m g) 410.04  +  7.20 391.99 +  8.98 N S
T ra c e  elem ents
Zinc (m g) 10.49 ± 0.27 9.49 ± 0.25 0.01
Copper (m g) 1.77 +  0.06 1.69 +  0.06 N S
Zinc/Copper ratio 6.39 +  0 .14 5.95 +  0.15 0.04
Protein/Zinc 8.67 +  0.10 8.58 +  0.12 N S
Selenium (pg) 103.41 +  3.80 89.86 +  3.80 0.02
A ntiox idan ts
V itam in  E  (m g) 6.50 +  0.19 6.12 +  0.18 N S
V itam in  C (m g) 42.48 ± 2 .94 48.48 +  4.15 N S
Carotene (pg) 2145.7  +  79.0 2055.2 ± 85.3 N S
O thers
Fe (m g) 16.16 +  0.53 15.42 +  0.54 N S
Folate (pg) 288.01 ± 7.80 268.41 ± 7.73 N S
M g  (m g) 3 9 3 .4 +  11.7 387.7 ±12.4 N S
Phosphorus (m g) 1628.6 +  38.4 1600 +  41.8 N S
K  (m g) 4 080  ± 848 4180 +  1508 N S
Ca (m g) 1076.6 +  28.2 1165.5 +  33.1 0.04
V itam in  D  (pg ) 5.13 +  0.19 4.26 ± 0 .20 0.002
Values are expressed as M e a n  ± S E M . O ne-w ay A N O V A  used for comparison between 
the patients and controls.
N S  =  N o t significant
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The dietary intake o f  protein differed significantly between sub-categories o f  
dyslipidaemic subjects w ith  and w ithout C H D , M S , hypertriglyceridaem ia, obesity 
respectively, and high, moderate and normal blood pressure compared w ith  control 
subjects (Table 4.5a). Significant differences for dietary total fat intake were observed 
between hypertriglyceridaem ic subjects and both controls and non- 
hypertriglyceridaem ia subgroups (Table 4.5a).
D ietary  intake o f  fibre and starch differed significantly between all sub-categories o f  
patients compared w ith  control subjects (Tab le 4.5b). S ignificant differences for 
dietary fibre intake were also observed between the subgroup o f  dyslipidaemic 
patients w ith  high, moderate, and norm al blood pressure (Tab le 4.5b).
Dietary intake of other nutrients
A  lower intake o f  calcium  and higher intake o f  v itam in D  was observed in the 
dyslipidaemic patients compared w ith  controls (/K 0 .0 5 , Table 4.4).
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Table 4.5a Comparison o f  macronutrients dietary intake between different subgroups o f  
dyslipidaemic patients segmented according to the possession o f  specific coronary risk 
factors.
N u m b e r
G roups
P ro te in  (g) T o ta l fa t  (g) C H O  (g)
E stablished C H D
C H D +
C H D -
55
182
89.86 ± 3 .98 1 
8 7 .0 5 + 2 .1 2
79.23 +  3.69  
76.16 ± 1 .7 9
2 9 0 .0 0 + 1 7 .2 0  
280.82 ± 09.89
M e tab o lic  S yndrom e
M S +  142 
M S - 95
8 9 .5 0 +  2 .3 5 1 
85.09 +  3.05
77.80 +  2.15  
75.38 +  2.43
280.00 +  11.50 
2 8 6 .0 0 +  13.20
D iabetic  M e llitu s
D M +
Im paired G T  
D M -
42
21
174
86.89 +  4.47  
91.63 +  6.94  
87.26 +  2.17
7 3 .1 1 + 4 .3 5  
71.94 ± 5 .2 3  
78.10+  1.83
279.80  +  22.20  
294.40 ±23.80  
281.70  +  10.20
O besity
Obese+
O ver weight 
Norm al w eight
82
112
43
91.43 +  3 .37 1 
85.87 +  2 .69  
8 5 .6 1 + 4 .1 4
79.03 +  3.35  
76.96 +  2 .12  
72.87 +  3.21
2 8 4 .0 0 + 1 6 .4 0  
2 7 8 .2 0 +  11.80  
2 9 0 .2 0 +  19.50
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 
N orm al T .G . 61
8 8 .7 9 +  2 .1 2 1 
84.52 +  3.90
78.66 ± 1 .911*  
71.82 +  2 .90
281.41 + 0 9 .9 3  
2 8 5 .6 0 +  17.40
B lood pressure  
H igh  BP  
Moderate BP  
N orm al BP
76
111
50
93.42  +  3 .342 
85.45 +  2.50  
8 1 .6 1 + 4 .7 5
79.76 +  3.19  
75.29 +  2.08  
74.79 ± 3.52
303.80 +  14.70  
2 7 1 .5 0 +  11.80  
271.10 +  23.20
C alcu la ted  10 -year  
C o ro n a ry  R is k
H igh  > 3 0 %  42  
Moderate 2 0 -30%  54  
Low  < 20 %  141
88.57 +  4 .27  
88.95 +  3.47  
86.65 ± 2.62
76.45 +  4 .20  
79.36 +  2.87  
75.70 +  2 .17
290.00 ± 20.70  
2 9 9 .2 0 + 1 8 .0 0  
2 7 2 .4 0 + 1 1 .1 0
Contro ls 135 80^91 +  1.99 7 1 .5 3 + 2 .0 1 276.17 +  0.02
Values are expressed as Mean ± SEM. 1=/K0.05, 2=/K0.01 comparison between the
groups including patients and controls, and *=p<0.05 comparison between sub­
categories of the dyslipidaemic patients by using one-way ANOVA.
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Table 4.5b Comparison o f  macronutrient dietary intake between different subgroups o f  
dyslipidaemic patients segmented according to the possession o f  specific coronary risk
factors._________________________________________________________________________________
N u m b e r S ugar (g ) F ib re  (g) E n e rg y  (K J )  S tarch  (g)
G roups
Established C H D
C H D +  55
C H D - 182
149.40+12.5
144.38+6.72
21.79+1.18
21 .43+0.84
9 .47+  0.52  
9 .83+  0.28
135.19+8.68
131.73+4.68
M e tab o lic  S yndrom e
M S +  142 144.75+8.20 21 .4 0 + 0 .9 5 1 9 .38+0.29 130.32+5.222
M S - 95 146.15+8.52 21.62+1.08 10.26+0.44 135.16+6.66
Diabetes M e llitu s
D M + 42 148.90+17.7 21 .75+1.78 9 .17+0.50 128.45+9.452
Im paired G T 21 156.60+15.9 21 .83+1.86 10,19+0.83 129.18+8.49
D M - 174 138.99+5.96 21 .40+0.84 10.18+0.31 133.62+5.03
O besity
Obese+ 82 137.20+10.8 21 .71+1.28 9.62+0 .40 133.87+7.03
O ver weight 112 142.07+7.38 21.40+1.02 10.06+0.38 130.29+6.10
N orm al weight 43 149.80+11.7 21 .97+1.56 10.54+0.62 134.83+9.39
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 143.97+7.06 2 1 .10+ 0 .851 9796+0.29 132.53+4.662
N orm al T .G . 61 148.90+11.0 22 .54+1.29 9662+0.52 132.07+8.65
B lood pressure
H igh  BP 76 155.86+10.6 23 .41+1.19  * 10 .28+0.44 135.61+7.35
Moderate BP 111 133.99+7.78 21.19+1.02 9 .35+0 .34 133.95+5.40
N orm al BP 50 138.21+15.7 18.27+1.64 9.93+0.73 120.49+9.30
C alcu la ted  10 -year  
C o ro n a ry  R is k
H igh  > 30 %  42 148.40+14.8 22 .24+ 1 .632 9.96+0.61 139.09+9.732
Moderate 2 0 -30% 54 158.70+13.6 22 .84+1.39 9.74+0.43 132.23+7.70
L o w  < 20% 141 138.11+7.02 20.63+0.96 9 .70+0 .36 130.30+5.66
C ontro ls 135 160.84+7.16 18.69+0.63 10.06+.0 .29 111.11+3.89
Values are expressed as Mean ± SEM. 1=/K0.05, 2=/K0.01 comparison between the
groups including patients and controls, and *=Jp<0.05 comparison between sub­
categories of the dyslipidaemic patients by using one-way ANOVA.
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The dyslipidaemic patients had a significantly higher intake o f  monounsaturated fat 
(p<0 .05) compared w ith  control subjects (Table 4.6). N o  significant difference was 
observed for dietary intake o f  cholesterol between patients and controls, nor between 
subgroups o f  patients (Tab le  4 .6).
Significant differences in  dietary m ono- and polyunsaturated fat intake were observed 
between hypertriglyceridaem ic, non-hypertriglyceridaemia and control groups 
(p<0.05, Table 4 .6). A lso, significant differences for dietary intake o f  cholesterol were 
observed between obesity and both controls and non-obese subgroups (/K 0 .0 5 , Table
4.6).
Dietary intake of sub-classifications offat
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Table 4.6 Comparison o f  dietary fat intake between different subgroups o f  dyslipidaemic
patients segmented according to the possession o f  specific coronary risk factors.__________
N u m b e r S a tu ra te d  fa t  (g) M U F A  (g ) P U F A  (g) C ho lestero l (m g)
G roups
Established C H D
C H D +  55 29 .98+1.43  28.67±1.41 1 1 .3 5 + 0 .5 0  405.00±14.50
C H D - 182 29.21±0.71 27.50±0.69 10.38±0.24 411.26±08.24
M e tab o lic  S yndrom e
M S +  142 29.55±0.83 28.05±0.83 10.69±0.30 4 2 2 .2 0 1 10 .1 1*
M S - 95 29 .11+ 1.00  27 .30+0.94  10.4010.33 393.92+09.73
Diabetes M e llitu s
D M + 42 26.65+1.49 26.24±1.70 10.11±0.59 403.40122 .30
Im paired G T 21 28.70±2.45 25.15±1.86 9.87±0.66 397.20125.50
D M - 174 30.01+0.73 28.35±0.71 10.75±0.25 412.99107.85
O besity
Obese+ 82 30.28±1.29 28.31±1.27 10.37+0.43 431.20+15.3  *
Over weight 112 29.24±0,81 27.94+0.82 10,75±0.31 406.5719.08
N on nal weight 43 28.22±1.43 26.37±1.29 10.46+0.46 385.60113.8
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 29.90+0.73 28 .5 2 1 0 .7 3 1* 10 .86+ 0 .261* 416.79+08.39
N orm al T .G . 61 27.95±1.30 25.68±1.13 09.81±0.38 392.60113.80
B lood pressure
H igh  BP 76 30.43±1.24 28.44±1.24 10.57±0.43 427.80113 .60
Moderate BP 111 28.51±0.80 27.47+0.81 10.71±0.29 400.90110.10
N on nal BP 50 29.69±1.62 26.97±1,25 10.10+0.51 399.90112.70
C alcu la ted  10 -year 
C o ro n a ry  R is k
H igh  > 30 %  42 27.93±1.38 27.70+1.71 10.62+0.61 427.80113 .60
M oderate 2 0 -30% 54 30.48±1.12 28.89±1.08 10.98±0.40 400.90110 .10
Low  < 20% 141 29.30+0.91 27.19±0.82 10.36±0.29 399.90112.70
C ontro ls 135 28.22±0.88 25.65±0.78 10.02±0.28 391.99+08.98
Values are expressed as M ean  ± S E M . l=/><0.05, 2=p<0.01 comparison between the 
groups including patients and controls, and * = /j< 0.05 comparison between sub­
categories o f  the dyslipidaemic patients b y  using one-way A N O V A .
M U F A ; monounsaturated fatty acid, P U F A ; polyunsaturated fatty acid
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The dyslipidaemic patients had significantly higher estimated unadjusted dietary  
intake o f  selenium (p <0 .05 ) compared w ith  control subjects (Tab le 4 .7).
Significant differences for dietary selenium intake were observed between sub­
categories w ith  and w ithout C H D , hypertriglyceridaemia, and obesity respectively and 
high, moderate and norm al blood pressure and calculated 10 year coronary risk  
compared w ith  control subjects (Table 4.7).
Dietary intake of zinc and copper
The dyslipidaemic patients had significantly higher estimated unadjusted dietary  
intake o f  zinc (p <0 .01), and zinc / copper ratio (p <0 .05) compared w ith  control 
subjects (Table 4.7).
The dietary intake o f  zinc differed significantly between all sub-categories o f  patients 
compared w ith  control subjects, and remained significant after adjustment for age, 
gender, and smoking habit only for subgroups o f  patients w ith  obesity and 
hypertension (Tab le  4 .7). A lso, significant differences for dietary zinc intake were 
observed between obese and non-obese as w e ll as high, moderate, and norm al blood  
pressure subgroup o f  patients.
Significant differences were observed for dietary intake o f  copper between subgroups 
o f  patients w ith  different categories o f  blood pressure and controls (p<0.05, Table
4.7).
The dietary intake o f  zinc /  copper ratio differed significantly between sub-categories 
w ith  and w ithout m etabolic syndrome, hypertriglyceridaemia, and obesity 
respectively compared w ith  control subjects (Tab le 4.7).
Dietary intake of selenium
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Table 4.7  Comparison o f  dietary trace element intake between different subgroups o f  
dyslipidaemic patients segmented according to the possession o f  specific coronary risk 
factors.
N u m b e r Z in c  (m g) C o p p e r (m g) Z n /C u  R a tio  Selenium  (pg)
G roups
Established C H D
C H D +
C H D -
55
182
10 .92+0.691
10.39+0.30
1.74+0.13
1.78+0.07
6.40+0.28
6 .39+0.16
114.20+8.6 4 1 
100.81+4.21
M e tab o lic  S yndrom e
M S +  142 
M S - 95
10 .59+ 0.331
10.35+0.46
1.76+0.08
1.79+0.09
6 .5 5 + 0 .1 9 1
6.18+0.21
102.45+4.82
104.68+6.13
Diabetes M e llitu s
D M +
Im paired G T  
D M -
42
21
174
10 .47+0.631
9 .95+0.80
10.55+0.33
1.77+0.17
1.84+019
1.77+0.33
6.59+0.38
5 .65+0.32
6 .59+0.17
103.79+9.59
100.20+10.6
103.72+4.48
O besity
Obese+
Over weight 
N orm al w eight
82
112
43
11.30+0.482*
10.19+0.40
9.90+0.57
1.82+0.11
1.71+0.08
1.85+0.14
6 .72 + 0 .2 8 1*
6 .42+0 .20
5 .84+0.29
102.71+6.47
103.19+5.88
104.93+7.80
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 
N orm al T .G . 61
10 .56+0.311
10.29+0.57
1.76+0.07
1.81+0.12
6 .52 + 0 .1 7 1
6 .08+0 .24
104 .75+4 .511 
99.93+7.09
B lood pressure
H igh  BP  
Moderate BP  
N orm al BP
76
111
50
11.39+0.502*
10.19+0.36
09.41+0.62
1 .98+0.101
1.71+0.08
1.54+0.16
6.05+0.25
6 .52+0 .20
6 .74+0 .34
111.64+5.942
103.40+5.51
85.36+9.90
C a lcu la ted  10 -year  
C o ro n a ry  R is k
H igh  > 30 %  42  
M oderate 2 0 -3 0%  54  
Low  < 20 %  141
11 .24+0.721
10.62+0.45
10.18+0.37
1.78+0.15
1.88+0.12
1.72+0.08
6 .61+0 .39
6 .28+0 .29
6 .38+0.18
117.OO+10.21
100.72+5.78
100.24+5.28
C ontro ls 135 09.49+0.25 1.69+0.06 5.95+0.15 89.86+3.80
Values are expressed as Mean ± SEM. 1=/K0.05, 2=/K0.01 comparison between the
groups including patients and controls, and *=p<0.05 comparison between sub­
categories of the dyslipidaemic patients by using one-way ANOVA.
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Dietary intake of antioxidant vitamins
Neither significant differences for dietary intake o f  antioxidant vitam ins were 
observed between the dyslipidaemic patients and control groups O > 0 .0 5 ), nor 
between subgroups o f  patients (Tables 4.4  and 4.8).
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Table 4.8 Comparison o f  dietary antioxidant intake between different subgroups o f  
dyslipidaemic patients segmented according to the possession o f  specific coronary risk  
factors.
N u m b e r
G roups
V ita m in  E  (m g) V ita m in  C  (m g ) C aro ten e  (m g)
E stablished C H D
C H D +  55 
C H D - 182
6.5510 .42
6.49+0.21
48.7817.43
40.9613.18
2 0031180
2180196.6
M e tab o lic  S yndrom e
M S +  142 
M S - 95
6 .41+0.25
6 .6210 .29
45 .0313 .84
39.1014 .57
21111119
21921122
Diabetes M e llitu s
D M +  42  
18851191  
Im paired G T  21 
D M - 174
6.2310 .54
5.7410.43
6 .6510 .22
43 .1716.55
57.48+8.63
40.52+3.50
19061181
2092179
O besity
O bese! 82 
O verw eigh t 112 
N on nal w eight 43
6 .2810.36
6 .4110 .27
6 .2810.38
37.2314.93
44 .2114.18
46.61+3.64
20331135
2068195.7
19991139
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 
N orm al T .G . 61
6 .5410 .24
6.4010.31
41.4413 .47
45.17+5.58
21291107
21881134
Blood pressure
H igh  BP 76  
M oderate BP 111 
N orm al BP 50
6.89+0.35
6.3010.25
6 .2810.48
44 .7814.72
44.6414 .59
30.6015.34
2460+165
19091106
22041196
C alcu la ted  10 -year  
C o ro n a ry  R is k
H igh  > 3 0 %  42  
M oderate 2 0 -3 0%  54 
Low  < 20%  141
6 .3010 .52  
■ 6.6410.31  
6.5010 .26
42.85+7.28
42.8215 .28
42.2014 .05
16361148
21491162
23101120
C ontro ls  135 6 .1210.18 48.4814.15 2055+79.0
Values are expressed as Mean ± SEM. l=/><0.05, 2=/K0.01, 3=/K0.001 comparison
between the groups including patients and controls, and *=p<0.05, **=/><0.01
comparison between sub-categories of the dyslipidaemic patients by using one-way
A N O V A .
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4.2.2  D ie ta ry  in ta k e  in  m etabolic  syndrom e
W ith in  the dyslipidaemic group, dietary intake o f  protein and zinc rose w ith  
accumulating o f  features o f  the metabolic syndrome (/K 0 .0 5 , Table 4 .9 ), whereas other 
dietary macro- and micronutrients did not d iffer significantly w ith  accumulating features 
o f  metabolic syndrome (p > 0 .0 5 , Table 4.9).
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Table 4 .9  Relationship between m acro- and m icronutrient dietary intake and accumulation o f  
features o f  metabolic syndrome in dyslipidaemic patient_____________________________________
N u m b e r o f  
Features
0 1 2 3 4 5
N u m b e r o f 
Subjects (n ) 10 28 61 62 56 20
M a c ro n u trie n ts
P ro te in  (g ) 75 .68+9.88  
T o ta l F a t (g ) 69 .32+7.00  
C H O (g )  252.1+45.1  
E n erg y  (K J )  9886+1792  
S tarch (g ) 113.2+23.3  
S ugar (g) 137.9+29.1  
F ib re  (g ) 18.02+3.20
73.18+4.74
66 .90+4.89
257.2+26 .2
8705+701
115.8+13.6
139.8+16.9
18.67+1.91
91.43+3.86
78.84+2.72
303.8+16.8
10873+565
145.7+7.73
151.5+11.1
23 .23+1.44
91.15+3.67
79 .74+3.05
264.9+14.5
9440+432
131.8+7.85
127.8+7.84
20 .81+1.29
85.68+3.30
77.35+3.56
301.0+21.7
9682+492
127.9+8.67
167.9+17.2
22 .60+1.69
9 5 .8 3 + 6 .2 *
76.71+7.01
2 7 9 .2 + 2U
8875+621
137.5+11.1
138.5±19.(
2 1 .2 9 + 1 .8f
F a t
S F A  (g) 
M U F A  (g) 
P U F A  (g) 
C holesterol
(m g )
28 ,06+ 3.24
24 .57+ 2.32
09 .57+1.07
403.0+ 22 .9
25 .78+2.14
24.47+1.96
09.61+0.68
365.7+16.8
30.31+1.08
28.61+1.08
10.84+0.39
405.8+12.8
30.02+1.11
28 .59+1.14
10.88+0.42
430.9+14.5
29.71+1.55
28.44+1.42
10.71+0.49
403.3+15.4
29.08+2.3*
26 .4 5 + 2 .5 '
10.17+0.81
440.8+33.1
T ra c e  elements  
Z in c  (m g ) 9 .07+1.36  
C o p p er (m g ) 1 .72+0.04  
Z n /C u  R a tio  5 .86+0.62  
Selenium  (p g )93 .7+21.9
8.39+0.70
1.56+0.17
5 .94+0.42
81.16+9.78
11.23+0.59
1.88+0.12
6 .38+0.28
114.87+7.95
10.51+0.48
1.66+0.11
6 .81+0.23
101.39+6.01
10.61+0.55
1.90+0.14
6.15+0.37
103.21+8.56
II .5 4 + 0 .8 *  
1.83+0.19  
6.62+0 .50
I I I . 7+15.(
A n tiox idan ts
V it .  E  (m g) 
V it .  C  (m g) 
C arotene
5.50+0.58
23853+6705
2055+ 21 .4
6 .33+0.60
37018+7555
2403+251
6.89+0.38
42575+6391
2181+166
6.46+0.35
44825+6030
2021+182
6.58+0.43
48030+5786
2155+180
5.91+0.62  
37313+9 li 
2094+254
(m g)
Values are expressed as M ean  ± S E M . O ne-w ay A N O V A  used for comparison between groups; 
*= /K 0 .0 5
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In  the present study, male subjects had a significantly higher dietary intake o f  energy 
compared w ith  fem ale subjects. It  is consistent w ith  other reports and reference values 
w hich are higher for m en than wom en (Thomas, 2001; W atanabe et al., 2004). This 
m ay be related to different dietary intake between men and w om en as they have the 
different life  style and energy requirements.
Dietary fat in conditions related to CHD
In  the present study w e  found that dietary fat intake was higher in  patients at coronary 
risk compared w ith  controls as previously shown in other studies (Boniface and Tefft, 
2002; Esrey et al., 1996). Consistent w ith  the results o f  Jakobsen et al (Jakobsen et 
al., 2004), w e found that the M U F A  intake o f  dietary was higher in  patients w ith  
dyslipidaemia. In  the present study, dietary P U FA s did not d iffe r significantly 
between the patients and controls. The reasons for these findings are unclear. It  m ay  
be related to im proved diet in  the patients, in  response to general dietary advice given 
during their attendance at the lip id  clinic. I t  m ay also, in  part, be due to intake o f  trans 
fatty acids, w hich are included in  the sum o f  M U F A s . H ow ever, the reported trans 
fatty acids intakes range from  0 .5%  to 2 .1%  o f  energy intake among m en and from  
0.8%  to 1.9%  among w om en (1 .2 -6 .7  g/d and 1.7-4.1 g/d, respectively) in  western 
European countries including the U K  (H u lsh o f et al., 1999).
Dietary selenium in conditions related to CHD
Several studies have suggested that selenium insufficiency m ay be associated w ith  an 
increased risk o f  C H D  (Suadicani et al., 1992; Salonen et al., 1982). The dietary 
source o f  selenium m ay be important in disease prevention as the form  o f  selenium  
m ay affect its b ioavailab ility  (M iya za k i et al., 2002). It  has been reported that the
4.3 Discussion
Effects of gender on macro- and micronutrients dietary intake
145
dietary intake o f  non-fish selenium is positively associated w ith  H D L  cholesterol 
concentrations in  blood and negatively correlated w ith  the total cholestero l/HDL- 
cholesterol ratio. O n the other hand, the dietary intake o f  fish-selenium was reported 
to have no relationship w ith  any serum lipids (M iyazak i et al., 2002).
In  the present study, w e found that dyslipidaemic patients had a significantly higher 
dietary selenium intake compared w ith  control subjects. I t  m ay be related to selenium  
derived from  fish as a m ain source o f  their selenium status, but it  was not possible to 
calculate fish-selenium intake in  the present study. Patients at coronary risk not only  
had higher dietary selenium intake but also, had higher dietary protein and total fat 
intake compared w ith  control subjects.
Dietary zinc and copper in conditions related to CHD
In  the present study, w e  found that the dietary intake o f  zinc and dietary zinc/copper 
ratio was higher among patients w ith  dyslipidaemia compared w ith  controls. K levay  
has proposed the hypothesis that an imbalance in zinc/copper metabolism  predisposes 
to C H D . According to this hypothesis, dietary copper deficiency, either alone or in  
association w ith  a high zinc intake leads to hypercholesterolaemia and development o f  
atherosclerosis (K levay, 1975).
Dietary fibre in conditions related to CHD
Fibre particularly soluble forms o f  fibre low er serum total cholesterol and serum L D L  
without significant alteration in  serum H D L  and triacylglycerol (M ia  et al., 2002). 
Also, an increased fibre intake m ay decrease blood pressure slightly, assist in weight 
management, alter blood clotting factors, and increase insulin sensitivity (Anderson, 
1995). Intake o f  dietary fibre and complex carbohydrate appear to have a protective 
role for C A D  (M ia  et al., 2002; Anderson, 1995). The fibre intake o f  dietary was 
higher in  patients w ith  dyslipidaem ia compared w ith  controls in  the present study. The
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reasons for this finding are unclear. It  m ay be related to im proved diet in  the patients, 
in  response to general dietary advice given during their attendance at the lip id  clinic.
Dietary antioxidants in conditions related to CHD
Several epidem iological studies have suggested that higher intakes o f  fruit, vegetables, 
and whole grain are related to a low er risk o f  C H D  reviewed b y  (K nekt et al., 2004). 
One hypothesised explanation for this finding is a reduction in  o x -L D L , which is 
thought to p lay an im portant role in  the development o f  atherosclerosis (K nekt et al., 
2004). Because o f  their antioxidant properties, carotenoids, v itam in  E , and vitam in C  
m ay protect against oxygen-related free radicals and lip id  peroxidation and 
accordingly inhib it the development o f  atherosclerosis. Findings from  observational 
cohort studies on this topic are inconsistent (Boaz et al., 2000; Y u s u f et al., 2000). The  
reasons w h y  these previous studies have not supported the antioxidants hypothesis 
m ay include; a lack o f  pow er to detect associations, inaccurate assessment o f  
antioxidant intake, unsatisfactory control for potential confounding factors, an 
inability  to investigate subpopulations, habitual diet o f  subjects m ay not have been 
low  in  the antioxidants under study, not a ll antioxidants have equal potency, oxidation  
m ay only be involved at an early stage o f  atherosclerosis and it m ay be too late to 
reverse it, and antioxidants m ay be unable to access the necrotic core o f  the plaque, or 
even i f  they do they m ay not be effective in  preventing lip id  oxidation.
In  the present study, dietary intake o f  antioxidants did not d iffer in  patients and 
controls. Again  our finding did not support the antioxidants hypothesis. Therefore, the 
use o f  antioxidant supplementations in  patients at coronary risk is not recommended.
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There are several lim itations to our study design. O ur study design was a cross- 
sectional study; hence w e can only m ake associations rather than attribute direct 
causative relationships between nutritional intake and coronary risk.
There is the potential for FFQ s to have a number o f  errors associated w ith  estimating 
macro- and micronutrients dietary intake. A lso, our study group was a small 
heterogeneous sample o f  dyslipidaemic patients. It  would be important to confirm  
these findings in  a larger sample size.
In  conclusion, w e have demonstrated that dietary macronutrients such as total fat and 
micronutrients such as zinc, zinc/coper ratio and selenium w ere associated w ith  
coronary risk factors. I t  m ay be important fo r the patients w ith  dyslipidaem ia to have 
more individualised dietary advice, especially to reduce their dietary intake o f  total 
fat.
Limitation of the study
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CHAPTER 5
S e r u m  C R P  i n  c o n d i t i o n s  r e l a t e d  t o  
c o r o n a r y  r i s k  f a c t o r s
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5. S erum  C R P  in  conditions re la ted  to coronary  r is k  factors
Elevated levels o f  C R P  have been associated w ith  increased risk o f  cardiovascular 
m orbid ity and m ortality  (B erk  et al., 1990; Ford and Giles, 2000). Several large-scale 
prospective studies demonstrate that CRP is a strong independent predictor o f  future 
M I  and stroke (review ed b y  R idker, 2001). One prospective study investigated direct 
comparisons o f  CR P w ith  other markers o f  vascular risk and showed that C R P was 
the single strongest predictor o f  risk (R R  4.4 for the highest versus lowest quartile) 
(R idker et al., 2000). H ow ever, more recently Levinson et al (2 0 0 4 ) questioned the 
predictive value o f  high-sensitivity CRP for C H D . They argue that serum CRP is 
like ly  to lead to errors estimating risk and that their measurement is economically  
unjustified (Tab le 5.1).
I t  is perhaps too early to abandon the use o f  hs-CRP for estimating coronary risk. Its 
predictive value m ay be im proved by  combining it w ith  other measurement o f  
inflam m ation, or by  repeated measures, in specific category o f  subjects. It  m ay not be 
economic at the present tim e, but much cheaper automated methods are being 
introduced. Physiological conditions such as age and gender also influence serum 
CRP concentrations (Tab le  5 .1)
W e  investigated the effects o f  conditions related to C H D  risk factors on serum CRP  
concentrations as a m arker o f  inflam m ation in  dyslipidaemic patients and healthy  
subjects.
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5.1 S erum  C R P  in  hea lth y  subjects
5.1.1 Physio logical v a ria tio n  in  serum  C R P
Gender
Am ong the 189 control subjects, 95 subjects were males and 94 w ere females (fo r 
more details refer to appendix 4 and section 4 .1 .1 ). Serum C R P concentrations were  
significantly higher in  healthy females [1 .26 (0 .23 -2 .64 )] than healthy males [0.65  
(0 .18 -1 .56 )] Cp<0.05).
Age
The healthy m ale and fem ale subjects were divided into 6 age categories. The age 
distribution for the groups w ere as follows: 20-29  years (n  =  13 males and 13 
females), 30-39  years (n  =  9 males and 9 females), 40-49  years (n  =  24  males and 23 
females), 50 -59  years (n =  28 males and 31 females), 60 -69  years (n  =  14 males and 
11 females), and 70 years and above (n =  7 males and 7 females).
Although median serum C R P  levels did not vary significantly w ith  age for either 
gender (Tab le 5 .2 ,/> >0 .05 ), there was a significant correlation between age and serum 
CRP concentrations (r= 0 .1 8 ,/K 0 .0 5 )  in  healthy subjects.
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Physical activity levels
In  healthy subjects, physical activity levels were positively associated w ith  H D L  
cholesterol levels O < 0 .0 1) and negatively associated w ith  B M I  (p < 0 .0 01 ) and W H R  
O < 0.0 0 1 , Table 5 .3). In  the patient group, physical activity levels w ere positively  
associated w ith  H D L  cholesterol level O < 0 .0 0 1 , Table 5 .3) and negatively associated 
w ith  B M I  (p O .O O l), serum triglycerides (p<0.001), diastolic blood pressure O < 0 .0 1 )  
and calculated 10-year coronary risk O < 0 .0 5 , Table 5 .3) (fo r m ore details refer to 
appendix 6). N o  significant correlations between serum CR P levels and physical 
activity levels w ere observed in either patient or control groups (^ > 0 .05 , Table 5.3).
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Table 5.3 Correlations (r) between physical activity levels and individual coronary 
risk factors ______________________________________
C ontro ls Patients
n 135 237
Fasting blood glucose 0.01 -0 .02
B M I -0 .3 4 * * * -0 .2 4 * *
W aist: H ip  ratio -0 .4 6 * * * -0 .4 1 * * *
H D L 0 .2 4 * * 0 .3 1 * * *
Triglycerides -0 .10 -0  2 7 * * *
Systolic BP 0.07 0.05
Diastolic BP -0.12 -0 .2 3 * *
Calculated 10-year 
Coronary risk
-0 .14 -0 .1 6 *
CRP 0.10 -0 .10
Correlations were assessed using Pearson correlation coefficients; *= p < 0 .0 5 , **=p<0.01, 
* * *= /K 0 .0 0 1 .
N on-norm ally  distributed data such as serum C R P and triglycerides log transformed 
before using the Pearson correlations.
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Smoking
Am ong the 189 control subjects, 123 subjects had never smoked and 66 were current 
or ex-smokers. There w ere 32 current smokers and 34 ex-smokers (fo r more details 
refer to appendix 5 and section 4.1.2). A lthough the median serum CRP  
concentrations were higher in  both current smokers [1 .00 (0 .4 7 -2 .2 1 )] and ex-smokers 
[0 .94 (0 .28 -2 .95 )] compared w ith  non-smokers [0 .70 (0 .1 7 -2 .1 4 )], this failed to reach 
statistical significance (p>0.05).
Obesity
Am ong the 189 control subjects, 33 were obese, 58 were over w eight, and 78 were o f  
optimal w eight (fo r more details refer to Table 3.3 and section 4 .1 .2 ). Obese subjects 
had significantly higher median serum C R P concentrations compared w ith  over 
weight and optim al w eight subjects (p O .0 0 1 , Table 5.4). These results were shown to 
be statistically significant fo r m ale and female groups respectively and for the 
combined group (p O .0 0 1 , Table 5.4).
5.1.2 Pathophysiological conditions and their association with serum CRP levels
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Table 5.4 Association between BMI and serum CRP concentrations in healthy subjects
M ales
Obese O verweight N orm al weight
Num ber o f  subjects 19 36 31
CRP (m g /L ) 1.63 (0 .9 4 -3 .5 5 )* * * 0.58 (0 .30 -1 .03 ) 0.17 (0 .07 -0 .72 )
Fem ales
Num ber o f  subjects 14 22 47
CRP (m g /L ) 2 .75 (1 .5 7 -1 0 .6 3 )* * * 1.80 (0 .48 -4 .09 ) 0.58 (0 .08 -1 .43 )
M ales  &  Fem ales
Num ber o f  subjects 33 58 78
CRP (m g /L ) 1.97 (1 .1 4 -5 .9 6 )* * * 0.78 (0 .31 -1 .88 ) 0.41 (0 .07 -1 .35 )
Values are expressed as m edian and interquartile range. Between group comparisons 
were assessed b y  K ruskal-W allis  as they are non-normal distribution data; ***==p<0.001. 
Results when analysing log-transformed serum CRP concentrations were sim ilar to 
results using non-log-transformed data.
Subjects w ith  B M I  greater than 30, between 25 and 30, and less than 25 defined as 
obese, over weight, and norm al w eight respectively (British N utrition  Foundation Task 
Force, 1999).
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5.2 S erum  C R P  in  conditions re la ted  to C H D
5.2.1 S eru m  C R P  and  C H D  r is k  factors
Serum CRP concentrations were significantly higher in  the dyslipidaem ic patients 
compared w ith  controls for both male (p <0 .001) and fem ale (p < 0 .0 1 ) subgroups and 
for groups combined (p <0 .001 , Table 5.5).
Serum CR P concentrations differed significantly between sub-categories w ith  and 
without respectively; the presence o f  established C H D , m etabolic syndrome, diabetes 
m ellitus type 2, and obesity, and calculated 10-year coronary risk scores (p<0.05, 
Tables 5.6 and 5.7).
In  an analysis o f  covariance the difference in  serum C R P  concentrations in  
dyslipidaemic patients compared w ith  controls was no longer significant when B M I  
was used as a covariate (p>0.05). Analysis using log-transformed serum CRP  
concentrations was sim ilar to results using untransformed data.
Correlation between CHD risk factors and serum CRP
In  control subjects, serum C R P  concentrations were positively associated w ith  age 
(P < 0 .05 ), B M I (P O .O O l), waist/hip ratio (P < 0 .05 ), serum triglycerides (P O .O O l), 
serum total cholesterol (P O .O l)  and systolic and diastolic blood pressure (p<0.01, 
Table 5.7). In  the patient group, serum CR P concentrations w ere positively associated 
w ith  B M I (P O .O O l), waist/hip ratio (P < 0 .0 0 1 ) and serum triglycerides (p<0.001, 
Table 5.8).
158
Table 5.5 Comparison o f  serum CR P concentrations between dyslipidaemic patients and 
control subjects_________________ _______________________________________________________
M ales
N um ber o f  subjects 
CRP (m g /L ) 
Fem ales
N um ber o f  subjects 
CRP (m g /L )
M ales  &  Fem ales  
Num ber o f  subjects 
CRP (m g /L )
Patients
95
1.54 (0 .5 0 -4 .4 7 )**
C on tro ls
142 67
1.08 (0 .3 7 -3 .1 9 )* * *  0.41 (0 .16 -0 .93 )
68
0 .94  (0 .20 -2 .14 )
237 135
1.25 (0 .4 2 -3 .2 6 )* * *  0 .58 (0 .17 -1 .42 )
Values are expressed as m edian and interquartile range. Between patient and control 
group comparisons w ere assessed b y  Kruskal-W allis  as they are non-normal 
distribution data; * * = /K 0 .0 1 ,  ***= /? < 0 .0 01 .
Results when analysing log-transformed serum CR P concentrations w ere sim ilar to 
results using non-log-transformed data.
In  an analysis o f  covariance the difference in  serum C R P concentrations in  
dyslipidaemic patients compared w ith  controls was no longer significant when B M I  
was used as a covariate (p >0 .05).
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Table 5.6 Comparisons o f  serum CR P (m g /L ) for different subgroups o f  dyslipidaemic  
patients segmented according to the possession o f  specific coronary risk factors (in  
combined m ale and fem ale group).______________________________________________________
N u m b e r M a le s  &  Fem ales
G roups
E stablished C H D
C H D + 55 1.80 (0 .4 3 -6 .0 9 )3*
C H D - 182 1 .1 7 (0 .4 2 -2 .9 6 )
M e tab o lic  S yndrom e
M S + 142 1.70 (0 .6 0 -4 .5 7 )3* * *
M S - 95 0.79 (0 .2 9 -2 .2 7 )
Diabetes M e llitu s
D M + 42 2.06  (0 .6 2 -5 .7 9 )3*
Im paired G T 21 1.54 (0 .4 0 -2 .8 6 )
D M - 195 1 .1 0 (0 .4 1 -3 .1 9 )
O besity
Obese+ 82 2.89 (1 .0 3 -5 .8 1 )3* * *
O ver weight 112 0.91 (0 .3 7 -2 .4 6 )
N orm al weight 43 0.61 (0 .1 9 -1 .5 2 )
H y p e rtr ig ly c e rid a e m ia
H igh  T .G . 176 1.54 (0 .4 9 -3 .2 3 )3
N orm al T .G . 61 0 .74  (0 .3 2 -3 .9 9 )
B lood pressure
H igh  BP 76 1.61 (0 .4 9 -3 .47)3
Moderate BP 111 1.25 (0 .3 9 -3 .1 9 )
N orm al BP 50 1.22 (0 .4 6 -3 .5 5 )
C a lcu la ted  10 -year
C o ro n a ry  R is k
H igh  > 30 % 42 2.71 (0 .4 9 -6 .10)3*
Moderate 2 0 -3 0% 54 1.14 (0 .4 5 -4 .7 0 )
Lo w  < 20 % 141 0.98 (0 .4 0 -2 .6 6 )
C ontro ls 135 0 .5 8 (0 .1 7 -1 .4 2 )
Values are expressed as m edian and interquartile range. Between group comparisons 
were assessed by  K ruskal-W allis , as they are non-norm ally distributed data. 
l= /i< 0 .0 5 , 2=/><0.01, 3=/;<0.001 comparison between the groups including patients 
and controls, and *= /><0.05, * * * =  /K 0 .0 0 1  comparison between sub-categories o f  the 
dyslipidaemic patients.
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Table 5.7 Comparison of serum CRP (mg/L) between different subgroups of dyslipidaemic
patients segmented according to the possession of specific coronary risk factors (in separate
males and females).____________________
N u m b e r M ales  N u m b e r Fem ales
G roups
Established C H D
C H D + 37 1.76 (0 .5 2 -6 .02 )3 18 2 .20  (0 .3 1 -6 .3 2 )1
C H D - 105 0.92 (0 .34 -2 .48 ) 77 0 .94  (0 .20 -2 .14 )
M e tab o lic  S yndrom e
M S + 84 1.37 (0 .39 -3 .96 ) 58 2.27 (0 .85 -5 .46 ) * *
M S - 58 0.82 (0 .30 -2 .15 ) 37 0.68 (0 .27 -.2 .41 )
Diabetes M e llitu s
D M + 28 1.56 (0 .44 -4 .91 ) 14 2 .79  (1 .46 -6 .50 )
D M - 114 0.99 (0 .36 -2 .85 ) 81 1.28 (0 .48 -3 .37 )
O besity
Obese+ 50 2.05 (0 .72 -4 .68 ) * * 32 3.71 (2 .02 -7 .46 ) * * *
Obese- 92 0.77 (0 .26 -1 .95 ) 63 0.88 (0 .41 -2 .27 )
H y p e rtr ig ly e e rid a e m ia
H igh  T .G . 114 1.19 (0 .3 8 -2 .9 1 )3 62 2.10  (0 .77 -4 .54 )2*
N orm al T .G . 28 0.73 (0 .35 -4 .70 ) 33 0.87 (0 .27 -3 .66 )
Blood pressure
H igh  BP 34 1.62 (0 .61 -3 .66 ) 42 1.45 (0 .4 5 -3 .5 7 )1
M oderate BP 77 0.91 (0 .29 -3 .08 ) 34 1.71 (0 .87 -4 .06 )
Norm al BP 31 1.21 (0 .54 -2 .82 ) 19 1.52 (0 .41 -5 .06 )
C alcu la ted  10 y e ar  
C o ro n a ry  R is k
H igh  > 30 % 35 2.49 (0 .4 2 -5 .9 6 )3* 7 3.37 (1 .6 7 -6 .8 7 )1
Moderate 20 -30% 37 0.99 (0 .48 -4 .70 ) 17 1.83 (0 .30 -5 .24 )
L o w  < 20 % 70 0.81 (0 .34 -1 .80 ) 71 1.34 (0 .50 -3 .51 )
C ontro ls 67 0.41 (0 .16 -0 .93 ) 68 0 .94  (0 .20 -2 .14 )
Values are expressed as m edian and interquartile range. Between group comparisons were  
assessed by  K ruskal-W allis , as they are non-norm ally distributed data. 1 = /K 0 .0 5 , 2= /i<0.01 , 
3=/j<0.001 comparison between the groups including patients and controls, and -*-p<0.05, 
* * * = /K 0 .0 0 1  comparison between sub-categories o f  the dyslipidaemic patients.
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Table 5.8 Correlations (r) between serum C R P  concentrations (m g /L ) w ith  individual
coronary risk factors___________________________________________________________________
Patients C on tro ls
n 238 135
Age 0.11 0.18*
Fasting blood glucose 0.10 0.06
B M I 0.42*** 0.42***
W aist: H ip  ratio 0.28*** 0.17*
H D L -0.06 -0.07
Triglyceride 0.26*** q 27***
Systolic BP 0.02 0 2 5 **
Diastolic BP 0.06 0.19**
Total cholesterol 0.09 0.23**
Correlations w ere assessed using Pearson correlation coefficients; *= p < 0 .0 5 , **= /><0.01 ,
* **= p < 0 .0 0 1 .
N on-norm ally  distributed data such as serum CRP and triglycerides log transformed 
before using the Pearson correlations.
M a le  subjects had significantly low er serum CRP concentrations compared w ith  female 
(p<0 .05) in control subjects and borderline (p =0 .08) in  patient subjects.
Smokers had significantly higher serum CRP concentrations compared w ith  non-smokers 
(p<0.05) in patient subjects and borderline (p=0.08) in control subjects.
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W ith in  the dyslipidaemic group, serum CR P concentrations rose w ith  accumulating o f  
features o f  the metabolic syndrome in  males O > 0 .0 5 ), females O < 0 .0 5 ) and in  the 
combined group O < 0 .0 1 , Figure 5.1). In  an analysis o f  covariance, significance difference 
between the patients and controls was lost after adjustment for B M I  as a covariate 
O > 0 .0 5 ). O ne-w ay A N O V A  o f  log-transformed data showed that patients w ith  3 or more 
features o f  metabolic syndrome had significantly higher serum CR P levels compared w ith  
patients w ith  2 or less features (p<0.05, Figure 5.1).
5.3 M u lt ifa c to r ia l analysis o f serum  C R P
In  order to evaluate the factors determing serum CR P concentrations in  the dyslipidaemic 
patients, and in  the patients w ith  metabolic syndrome, stepwise m ultip le  regression analysis 
was undertaken (fo r more details refer to section 3.8). The best m odel explained a total o f  
13.5%  o f  the variation serum C R P  concentrations among the dyslipidaemic patients and the 
m ajor determinant factor being obesity in  this group. The best m odel explained 14%  o f  the 
variation in  serum C R P  in  the metabolic syndrome group w ith  the m ain  determinant factor 
being B M I. This m irrored the results obtained in the univariate analysis where there were  
highly significant effects o f  parameters associated w ith  obesity and 3 or more features 
associated w ith  M S  (Figure 5.1). Adding extra terms to the m odel had little  effect on 
explaining the variab ility  in  the values for C R P in  the patients as measured by the adjusted 
R 2 values.
5.2.2 Serum CRP and metabolic syndrome
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Figure 5.1 Relationship between serum CR P (m g /L ) and accumulation o f  features o f  
metabolic syndrome in  dyslipidaemic patients
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Features of metabolic syndrome
Between group comparisons o f  m edian C R P concentrations were assessed by one-way  
A N O V A  o f  log-transformed data and Fisher’s (post-hoc test) for determining differences 
w ith in  individual groups showed that patients w ith  3 or m ore features o f  metabolic 
syndrome had significantly higher serum C R P levels compared w ith  patients w ith  2 or less 
features (p<0.01).
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5.4 S erum  C R P  concentrations and im portan ce  o f d ie ta ry  features
Raised serum C R P concentrations have been reported in subjects w ith  atherosclerosis. The  
im m une-m odulating effects o f  dietary fat and antioxidants have been investigated 
previously. W e  determined whether dietary antioxidants and fat intake were associated 
w ith  serum CR P concentrations in  dyslipidaemic subjects.
Results o f  stepwise m ultip le regressions in  the dyslipidaemic patient group showed that 
approximately 4 %  o f  the variation in  serum CRP could be explained b y  dietary cholesterol 
intake (p=0.015 , + 2 .8 % ), and dietary vitam in C  intake (p>0.05, -1 .2 % ). W ith in  the 
subgroup w ith  m etabolic syndrome, 1.5 % o f  the variation could be explained by  dietary 
mono unsaturated fat (p >0 .05). In  controls, no relationship between dietary intake and 
serum CRP concentrations was found (Table 5.9).
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Table 5.9 Multifactorial analyses of serum CRP concentrations (mg/L)
D yslip idaem ia
M e tab o lic  syndrom e
C onfounders C oeffic ien t R P
%
Obesity +0.510 12.1 <0.001
Smoking +0.280 3.8 0.004
Gender -0 .287 3.9 0.003
D ie tary  cholesterol +0.0013 2.8 0.01
Age +0.0074 1.6 0.04
D ie tary  vitam in C +0.01 1,2 0.06
B M I +0.203 9.4 0.002
Systolic blood pressure -0.039 4.5 0.02
D ie tary  monounsaturated fat +0.063 1.5 0.11
Stepwise regression was used.
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Consistent w ith  some reports (Colhoun et al., 2002; Scholin et al., 2004 ), w e found higher 
concentrations o f  C R P  in  w om en than men. This remained significant after adjusting for 
B M I. The differences in  C R P  levels between males and females m ay reflect differences in  
adiposity between the genders (Yki-Jarvinen, 1984). How ever, Herbeth et al. (2001) did  
not observe significant gender differences in  serum CR P concentrations in  the elderly  
(Herbeth et al., 2001).
Effects of age on serum CRP concentrations
W e  and Saito et al. (Saito et al., 2003) found a w eak positive correlation between age and 
CRP levels. This m ay be related to two reasons: (1 ) The higher prevalence o f  inflam m ation  
and infection w ith  increasing age. (2 ) Increased unfavourable body fat accumulation, 
especially w ith in  the visceral depots, during the process o f aging (Jankowska et al., 2000). 
Effects of physical activity levels on serum CRP concentrations
Aronson et al. (2 0 0 4 ) found a negative correlation between serum C R P  concentrations and 
physical activity levels (Aronson et al., 2004). W e  found a borderline significant 
correlation between serum C R P concentrations and physical activ ity  levels. Negative  
correlation between physical activity levels and serum CRP m ay be related to decrease fat 
tissue by exercising.
Effects of smoking on serum CRP concentrations
Sim ilar to Saito’s report (Saito et al., 2003), w e found higher serum C R P  concentrations in  
smokers compared w ith  non-smokers. There is good evidence that smoking induces 
oxidative and pro-inflam m ation stim uli (K im  et al., 2003).
5.5 Discussion
Effects of gender on serum CRP concentrations
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Consistent w ith  Fredrikson’s report (Fredrikson et al., 2004 ), w e found that serum 
concentrations o f  C R P  w ere not significantly associated w ith  dietary intake o f  total energy, 
total fat, saturated fat, M U F A , P U FA s, v itam in E  and vitam in  C  in  healthy controls. 
How ever in the dyslipidaemics, C R P concentrations were associated positively w ith  dietary  
cholesterol and negatively w ith  vitam in C.
Effects of CHD risk factors on serum CRP concentrations
The relationship between serum inflam m atory markers such as C R P  and C H D  has been 
shown in  cohort studies (Scholin et al., 2004), and has been supported b y  meta-analysis 
data (Scholin et al., 2004). S im ilar to our findings, recent studies have reported that levels 
o f  serum CRP are related to individual coronary risk factors including the metabolic 
syndrome (Linnem ann et al., 2003; Scholin et al., 2004).
W e  and others (A lb ert et al., 2003) have also demonstrated that serum CR P levels 
significantly correlate w ith  calculated 10-year coronary risk.
Effects of adiposity on serum CRP concentrations
W e  found a strong relationship between CR P and indices o f  adiposity in  subjects w ith  
dyslipidaemia as previously reported for other groups o f  subjects (Forouhi et al., 2001). 
Sim ilar to previous studies (V isser et al., 1999), w e have found that serum CRP  
concentrations were elevated in  overweight and obese subjects.
Serum CR P concentrations had a closer correlation w ith  B M I than w ith  other coronary risk 
factors such as serum lipids and systolic and diastolic blood pressure. There are two  
possible reasons for this: (1 ) The measures o f  B M I are more robust and less liable to intra 
individual variation compared to blood pressure, plasma glucose or serum lipids. (2 ) 
Adipose tissue secretes IL -6 , a potent stimulant o f  hepatic CR P synthesis (Y ud kin  et al., 
1999).
Effects of diet on serum CRP concentrations
168
Association between metabolic syndrome and serum CRP concentrations 
W e, like  Tam akoshi and colleagues (Tam akoshi et al., 2 003 ) and R idker et al (R idker et 
al., 2003), found that C R P  concentrations rose w ith  an increasing num ber o f  features o f  the 
metabolic syndrome, and the relative values were sim ilar in  our population to those 
reported in  their Caucasian populations. These investigators have also reported a positive 
association between serum C R P  levels and fasting glucose, triglycerides and systolic blood  
pressure and a negative association w ith  H D L  cholesterol (Tam akoshi et al., 2003).
W e  found a significant positive association between serum C R P  and triglycerides, total 
cholesterol and systolic and diastolic blood pressure and the negative association w ith  H D L  
cholesterol was non significant. The association between serum C R P  concentrations and 
total cholesterol and systolic and diastolic blood pressure was not observed in  the patient 
group. This m ay be related to use o f  anti-hypertensive and lip id  low ering drugs in  patients. 
There was no relationship between fasting blood sugar level and C R P  in  our group as has 
been reported b y  others in  healthy m iddle-age subjects (Aronson et al., 2004).
I t  is conceivable that individual features o f  the metabolic syndrome such as hypertensive, 
dyslipidaem ia synergistically prom ote atherosclerosis, causing a low-grade systemic 
chronic in flam m atory state.
CRP has been reported to upregulate adhesion molecule expression (Pasceri et al., 2000) 
and downregulate the production o f  nitric oxide (V erm a et al., 2 0 02 ) and could therefore 
directly promote endothelial dysfunction. S im ilarly , the m etabolic syndrome m ay influence  
endothelial function through a non-inflam m atory pathway, such as hypertension and/or 
insulin resistance.
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In  conclusion, serum C R P  concentrations were significantly related to obesity or B M I.  
Also, a variety o f  features o f  metabolic syndrome are associated w ith  elevated CRP  
concentrations in  a systemic low-grade chronic inflam m atory state.
In  the healthy controls, serum C R P concentrations were not associated w ith  dietary factors. 
H ow ever in the dyslipidaemics, C R P concentrations were associated positively w ith  dietary  
cholesterol and negatively w ith  vitam in  C.
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CHAPTER 6
A n t i b o d y  t i t r e s  t o  H s p s  i n  c o n d i t i o n s  
r e l a t e d  t o  c o r o n a r y  r i s k  f a c t o r s
Cells respond to a variety o f  environmental stresses b y  expressing several families o f  
proteins called the heat shock proteins (Hsps) (M orim oto , 1993; Udelsm an et al., 1993). 
These proteins are involved in  the process o f  rematuration o f  other proteins damaged by  
exposure to these environmental stressors, however they m ay themselves be damaged in  
the process and become antigenic (Lam b et al., 2003; M orim oto , 1993). C lin ical studies 
have reported positive associations between plasma levels o f  anti-Hsps and extent o f  C H D  
(B im ie  et al., 1998; B urian et al., 2001; Chan et al., 1999; Frostegard et al., 1996; Gruber et 
al., 1996; Hoppichler et al., 2000; H uittinen et al., 2002; M ukherjee et al., 1996; Prohaszka 
et al., 1999; Prohaszka et al., 2001; X u  et al., 1993). I t  is not clear, however, at which  
stages o f  C H D  these antibodies appear, and therefore w hat factors influence their 
appearance.
The im m une-m odulating effects o f  dietary fat and antioxidants have been investigated 
previously (Stulnig, 2003; Bub et al., 2003), but their effects on anti-Hsps have not been 
reported in human. The effects o f  dietary constituents o f  fat and antioxidants on Hsps have 
been studied in  anim al models (Andres et al., 2000; K e lly  et al., 1996; Khassaf et al., 2003; 
Lam b and Ferns, 2002). To  our knowledge no studies have yet examined the association 
between Hsps antibody titers and traditional coronary risk factors or dietary intake in  
humans. Hence, w e investigated the association between some know n C H D  risk factors on 
Hsp antibody titres. W e  also w ish to investigate whether dietary factors are associated w ith  
Hsps antibody titers in  dyslipidaem ic patients and healthy control subjects.
6. Anti-Hsps titres in conditions related to C H D
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6.1 A n ti-H s p s  titres  in  h e a lth y  subjects
6.1.1 Physio logical v a r ia tio n  in  an ti-H sps  titres
Gender
Am ong the 189 healthy subjects, 95 subjects w ere males and 94 w ere females (fo r more  
details refer to appendix 4  and section 4 .1 .1 ). Plasma antibody titres to H sp-60, -65, and - 
70 did not d iffer significantly between m ale and fem ale subjects (jj<0.05, Table 6.1).
Table 6.1 Effects o f  gender and smoking habit on plasma antibody titres to Hsps (absorbance
unit) in  healthy subjects_______________
A nti-H sp -60
G en d er
M ales 0 .2 4 (0 .1 7 -0 .3 6 )
(n=95)
Females 0 .2 6 (0 .1 6 -0 .3 7 )
(n=94)
Sm oking
Smokers 0 .27 (0 .2 0 -0 .4 7 )*  0 .32 (0 .23 -0 .52 ) 0 .22  (0 .14 -0 .34 )
(n=66)
Non-smokers 0.23 (0 .1 6 -0 .3 2 ) 0.33 (0 .23 -0 .52 ) 0.21 (0 .14 -0 .30 )
(n=123)______________________________________________________________________________________
Values are expressed as m edian and interquartile range. Between group comparisons were  
assessed b y  K ruskal-W allis  as they are non-norm al distribution data; *= /K 0 .0 5  
Results when analysing log-transformed antibody titres to Hsps w ere sim ilar to results using 
non-log-transformed data.
A nti-H sp-65  A n ti-H sp -70
0.34  (0 .23 -0 .58 ) 0.21 (0 .15 -0 .33 )
0.31 (0 .2 3 -0 .5 3 ) 0 .20  (0 .14 -0 .31 )
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Age
The male and fem ale subjects from  the healthy group were divided into 6 groups based on 
their age (fo r m ore details refer to section 5 .1 .1). W ith in  these 6 groups, antibody titres to 
Hsp-60, -65 , and -70  did not d iffe r significantly O > 0 .0 5 , Table 6.2).
Physical activity levels
In  healthy subjects, there was no significant correlation between physical activity levels 
and antibody titres to H sp-60  (r= 0 .12 ), Hsp-65 (r= -0 .0 5 ) and H sp-70  (r= 0 .07 ). N o r was 
there a significant correlation between physical activity levels and antibody titres to Hsp-60  
(r= -0 .1 0 ), H sp-65 (r= -0 .0 1 ) and H sp-70  (r= -0 .0 5 ) in  the patient group (> > 0 .05 ) (fo r more 
details refer to appendix 6 and section 5 .1.1).
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6.1.2 Pathophysio log ical conditions and th e ir  association w ith  an ti-H sps  titres
Smoking
Am ong the 189 control subjects, 123 subjects had never smoked and 66 were current 
or ex-smokers including 32 current smokers and 34 ex-smokers (fo r m ore details refer 
to appendix 5 and section 4 .1 .2 ). The median plasma anti-H sp-60 titres were  
significantly higher in  smokers than non-smokers (p<0.05). H ow ever, antibody titres 
to Hsp-65, and -70  did not d iffe r significantly between smokers and non-smokers 
(p>0.05, Table 6.1).
Obesity
Am ong the 189 control subjects, 33 w ere obese, 58 were overweight, and 78 were o f  
normal w eight (fo r m ore details refer to Table 3.3 and section 4 .1 .2 ). O verall, obese 
subjects had significantly higher anti-Hsp-60 (/K 0 .0 0 1 ), anti-Hsp-65 (p <0 .05), and 
anti-Hsp-70 (p<0 .05 ) compared w ith  overweight and norm al w eight subjects (Table  
6.3). M a le  obese subjects had significantly higher serum titres to anti-Hsp-60  
(p<0 .001) and anti-H sp-70 (p<0.05) compared w ith  controls (Tab le  6.3). Female  
obese subjects had significantly higher anti-Hsp-60 titres (p <0 .05). D ifferences were 
borderline fo r anti-Hsp-65 (p =0 .07), but not significant fo r anti-Hsp-70 titre (p>0.05) 
compared w ith  controls (T ab le  6.3).
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Table 6.3 Association between B M I  and plasma antibody titres to Hsps (absorbance 
unit) in healthy subjects_________________________________________________________________
M ales
Obese O verweight N orm al weight
Num ber o f  subjects 19 36 31
A nti-H sp-60 0.42 (0 .2 7 -0 .6 5 )* * * 0.23 (0 .17 -0 .31 ) 0.21 (0 .16 -0 .32 )
A nti-H sp-65 0.48 (0 .2 7 -0 .8 6 ) 0.33 (0 .21 -0 .47 ) 0.35 (0 .23 -0 .57 )
A nti-H sp-70 0 .29  (0 .1 6 -0 .4 9 )* 0 .1 8 (0 .1 3 -0 .2 5 ) 0 .20  (0 .14 -0 .35 )
Fem ales
Num ber o f  subjects 15 22 47
A nti-H sp-60 0.31 (0 .2 6 -0 .6 7 )* 0 .22 (0 .11 -0 .31 ) 0 .24  (0 .15 -0 .28 )
A nti-H sp-65 0.32  (0 .25 -0 .72 ) 0 .36 (0 .24 -0 .49 ) 0 .26 (0 .20 -0 .53 )
A nti-H sp-70 0.23 (0 .1 5 -0 .3 9 ) 0 .1 8 (0 .1 5 -0 .3 1 ) 0.21 (0 .12 -0 .27 )
M ales  &  Fem ales
N um ber o f  subjects 34 58 77
A nti-H sp-60 0.41 (0 .2 8 -0 .6 5 )* * * 0.22 (0 .16 -0 .29 ) 0.22 (0 .15 -0 .30 )
A nti-H sp-65 0 .40  (0 .2 5 -0 .7 2 )* 0.33 (0 .24 -0 .49 ) 0 .30  (0 .20 -0 .53 )
A nti-H sp-70 0.26 (0 .1 6 -0 .4 7 )* 0 .1 9 (0 .1 4 -0 .2 6 ) 0 .20  (0 .13 -0 .29 )
Values are expressed as m edian and interquartile range. Betw een group comparisons 
were assessed b y  K ruska l-W allis  as they are non-normal distribution data; *= /K 0 .0 5 ,
* * *= p < 0 .0 0 1 .
Results w hen analysing log-transformed antibody titres to Hsps w ere sim ilar to results 
using non-log-transformed data.
Subjects w ith  B M I  greater than 30, between 25 and 30, and less than 25 were defined as 
obese, over weight, and norm al w eight respectively (B ritish  N u tritio n  Foundation Task  
Force, 1999).
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6.2 A n ti-H sp s  titres  in  conditions re la ted  to C H D
6.2.1 A n ti-H s p s  titres  and C H D  r is k  factors
Dyslipidaem ic patients had higher anti-Hsp-60 titres in  males (p < 0 .0 1 ), females 
(p=0.09) and the combined group (p <0 .01) compared w ith  controls (Tab le  6.4). A n ti-  
Hsp-65 titres in  males (p <0 .01 ), females (p <0 .001 ) and the combined group 
(p <0 .001) w ere higher in  dyslipidaem ic patients compared w ith  controls (Tab le  6.4). 
A nti-H sp-70  titres w ere also higher in  the total and male subgroup (p <0 .05 ), but not 
for the fem ale subgroup (p >0 .05 ) o f  dyslipidaemic patients compared w ith  controls 
(Table 6.4).
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Table 6.4 Comparison of Hsps antibody titres (absorbance unit) between
dyslipidaemic patients and controls_____________________________________________________
Males
N u m b er o f  su b jects  
A n t i-H s p -6 0  
A n ti-H sp -6 5  
A n t i-H sp -7 0  
Females
N u m b er o f  su b jects  
A n t i-H s p -6 0  
A n ti-H sp -6 5  
A n t i-H s p -7 0  
Males & Females 
N u m b er o f  su b jects  
A n t i-H sp -6 0  
A n ti-H sp -6 5
Patients
142
0 .2 6  (0 .1 9 -0 .3 8 )* *  
0 .4 5  (0 .2 7 -0 .7 8 )* *  
0 .2 3  (0 .1 7 -0 .3 0 )*
95
0 .2 7  (0 .1 6 -0 .3 6 ) 
0 .4 5  (0 .2 9 -0 .8 1 )* * *  
0 .2 0  (0 .1 6 -0 .3 0 )
2 3 7
0 .2 7  (0 .1 8 -0 .3 7 )* *  
0 .4 5  (0 .2 8 -0 .7 9 )* * *
Controls
67
0 .21  (0 .1 7 -0 .3 2 )  
0 .3 3  (0 .2 2 -0 .5 4 )  
0 .1 9 (0 .1 3 -0 .2 6 )
68
0 .2 3  (0 .1 5 -0 .2 8 ) 
0 .2 9  (0 .2 1 -0 .4 9 ) 
0 .1 9 (0 .1 4 -0 .2 9 )
135
0 .2 2  (0 .1 6 -0 .3 0 )  
0 .31  (0 .2 2 -0 .5 0 )  
0 .1 9 (0 .1 3 -0 .2 7 )A n t i-H s p -7 0  0 .2 2  (0 .1 7 -0 .3 0 )*
V a lu es  are ex p ressed  as m ed ia n  and interquartile  range. * = /K 0 .0 5 ,  * * = /K 0 .0 1 ,
* * * = p < 0 .0 0 1  co m p a r is o n  b e tw e e n  patients and co n tro ls  b y  u s in g  o n e -w a y  A N O V A . 
R esu lts  w h e n  an a lys in g  lo g -tra n s fo rm e d  a n tib od y  titres to  H sp s  w e re  s im ilar to  
results u sin g  n o n -lo g -tra n s fo rm e d  data.
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In  gen era l a n tib o d y  titres to  H sp s , rem a in ed  s ig n ifica n tly  h ig h er  in  patients co m p a re d  
w ith  co n tro ls  fo r  su b -ca te g o r ie s  o f  d y s lip id a e m ic  patients, e v e n  fo r  th ose  su b ­
ca teg ories  w ith ou t the re sp e c tiv e  co ro n a ry  risk  fa ctor. F o r  e x a m p le  sm all but 
s ign ifica n t d if fe re n ce s  fo r  a n ti-H sp -6 0  titres w e re  o b s e rv e d  b e tw e e n  the 
h y p ertr ig ly cer id a em ia  [0 .2 7  (0 .1 9 -0 .3 9 ) ]  and n o n -h y p ertr ig ly cer id a em ia  [0 .2 5  (0 .1 6 - 
0 .3 3 )] su bgrou p s. S ig n ifica n t d if fe re n ce s  fo r  a n ti-H sp -7 0  titres w e re  a lso  o b se rv e d  
b etw een  su b g rou p s  w ith  [0 .2 4  (0 .1 8 -0 .3 6 ) ]  and w ith ou t C H D  [0 .2 1  (0 .1 6 -0 .3 0 ) ]  as 
w e ll as w ith  [0 .2 6  (0 .1 8 -0 .3 4 ) ]  and w ith ou t D M  [0 .2 2  (0 .1 6 -0 .2 8 ) ]  (p = 0 .0 4 , T a b les  
6 .5 , 6 .6  and 6 .7 ) . T h e  resu lts o f  an a lysin g  log -tra n s fo rm ed  a n ti-H sp s titres w ere  
s im ilar to  n o n -lo g -tra n s fo rm e d  data fo r  a b o v e  analysis.
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Table 6.5 Comparison o f anti-heat shock proteins (Anti-Hsp) between different subgroups o f
combined male and female dyslipidaemic patients segmented according to the possession o f
specific coronary risk factors._____________________________________________________________________
Group
n Anti-Hsp-60 Anti-Hsp-65 Anti-Hsp-70
Established CHD
C H D +
C H D -
55
182
0 .2 7  (0 .1 9 -0 .3 5 )2 
0 .2 6  (0 .1 8 -0 .3 8 )
0 .4 3  (0 .2 9 -0 .8 7 )3 
0 .4 6  (0 .2 6 -0 .7 7 )
0 .2 4  (0 .1 8 -0 .3 6 )2* 
0 .21  (0 .1 6 -0 .3 0 )
Metabolic Syndrome
M S +
M S -
142
95
0 .2 7  (0 .1 9 -0 .3 8 )2 
0 .2 7  (0 .1 6 -0 .3 6 )
0 .4 7  (0 .2 9 -0 .8 0 )3 
0 .3 9  (0 .2 5 -0 .7 7 )
0 .23  (0 .1 7 -0 .3 1 )1 
0 .2 0  (0 .1 6 -0 .2 8 )
Diabetes Mellitus
D M +
Im paired  G T  
D M -
42
21
174
0 .2 3  (0 .1 8 -0 .3 6 )2 
0 .3 0  (0 .1 7 -0 .4 0 )  
0 .2 7  (0 .1 8 -0 .3 7 )
0 .4 4  (0 .2 9 -0 .8 2 )3 
0 .4 9  (0 .2 9 -0 .5 9 )  
0 .45  (0 .2 7 -0 .8 0 )
0 .2 6  (0 .1 8 -0 .3 4 )2* 
0 .2 0  (0 .1 5 -0 .2 8 ) 
0 .2 2  (0 .1 7 -0 .2 8 )
Obesity
O b e s e +
O v e r  w e ig h t 
N orm a l w e ig h t
82
112
43
0 .2 7  (0 .1 9 -0 .3 8 )2 
0 .2 5  (0 .1 7 -0 .3 5 )  
0 .3 0  (0 .1 7 -0 .3 9 )
0 .4 6  (0 .3 0 -0 .8 3 )3 
0 .4 8  (0 .2 6 -0 .8 0 )  
0 .3 9  (0 .3 1 -0 .6 6 )
0 .2 4  (0 .1 7 -0 .3 Q )1 
0 .21  (0 .1 6 -0 .2 8 ) 
0 .21  (0 .1 6 -0 .3 0 )
Hypertriglyceridaemia
H ig h  T .G . 176 
N o n n a l T .G . 61
0 .2 7  (0 .1 9 -0 .3 9 )3* 
0 .2 5  (0 .1 6 -0 .3 3 )
0 .4 6  (0 .2 9 -0 .7 7 )3 
0 .43  (0 .2 5 -0 .8 7 )
0 .2 3  (0 .1 7 -0 .3 0 )1 
0 .1 9 (0 .1 6 -0 .2 8 )
Blood pressure
H ig h  B P  
M od era te  B P  
N orm a l B P
7 6
111
5 0
0 .2 7  (0 .1 8 -0 .3 8 )1 
0 .2 7  (0 .1 9 -0 .3 9 )  
0 .2 5  (0 .1 7 -0 .3 5 )
0 .4 7  (0 .3 0 -0 .9 2 )3 
0 .43  (0 .2 8 -0 .6 9 )  
0 .41  (0 .2 5 -0 .7 8 )
0 .23  (0 .1 7 -0 .3 0 ) 
0 .2 0  (0 .1 6 -0 .3 2 ) 
0 .2 2  (0 .1 7 -0 .2 8 )
Calculated 10-year 
Coronary Risk
H ig h  > 3 0 %  
M od era te  2 0 -3 0 %  
L o w  < 2 0 %
4 2
54
141
0 .2 8  (0 .2 0 -0 .5 1)2 
0 .2 5  (0 .1 7 -0 .3 5 ) 
0 .2 6  (0 .1 7 -0 .3 7 )
0 .5 0  (0 .3 5 -0 .8 9 )3 
0 .4 0  (0 .2 6 -0 .7 5 )  
0 .4 5  (0 .2 8 -0 .7 9 )
0 .2 3  (0 .1 7 -0 .3 3 ) . 
0 .21  (0 .1 7 -0 .2 8 )  
0 .2 2  (0 .1 6 -0 .3 0 )
Controls 135 0 .2 2  (0 .1 6 -0 .3 0 ) 0 .31  (0 .2 2 -0 .5 0 ) 0 .1 9 (0 .1 3 -0 .2 7 )
V a lu es  are e x p re sse d  as m ed ia n  and interquartile range. l= /> < 0 .0 5 , 2 = /K 0 .0 1 , 3 = /K 0 .0 0 1  
co m p a riso n  b e tw e e n  the g rou p s  in c lu d in g  patients and co n tro ls , and * = P < 0 .0 5  co m p a riso n  
b e tw een  su b -ca te g o r ie s  o f  the d y s lip id a e m ic  patients. B e tw e e n  g rou p  com p a rison s  w e re  
assessed  b y  K ru sk a l-W a llis , as th ey  are n o n -n o rm a l d istribu tion  data.
R esu lts  w h en  an a lysin g  lo g -tra n s fo rm e d  a n tib od y  titres to  H sp s  w e r e  s im ilar to  results u s in g  
n o n -lo g -tra n s fo rm e d  data.
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T a b le  6 .6  C o m p a r iso n  o f  anti-heat sh o ck  prote in s (A n ti-H sp ) b e tw e e n  d iffe ren t su b grou p s o f  
m a le  d y s lip id a e m ic  patients seg m en ted  a cco rd in g  to  the p o s s e s s io n  o f  s p e c if ic  co ro n a ry  risk  
factors.
Group
n Anti-Hsp-60 Anti-Hsp-65 Anti-Hsp-70
Established CHD
C H D +
C H D -
37
105
0 .2 9  (0 .2 1 -0 .3 6 )1 
0 .2 5  (0 .1 9 -0 .3 9 )
0 .4 4  (0 .3 1 -0 .9 4 )2 
0 .45  (0 .2 5 -0 .7 2 )
0 .2 4  (0 .1 9 -0 .2 9 )1 
0 .2 2  (0 .1 6 -0 .3 0 )
Metabolic Syndrome
M S +
M S -
84
58
0 .2 9  (0 .2 0 -0 .4 0 )2* 
0 .2 5  (0 .1 6 -0 .3 5 )
0 .4 6  (0 .2 9 -0 .7 9 )2 
0 .4 2  (0 .2 4 -0 .8 0 )
0 .2 4 (0 .1 7 -0 .3 0 )  
0 .21  (0 .1 7 -0 .2 8 )
Diabetes Mellitus
D M +
D M -
28
114
0 .2 5  (0 .1 9 -0 .4 3 )1 
0 .2 7  (0 .1 9 -0 .3 8 )
0 .4 5  (0 .2 8 -0 .8 5 )2 
0 .45  (0 .2 6 -0 .7 8 )
0 .2 6  (0 .1 9 -0 .3 2 )1 
0 .2 2  (0 .1 7 -0 .2 8 )
Obesity
O b e s e +
O b e se -
50
92
0 .2 9  (0 .2 3 -0 .4 4 )2 
0 .2 5  (0 .1 8 -0 .3 5 )
0 .51  (0 .3 2 -0 .8 7 )2 
0 .4 2  (0 .2 5 -0 .7 7 )
0 .2 4  (0 .1 8 -0 .2 9 ) 
0 .2 2  (0 .1 6 -0 .3 2 )
Hypertriglyceridaemia
H ig h  T .G . 114  
N orm a l T .G . 28
0 .2 7  (0 .1 9 -0 .3 9 )2 
0 .2 5  (0 .1 4 -0 .3 0 )
0 .4 5  (0 .2 8 -0 .7 5 )1 
0 .43  (0 .2 3 -0 .8 8 )
0 .23  (0 .1 7 -0 .3 0 ) 
0 .2 0  (0 .1 6 -0 .2 7 )
Blood pressure
H ig h  B P  
M od era te  B P  
N orm a l B P
3 4
77
31
0 .2 7  (0 .1 9 -0 .4 2 )2 
0 .2 9  (0 .2 1 -0 .3 9 )  
0 .2 2  (0 .1 6 -0 .3 0 )
0 .5 0  (0 .2 7 -0 .9 3 )1 
0 .4 2  (0 .2 7 -0 .7 1 )  
0 .4 6  (0 .2 5 -0 .8 7 )
0 .2 5  (0 .2 1 -0 .3 1)2* 
0 .2 0  (0 .1 6 -0 .3 1 ) 
0 .2 2  (0 .1 7 -0 .2 7 )  ‘
Calculated 10-year 
Coronary Risk
H ig h  > 3 0 %  
M od era te  2 0 -3 0 %  
L o w  < 2 0 %
35
37
7 0
0 .31  (0 .2 3 -0 .5 3 )2*  
0 .2 6  (0 .1 9 -0 .3 6 )  
0 .2 4  (0 .1 9 -0 .3 5 )
0 .4 8  (0 .2 7 -0 .7 8 )1 
0 .3 8  (0 .2 4 -0 .7 0 )  
0 .4 6  (0 .3 2 -0 .9 4 )
0 .23  (0 .1 7 -0 .3 2 )  
0 .2 2  (0 .1 7 -0 .2 8 )  
0 .2 2  (0 .1 6 -0 .3 0 )
Controls 67 0 .21  (0 .1 7 -0 .3 2 ) 0 .33  (0 .2 2 -0 .5 4 ) 0 .1 9 (0 .1 3 -0 .2 6 )
V a lu es  are e x p re sse d  as m e d ia n  and interquartile  range. 1 = /K 0 .0 5 , 2 = /;< 0 .0 1 , 3 = /K 0 .0 0 1  
co m p a r iso n  b e tw e e n  the g rou p s  in c lu d in g  patients and co n tro ls , and  *=P<0.05 co m p a r iso n  
b e tw een  su b -ca te g o r ie s  o f  the d y s lip id a e m ic  patients. B e tw e e n  g rou p s  com p a r ison s  w e re  
assessed  b y  K ru sk a l-W a llis , as th e y  are n on -n orm a l d istribu tion  data.
R esu lts  w h e n  a n a lysin g  lo g -tra n s fo rm e d  a n tib o d y  titres to  H sp s  w e r e  s im ilar to  results u sin g  
n o n -lo g -tra n s fo rm e d  data.
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T a b le  6 .7  C o m p a r iso n  o f  anti-heat s h o c k  prote in s  (A n ti-H sp ) b e tw e e n  d iffe ren t su b grou p s  o f  
fem a le  d y s lip id a e m ic  patients seg m en ted  a cco rd in g  to  the p o s s e s s io n  o f  s p e c if ic  co ro n a ry  
risk  factors.
Group
n Anti-Hsp-60 Anti-Hsp-65 Anti-Hsp-70
Established CHD
C H D +
C H D -
18
77
0.21  (0 .1 5 -0 .2 8 )  
0 .2 8  (0 .1 6 -0 .3 7 )
0 .43  (0 .2 4 -0 .5 8 )3 
0 .4 6  (0 .3 0 -0 .8 3 )
0 .2 5  (0 .1 7 -0 .4 1 ) 
0 .1 9 (0 .1 6 -0 .2 8 )
Metabolic Syndrome
M S +
M S -
58
37
0 .2 5  (0 .1 6 -0 .3 1 )  
0 .2 9 (0 .1 6 -0 .3 8 )
0 .4 7  (0 .3 0 -0 .8 2 )3 
0 .3 9  (0 .2 6 -0 .7 5 )
0 .21  (0 .1 7 -0 .3 2 ) 
0 .1 9 (0 .1 6 -0 .2 9 )
Diabetes Mellitus
D M +
D M -
14
81
0 .1 9 (0 .1 6 -0 .2 8 )  
0 .2 8  (0 .1 7 -0 .3 7 )
0 .4 4  (0 .3 0 -0 .8 2 )3 
0 .4 6  (0 .2 9 -0 .8 1 )
0 .2 5 (0 .1 8 -0 .3 6 )  
0 .2 0  (0 .1 6 -0 .2 8 )
Obesity
O b e s e +
O b e s e -
3 2
63
0 .2 4  (0 .1 5 -0 .2 8 )  
0 .2 8  (0 .1 6 -0 .3 8 )
0 .4 4  (0 .2 8 -0 .7 8 )3 
0 .4 6  (0 .2 9 -0 .8 1 )
0 .23  (0 .1 6 -0 .3 6 ) 
0 .2 0  (0 .1 6 -0 .2 8 )
Hypertriglyceridaemia
H ig h  T .G . 62  
N orm a l T .G . 33
0 .2 7  (0 .1 7 -0 .3 8 ) 
0 .2 7  (0 .1 6 -0 .3 4 )
0 .4 7  (0 .3 0 -0 .8 2 )3 
0 .43  (0 .2 5 -0 .7 5 )
0 .2 2  (0 .1 7 -0 .3 1 ) 
0 .1 9 (0 .1 6 -0 .2 9 )
Blood pressure
H ig h  B P  
M od era te  B P  
N orm a l B P
4 2
3 4
19
0 .2 6  (0 .1 6 -0 .3 7 )  
0 .2 6  (0 .1 6 -0 .3 5 )  
0 .3 0  (0 .1 7 -0 .3 7 )
0 .4 7  (0 .3 1 -0 .9 2 )3 
0 .4 4  (0 .2 9 -0 .6 5 )  
0 .3 9  (0 .2 4 -0 .6 2 )
0 .1 8 (0 .1 6 -0 .2 9 )  
0 .21  (0 .1 6 -0 .3 2 ) 
0 .2 2  (0 .1 7 -0 .2 8 )
Calculated 10-year 
Coronary Risk
H ig h  > 3 0 %  
M od era te  2 0 -3 0 %  
L o w  < 2 0 %
7
17
71
0 .2 0  (0 .1 6 -0 .2 8 )  
0 .2 3  (0 .1 5 -0 .2 9 )  
0 .2 8  (0 .1 6 -0 .3 8 )
0 .53  (0 .4 3 -0 .8 7 )2 
0 .4 4  (0 .2 8 -0 .8 0 )  
0 .4 4  (0 .2 9 -0 .8 2 )
0 .1 9 (0 .1 6 -0 .3 6 )  
0 .1 8 (0 .1 7 -0 .2 8 )  
0 .2 2  (0 .1 6 -0 .3 0 )
Controls 68 0 .23  (0 .1 5 -0 .2 8 ) 0 .2 9  (0 .2 1 -0 .4 9 ) 0 .1 9 (0 .1 4 -0 .2 9 )
V a lu es  are e x p ressed  as m ed ia n  and interquartile  range. l= /> < 0 .0 5 , 2 - /K 0 .0 1 ,  3 = /K 0 .0 0 1  
co m p a r iso n  b e tw e e n  the g rou p s  in c lu d in g  patients and co n tro ls , and * = P < 0 .05 co m p a r iso n  
b etw een  su b -ca teg or ie s  o f  the d y s lip id a e m ic  patients. B e tw e e n  g rou p  com p a r ison s  w e re  
assessed  b y  K ru sk a l-W a llis , as th ey  are n on -n orm a l d istribu tion  data.
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S tron g  corre la tion s  w e re  o b s e rv e d  w ith in  patient and h ea lth y  g rou p s  b e tw een  
a n tib od y  titres to  H s p -6 0 , -6 5 , and  -7 0  (p < 0 .0 0 1 , T a b le  6 .8  and F igu re  6 .1 ) .
T a b le  6 .8  C orre la tion  (r ) b e tw e e n  a n tib od y  titres to  H sp -6 0 , H sp -6 5  and  H sp -7 0  in  
patients and h ea lth y  su b je cts  _____________________ ___________________ _____________________
A n t ib o d y  titres to  H sp s H sp -6 0 H sp -6 5 H sp -7 0
H sp -6 0
Patients - 0 .31 0 .55
H ea lth y  su b jects - 0 .6 5 0 .8 0
H sp -6 5
Patients 0.31 - 0 .23
H ea lth y  su b jects 0 .65 - 0 .63
C orre la tion s  w e re  a ssessed  u s in g  P earson  co rre la tion  c o e ff ic ie n ts . P  va lu es  fo r  all 
corre la tion  w e re  p < 0 .0 0 1 .
N o n -n o rm a lly  d istribu ted  data su ch  as p la sm a  a n tib od y  titres to  H sp s  w ere  lo g  
tran sform ed  b e fo r e  u s in g  the P ea rson  corre la tion s .
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F igu re  6.1 C orre la tion  b e tw e e n  a n tib o d y  titres to  H sp s  in  h ea lth y  su b jects  
a)
Anti-Hsp-60
b )
0.8 1.2 
Anti-Hsp-60
0.8 1.2
Anti-Hsp-65
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T here  w a s  n o  s ig n ifica n t co rre la t io n  b e tw e e n  a n ti-H sp -6 0 , -6 5 , and  -7 0  titres w ith  age  
o r  w ith  B M I  in  patient o r  co n tro l grou p s (T a b le  6 .9 ) , In co n tro l su b jects , a n tib od y  
titres to  H s p -6 0  and -6 5  w e re  n o t a ssoc ia ted  w ith  c la ss ica l C H D  risk  fa cto rs  (p > 0 .0 5 ), 
h o w e v e r  a n ti-H sp -7 0  titres w e re  n e g a tiv e ly  a ssoc ia ted  w ith  seru m  tr ig ly cer id es  
(p < 0 .0 5 , T a b le  6 .9 ) . In  the patient g rou p , titres to  H sp -6 0  w e re  n e g a t iv e ly  associa ted  
w ith  fastin g  b lo o d  g lu c o s e  le v e ls  (p < 0 .0 5 , T a b le  6 .9 ). A n t i-H s p -6 5  titres w ere  
p o s it iv e ly  related  to  w a ist: h ip  ra tio , sy s to lic  and d ia sto lic  b lo o d  pressure, and 
n e g a tiv e ly  rela ted  to  seru m  H D L -ch o le s te ro l le v e ls  (p < 0 .0 5 , T a b le  6 .9 ) . N o  
sign ifica n t a ssoc ia tion  b e tw e e n  a n ti-H sp -7 0  and  C H D  risk  fa cto rs  w e re  o b se rv e d  
{p>0 .0 5 , T a b le  6 .9 ) .
Correlation between CHD risk factors and anti-Hsp titres
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T a b le  6 .9  C orre la tion  (r ) b e tw e e n  anti H sp  titres (a b so rb a n ce  u n it) and 
in d iv id u a l co ro n a ry  risk  fa ctors______________________________________________ ____________
Patients (n=237)
Anti-Hsp-60 Anti-Hsp-65 Anti-Hsp-70
A g e 0 .0 7 0 .0 6 0 .0 4
F asting  b lo o d  g lu c o s e 0 .1 3 1 -0 .0 2 -0 .0 3
B M I 0.01 0 .0 9 0 .11
W aist: H ip  ratio 0 .1 0 0 .1 3 * 0 .0 8
H D L -0 .0 8 -0 .1 4 * -0 .0 5
T r ig ly ce r id e -0 .01 -0 .0 0 0 .0 2
S y sto lic  B P 0 .05 0 .1 6 * 0 .0 2
D ia s to lic  B P 0 .0 9 0 .1 6 * 0 .0 5
C R P 0 .0 9 0 .0 6 0 .0 9
Controls (n=189)
A g e 0.11 0 .1 6 -0 .1 6
F asting  b lo o d  g lu c o s e 0 .1 0 -0 .0 0 -0 .0 2
B M I -0 .0 4 -0 .0 4 -0 .0 7
W a ist: H ip  ratio 0 .1 0 -0 .01 -0 .1 4
H D L 0 .0 2 0 .1 7 -0 .0 3
T r ig ly ce r id e -0 .11 -0 .1 4 -0 .1 9 *
S y s to lic  B P 0 .11 0 .1 0 -0 .0 3
D ia s to lic  B P 0 .1 0 0 .0 9 0 .0 2
C R P 0 .0 0 0 .0 6 -0 .0 6
C orre la tion s w e re  a ssessed  u sin g  P earson  co rre la tion  c o e ff ic ie n ts ; * = /K 0 .0 5
N o n -n o rm a lly  d istribu ted  data su ch  as p la sm a  a n tib od y  titres to  H sp s  w e re  lo g  
tran sform ed  b e fo r e  u s in g  the P ea rson  corre la tion s.
P lasm a anti-H sps titres d id  n o t d if fe r  s ig n ifica n tly  b e tw een  m a le  and fem a le  in  
patient o r  co n tro l su b jects  (p>0 .0 5 ).
P lasm a  a n ti-H sp -6 5 , and -7 0  d id  n o t d iffe r  s ig n ifica n tly  b e tw e e n  sm o k e r  and 
n o n -sm o k e r  in  patient o r  c o n tro l su b jects  (p > 0 .0 5 ). S m ok ers  h ad  s ig n ifica n tly  
h igh er a n ti-H sp -6 0  titres than n o n -sm o k e r  in  co n tro l su b jects  (p < 0 .0 5 ) , bu t n ot 
in  the patient grou p .
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W ith in  the d y s lip id a e m ic  g rou p , p la sm a  a n tib od y  titres to  H sp -6 0 , -6 5 , and -7 0  d id  
n ot d if fe r  s ig n ifica n tly  w ith  a ccu m u la tin g  o f  features o f  m e ta b o lic  sy n d ro m e  in  m a le  
or  fem a le  patients o r  the c o m b in e d  m a le  and fem a le  g rou ps (p > 0 .0 5 , T a b le  6 .1 0 ). T h e  
results o f  an a lysin g  o f  lo g -tra n s fo rm e d  p la sm a  a n tib od y  titres to  H s p -6 0 , -6 5 , and -7 0  
w ere  sim ilar to  n o n -lo g -tra n s fo rm e d  data fo r  a b o v e  analysis.
6.2.2 Anti-Hsps titres and metabolic syndrome
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Table 6.10 Effects o f features o f metabolic syndrome on antibody titres to Hsps (Absorbance units'
in  d y s lip id a e m ic  patients
Number of 0 
Features
1 2 3 4 5
Males
Numbers 3 15 4 4 41 34 5
Hsp-60 0 .2 9
(0 .1 3 -0 .3 2 )
0 .1 9
(0 .1 3 -0 .2 6 )
0 .2 6
(0 .1 9 -0 .3 9 )
0 .33
(0 .1 9 -0 .4 4 )
0 .2 7
(0 .2 1 -0 .3 6 )
0 .25
(0 .2 1 -0 .8 4 )
Hsp-65 0 .31
(0 .1 2 -0 .9 7 )
0 .33
(0 .2 5 -0 .8 7 )
0 .4 8
(0 .2 4 -0 .6 7 )
0 .4 7
(0 .2 9 -0 .8 2 )
0 .43
(0 .2 8 -0 .7 0 )
0 .7 4
(0 .5 0 -1 .0 1 )
Hsp-70 0 .1 9
(0 .0 8 -0 .2 3 )
0 .1 9
(0 .1 3 -0 .2 4 )
0 .2 2
(0 .1 7 -0 .3 6 )
0 .23
(0 .1 6 -0 .3 0 )
0 .2 6
(0 .1 9 -0 .3 2 )
0 .2 2
(0 .1 8 -0 .4 5 )
Females
Numbers 7 13 17 21 22 15
Hsp-60 0 .3 3
(0 .1 7 -0 .3 7 )
0 .2 8
(0 .1 9 -0 .3 9 )
0 .2 9
(0 .1 6 -0 .3 9 )
0 .2 4
(0 .1 6 -0 .3 3 )
0 .2 8
(0 .1 6 -0 .3 3 )
0 .2 0
(0 .1 6 -0 .2 8 )
Hsp-65 0 .3 4
(0 .1 6 -0 .3 9 )
0 .5 3
(0 .2 8 -0 .9 3 )
0 .3 7
(0 .2 9 -0 .8 6 )
0 .45
(0 .2 7 -0 .9 5 )
0 .5 4
(0 .4 2 -0 .7 8 )
0 .4 7
(0 .2 8 -0 .8 1 ]
Hsp-70 0 .2 4
(0 .1 6 -0 .2 8 )
0 .1 7
(0 .1 5 -0 .2 3 )
0 .2 2
(0 .1 6 -0 .3 0 )
0 .1 9
(0 .1 5 -0 .3 0 )
0 .2 2
(0 .1 7 -0 .2 9 )
0 .3 0
(0 .1 7 -0 .3 6 ]
Males & Females
Numbers 10 2 8 61 62 56 2 0
Hsp-60 0 .3 0
(0 .1 6 -0 .3 4 )
0 .23
(0 .1 4 -0 .2 9 )
0 .2 7
(0 .1 7 -0 .3 9 )
0 .2 8
(0 .1 9 -0 .4 2 )
0 .2 8
(0 .1 9 -0 .3 6 )
0 .2 4
(0 .1 7 -0 .3 7 )
Hsp-65 0 .3 2
(0 .1 5 -0 .4 0 )
0 .4 2
(0 .2 6 -0 .8 7 )
0 .4 6
(0 .2 5 -0 .7 3 )
0 .4 6
(0 .2 9 -0 .8 6 )
0 .45
(0 .3 2 -0 .7 6 )
0 .53
(0 .3 0 -0 .8 4 )
Hsp-70 0.21
(0 .1 4 -0 .2 8 )
0 .1 8
(0 .1 5 -0 .2 4 )
0 .2 2
(0 .1 7 -0 .3 3 )
0 .2 3
(0 .1 6 -0 .3 0 )
0 .2 4
(0 .1 7 -0 .3 0 )
0 .2 6
(0 .1 8 -0 .3 6 )
V a lu es  are ex p ressed  m ed ia n  and interquartile  range. B e tw e e n  g rou p  co m p a r iso n s  w e re  a ssessed  b }  
K ru sk a l-W a llis , as th e y  are n o n -n o rm a l d istribu tion  data.
R esu lts  w h e n  a n a lysin g  lo g -tra n s fo rm e d  a n tib od y  titres to  H sp s  w e re  sim ilar to  results u sin g  n o n ­
log -tra n sfo rm ed  data.
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6.3 Multifactorial analysis of anti-Hsps titres
In  gen era l, little o f  the varia tion  in  the 2 3 7  d y s lip id a e m ic  patients an ti-H sp  titres c o u ld  
b e  ex p la in ed  b y  the b e s t  fittin g  m o d e ls  d e r iv e d  fro m  step w ise  m u ltip le  linear 
regression s. O f  the va ria tion  in  a n ti-H sp -6 0  3 %  c o u ld  b e  attributed to  
h y p ertr ig ly cer id a em ia  (p -0 .0 2 ) and g en d er  (p = 0 .0 1 ), 1 %  fo r  a n ti-H sp -6 5  and 4 %  o f  the 
varia tion  in  a n ti-H sp -7 0  c o u ld  b e  attributed to  m e ta b o lic  sy n d ro m e  (p = 0 .0 2 ) and  its 
a ccu m u la tion  o f  features (p = 0 .0 0 8 ).
In  the 142  su b je cts  w ith  m e ta b o lic  sy n d rom e  the co rre sp o n d in g  p ro p o r tio n s  w e re  8 %  
fo r  a n ti-H sp -6 0  attributed to  sy s to lic  (p = 0 .0 2 ) and d ia sto lic  b lo o d  pressu re  (p = 0 .0 0 7 ), 
3 %  fo r  a n ti-H sp -6 5  and  1 %  fo r  a n ti-H sp -7 0  titres. T h is  w a s  in  agreem en t w ith  the 
results ob ta in ed  fr o m  the un ivaria te  an a lyses. T a b les  6 .1 1 -6 .1 3  su m m arises the results 
o f  m u ltifa ctoria l an a lysis  o f  an ti-H sps fo r  b o th  co ro n a ry  risk  fa ctors  and d ietary  intake 
o f  fat and an tiox id an t v itam in s.
6.4 Relationship between macro and micro nutrient and anti-Hsps titres
Anti-Hsp-60 titres
R esu lts  o f  s tep w ise  m u ltip le  reg ress ion  in  the d y s lip id a e m ic  patient g rou p  sh o w e d  that 
a p p rox im a te ly  11 %  o f  the va ria tion  in  a n ti-H sp -6 0  c o u ld  b e  e x p la in e d  b y  the fo l lo w in g  
fa ctors : d ie tary  v ita m in  C  in take (p = 0 .0 0 6 , + 4 .1 % ) , g en d er  (p = 0 .0 1 , + 2 .6 % ) , 
h y p ertr ig ly cer id a em ia  (p = 0 .0 4 , + 1 .3 % ) , d ietary  v itam in  E  0 = 0 .0 4 ,  -1 .2 % ) ,  and total fat 
0 = 0 .0 3 ,  + 1 .8 % )  intake. W ith in  the su bgrou p  w ith  m e ta b o lic  sy n d ro m e , 1 6 .2 %  o f  the 
varia tion  c o u ld  b e  e x p la in e d  b y  fo l lo w in g  fa ctors : sy s to lic  O = 0 -0 0 6 , + 6 .8 % )  and 
d ia sto lic  O = 0 -0 1 , + 5 .9 % )  b lo o d  pressure, and d ietary  v ita m in  C  O = 0 * 0 3 , + 3 .5 % ). 
D ieta ry  m on ou n satu ra ted  fat O = 0 -0 9 , -1 .4 % ) , and  v itam in  E  O = 0 .1 2 , -1 .8 % )  intake 
fa iled  to  rea ch  statistical s ig n ifica n ce . In  the con tro ls , d ie tary  m on ou n satu ra ted  fat
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(p = 0 .0 4 , -2 .2 % ) ,  and  ca ro ten e  (p=0 .1 2 , -1 .3 % )  intake appeared  to  m a k e  sm all, n o n ­
s ign ifica n t con tr ib u tion s  (T a b le  6 .1 1 ).
Anti-Hsp-65 titres
In  the patient g rou p , varia tion  in  an ti-H sp -65  w a s  attributable to  d ieta ry  v itam in  C  
intake (p = 0 .0 0 2 , + 5 .3 % ) . T h e  p re se n ce  o f  o b e s ity  ($ = 0 .0 8 , 1 .2 % ), and a p o s it iv e  
sm ok in g  habit (p=0 .1 2 , -0 .8 % )  appeared  to  m a k e  a sm all, th ou g h  n o n -s ig n ifica n t 
con tribu tion . In the su b g rou p  o f  in d iv id u a ls  w ith  m e ta b o lic  sy n d rom e , the varia tion  in  
an ti-H sp65  titres c o u ld  b e  e x p la in ed  b y  d ietary  v itam in  C  in take ($ = 0 ,0 0 7 , + 6 .6 % ) . In 
con tro ls , the varia tion  in  an ti-H sp65  titres w a s  ex p la in ed  b y  d ietary  v ita m in  E  ($ = 0 .0 2 , 
-4 .4 % )  in take (T a b le  6 .1 2 ) .
Anti-Hsp-70 titres
R esu lts  o f  s tep w ise  m u ltip le  re g re ss io n  in  the d y s lip id a e m ic  patient g rou p  rev ea led  that 
3 .7 %  o f  varia tion  in  a n ti-H sp -7 0  c o u ld  b e  ex p la in ed  b y  m e ta b o lic  sy n d rom e  and 
accu m u la tin g  features o f  the m e ta b o lic  s y n d r o m e .($ = 0 .0 4 ). In  the patients w ith  
m e ta b o lic  sy n d rom e , 1 4 .9 %  o f  the total varia tion  in  a n ti-H sp -7 0  titres c o u ld  b e  
ex p la in ed  b y : d ia s to lic  b lo o d  pressu re  ($ = 0 ,0 0 9 , + 6 .2 % ) , seru m  tr ia cy lg ly ce ro l ($ = 0 .0 4 , 
+ 3 .4 % ) , d ietary  saturated fat ($ = 0 .0 4 , + 3 .3 % ) , and ca ro ten e  (p = 0 .0 3 , - 2 % )  intake. In 
con tro ls , 1 0 .7 %  o f  the va ria tion  c o u ld  b e  ex p la in ed  b y  d ietary  ca ro ten e  ($ = 0 .0 2 , - 
3 .8 % ), ch o le s te ro l (p = 0 .0 0 5 , + 3 .6 % )  intake and a ge  ($ = 0 .0 2 , + 3 .3 % , T a b le  6 .1 3 ).
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Table 6.11 Multifactorial analysis o f anti-Hsp-60 (absorbance units)
Confounders Coefficient
Dyslipidaemia
(n =  2 3 8 )
Metabolic syndrome
(n = 1 4 2 )
Controls
(n = 1 3 5 )
%
D ie ta ry  v ita m in  C + 0 .0 0 0 0 0 0 3 4.1
G en d er + 0 .0 0 1 9 2 .6
H y p ertr ig ly cer id a em ia + 0 .0 6 8 1.3
D ie ta ry  v ita m in  E -0 .0 1 0 2 1.2
T ota l fat intake + 0 .0 0 1 7 1.8
S y s to lic  b lo o d  pressure + 0 .0 0 2 7 6 .8
D ia s to lic  b lo o d  pressure + 0 .0 0 5 9 5 .9
D ie ta ry  v ita m in  C + 0 .0 0 0 0 0 0 3 3 .5
D ie ta ry  m on ou n satu ra ted  fat + 0 .0 0 5 4 1.8
D ie ta ry  v ita m in  E -0 .0 2 5 1.4
D ie ta ry  m on ou n satu ra ted  Fat -0 .0 0 4 2 .2
D ie ta ry  ca ro ten e + 0 .0 0 0 0 2 1.3
S tep w ise  reg ress ion  w a s  u sed .
P
0 .03
0.01
0 .0 4
0 .0 4
0 .03
0 .0 0 6
0.01
0 .03
0 .0 9
0 .1 2
0 .0 4
0 .1 2
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Table 6.12 Multifactorial analysis o f anti-Hsp-65 (absorbance units)
Dyslipidaemia
(n = 2 3 8 )
Confounders Coefficient R
%
D ieta ry  v ita m in  C  + 0 .0 0 0 0 0 1  5 .3
O b e s ity  + 0 .0 5 4 9 3  1.2
S m o k in g  hab it -0 .0 5 1 4 9  0 .8
Metabolic syndrome
(n = 1 4 2 )
D ie ta ry  v ita m in  C  + 0 .0 0 0 0 0 1  6 .6
S y s to lic  b lo o d  pressu re  + 0 .0 0 0 8 1  1.6
Controls
(n = 1 3 5 )
D ie ta ry  v ita m in  E  -0 .0 3 2  4 .4
S tep w ise  reg re ss io n  w a s  u sed .
P
0 .0 0 2
0 .0 8
0 .1 2
0 .0 0 8
0 .1 4
0 .0 2
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Table 6.13 Multifactorial analysis o f anti-Hsp-70 (absorbance units)
Coufounders
Dyslipidaemia
(n==238)
M e ta b o l ic  sy n d ro m e  (M S )  
A c c u m u la t io n  features o f  the M S
Coefficient
+ 0 .0 6 4 6
+ 0 .0 3 5 6
R
%
1.9
1.8
Metabolic syndrome
(n = 1 4 2 )
Controls
(n = 1 3 5 )
D ia s to lic  b lo o d  pressu re  
D ie ta ry  saturated fat 
D ie ta ry  ca ro ten e  
S eru m  tr ig ly ce r id e
D ie ta ry  ca ro ten e  
D ie ta ry  ch o le s te ro l 
A g e
+ 0 .0 0 1
-0 .0 8 4
-0 .0 5 4
-0 .0 9 4
-0 .0 0 0 0 3
+ 0 .0 0 0 3 2
-0 .0 0 1 9
6 .2
3 .3  
2 .0
3 .4
3 .8
3 .6
3 .3
S tep w ise  re g re ss io n  w a s  u sed .
P
0 .0 4
0 .0 4
0 .0 0 9
0 .0 4
0 .03
0 .0 4
0 .0 2
0 .0 0 5
0 .03
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It has b e e n  rep orted  that in fla m m a tory  ce lls  are presen t du rin g  a ll stages o f  the 
a th erosclero tic  le s io n  d e v e lo p m e n t. H s p -6 0 , H sp -6 5 , and H s p -7 0  are a g rou p  o f  
p o s s ib le  antigens that m a y  b e  resp on s ib le  fo r  this im m u n oa ct iv a tion  during 
a th erogen esis  (M e tz le r  et a l., 1 9 9 8 ). C lin ica l studies h ave  rep orted  a ssoc ia tion s  b etw een  
p lasm a  lev e ls  o f  an ti-H sps and C H D , and in  m o s t  studies le v e ls  o f  th ese  an tibod ies  
h ave  b e e n  fo u n d  to  b e  s ig n ifica n tly  h ig h er  in  su b jects  w ith  C H D  (B im ie  et al., 1998 ; 
B urian  et ah, 2 0 0 1 ; C h an  et a l., 1 9 9 9 ; F rostegard  et ah, 1 9 9 7 ; G ru b er  et ah, 1 996 ; 
H o p p ich le r  et ah , 2 0 0 0 ; H u ittin en  et al., 2 0 0 2 ; M u k h erjee  et ah , 1 9 9 6 ; P roh aszk a  et ah, 
19 99 ; P roh aszk a  et ah , 2 0 0 1 ; X u  et ah , 19 9 3 ). It is n ot clear, h o w e v e r , at w h ich  stages 
o f  C H D  these a n tib od ies  appear, and  th ere fore  w hat fa ctors  in flu e n ce  their appearance.
Effects o f age, gender and physical activity levels on anti-Hsps titres 
T h e  a ssoc ia tion  o f  age, g en d er  and p h y s ica l a ctiv ity  le v e ls  w ith  an ti-H sps titres h a ve  
n ot b e e n  eva lu ated  p re v io u s ly . In  the current study, p la sm a  a n ti-H sp -6 0 , an ti-H sp -65 , 
and a n ti-H sp -7 0  d id  n o t  a ssoc ia te  w ith  p h y s ica l a ctiv ity  le v e ls  and d id  n o t d if fe r  
b e tw een  m a les  and  fem a les  and  in  d iffe ren t age groups.
Effects o f CHD on antibody titres to Hsps
T h e  a ssoc ia tion  b e tw e e n  a n tib o d y  titres to  the H sp s and a th erosc le ros is  is less 
con sisten t (K o c s is  et ah, 2 0 0 2 ; X u  et ah , 1 9 9 9 ; X u  et ah, 2 0 0 0 ). P o c k le y  et a.l (P o c k le y  
et ah, 2 0 0 2 ) h a v e  rep orted  that a n ti-H sp -7 0  and an ti-H sp -65  a n tib o d y  lev e ls  w ere  
e leva ted  in  su b je cts  w ith  h yp erten sion , w h ereas  H sp -6 0 , H s p -7 0  and an ti-H sp -60  
a n tib od y  le v e ls  in  h yp erten s iv e  su b jects  w e re  sim ilar to  th ose  in  n o rm o te n s iv e  con tro ls .
6.5 Discussion
6.5.1 Antibody titres to Hsps and CHD risk factors
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A n t ib o d y  titres to  H s p -6 0 , -6 5 , and -7 0  w e re  rep orted  to  b e  p o s it iv e ly  re lated  to  risk  o f  
vascu lar d isea se  and ca rd iov a scu la r  en dpoin ts. A lth o u g h  h ig h  a n ti-H sp -6 0  an tib od y  
titres w e re  p re d ic t iv e  o f  c o ro n a ry  risk , the e ffe c ts  w e re  rep orted  as m o d e s t  in  the 
a b sen ce  o f  oth er c la ss ica l r isk  fa ctors  (K e rv in e n  et al., 2 0 0 3 ). H ig h  le v e ls  o f  hum an 
H sp -7 0  w e re  rep orted  to  b e  a ssoc ia ted  w ith  the lo w  C H D  risk , p ro b a b ly  th rou gh  its 
m u ltip le  p ro te ct iv e  e ffe c ts  o n  a c e ll 's  re sp on se  to  stress (Z h u  et a l., 2 0 0 3 ). K o c s is  et al. 
(2 0 0 2 ) h a ve  re ce n tly  rep orted  that a n ti-H sp -7 0  titres are n ot e lev a ted  in  su b jects  w ith  
severe  co ro n a ry  a th erosc le ros is , w h erea s  titres to  H sp -6 0  and -6 5  w e r e  s ig n ifica n tly  
raised  in  these patients, there b e in g  n o  a ssoc ia tion  b e tw e e n  a n tib o d y  titres against H sp - 
7 0  w ith  either H s p -6 0 , o r  -6 5  (K o c s is  et a l., 2 0 0 2 ). It has a lso  b e e n  rep orted  that 
patients w ith  ty p e  II d iabetes  m ellitu s  h a v e  s ig n ifica n tly  h ig h er  anti-H sp  titres 
com p a red  w ith  n o n -d ia b e tic  co n tro ls  (S im s  et a l., 2 0 0 2 ).
Correlation between antibody titres to Hsp-60, -65, and-70
In the presen t study, a stron g  co rre la tion  w as o b se rv e d  in  patients and h ea lth y  grou p s  
b e tw een  a n tib od y  titres to  H s p -6 0 , -6 5 , and -7 0  0 = 0 .0 0 1 ) .  T h is  stron g  co rre la tion  m a y  
b e  related  to  stron g  a n tig en ic  h o m o lo g y  b e tw e e n  H sp -6 0 , -6 5  and  - 7 0 ,  d esp ite  the la ck  
o f  o b v io u s  structural re se m b la n ce  b e tw e e n  th em  (B o n k  et a l., 1 9 9 6 ; F lo re s  and C u ezv a , 
1 997).
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T h is is the first s tu d y  in v estig a tin g  the re la tion sh ip  b e tw e e n  p la sm a  an ti-H sps titres and 
d ietary  fa ctors  in  m an . O u r resu lts s h o w  that d ietary  con stituen ts m a y  m od u la te  the 
im m u n e  resp on se  to  H sp s  in  patients w ith  co ro n a ry  risk  fa ctors .
Hsp antibody titers and dietary fat intake
S evera l recen t stu d ies h a v e  d em on strated  that saturated and unsaturated fatty  a cid s  can  
b o th  a ffe c t  im m u n e  resp on ses  (S tu ln ig , 2 0 0 3 ; Y a q o o b  et al., 1 9 9 4 ). M o r e o v e r , R o m a n o  
et al (1 9 9 9 )  h a ve  s h o w n  that a  d iet r ich  in  saturated fatty  a cid s  in d u ces  the ex p ress ion  
o f  H sp -7 0 , -6 0 , and - 2 5  in  m ic e  sp len ic  ly m p h o cy te s  (R o m a n o  et a l., 1 9 9 9 ). O u r grou p  
h ave  a lso  dem on stra ted  that seru m  a n ti-H sp -65  titers r ise  in  rabb its  fe d  a h igh  
ch o le s te ro l d iet (L a m b  and F erns, 2 0 0 2 ). In  the presen t stu dy  w e  h a v e  fo u n d  p o s it iv e  
a ssoc ia tion s  b e tw e e n  a n ti-H sps titers and d ietary  tota l fat, saturated fat, and ch o le ste ro l. 
T h ese  a ssoc ia tion s  m a y  b e  du e to  a c o m b in a t io n  o f  an in crea sed  e x p re ss io n  o f  the H sp s 
and en h a n ced  im m u n e  re sp o n se  that are b o th  a ssoc ia ted  w ith  a  h ig h  saturated fat diet. 
N o  s ig n ifica n t re la tion sh ip s  w e re  fo u n d  b e tw e e n  anti-H sps titers and  unsaturated fat in  
ou r study.
Hsp antibody titres and dietary antioxidants intake
V ita m in  E  is  a p oten t lip id  s o lu b le  an tiox idant and d ietary  su p p lem en t has b een  
reported  to  p reven t o x id a t iv e  in ju ry  (W in k lh o fe r -R o o b  et a l., 2 0 0 3 ). V ita m in  E  
d ep le tion  in  rats ca u sed  a s ig n ifica n t in crease  in  H sp 3 2  and H s p -7 0  ex p ress ion  b y  
a lveo la r  and  liv e r  c e lls  and the le v e ls  o f  ex p ress ion  o f  the H sp s  w e re  returned  to a lm ost 
n orm al le v e ls  a fter v ita m in  resu p p lem en ta tion  (T o p b a s  et a l., 2 0 0 0 ). A n d res  and 
C a sca les  s h o w e d  that c y c lo s p o r in e  A -in d u c e d  e x p ress ion  o f  H s p -7 0  b y  rat h ep a tocy tes ,
6.5.2 Effects o f macro and micronutrient on anti-Hsps titres
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m ed ia ted  b y  the re lea se  o f  rea ctiv e  o x y g e n  sp e c ie s , is  s ig n ifica n tly  d ecrea sed  in  the 
p resen ce  o f  v ita m in  E  in vitro (A n d re s  et al., 2 0 0 0 ; A n d res  and C a sca le s , 2 0 0 2 ). T h e  
p o s s ib le  m o d u la t io n  o f  the heat s h o ck  s ign a l tran sdu ction  p a th w a y  b y  v ita m in  E  has 
p re v io u s ly  b e e n  rep orted  in  exp erim en ts  o n  h um an  sk in  fib rob la sts  (C a la b rese  et al., 
2 0 0 1 ). In  the p resen t study, w e  fo u n d  an in verse  rela tion sh ip  b e tw e e n  d ietary  v itam in  E  
intake and a n ti-H sp -6 0  titres in  patients and a n ti-H sp -65  titres in  the co n tro l grou p . T h is  
a ssoc ia tion  m a y  b e  re la ted  to  the re d o x  m ech a n ism s a ffe cte d  b y  v ita m in  E .
V ita m in  C  is an im portan t w ater  so lu b le  an tiox idant that has b e e n  p ro p o s e d  to  b e  
p o ten tia lly  b e n e fic ia l in  re d u c in g  ox id a tiv e  tissue d am age  b y  ch e m ica l red u ction  o f  
ox id a n t sp ec ie s  (F rei, 1 9 9 1 ). E p id e m io lo g ic a l data in d ica te  that a h ig h  in take o f  v itam in  
C  ca n  p ro v id e  p ro te c t io n  against o x id a tiv e  d am age  in vivo, w h eth er  th is is  so  rem ains 
unclear (S im o n s  et a l., 1 9 9 9 ; K h a s s a f et a l., 2 0 0 3 ). T h e  v itam in  C -in d u ce d  in crease  in  
b a se lin e  e x p re ss io n  o f  H s p -6 0 , and H sp -7 0  has b e e n  rep orted  p r e v io u s ly  and its 
m ech a n ism s are u n clea r  (K h a s s a f et al., 2 0 0 3 ). It has b e e n  p r o p o s e d  that v ita m in  C  m a y  
exert p ro -o x id a n t e ffe c ts  in  s o m e  situations (K h a s s a f et al., 2 0 0 3 ). In  the presen t study, 
a p o s it iv e  a ssoc ia tion  b e tw e e n  d ietary  v itam in  C  intake and a n ti-H sp -6 0  and - 6 5  in  
d y s lip id a e m ic  patients and su b g rou p  w ith  m e ta b o lic  sy n d rom e  m a y  b e  related  to  an 
in creased  e x p re ss io n  o f  H sp s  a ssoc ia ted  w ith  a p ro -o x id a n t e f fe c t  o f  v ita m in  C .
In co n c lu s io n  w e  h a v e  fo u n d  that a n tib od y  titres to  H sp -6 0 , -6 5  and  -7 0  are ra ised  in  
patients w ith  c la ss ica l c o ro n a ry  risk  fa ctors  and associa ted  w ith  d ietary  fa ctors . 
E leva ted  a n tib od y  titres to  H sp s  in  these patients m a y  b e  re lated  to  a h e ig h ten ed  state o f  
im m u n oa ctiv a tion  a ssoc ia ted  w ith  a th eroscleros is  in  th is g rou p , and the stron g  
co rre la tion  b e tw e e n  a n tib o d y  titres to  H s p -6 0 , -6 5 , and -7 0  (p = 0 .0 0 1 )  su pports this. O ur 
data su ggest that a n tib od y  titres to  H sp -6 0 , -6 5 , -7 0  w e re  a ssoc ia ted  w ith  dietary  fat and 
antioxidants and  w e re  in d ep en d en t o f  c la ss ica l co ro n a ry  risk  fa ctors . B o th  fin d in g s  are
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rep orted  fo r  the first tim e. A  lim ita tion  o f  ou r  stu dy  is its c r o s s -s e c t io n a l d esign . It is 
n ot p o s s ib le  to  b e  certain , that the a ssoc ia tion s  b e tw e e n  d ietary  con stituen ts  and H sps 
a n tib od y  titers are du e to  d irect  cau sation . A ls o , ou r  stu dy  g rou p  w a s  a sm all 
h e te rog en eou s  sa m p le  o f  d y s lip id a e m ic  patients. It w o u ld  b e  im portan t to  c o n firm  these 
fin d in gs  in  a larger sa m p le  s ize . N ev erth e less  ou r fin d in g s  are con s is ten t w ith  p rev iou s  
studies in  w h ic h  a d irect e f fe c t  o f  an tiox idants and fatty  a c id s  o n  H sp -re la ted  prote in s 
has b e e n  dem on strated .
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CHAPTER 7
S e r u m  T r a c e  E l e m e n t  S t a t u s  i n  c o n d i t i o n s  
r e l a t e d  t o  c o r o n a r y  r i s k  f a c t o r s
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T h ere  is co n s id e ra b le  e v id e n c e  that free  rad ica ls  p la y  a r o le  in  the p a th og en es is  o f  
C H D . H e n ce  the a c t io n  o f  the an tiox idant en zy m es , g lu tath ione p e ro x id a s e , su p erox id e  
d ism utase, and cata lase  m a y  p la y  an im portant p ro te ct iv e  ro le . T h e  trace  e lem ents z in c , 
c o p p e r  and se len iu m  are essen tia l co m p o n e n ts  o f  these e n zy m e s , b u t m a y  a lso  b e  
in v o lv e d  in  lip id  o x id a t io n  (C ra ig  et al., 1 9 9 5 ; F erns et al., 2 0 0 0 b ; R a ym a n , 2 0 0 0 ; R o th  
and K irch g essn er , 1 9 9 1 ; K h a s s a f et al., 2 0 0 3 ).
E ffe c ts  o f  age , g en d er, sm o k in g  hab it and B M I  o n  trace  e lem en t status h a v e  b e e n  
p re v io u s ly  eva lu ated , bu t in con s is ten t resu lts w e re  rep orted  (G ra n d jea n  et al., 1992 ; 
J oh n son  et al., 1 9 9 2 ; K im  et al., 2 0 0 3 ). W e  h a ve  in vestiga ted  the a sso c ia tio n  b e tw een  
p h y s io lo g ic a l and p a th o lo g ica l co n d it io n s  re lated  to  C H D  risk  fa ctors  o n  serum  trace 
e lem en t status in  d y s lip id a e m ic  patients and hea lth y  su b jects.
7.1 Serum trace elements in healthy subjects
7.1.1 Physiological variation in serum trace element status 
Gender
A m o n g  the 189 co n tro l su b jects , 95  su b jects  w e re  m a les  and 9 4  w e r e  fem a les  ( fo r  m o re  
details re fer  to  a p p en d ix  4  and  se ct io n  4 .1 .1 ). S eru m  se len iu m , G P x , and c o p p e r / 
ca eru lop la sm in  ratio  d id  n o t  d iffe r  s ig n ifica n tly  b e tw e e n  m a le  and fem a le  su b jects  
(p > 0 .0 5 , T a b le  7 .1 ) . H o w e v e r , m a le  su b jects  h ad  s ig n ifica n tly  lo w e r  serum  co p p e r  
O < 0 .0 0 1 ) ,  ca eru lop la sm in  (p < 0 .0 0 1 ), and h igh er serum  z in c  ( /K 0 .0 5 ) ,  and z in c / c o p p e r  
ratio (p < 0 .0 0 1 , T a b le  7 .1 ) than fe m a le  su b jects .
7. Serum trace elements in conditions related to coronary risk factors
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Table 7.1 Effects o f gender on indices o f serum trace element status in control subjects
M a le s F e m a le s
N u m b ers  o f  su b jects 95 9 4
Z in c  (p m o l /L ) 1 3 .8 6 ± 0 .2 3 * 1 3 .3 0  +  0 .2 4
C o p p e r  (p m o l /L ) 1 4 .76  ±  0 .3 2 * * * 1 7 .5 2  +  0 .3 4
Z n /C u  R a tio 0 .9 7  ±  0 .0 2 * * * 0 .7 8  ±  0 .0 2
C p  (g /L ) 0 .1 6  +  0 .0 1 * * * 0 .1 9  +  0 .01
C u /C p  R a tio  (p m o l /g ) 1 0 0 .5 0  +  3 .5 4 9 7 .8 6  +  3 .1 2
S e len iu m  (p m o l /L ) 1 .05 +  0 .0 2 1 .0 1 + 0 .0 2
G P x  (U /m L ) 0 .3 5  +  0 .01 0 .3 6  +  0 .01
V a lu es  are e x p ressed  as M e a n  ±  S E M ; *= /> < 0 .05 , * **= /> < 0 .0 0 1  co m p a r is o n  b e tw een  
patients and  co n tro ls  b y  u s in g  o n e -w a y  A N O V A .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
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Age
T h e  m a le  and fe m a le  c o n tro l su b jects  w e re  separate ly  d iv id e d  in to  6  g rou p s  b a sed  o n  
their age  ( f o r  m o re  d eta ils  re fe r  to  s e c t io n  5 .1 .1 ). W ith in  the m a le  g rou p s , s ign ifican t 
d iffe re n ce s  w e re  o b s e rv e d  in  seru m  ca eru lop la sm in  con cen tra tion s  (p < 0 .0 1 )  w ith  age, 
b e in g  s ig n ifica n tly  lo w e r  in  the grou p  2 0 -2 9  years o f  a ge  co m p a re d  w ith  the other 
grou p s  o f  age (4 0 -4 9 , 5 0 -5 9 , and 6 0 -6 9  years). S ig n ifica n t d if fe re n ce s  in  seru m  co p p e r / 
ca eru lop la sm in  con cen tra tion s  ratio  (p < 0 .0 0 1 ) , and b ord er lin e  d if fe re n ce s  in  serum  G P x  
(p = 0 .0 9 ), w e re  a lso  s ig n ifica n tly  h ig h er  in  the grou p  a g ed  b e tw e e n  2 0 -2 9  years 
co m p a re d  w ith  the g rou p  a g ed  7 0  o r  a b o v e  years. M a le  su b jects  a g ed  b e tw e e n  3 0 -3 9 , 
4 0 -4 9 , and 6 0 -6 9  years h ad  s ig n ifica n t h igh er  serum  z in c / c o p p e r  ra tio  co m p a re d  w ith  
the g rou p  aged  7 0  o r  a b o v e  years (T a b le  7 .2 ) .
W ith in  the fe m a le  g rou p s , s ig n ifica n t d if fe re n ce s  w e re  o b s e rv e d  in  serum  co p p e r  
con cen tra tion s  (p < 0 .0 5 ) , b e in g  s ig n ifica n tly  h ig h er  in  g rou p s a g ed  b e tw e e n  3 0 -3 9 , 4 0 - 
4 9 , 5 0 -5 9 , and  6 0 -6 9  years co m p a re d  w ith  the g rou p  aged  70  o r  a b o v e  years. F em ale  
su b jects  a g ed  b e tw e e n  5 0 -5 9  years h ad  s ig n ifica n tly  h igh er seru m  se len iu m  com p a red  
w ith  the grou p  a g ed  7 0  o r  a b o v e  years (T a b le  7 .2 ).
Physical activity levels
In h ea lth y  su b jects , p h y s ica l a ctiv ity  le v e ls  w e re  p o s it iv e ly  a ssoc ia ted  w ith  serum  
co p p e r  con cen tra tion s  (p < 0 .0 0 1 )  and n e g a tiv e ly  associa ted  w ith  Z n /C u  ratio ($ < 0 ,0 0 1 , 
T a b le  7 .3 ). In  the patient g rou p , p h y s ica l a ctiv ity  le v e ls  w e re  p o s it iv e ly  a ssoc ia ted  w ith  
serum  co p p e r  con cen tra tion s  (p < 0 .0 1 , T a b le  7 .3 ) and n e g a tiv e ly  a ssoc ia ted  w ith  serum  
tr ig ly cer id e  ($ < 0 .0 0 1 )  and seru m  z in c /c o p p e r  ratio ($ < 0 .0 1 , T a b le  7 .3 ). P h ysica l 
a ctiv ity  le v e ls  w e re  a ssoc ia ted  w ith  co ro n a ry  risk  fa ctors  in c lu d in g  o b e s ity  and lip id  
p ro file , w h ic h  su p p orted  v a lid a tio n  o f  ou r  qu estion n aire  ( f o r  m o r e  deta ils  re fer  to 
ap p en d ix  6  and se c t io n  5 .1 .1 ).
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Table 7.3 Correlations (r) between physical activity levels and indices o f serum
trace element status
Controls Patients
n 135 2 3 7
Z in c  (p m o l /L ) -0 .1 4 -0 .0 7
C o p p e r  (p m o l /L ) 0 .3 0 * * * 0 .2 1 * *
Z n /C u  ratio -0 .3 3 * * * -0 .2 2 * *
C p ( g /L ) 0 .1 8 0 .0 8
C u /C p  ratio (p m o l /g ) -0 .0 1 0 .0 4
S elen iu m  (p m o l /L ) -0 .0 1 0 .0 2
G P x  (U /m L ) 0 .0 5 0 .0 8
V it  E  (p g /m L ) -0 .1 0 -0 .1 1
V it  E /  T C  ratio (p g /m m o l) -0 .1 6 -0 .0 7
C orre la tion s w e re  a ssessed  u s in g  P ea rson  corre la tion  c o e f f ic ie n ts ; * * = /K 0 .0 1 , 
* * * = p < o  o o i
C p  =  C a eru lop la sm in ; C u  =  C o p p e r ; T C  =  total ch o lestero l.
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Association between dietary trace elements and their serum levels 
T h e w e a k  and s ig n ifica n t a sso c ia tio n  b e tw e e n  d ietary  trace e lem en ts and their serum  
lev e ls  w e re  o b s e iv e d ; z in c  [patients (r= 0 .1 6 , p = 0 .0 4 ) , co n tro ls  (r= 0 .1 8 , p = 0 .0 2 ) ] ,  c o p p e r  
[patients (r= 0 .0 3 , p = 0 .8 3 ) , co n tro ls  (r= 0 .1 7 , p = 0 .0 3 ) ] , and se len iu m  [patients (r= 0 .1 5 , 
p = 0 .0 4 ) , co n tro ls  (r= 0 .1 9 , p = 0 .0 2 ) ] .
7.1.2 Pathophysiological conditions and their effects on trace element status
Smoking
A m o n g  the 189  co n tro l su b je cts , 123 su b jects  h ad  n ev er  sm o k e d  and 6 6  w e re  current o r  
e x -sm o k e rs  in c lu d in g  3 2  current sm ok ers  and 3 4  ex -sm o k e rs  ( f o r  m o re  deta ils  re fer  to 
ap p en d ix  5 and se c t io n  4 .1 .2 ) . S eru m  con cen tra tion s  o f  z in c , co p p e r , z in c /  co p p e r  ratio, 
ca eru lop la sm in , and c o p p e r / ca eru lop la sm in  con cen tra tion s  d id  n o t d if fe r  s ig n ifica n tly  
b e tw een  sm ok ers  and n o n -sm o k e rs  (p > 0 .0 5 , T a b le  7 .4 ). S m ok ers  h ad  a s lig h tly  lo w e r  
m ean  serum  con cen tra tion s  o f  se len iu m  (p = 0 .0 8 ) and G P x  (p=0 .0 9 ) c o m p a re d  w ith  n o n - 
sm ok ers ($ > 0 .0 5 , T a b le  7 .4 ).
Obesity
A m o n g  the 189 co n tro l su b jects , 33  w e re  o b e s e , 58  w e re  o v e r  w e ig h t, and 78 w e re  n orm al 
w e igh t ( f o r  m o re  deta ils re fe r  to  T a b le  3 .3  and se ct io n  4 .1 .2 ). O v era ll, o b e s e  su b jects  had 
s ig n ifica n tly  lo w e r  seru m  con cen tra tion s  o f  z in c  (p<0 .0 5 ), and b o rd e r lin e  w ith  z in c / co p p e r  
ratio ($ = 0 .0 8 ) , and G P x  ($ = 0 .0 7 )  co m p a re d  w ith  o v e rw e ig h t and n orm a l w e ig h t su b jects  
(T a b le  7 .5 ). M a le  o b e s e  su b je cts  h ad  s ig n ifica n tly  lo w e r  serum  con cen tra tion s  o f  z in c  
($ < 0 .0 5 ), z in c / c o p p e r  ratio  ( $ 0 . 0 5 ) ,  and G P x  ( $ 0 . 0 5 )  co m p a re d  w ith  ov e rw e ig h t and 
n orm al w e ig h t su b je cts  (T a b le  7 .5 ) . F em a le  o b e s e  su b jects  h a d  b o rd e r lin e  s ig n ifica n tly
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h igh er seru m  ca eru lop la sm in  con cen tra tion s  (p = 0 .0 6 ) co m p a re d  w ith  su b je cts  o f  n orm al 
w e ig h t (T a b le  7 .5 ).
T a b le  7 .4  E ffe c ts  o f  s m o k in g  status o n  in d ice s  o f  seru m  trace e lem en t status in  
c o n tro l su b jects___________________________________________________________________________________
S m o k e r s N o n -s m o k e r s
N u m b ers  o f  su b jects 66 123
Z in c  (p m o l /L ) 13 .83  ± 0 .2 8 1 3 .45  ± 0 .2 1
C o p p e r  (p m o l /L ) 16 .25  ± 0 .4 0 1 6 .0 7  ± 0 .3 3
Z n /C u  R a tio 0 .8 7  ±  0 .03 0 .8 8  ±  0 .0 2
C p  (g /L ) 0 .1 8  ± 0 .0 1 0 .1 7  ± 0 .0 1
C u /C p  R a tio  (p m o l /g ) 1 0 0 .2 5  ±  3 .9 7 9 7 .1 7  ± 2 .9 3
S elen iu m  (p m o l /L ) 0 .9 9  ±  0 .03 1 .05 ± 0 .0 2
G P x  (U /m L ) 0 .3 3  ±  0 .0 2 0 .3 6  ± 0 .0 1
V a lu es  are e x p ressed  as M e a n  ±  S E M . O n e -w a y  A N O V A  u sed  fo r  co m p a r iso n  
b e tw een  sm ok ers  and  n o n -sm o k e rs .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
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Table 7.5 Association between BMI and indices of serum trace element status in healthy
subjects_________________________________________________________________________________________
O b e s e  O v e rw e ig h t N o rm a l w e ig h t
M a le s
N u m b er o f  su b jects 19 36 31
Z in c  (p m o l /L )  
C o p p e r  (p m o l /L )  
Z n /C u  R a tio  
C p  (g /L )
C u /C p  ratio (p m o l /g )  
S e len iu m  (p m o l /L )  
G P x  (U /m L )
1 2 .9 4  ± 0 .3 9 *  
1 5 .4 2  ± 0 .7 0  
0 .8 7  ± 0 .0 5 *  
0 .1 7 1  ± 0 .0 1  
1 1 1 .3 7  ±  2 .1 8  
1 .06  ± 0 .0 6  
0 .3 0  ± 0 .0 3 *
1 4 .06  ±  0 .3 2  
14.91 ± 0 .4 4  
0 .9 7  ±  0 .03  
0 .1 5 8  ± 0 .0 1  
100 .63  ± 2 .9 3
1 .06  ± 0 .0 5  
0 .3 9  ±  0 .0 2
1 4 .5 9  ±  0 .4 2
1 4 .0 4  ± 0 .6 1  
1 .05  ± 0 .0 4  
0 .1 4 7  ± 0 .0 1  
1 3 .8 4  ± 0 .2 0
1 .04  ± 0 .0 4  
0 .3 4  ±  0 .0 2
F e m a le s
N u m b er  o f  su b jects 15 22 47
Z in c  (p m o l /L )  
C o p p e r  (p m o l /L )  
Z n /C u  R atio  
C p  (g /L )
C u /C p  ratio (p m o l /g )  
S e len iu m  (p m o l /L )  
G P x  (U /m L )
1 2 .4 4  ± 0 .5 2  
17 .85  ± 0 .7 6  
0 .7 2  ±  0 .05  
0 .2 0 2  ±  0 .01  
8 9 .6 5  ± 6 .1 1  
1 .00  ± 0 .0 6  
0 .3 2  ±  0 .0 4
1 3 .3 0  ± 0 .5 6  
1 7 .9 6  ± 0 .7 0  
0 .7 6  ±  0 .0 4  
0 .2 1 6  ±  0 .0 2  
8 8 .4 8  ± 4 .6 0  
1 .08  ± 0 .0 5  
0 .3 4  ±  0 .0 2
1 3 .5 0  ± 0 .3 5  
1 6 .9 7  ± 0 .4 1  
0 .8 2  ±  0 .03  
0 .1 7 9  ± 0 .0 1
1 0 2 .5 0  ± 4 .8 0  
0 .9 9  ±  0 .03  
0 .3 7  ±  0 .0 2
M a le s  &  F e m a le s
N u m b er o f  su b jects 3 4 58 7 7
Z in c  (p m o l /L )  
C o p p e r  (p m o l /L )  
Z n /C u  R a tio  
C p  (g /L )
C u /C p  ratio (p m o l /g )  
S e len iu m  (p m o l /L )  
G P x  (U /m L )
12 .73  ± 0 .3 5 *  
16 .45  ± 0 .5 5  
0 .81  ± 0 .0 4  
0 .1 8 4  ± 0 .0 1  
9 2 .5 9  ±  4 .25  
1 .03  ± 0 .0 4  
0 .31  ± 0 .0 2
1 3 .77  ± 0 .2 9  
1 6 .07  ± 0 .4 3  
0 .8 9  ±  0 .03  
0 .1 8 0  ± 0 .0 1  
1 00 .13  ± 4 .7 2  
1 .06  ± 0 .0 3  
0 .3 7  ±  0 .0 2
13 .93  ± 0 .2 7  
15.81 ± 0 .3 8  
0 .91  ± 0 .0 3  
0 .1 6 6  ± 0 .0 1  
1 0 1 .4 0  ± 3 .7 1  
1.01 ± 0 .0 3  
0 .3 6  ± 0 .0 1
V a lu es  are exp ressed  as M e a n  ±  S E M . B e tw e e n  grou p  co m p a r iso n s  w e re  assessed  b y  
K ru sk a l-W a llis  as th ey  are n o n -n o rm a l d istribu tion  data; * = /?< 0 .0 5 .
S u b jects  w ith  B M I  greater than 3 0 , b e tw e e n  25 and 3 0 , and less  than 25  w e re  d e fin e d  as 
o b e se , o v e r  w e ig h t, and  n orm a l w e ig h t re sp e c tiv e ly  (B ritish  N u tr ition  F ou n d a tion  T ask  
F orce , 19 9 9 ).
C p  =  C a eru lop la sm in ; C u  =  C o p p e r .
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7.2 Trace elements in conditions related to CHD
7.2.1 Trace elements and CHD risk factors
Trace element status in dyslipidaemia
O vera ll, d y s lip id a e m ic  patients h ad  s ig n ifica n tly  h ig h er  serum  c o p p e r  le v e ls  (p O .O O l) ,  
co p p e r / ca eru lop la sm in  ratio  ( $ 0 . 0 1 ) ,  and  se len iu m  (p < 0 .0 5 ) and lo w e r  G P x  (p < 0 .0 0 1 ), 
and z in c / c o p p e r  ra tio  (p < 0 .0 5 )  co m p a re d  w ith  co n tro ls  (T a b le  7 .6 ) . In  the m a le  su bgrou p , 
d y s lip id a e m ic  patients h ad  s ig n ifica n tly  h ig h er  seru m  co p p e r  le v e ls  (p < 0 .0 0 1 ) , and lo w e r  
G P x  (p < 0 .0 5 ), and z in c /  c o p p e r  ratio ( $ 0 . 0 1 )  co m p a re d  w ith  co n tro ls  (T a b le  7 .6 ) . In 
fem a le  su b jects , d y s lip id a e m ic  patients had  s ig n ifica n tly  h igh er c o p p e r  ( $ 0 , 0 0 1 ) ,  and 
co p p e r /ca e ru lo p la sm in  ratio  ( $ 0 . 0 1 ) ,  and lo w e r  G P x  ( $ 0 . 0 5 )  co m p a re d  w ith  con tro ls  
(T a b le  7 .6 ).
Trace element status in established CHD
M a le  patients w ith  esta b lish ed  C H D  h ad  s ig n ifica n tly  lo w e r  seru m  z in c  con cen tra tion s  
and z in c / co p p e r  ra tio  co m p a re d  w ith  patients w ith ou t C H D  ( $ 0 , 0 0 1 ) .  T h e  co m b in e d  
grou p  o f  m a le  and fe m a le  patients ( $ 0 . 0 1 )  had  h igh er  serum  c o p p e r  and ca eru lop la sm in  
con cen tra tion s  in  the su b g rou p  o f  m a le  patients ( / ; 0 . 0 5 ) ,  and  seru m  G P x  in  the 
co m b in e d  m a le  and  fe m a le  patients ( $ 0 . 0 5 ,  T a b les  7 .7 a -b  and 7 .8 a -b ). H o w e v e r , 
d iffe re n ce s  in  seru m  G P x  d id  n o t  rem ain  s ig n ifica n t after age -a d ju stm en t ($ > 0 .0 5 ). N o n e  
o f  the a b o v e  seru m  trace  e lem en ts  d iffe re d  b e tw e e n  patients w ith  and w ith ou t established  
C H D  in  the fe m a le  su b g rou p  o f  patients (p > 0 .0 5 , T a b le  7 .9 a -b ).
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Patients Controls
Table 7.6 Comparison o f indices of serum trace element status between dyslipidaemic
patients and controls____________________________________________________________________________
Males
N u m b ers  o f  su b jects 142 67
Z in c  (p m o l /L ) 1 4 .1 7  ± 0 .1 8 1 4 .3 0  ± 0 .2 6
C o p p e r  (p m o l /L ) 16 .17  ± 0 .2 5 * * * 14 .51  ± 0 .3 7
Z n /C u  R a tio 0 .9 0  ±  0 .0 2 * * 1.01 ± 0 .0 3
C p  (g /L ) 0 .1 6  ± 0 .0 1 0 .1 5  ± 0 .0 1
C u /C p  R a tio  (p m o l /g ) 1 1 1 .03  ± 2 .6 5 1 0 3 .7 7  ± 4 .5 8
S elen iu m  (p m o l /L ) 1 .09  ± 0 .0 2 1 .05  ± 0 .0 3
G P x  (U /m L ) 0 .33  ± 0 .0 1 * 0 .3 7  ±  0 .0 2
Females
N u m bers o f  su b jects 95 68
Z in c  (p m o l /L ) 13 .75  ±  0 .2 0 1 3 .3 8  ± 0 .2 9
C o p p e r  (p m o l /L ) 1 8 .7 4  ± 0 .3 7 * * 1 7 .2 9  ± 0 .3 8
Z n /C u  R a tio 0 .7 6  ±  0 .0 2 0 .8 0  ± 0 .0 2
C p  (g /L ) 0 .1 9  ± 0 .0 1 0 .1 9  ± 0 .0 1
C u /C p  R a tio  (p m o l /g ) 1 1 1 .8 9  ± 3 .7 5 * * 9 7 .5 2  ± 3 .6 7
S elen iu m  (p m o l /L ) 1 .08  ± 0 .0 3 1 .02  ± 0 .0 3
G P x  (U /m L ) 0 .31  ± 0 .0 1 * * 0 .3 6  ±  0 .0 2
Males & Females
N u m b ers  o f  su b jects 2 3 7 135
Z in c  (p m o l /L ) 1 4 .0 0  +  0 .13 1 3 .8 4  ± 0 .2 0
C o p p e r  (p m o l /L ) 1 7 .20  ±  0 .2 * * * 15 .91  ± 0 .2 9
Z n /C u  R a tio 0 .8 5  ± 0 .0 1 * 0 .9 0  ± 0 .0 1
C p  (g /L ) 0 .1 7  ± 0 .0 1 0 .1 7  ± 0 .0 1
C u /C p  R a tio  (p m o l /g ) 1 1 1 .3 7  ±  2 .1 8 * * 1 0 0 .6 3  ± 2 .9 3
S e len iu m  (p m o l /L ) 1 .09  ± 0 .0 2 * 1 .03 ± 0 .0 2
G P x  (U /m L ) 0 .3 2  ±  0 .0 1 * * * 0 .3 6  ± 0 .0 1
V a lu es  are exp ressed  as M e a n ±  S E M . *-p < 0 .0 5 , **= /> < 0 .0 1 , ***=p<0 .0 0 1  co m p a r iso n  
b e tw een  patients and  co n tro ls  b u  u s in g  o n e -w a y  A N O V A .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
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O b e se  patients c o m p a re d  w ith  n o n -o b e s e  patients h ad  s ig n ifica n tly  lo w e r  serum  
z in c /c o p p e r  ratio in  fe m a le  patients (p<0 .0 5 ) and seru m  G P x  in  m a le  ($ < 0 .0 5 ) , fem a le  
(p<0 .0 5 ) and the c o m b in e d  g rou p  ($ < 0 ,0 0 1 , T a b les  8 .6 a -b , 8 .7 a -b  and  7 .9 a -b ). A ls o , 
o b e s e  patients h ad  s ig n ifica n tly  h igh er  serum  co p p e r  in  fe m a le  (p < 0 .0 1 )  and the 
co m b in e d  m a le  and fe m a le  patients ($ < 0 .0 1 )  and  ca eru lop la sm in  con cen tra tion s  in  the 
m a le  su b grou p  o f  patients ($ < 0 .0 5 )  and in  the c o m b in e d  g rou p  o f  m a le  and fem a le  
patients ($ < 0 .0 5 , T a b les  7 .7 a -b , 7 .8 a -b  and 7 .9 a -b ).
Trace element status in hypertriglyceridaemia
Patients w ith  h y p ertr ig ly cer id a em ia  h ad  s ig n ifica n tly  h igh er seru m  z in c  con cen tra tion s  
and z in c / c o p p e r  ra tio  co m p a re d  w ith  patients w ith ou t h y p ertr ig ly cer id a em ia  in  the 
co m b in e d  m a le  and fe m a le  patients (p<0 .0 5 , T a b les  7 .7 a -b ), bu t n o t  in  m a le  ($ < 0 .0 5 , 
T a b les  7 .8 a -b ) o r  fe m a le  patients ($ < 0 .0 5 , T a b les  7 .9 a -b ). H o w e v e r , d if fe re n ce s  in  serum  
z in c  and z in c / c o p p e r  ratio  le v e ls  d id  n o t rem ain  s ig n ifica n t a fter age-ad ju stm ent 
(p>0 .0 5 ). A ls o , patients w ith  m e ta b o lic  sy n d rom e  had s ig n ifica n tly  h igh er serum  
ca eru lop la sm in  con cen tra tion s  co m p a re d  w ith  patients w ith ou t m e ta b o lic  sy n d rom e  in  the 
co m b in e d  m a le  and fe m a le  patients ($ < 0 .0 5 , T a b le s  7 .7 a -b ), bu t n o t  in  m a le  ($ < 0 .0 5 , 
T a b les  7 .8 a -b ) o r  fe m a le  patients (p < 0 .0 5 , T a b les  7 .9 a -b ).
Association between trace element status and calculated 10-year coronary risks 
W ith  in creased  ca lcu la ted  1 0 -y ea r  co ro n a ry  risks in  patients, serum  se len iu m  in  m a le  and 
the c o m b in e d  m a le  and fe m a le  and G P x  in creased  in  the c o m b in e d  m a le  and fem a le  
g rou p  (p<0 .0 5 , T a b les  7 .7 a -b  and  7 .8 a -b ). H o w e v e r , d if fe re n ce s  in  seru m  se len iu m  and 
G P x  le v e ls  d id  n o t rem ain  s ig n ifica n t a fter age -ad ju stm en t (p>0 .0 5 ).
Trace element status in obesity
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T a b le  7 .7 a  C o m p a r iso n  o f  seru m  trace  e lem en t status b e tw e e n  d iffe ren t su b grou p s o f  the 
c o m b in e d  m a le  and fe m a le  d y s lip id a e m ic  patients segm en ted  a c co rd in g  to  the p o sse ss io n  o f
Number Zinc Copper Zinc/Copper
(pmol/L) (pmol/L) Ratio
Group
Established CHD
C H D + 55 1 3 .2 9  +  0 .2 0 1* * 1 7 .97  ± 0 . 4 8 3 0 .7 7  ±  0 .0 3 3* *
C H D - 182 1 4 .2 2  +  0 .1 5 1 6 .97  ± 0 .2 6 0 .8 7  +  0 .0 2
Metabolic Syndrome
M S + 142 14 .05  ± 0 .1 7 1 7 .3 4  ± 0 .2 9 2 0 .8 4  ±  0 .0 2
M S - 95 13 .93  ± 0 .2 1 16 .99  ± 0 .3 6 0 .8 5  ±  0 .0 2
Diabetes Mellitus
D M + 4 2 13 .65  ± 0 .2 7 1 7 .29  ± 0 .4 6 2 0 .81  ±  0 .0 1 1
Im paired  G T 21 1 3 .8 0  ± 0 .4 0 18.11 ± 0 .7 8 0 .8 0  ± 0 .0 2
D M - 1 74 14.11  ± 0 .1 6 1 7 .0 7  ± 0 .2 7 0 .8 6  ±  0 .01
Obesity
O b e se + 82 14.01  ±  0 .2 4 1 8 .0 0  ± 0 . 4 3 3* * 0 .8 2  ±  0 .0 2 1
O v e r  w e ig h t 43 1 4 .0 6 ±  0 .2 0 16 .69  ±  0 .2 9 0 .8 7  ±  0 .0 2
O b e s e - 112 1 3 .8 4 ±  0 .2 5 17 .08  ± 0 .5 7 0 .8 4  ±  0 .03
Hypertriglyceridaemia
H ig h  T .G . 176 1 4 .1 7  ± 0 .1 6 * 1 7 .0 4  ± 0 .2 6 2 0 .8 6  ±  0 .0 2 1*
N o n n a l T .G . 61 1 3 .5 2  ± 0 .2 4 17 .65  ± 0 .4 7 0 .8 0  ± 0 .0 3
Blood pressure
H ig h  B P 76 13 .73  ± 0 .2 5 17 .66  ± 0 .4 1 2 0 .81  ±  0 .0 2 1
M od era te  B P 111 1 4 .1 4  ± 0 .1 8 16 .93  ± 0 .3 4 0 .8 7  ±  0 .0 2
N orm a l B P 5 0 1 4 .1 2  ± 0 .3 2 17.11 ± 0 .4 6 0 .8 5  ±  0 .03
Calculated 10-year 
Coronary Risk
H ig h  > 3 0 %  
M od era te  2 0 -3 0 %  
L o w  < 2 0 %  
Controls
4 2 1 3 .73  ± 0 .3 2 16 .78  ± 0 .5 2 2 0 .8 5  ±  0 .03
5 4 13 .83  ± 0 .2 4 1 7 .06  ± 0 .5 3 0 .8 5  ±  0 .03
141 14 .15  ± 0 .1 8 17 .38  ± 0 .2 9 0 .8 4  ± 0 .0 2
135 1 3 .8 4  ± 0 .2 0 15.91  ± 0 .2 9 0 .9 0  ±  0 .0 2
Values are expressed as M ean ±  SEM . 1= /K 0.05, 2=p<0.01, 3= /K 0.001 com parisons betw een group 
including patients and controls, and *=/><0.05, **= /K 0 .01  com parison betw een sub-categories o f  the 
dyslipidaem ic patients. D ifferences in serum zinc and z in c/ copper ratio levels did not remained 
significant after age-adjustm ent (p>0 .05) betw een patients with and without hypertriglyceridaemia.
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T a b le  7 .7 b  C o m p a r iso n  o f  in d ice s  o f  seru m  trace e lem en t status b e tw e e n  d iffe ren t 
su bgrou p s o f  the c o m b in e d  m a le  and  fe m a le  d y s lip id a e m ic  patients seg m en ted  a cco rd in g  
to the p o s s e s s io n  o f  s p e c if ic  c o ro n a ry  risk  fa ctors .
Group
Number Cp
(g/L)
Cu/Cp Ratio 
(pmol/g)
Selenium
(pmol/L)
GPx
(U/mL)
Established CHD
C H D +
C H D -
55
182
0 .1 7  +  0 .01  
0 .1 7  +  0 .01
118 .3  ± 4 .9 7 2 
1 0 9 .3 1 + 2 .4 0
1 .07  +  0 .0 3  
1 .09  +  0 .0 2
0 .3 5 + 0 .0 1 3*
0 .3 1 + 0 .0 1
Metabolic Syndrome
M S +
M S -
142
95
0 .1 8  +  0 .0 1 *  
0 .1 6  +  0 .01
1 0 8 .3 6  ± 2 .8 4 2 
1 1 5 .8 8  + 3 .3 7
1 .08  + 0 .0 2  
1 .09  +  0 .0 2
0 .3 2  ± 0 .0 1 2 
0 .3 1 + 0 .0 1
Diabetes Mellitus
D M +
Im paired  G T  
D M -
4 2
21
174
0 .1 8  + 0.01 
0 .1 9 +  0 .0 2  
0 .1 7  + 0 .01
1 0 8 .1 8 + 4 .9 4 1 
1 0 9 .6 2  + 9 .5 7  
1 1 2 .3 6  + 2 .4 8
1 .05  + 0 .0 4
1 .09  + 0 .0 4
1 .09  + 0 .0 2
0 .3 2  ±  0 .0 1 2 
0 .3 0  +  0.01 
0 .3 2  +  0 .01
Obesity
O b e s e +
O v e r  w e ig h t 
N orm a l w e ig h t
82
112
43
0 .1 8  ±  0 .0 1 1* 
0 .1 6  +  0 .01  
0 .1 7  +  0 .01
1 0 7 .4 8  + 3 . 7 5 2 
1 1 5 .4 6  +  3 .2 7  
1 0 8 .1 6  +  4 .4 8
1 .06  +  0 .0 3 1 
1 .09  +  0 .0 2  
1 .12  +  0 .0 4
0 .2 9  ±  0 .0 1 3* * h 
0 .3 4  +  0 .01  
0 .3 2  ±  0 .01
Hypertriglyceridaemia
H ig h  T .G . 176 
N orm a l T .G . 61
0 .1 7  +  0 .01  
0 .1 7  +  0 .01
1 1 0 .6 3 + 2 .6 0 1 
1 1 3 .5 2  +  4 .0 0
1 .08  +  0 .0 2  
1 .09  +  0 .03
0 .3 2  ±  0 .0 1 2 
0 .33  +  0 .01
Blood pressure
H ig h  B P  
M od era te  B P  
N orm a l B P
7 6
111
50
0 .1 8  +  0 .01  
0 .1 7  +  0 .01  
0 .1 7  +  0 .01  •
1 0 9 .7 4 +  3 .8 9 1 
1 1 1 .7 1 + 3 .3 3  
1 1 3 .0 9  +  4 .2 6
1 .09  +  0 .0 3  
1 .08  +  0 .0 2  
1 .08  +  0 .03
0 .3 4  ±  0 .0 1 3
0 .3 1 + 0 .0 1
0 .3 1 + 0 .0 1
Calculated 10 year 
Coronary Risk
H ig h  > 3 0 %  
M od era te  2 0 -3 0 %  
L o w  < 2 0 %
4 2
5 4
141
0 .1 7  +  0 .01 
0 .1 7  +  0 .01  
0 .1 7  +  0 .01
1 0 7 .5 8 +  4 .9 7 1 
1 1 1 .15  +  2 .8 2  
1 1 2 .5 9  +  2 .93
1 .17  +  0 .0 4 1 
1 .05  +  0 .03  
1 .07  +  0 .0 4
* 0 .3 4  ±  0 .0 1 3* 
0 .33  +  0 .01  
0 .3 0  +  0 .01
Controls 135 0 .1 7  +  0 .01 1 0 0 .63  +  2 .9 3 1 .0 3 + 0 .0 2 0 .3 6  ±  0 .01
Values are expressed as Mean ± SEM. l=p<0.05, 2=p<0.01, 3=p<0.001 comparisons between group including patients and 
controls, and *= p<0.05, ***=/><0.001 comparison between sub-categories of the dyslipidaemic patients. Differences in 
serum GPx did not remain significant after age-adjustment (p>0.05) between patients with and without established CHD. 
Differences in serum selenium and GPx with regard to changes 10 year calculated CHD risk did not remain significant after 
age-adjustment O>0.05). Cp=Caeruloplasmin; Cu=Copper.
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T a b le  7 .8 a  C o m p a r iso n  o f  seru m  trace  e lem en t status b e tw e e n  d iffe ren t su b g rou p s  o f  m a le  
d y s lip id a em ic  patients seg m en ted  a cco rd in g  to  the p o sse ss io n  o f  s p e c if ic  co ro n a ry  risk  
factors.
Number
Group
Zinc
(pmol/L)
Copper
(prnol/L)
Zinc/Copper
Ratio
Established CHD
C H D +  37 
C H D - 105
13.14 ±0 .3 9 2*** 
14.54 + 0.19
17.14 + 0.503* 
15.83 + 0.28
0.79 ±  0.043*** 
0.94 ±  0.02
Metabolic Syndrome
M S +  84 
M S - 58
14.11 + 0.23 
14.26 ±  0.29
16.13+ 0.302 
16.24 + 0.43
0.90 ±  0.022 
0.91 ±  0.03
Diabetes Mellitus
D M +  28 
D M - 114
13.97 + 0.34 
14.22 + 0.21
16.61+0.442 
16.07 + 0.29
0.85 ±  0.022 
0.91+0.02
Obesity
O b e s e +  50 
O b e s e - 92
14.19 + 0.31 
14.16 + 0.22
16.63+ 0.453 
15.93 + 0.30
0.88 ±  0.032 
0.91 ±  0.02
Hypertriglyceridaemia
H igh  T .G . 114 
N orm a l T .G . 28
14.27 + 0.19 
13.76 + 0.45
16.15 + 0.272 
16.26 + 0.65
0.91 +0.022 
0.88 + 0.04
Blood pressure
H ig h  B P  3 4  
M od era te  B P  77  
N orm a l B P  31
13.93 + 0.43 
14.20 + 0.19 
14.37 ±  0.47
16.31+0.452 
16.04 + 0.36 
16.36 + 0.54
0.88 ±  0.042 
0.91 ±  0.02 
0.90 ±  0.05
Calculated 10 year 
Coronary Risk
H ig h  >30% 35 
M od era te  20-30% 37 
L o w  <20% 70
13.80 + 0.36 
13.91 + 0.30 
14.46 ±  0.27
15.97+ 0.462 
16.63 + 0.55 
16.07 ±  0.34
0.86 ± 0.032 
0.87 ±  0.04 
0.92 ± 0.03
Controls 67 14.30 ±  0.26 14.51+0.37 1.01+0.03
V a lu es  are ex p ressed  as M e a n  ±  S E M . 2 = /K 0 .0 1 , 3 = /i< 0 .0 0 1  co m p a r iso n s  b e tw e e n  grou p  
in c lu d in g  patients and  co n tro ls , and *= /> < 0 .05 , * * * = /K 0 .0 1  co m p a r is o n  b e tw e e n  su b­
ca tegories  o f  the d y s lip id a e m ic  patients b y  u s in g  o n e -w a y  A N O V A .
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Table 7.8b Comparison o f indices o f serum trace element status between different
subgroups o f male dyslipidaemic patients segmented according to the possession of
specific coronary risk factors._______________________________________________________________
Number Cp Cu/Cp Ratio Selenium GPx
(g/L) (pmol/g) (pmol/L) (U/mL)
Group
Established CHD
C H D +  3 7  0 .1 6  ± 0 .0 1  1 2 0 .7 0  ±  5 .8 1 1* 1 .08  ± 0 . 0 4  0 .3 5 ± 0 . 0 2 2
C H D - 105 0 .1 6  ± 0 .0 1  1 0 7 .6 2  ± 2 .8 9  1 .09  ± 0 .0 2  0 .31  ± 0 .0 2
Metabolic Syndrome
M S +  84
M S - 58
0 .1 7  ± 0 .0 1  
0 .1 5  ± 0 .0 1
106 .91  ±  3 .4 8  
1 1 6 .9 9  ± 4 .0 1
1.11 ± 0 .0 3  
1 .06  ± 0 .0 3
0 .3 4  ±  0 .0 1 1 
0 .31  ± 0 .0 1
Diabeties Mellitus
D M + 28 0 .1 7  ± 0 .0 1 1 0 8 .9 6  ± 4 .9 4 1 .08  ± 0 . 0 4 0 .33  ±  0 .0 2 1
D M - 114 0 .1 6  ± 0 .0 1 1 1 1 .5 4  +  3 .0 4 1 .09  ± 0 .0 2 0 .3 2  ±  0 .01
Obesity
O b e s e + 50 0 .1 8  ±  0 .0 1 2* 105 .33  ± 4 .5 7 1 .05 ± 0 .0 3 0 .3 0  ±  0 .0 2 2’
O b e se - 92 0 .1 5  ± 0 .0 1 114 .13  ± 3 .2 3 1.11 ± 0 .0 2 0 .3 4  ±  0 .01
Hypertriglyceridaemia
H ig h  T .G . 114 0 .1 6  ± 0 .0 1 110.41 ± 3 .0 0 1 .09  ± 0 .0 2 0 .3 2  ±  0 .0 1 1
N orm a l T .G . 28 0 .1 5  ± 0 .0 1 1 1 3 .5 4  ± 5 .7 2 1 .10  +  0 .0 4 0 .3 3  ±  0 .0 2
Blood pressure
H ig h  B P 34 0 .1 6  ± 0 .0 1 1 1 2 .6 7  ± 5 .7 0 1 .15 ± 0 .0 4 0 .35  ±  0 .0 2 1
M od era te  B P 7 7 0 .1 6  ± 0 .0 1 109 .43  ± 3 .6 9 1 .09  ± 0 .0 3 0 .31  ± 0 .0 1
N o n n a l B P 31 0 .1 6  ± 0 .0 1 1 1 3 .2 0  ±  5.11 1 .03 ± 0 .0 4 0 .3 2  ±  0 .0 2
Calculated 10 year 
Coronary Risk
H ig h  > 3 0 % 35 0 .1 6 ± 0 .01 1 1 0 .8 4 ± 5 .0 7 1 .18 ±
*'Voo
0 .35 i o b to
M od era te  2 0 -3 0 % 37 0 .1 7 ± 0 .01 1 1 2 .2 6 ± 6 .2 4 1.03 ± 0 .0 3 0 .33 i 0 .0 2
L o w  < 2 0 % 7 0 0 .1 6 i 0 .01 1 1 1 .0 6 ± 3 .45 1 .08 ± 0 .0 3 0 .31 ± 0.01
Controls 67 0 .1 5 i 0 .01 1 0 3 .7 7 ± 4 .5 8 1.05 ± 0 .03 0 .3 7 i 0 .0 2
V a lu es  are e x p ressed  as M e a n  ±  S E M . l= /> < 0 .0 5 , 2 = /K 0 .0 1  co m p a r is o n  b e tw e e n  grou p  
in c lu d in g  patients and co n tro ls , and  * = p < 0 .0 5 , co m p a r iso n  b e tw e e n  su b -ca te g o r ie s  o f  the 
d y s lip id a em ic  patients b y  u s in g  o n e -w a y  A N O V A .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
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Table 7.9a Comparison of serum trace element status between different subgroups of
female dyslipidaemic patients segmented according to the possession of specific
coronary risk factors.________________________________________________________________________
N u m b e r
G r o u p
Z in c
( p m o l /L )
C o p p e r
(p m o I /L )
Z in c /C o p p e r
R a t io
E s ta b lis h e d  C H D
C H D +
C H D -
18
7 7
1 3 .6 0  +  0 .41  
1 3 .78  +  0 .23
1 9 .6 6 +  0 .9 6 1 
1 8 .52  +  0 .41
0 .7 2  ±  0 .0 4  
0 .7 7  ±  0 .0 2
M e t a b o l ic  S y n d r o m e
M S +  58 
M S - 37
14 .95  ±  0 .2 8  
13 .43  +  0 .2 9
1 9 .09  +  0 .4 9 1 
18 .18  +  0 .5 9
0 .7 6  ±  0 .0 2  
0 .7 7  ±  0 .03
D ia b e te s  M e ll itu s
D M +
D M -
14
81
1 3 .0 1 + 0 .3 9  
1 3 .88  +  0 .23
18 .67  +  1 .0 0 1 
18 .75  +  0 .41
0 .7 3  ±  0 .0 4  
0 .7 7  ±  0 .0 2
O b e s ity
O b e s e +
O b e s e -
32
63
1 3 .6 0  +  0 .3 7  
1 3 .8 2  +  0 .25
2 0 .1 7  +  0 6 9 3* *  
1 8 .0 1 + 0 .4 2
0 .71  ±  0 .0 3 *  
0 .7 9  ±  0 .0 2
H y p e r t r ig ly c e r id a e m ia
H ig h  T .G . 62  
N orm a l T .G . 33
1 3 .9 7  +  0 .2 8  
1 3 .3 2  +  0 .23
18 .68  +  0 .4 9 1 
1 8 .8 4  +  0 .6 0
0 .7 8  ±  0 .03  
0 .73  ±  0 .03
B lo o d  p r e s s u r e
H ig h  B P  
M od era te  B P  
N orm a l B P
4 2
3 4
19
1 3 .5 6  +  0 .2 9  
1 4 .0 0  +  0.41 
13 .71  +  0 .3 2
18 .75  +  0 .6 0  
18 .95  +  0 .6 4  
1 8 .32  +  0 .7 6
0 .7 6  ±  0 .03  
0 .7 7  ±  0 .03  
0 .7 7  ±  0 .03
C a lc u la te d  10  y e a r  
C o r o n a r y  R is k
H ig h  > 3 0 %  7 
M od era te  2 0 -3 0 %  17 
L o w  < 2 0 %  71
1 3 .3 9  +  0 .6 8  
1 3 .5 2  +  0 .41  
1 3 .8 4  +  0 .25
2 0 .8 2 +  1 .3 3 1 
1 8 .17  +  1.11 
1 8 .67  +  0 .41
0 .6 6  ±  0 .05  
0 .7 9  ±  0 .05  
0 .7 7  ±  0 .0 2
C o n t r o ls 68 13 .38  +  0 .2 9 17 .29  ±  0 .3 7 0 .8 0  ±  0 .0 2
V a lu es  are ex p ressed  as M e a n  ±  S E M . l= /> < 0 .0 5 , 3 = /K 0 .0 0 1  co m p a r iso n s  b etw een  
grou p  in c lu d in g  patients and  con tro ls , and *==p<0 .0 5 , **= /> < 0 .01  co m p a r iso n  b e tw een  
su b -ca teg orie s  o f  the d y s lip id a e m ic  patients b y  u s in g  o n e -w a y  A N O V A .
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Table 7.9b Comparison o f indices of serum trace element status between different
subgroups of female dyslipidaemic patients segmented according to the possession of
specific coronary risk factors._______________________________________________________________
Number
Group
Cp
(g/L)
Cu/Cp Ratio 
(pmol/g)
Selenium
(pmoI/L)
GPx
(U/mL)
Established CHD
C H D +  18 
C H D - 77
0 .1 9  +  0 .0 2  
0 .1 8  +  0 .01
1 1 3 .0 2 +  4 .9 7 1 
11 1 .6 2  +  2 .4 0
1.03 +  0 .0 7  
1 .09  +  0 .0 3
0 .33  ±  0 .0 2 2 
0 .3 0  +  0 .01
Metabolic Syndrome
M S +  58 
M S -  37
0 .1 9  +  0 .01  
0 .1 8  +  0 .01
1 1 0 .4 5 +  4 .8 3 1 
1 1 4 .1 4  +  6 .0 2
1.05  +  0 .0 4  
1 .12  +  0 .0 4
0 .3 0  +  0 .0 1 2 
0 .3 1 + 0 .0 2
Diabetes Mellitus
D M +  14 
D M -  81
0 .21  +  0 .03  
0 .1 8  +  0 .01
1 0 6 . 6 0 + 1 0 .6 1 
1 1 2 .7 9  +  4 .0 2
0 .9 9  ±  0 .0 8  
1 .09  +  0 .0 3
0 .2 9  +  0 .0 3 1 
0 .3 1 + 0 .0 1
Obesity
O b e s e +  32  
O b e s e - 93
0 .2 0  ±  0 .0 2  
0 .1 8  +  0 .01
1 1 2 .6 2 +  6 .6 3 1 
1 1 1 .5 1 + 4 .5 8
1 .04  +  0 .0 5  
1 .10  +  0 .03
0 .2 7  ±  0 .0 1 2'1 
0 .3 2  +  0 .01
Hypertriglyceridaemia
H ig h  T .G . 62  
N orm a l T .G . 33
0 .1 9  +  0 .01  
0 .1 8  +  0 .01
111 .03  + 4 . 9 2 1 
1 1 3 .4 9  +  5 .6 7
1 .08  +  0 .0 3
1 .08 +  0 .0 4
0 .3 0  +  0 .0 2 1 
0 .3 2  +  0.01
Blood pressure
H ig h  B P  4 2  
M od era te  B P  3 4  
N orm a l B P  19
0 .1 9  +  0 .01  
0 .1 8  +  0 .01  
0 .1 8  +  0 .0 2
1 0 7 .3 7 +  3 .3 5 1 
1 1 6 .8 9  +  6 .9 6  
1 1 2 .9 2  +  7 .6 7
1 .05 +  0 .0 4
1 .06  +  0 .0 5  
1 .17  +  0 .0 5
0 .33  ±  0 .0 2 2 
0 .2 9  +  0 .01  
0 .2 8  ±  0 .0 2
Calculated 10 year 
Coronary Risk
H ig h  > 3 0 %  7 
M od era te  2 0 -3 0 %  17 
L o w  < 2 0 %  71
0 .2 5  ±  0 .01  
0 .1 7  +  0 .01  
0 .1 8  +  0 .01
9 1 .3 0 +  1 0 .8 1 
1 1 1 .1 8  +  8 .1 0  
1 1 4 .0 9  +  4 .4 7
1.13 +  0 .1 5  
1 .09  +  0 .0 6  
1 .07  +  0 .0 3
0 .31  + 0 .0 3 1 
0 .3 4  ±  0 .03  
0 .3 0  +  0 .01
Controls 68 0 .1 9  +  0 .01 9 7 .5 2  +  3 .6 7 1 .02  +  0 .0 3 0 .3 6  ±  0 .0 2
V a lu es  are e x p ressed  as M e a n  ±  S E M . l= /> < 0 .0 5 , 2 = /K 0 .0 1 , 3 = /;< 0 .0 0 1  co m p a riso n  
b e tw e e n  g rou p  in c lu d in g  patients and con tro ls , and * = //< 0 .0 5  co m p a r is o n  b e tw e e n  su b ­
ca teg or ies  o f  the d y s lip id a e m ic  patients b y  u s in g  o n e -w a y  A N O V A .
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Relationship between CHD risk factors and serum trace element status 
In co n tro l su b jects , seru m  c o p p e r  con cen tra tion s  w e re  p o s it iv e ly  a ssoc ia ted  w ith  H D L  
and serum  C R P  le v e ls  ( /K 0 .0 0 1 )  and n e g a tiv e ly  a ssoc ia ted  w ith  w a is t / h ip  ratio  ( /K 0 .0 5 ) . 
Serum  z in c /c o p p e r  ratio w a s  p o s it iv e ly  a ssoc ia ted  w ith  fastin g  b lo o d  g lu c o s e  (p < 0 .0 5 ), 
and w a is t / h ip  ratio  (p < 0 .0 1 )  and n eg a tiv e ly  a ssocia ted  w ith  H D L  (p<0 .0 5 ) and serum  
C R P  (p O .O O l) .  S eru m  ca eru lop la sm in  con cen tra tion s  w e re  p o s it iv e ly  a ssoc ia ted  w ith  
age (p < 0 .0 5 ) , H D L  (p<0 .0 5 ) , seru m  total ch o le s te ro l (p < 0 .0 1 ) and seru m  C R P  (p< 0 .0 0 1 ). 
Serum  c o p p e r / ca eru lop la sm in  ratio w a s  n e g a tiv e ly  a ssoc ia ted  w ith  a g e  (p < 0 .0 1 ) , fasting  
b lo o d  g lu c o s e  (p<0 .0 5 ) , tota l ch o le s te ro l (p < 0 .0 5 ) and sy s to lic  b lo o d  pressu re  (p < 0 .0 5 ). 
S eru m  G P x  w a s  n e g a tiv e ly  a ssoc ia ted  w ith  a ge  (p < 0 .0 5 ), sy s to lic  b lo o d  pressure 
O < 0 .0 5 )  and p o s it iv e ly  a ssoc ia ted  w ith  H D L  le v e ls  (p O .O O l)  and  d ia sto lic  b lo o d  
pressure (p<0 .0 5 , T a b le  7 .1 0 ) . T h ere  w e re  n ot an y  s ign ifica n t co rre la tion s  b e tw een  these 
co ro n a ry  risk  fa ctors  and seru m  con cen tra tion s  o f  z in c  and se len iu m  (p > 0 .0 5 , T a b le  
7 .1 0 ).
In the patient g rou p , seru m  con cen tra tion s  o f  z in c  w e re  n e g a tiv e ly  corre la ted  w ith  a ge  
(p < 0 .0 5 ). S eru m  c o p p e r  con cen tra tion s  w e re  p o s it iv e ly  a ssoc ia ted  w ith  B M I  (p < 0 .0 1 ), 
H D L  (p<0 .0 5 )  and seru m  C R P  le v e ls  (p < 0 .0 0 1 ). S eru m  z in c /c o p p e r  ra tio  w a s  p o s it iv e ly  
a ssocia ted  w ith  w a is t / h ip  ratio  (p < 0 .0 5 )  and n e g a tiv e ly  a ssoc ia ted  w ith  serum  C R P  
(p < 0 .0 0 1 ). S eru m  ca eru lop la sm in  con cen tra tion s  w e re  p o s it iv e ly  a ssoc ia ted  w ith  B M I  
(p<0 .0 5 ), seru m  tr ig ly cer id es  (p < 0 .0 5 ) and  serum  C R P  ( p O .0 0 1 ) .  S eru m  co p p e r / 
ceru lop la sm in  ratio w a s  n e g a t iv e ly  a ssoc ia ted  w ith  serum  tr ig ly ce r id e  (p<0 .0 5 ) and 
serum  C R P  (p<0.05). S eru m  G P x  w a s  p o s it iv e ly  associa ted  w ith  a g e  (p < 0 .0 5 ) , sy s to lic  
(p < 0 .0 1 ) and  d ia s to lic  b lo o d  pressu re  (p<0 .0 5 ) and n e g a tiv e ly  a ssoc ia ted  w ith  B M I  
O < 0 .0 5 ) ,  seru m  tr ig ly cer id es  O < 0 .0 5 )  and total ch o les te ro l (p < 0 .0 5 , T a b le  7 .1 0 ).
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T here  w e re  n o t an y  s ig n ifica n t co rre la tion s  b e tw e e n  these co ro n a ry  risk  fa ctors  w ith  
serum  con cen tra tion s  o f  se len iu m  (p>0.05, T a b le  7 .1 0 ).
Serum  z in c , co p p e r , z in c /c o p p e r  ratio, ca eru lop la sm in , c o p p e r / ca eru lop la sm in  ratio, 
se len iu m  and G P x  d id  n o t  d if fe r  s ig n ifica n tly  b e tw e e n  sm ok ers  and  n o n -sm o k e rs  in  
patient and co n tro l su b je cts  (p>0 .0 5 ) . S eru m  c o p p e r / ca eru lop la sm in  ra tio , se len iu m  and 
G P x  d id  n ot d if fe r  s ig n ifica n tly  b e tw e e n  m a les  and fem a les  in  patient and  co n tro l g rou ps 
(p > 0 .0 5 ). H o w e v e r , fem a les  h ad  h ig h er  serum  c o p p e r  and ca eru lop la sm in  than m a les  in  
patient and co n tro l g rou p s  (p < 0 .0 0 1 ). S eru m  z in c / c o p p e r  ratio w a s  s ig n ifica n tly  h igh er 
in  m a les  than fem a les  in  patient and  co n tro l g rou p s (p<0 .0 0 1 ) . M a le s  h ad  s ig n ifica n tly  
h igh er seru m  z in c  than fe m a le s  in  co n tro l (p<0 .0 5 ) , bu t th is w a s  n o t  the ca se  in  the 
patient g rou p  (p > 0 .0 5 ).
7.2.2 Trace element status and metabolic syndrome
W ith in  the d y s lip id a e m ic  g rou p , serum  con cen tra tion s  o f  z in c , co p p e r , z in c / co p p e r  ratio, 
ca eru lop la sm in , co p p e r , ca eru lop la sm in  and G P x  d id  n o t d if fe r  s ig n ifica n tly  w ith  
a ccu m u la tin g  features o f  m e ta b o lic  sy n d rom e  in  m a les  (p>0 .0 5 ) , fem a les  (p > 0 .0 5 ) and in  
the c o m b in e d  g rou p  Q p>0.05, T a b les  7 .1 1 a -b ). H o w e v e r , serum  se len iu m  con cen tra tion s  
d ecrea sed  s ig n ifica n tly  w ith  a ccu m u la tin g  features o f  m e ta b o lic  sy n d rom e  in  fem a le  
( /K 0 .0 1 )  and the c o m b in e d  m a le  and fem a le  patients (p < 0 .0 5 ), bu t n o t in  the m a le  patient 
grou p  (p>0 .0 5 , T a b le s  7 .1  l a  and b ) .
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T a b le  7 .1  l a  R e la tion sh ip  b e tw e e n  in d ice s  o f  seru m  trace e lem ents status and accu m u la tion  o f  feature 
o f  the m e ta b o lic  sy n d ro m e  in  m a le  and fem a le  d y s lip id a e m ic  patients_____________________________________
Number of 
Features
Males
Number of 
Subjects
Zinc
(pmol/L)
Copper
(pmol/L)
Zn/Cu
Ratio
Cp
(g/L)
Cu/Cp Ratio
(pmol/g)
Selenium
(pmol/L)
GPx
(U/mL)
Females
Number of 
Subjects
Zinc
(pmol/L)
Copper
(pmol/L)
Zn/Cu
Ratio
Cp
(g/L)
Cu/Cp Ratio
(pmol/g)
Selenium
(pmol/L)
GPx
(U/mL)
0
3
1 7 .5 6 ± 0 .9 4
1 2 .4 9 + 0 .6 7
1 .1 8 ± 0 .1 5
0 .1 1 ± 0 .0 1
1 1 9 .3 ± 1 1 .7
0 .9 6 ± 0 .1 1
0 .3 6 ± 0 .0 4
7
1 3 .4 7 ± 0 .3 2
1 7 .0 5 ± 1 .7 2
0 .8 3 + 0 .0 6
0 .1 8 ± 0 .0 3
1 0 4 .5 + 9 .0 1
1 .3 1 ± 0 .1 0
0 .3 0 + 0 .0 3
1
15
1 3 .5 5 ± 0 .5 1
1 7 .0 5 ± 0 .9 0
0 .8 4 ± 0 .0 6
0 .1 5 + 0 .0 1
1 2 3 .5 ± 7 .7 9
1 .0 5 ± 0 .0 7
0 .3 0 + 0 .0 3
13
1 3 .6 7 + 0 .3 5
1 8 .1 6 ± 0 .6 2
0 .7 6 ± 0 .0 3
0 .1 7 ± 0 .0 2
1 2 2 .7 + 1 3 .1
1 .0 7 ± 0 .0 7
0 .3 2 ± 0 .0 3
2
4 4
1 4 .3 0 ± 0 .3 3
1 6 .1 1 + 0 .4 6
0 .9 2 + 0 .0 3
0 .1 5 + 0 .0 1
1 1 5 .4 + 4 .7 6
1 .1 0 + 0 .0 3
0 .3 2 + 0 .0 2
17
1 3 .9 0 + 0 .6 5
1 8 .2 2 + 0 .8 0
0 .8 0 + 0 .0 6
0 .1 8 + 0 .0 2
1 1 2 .6 + 8 .2 3
1 .0 5 + 0 .0 4
0 .3 3 + 0 .0 3
3
41
1 4 .3 3 + 0 .3 4
1 6 .2 8 + 0 .4 2
0 .9 0 + 0 .0 3
0 .1 6 + 0 .0 1
1 0 9 .3 + 4 .9 4
1 .1 4 + 0 .0 4
0 .3 4 + 0 .0 2
21
1 3 .8 7 + 0 .5 0
2 0 .0 9 + 0 .9 2
0 .7 2 + 0 .0 3
0 .2 0 + 0 .0 2
1 1 2 .5 + 8 .3 3
1 .0 9 + 0 .0 6
0 .2 9 + 0 .0 2
4
34
1 3 .8 3 + 0 .3 3
1 6 .0 2 + 0 .5 3
0 .8 9 + 0 .0 4
0 .1 8 + 0 .0 1
1 0 0 .5 + 5 .4 4
1 .0 5 + 0 .0 4
0 .3 3 + 0 .0 2
22
1 3 .7 6 + 0 .4 2
1 8 .6 8 + 0 .8 8
0 .7 7 + 0 .0 4
0 .1 9 + 0 .0 2
1 0 5 .3 + 7 .2 4
1 .1 6 + 0 .0 5
0 .3 2 + 0 .0 2
5
5
13 .93+0.61
1 6 .4 7 ± 0 .7 (
0 .8 6 + 0 .0 7
0 .1 5 + 0 .0 1
1 1 6 .3 ± 1 4 .(
1 .1 0 + 0 .1 1
0 .3 0 + 0 .0 4
15
1 3 .5 6 + 0 .4 !
18 .80+ 0 .81
0 .7 4 + 0 .0 4
0 .1 8 + 0 .0 2
1 1 4 .1 + 9 .8 ?
0 .8 7 + 0 .0 4 *
0 .2 7 + 0 .0 2
V a lu es  are e x p ressed  as M e a n  ±  S E M . * * = p = 0 .0 0 2  co m p a r is o n  b e tw e e n  the g rou ps w ith  d iffe i 
n u m ber o f  features o n  m e ta b o lic  sy n d rom e  b y  u s in g  o n e -w a y  A N O V A .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
T a b le  7.1  l b  R e la tion sh ip  b e tw e e n  in d ice s  o f  seru m  trace e lem en ts status and a ccu m u la tion  o f  feature 
o f  the m e ta b o lic  sy n d ro m e  in  the c o m b in e d  g rou p  o f  m a le  and fe m a le  d y s lip id a e m ic  patients_________
N u m b e r  o f  
F e a tu re s  
N u m b e r  o f
0 1 2 3 4 5
S u b je c ts 10 28 61 62 56 2 0
Z in c
(p m o l /L )
1 4 .7 0 1 0 .7 1 1 3 .6 0 + 0 .3 1 1 4 .1 9 1 0 .3 0 1 4 .1 7 + 0 .2 8 1 3 .8 0 + 0 .2 6 13 .67+ 0 .3?
C o p p e r 1 5 .6 8 1 1 .3 8 1 7 .5 7 + 0 .5 6 1 6 .7 0 1 0 .4 2 1 7 .5 7 1 0 .4 7 1 7 .0 6 1 0 .5 0 1 8 .2 1 1 0 .6 :
(p m o l /L )
Z n /C u
R a t io
0 .9 3 1 0 .0 8 0 .8 0 + 0 .0 4 0 .8 8 1 0 .0 3 0 .8 4 1 0 .0 3 0 .8 4 + 0 .0 3 0 .7 7 1 0 .0 4
C p
(g /L )
0 .1 6 1 0 .0 2 0 .1 6 1 0 .0 1 0 .1 6 + 0 .0 1 0 .1 8 + 0 .0 1 0 .1 8 + 0 .0 1 0 .1 8 1 0 .0 1
C u /C p  R a t io  
( f im o l /g )
1 0 8 .9 2 + 7 .2 1 1 2 3 .1 2 1 7 .2 5 1 1 4 .5 8 1 4 .1 0 1 1 0 .3 6 1 4 .2 8 1 0 2 .4 1 1 4 .3 3 1 1 4 .6 1 1 8 .(
S e le n iu m 1 .2 0 + 0 .0 9 1 .0 6 + 0 .0 5 1 .0 8 1 0 .0 3 1 .1 2 1 0 .0 3 1 .0 9 1 0 .0 3 0 .9 3 1 0 .0 5 *
(p m o l /L )
G P x
(U /m L )
0 .3 2 1 0 .0 3 0 .3 1 + 0 .0 2 0 .3 2 + 0 .0 1 0 .3 2 1 0 .0 1 0 .3 3 1 0 .0 1 0 .2 7 + 0 .0 2
V a lu es  are e x p ressed  as M e a n  ±  S E M . * = p = 0 .0 2  co m p a r iso n  b e tw e e n  the g rou p s w ith  d if fe re n  
n u m ber o f  features o n  m e ta b o lic  sy n d rom e  b y  u sin g  o n e -w a y  A N O V A .
C p  =  C a eru lop la sm in ; C u  =  C op p er .
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In ord er  to  eva lu ate  the re la tion sh ip  b e tw e e n  serum  trace e lem en t con cen tra tion s  and 
C H D  risk  fa ctors  (in  the d y s lip id a e m ic  patients), and  the e ffe c ts  o f  a ccu m u la tin g  o f  
features o f  the m e ta b o lic  sy n d ro m e  o n  serum  trace e lem en t status, s tep w ise  m u ltip le  
reg ress ion  an a lysis  w a s  undertaken  (F o r  m o re  details see se c t io n  4 .3 .3 ) .
Serum zinc concentrations
In d y s lip id a e m ic  patients, 7 .9 %  o f  the varia tion  in  z in c  le v e ls  c o u ld  b e  ex p la in ed  b y  a 
h is tory  o f  estab lish ed  C H D  (p = 0 .0 0 6 , -2 .9 % ) , d ietary  z in c  ( / /= 0 .0 3 , + 2 % ) , 
h y p ertr ig ly cer id a em ia  (p = 0 .0 4 , + 1 .4 % ) ,  p o s s ib ly  treatm ent w ith  fib ra tes  (p = 0 .0 7 , - 
0 .9 % ), and sm o k in g  (p = 0 .0 8 , + 0 .9 % ) . In  the m e ta b o lic  sy n d rom e  g rou p , o n ly  2 .5 %  o f  
the varia tion  in  z in c  c o u ld  b e  ex p la in ed  b y  d ietary  z in c  (p = 0 .0 3 , + 2 .2 % ) , and serum  
H D L -ch o le s te ro l (p=0.09, + 1 .3 % ) .
Serum copper concentrations
In  d y s lip id a e m ic  patients, 2 9 .5 %  o f  the varia tion  in  c o p p e r  le v e ls  c o u ld  b e  exp la in ed  
b y  C R P  (p < 0 .0 0 1 , + 1 5 % ) ,  g en d er  (p < 0 .0 0 1 , -1 0 .6 % ) , d ietary  c o p p e e r  (1 M ).0 3 , 
+ 1 .5 % ) , treatm ent fo r  h y p erten s ion  (p = 0 .0 4 , -1 % ) ,  statin th erapy  (p = 0 .0 5 , -0 .9 % ) , and 
ca lcu la ted  10 years co ro n a ry  r isk  fa ctors  (p > 0 .0 5 , -0 .5 % ) . In the g rou p  w ith  m e ta b o lic  
syn d rom e , 1 9 .8 %  o f  the va ria tion  in  c o p p e r  c o u ld  b e  ex p la in ed  b y  B M I  (p = 0 .0 0 8 , 
+ 4 .2 % ) , w a ist m easu rem en t (p < 0 .0 0 1 , -1 0 .4 % ) , seru m  H D L -c h o le s te r o l ( / /= 0 .0 3 , 
+ 2 .3 % ) , d ietary  c o p p e e r  (P = 0 .0 3 , + 1 .5 % ) , and sy s to lic  b lo o d  p ressu re  (/>=0.07, - 
1 .4 % ).
7.3 Multifactorial analysis o f trace elements status
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In  d y s lip id a e m ic  patients, 1 2 .3 %  o f  the varia tion  in  ca eru lop la sm in  le v e ls  c o u ld  b e  
ex p la in ed  b y  seru m  C R P  ( /K 0 .0 0 0 1 , + 9 .8 % ) , and gen d er 0 = 0 .0 0 6 ,  -2 .5 % ) . In  the 
m e ta b o lic  sy n d ro m e  g rou p , 2 %  o f  the varia tion  in  ca eru lop la sm in  c o u ld  b e  exp la in ed  
b y  B M I  0 = 0 .0 5 , + 2 % ) .
Serum zinc/ copper ratio
In d y s lip id a e m ic  patients, 1 9 .7 %  o f  the varia tion  in  z in c /c o p p e r  ratio  c o u ld  b e  
ex p la in ed  b y  g en d er  0 ^ - 0 0 0 1 ,  + 1 0 .1 % ) , C R P  O ^ -O O O l,  -7 % ) ,  and a h istory  o f  
estab lish ed  C H D  0 = 0 .0 0 4 ,  -2 .6 % ) . In  the m e ta b o lic  sy n d rom e  g rou p , 1 2 .5 %  o f  the 
varia tion  in  z in c /c o p p e r  ratio  c o u ld  b e  ex p la in ed  b y  d ia sto lic  b lo o d  pressu re  0 = 0 .0 4 ,  
+ 2 .4 % ) , w a ist/h ip  ratio  O < 0 .0 0 1 , + 6 .5 % )  and B M I  0 = 0 .0 1 ,  -3 .6 % ) .
Serum selenium concentrations
In  d y s lip id a e m ic  patients, 7 .6 %  o f  the varia tion  in  serum  se len iu m  con cen tra tion s  
c o u ld  b e  ex p la in ed  b y  ca lcu la ted  10 years co ro n a ry  risk  fa ctors  0 = 0 .0 6 ,  + 1 .1 % ) , 
d ietary  se len iu m  0 = 0 .0 3 ,  + 2 .1 % ) , a ccu m u la tion  o f  features o f  m e ta b o lic  sy n d rom e 
0 = 0 .0 2 ,  -2 % ) ,  seru m  C R P  0 = 0 .0 4 ,  -1 .4 % )  and m e ta b o lic  sy n d ro m e  0 = 0 .0 7 ,  + 1 % ) . 
In the m e ta b o lic  sy n d ro m e  g rou p , 5 .6 %  o f  the varia tion  in  seru m  se len iu m  c o u ld  b e  
ex p la in ed  b y  serum  tr ig ly ce r id e s  le v e ls  O = 0 -0 2 , + 3 .4 % ) , and  d ieta ry  se len iu m  
0 = 0 .0 3 ,  + 2 .2 % ) .
Serum GPx concentrations
In d y s lip id a e m ic  patients, 1 0 .4 %  o f  the varia tion  in  serum  G P x  con cen tra tion s  co u ld  
b e  ex p la in ed  b y  o b e s ity  0 = 0 .0 0 2 ,  -3 .8 % ) , ca lcu la ted  10 years c o ro n a ry  risk  fa ctors
Serum caeruloplasmin concentrations
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0 = 0 .0 0 2 ,  + 3 .6 % ) , a h is to ry  o f  C H D  0 = 0 .0 5 ,  + 1 .1 % ) , seru m  C R P  0 = 0 .0 4 ,  -1 .4 % ) , 
and h y p erten sion  O > 0 .0 5 , + 0 .5 % ) . In  the m e ta b o lic  sy n d rom e  g rou p , 5 %  o f  the 
varia tion  in  serum  G P x  c o u ld  b e  e x p la in ed  b y  B M I  0 = 0 .0 1 ,  -3 .8 % ) ,  and d ia sto lic  
b lo o d  pressu re  O > 0 .0 5 , + 1 .2 % ) .
7 .4  D is c u s s io n
Effects o f gender on trace element status
C on sisten t w ith  p re v io u s  reports (G ra n d jea n  et al., 1 9 9 2 ; J oh n son  et a l., 1 9 9 2 ; M iln e  
and J oh n son , 1 9 9 3 ), h ea lth y  w o m e n  had  s ig n ifica n tly  h ig h er  seru m  c o p p e r  and 
ca eru lop la sm in  con cen tra tion s  and  lo w e r  z in c  lev e ls  than m en . A  gen der-re la ted  
d iffe re n ce  w a s  seen  in  seru m  z in c  con cen tra tion s , w h ich  m a y  b e  re la ted  to  d iffe re n ce s  
in  the eating habits o f  the tw o  sex es  and the re la tive  con trib u tion s  o f  th e  va riou s  fo o d  
sou rces  o f  z in c  m a y  d if fe r  b e tw e e n  m a les  and fem a les . W e  fo u n d  that w o m e n  h ad  a 
h igh er d ietary  in take o f  z in c  than m e n  (se e  se c t io n  4 .3  fo r  m o re  d eta ils ).
J oh son  et a l , (1 9 9 2 )  h a v e  rep orted  that in  d iffe ren t d ietary  c o p p e r  in take b e tw e e n  m en  
(1 .2 -1 .3  m g /d a y ) and  w o m e n  (0 .9 -1 .2  m g /d a y ) , net co p p e r  a b sorp tion  (p g  co p p e r /k g  
b o d y  w e ig h t/d a y ) d id  n o t  d iffe r . T hu s w o m e n  h a v e  a lo w e r  req u irem en t fo r  d ietary  
co p p e r  intake than d o  m e n  (J oh n son  et al., 1 9 9 2 ). T h is  su ggests  that gen der-re la ted  
d iffe re n ce s  in  seru m  c o p p e r  m a y  b e  related  to  d if fe re n ce s  in  c o p p e r  a b sorp tion  
b e tw een  m a les  and fem a les . H o w e v e r , it has b e e n  rep orted  that e x o g e n o u s  estrogen s 
(ora l co n tra cep tiv e  o r  p os tm en op a u sa l th erapy) e leva ted  p la sm a  co p p e r , bu t n ot 
c o p p e r  a b sorp tion  (J oh n son  et al., 19 9 2 ).
W h eth er there is  a g en d er  d if fe r e n c e  in  serum  se len iu m  le v e ls  rem ain s con trov ers ia l 
(B e a g le h o le  et a l., 1 9 9 0 ; B u rgu era  et al., 1 9 9 0 ; M a lv y  et al., 1 9 9 3 ; M cM a s te r  et al., 
1 9 90 ; R o b b e re ch t  and D eelstra , 1 9 9 4 ; T hu luvath  and T rig er , 1 9 9 2 ). W e  fo u n d  n o
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sign ifican t varia tion s in  the serum  se len iu m  con cen tra tion s  related  to  g en d er, as others 
h a ve  sh o w n  (B e a g le h o le  et a l., 1 9 9 0 ; M a lv y  et al., 1 9 93 ; R o b b e re ch t  and D eelstra , 
1 9 94 ; T hu luvath  and T riger , 19 9 2 ). P rev iou s  studies h a v e  rep orted  that hum an 
eryth rocyte  G P x  a ctiv ity  is e ither s lig h tly  h igh er (A n d ersen  et al., 1 9 9 7 ; G u em ou ri et 
al., 1 9 9 1 ), o r  n o  d iffe ren t (H a b if  et al., 2 0 0 1 ) in  fem a les  co m p a re d  w ith  m a les, and 
that serum  G P x  a ctiv ity  is n ot s ig n ifica n tly  a ffe c te d  b y  g en d er  (G u e m o u r i et al., 
1991 ). W e  fo u n d  n o  s ig n ifica n t gen d er d iffe re n ce s  fo r  seru m  G P x  con cen tra tion s , 
a lthou gh  R u sh  and  S a n d ifo rd  (2 0 0 3 )  d em on strated  that y o u n g , h ea lth y  fem a les  h ave 
h igh er seru m  G P x  con cen tra tion s  than their m a le  counterparts (R u sh  and  S a n d iford , 
2 0 0 3 ).
Effects o f age on trace element status
T here  w e re  s ig n ifica n t d if fe re n ce s  in  serum  co p p e r  and ca eru lop la sm in  con cen tra tion s  
related  to  a ge  in  o u r  study, w h ic h  are sim ilar to  p re v io u s  reports  (G ra n d jea n  et al., 
1 9 9 2 ; J oh n son  et a l., 1 9 9 2 ; M iln e  and Joh n son , 1 9 93 ; V iv o l i  et a l., 1 9 9 5 ). It w a s  
su ggested  that these ch a n g es  in  b io c h e m ic a l in d ices  o f  c o p p e r  status w ith  age  w ere  
n o t a cco m p a n ie d  b y  s ig n ifica n t ch a n ges  in  c o p p e r  a b sorp tion  o r  e x cre tio n  (V iv o l i  et 
al., 19 9 5 ). In  ou r  stu dy , the ch a n g es  in  b io c h e m ic a l in d ices  o f  c o p p e r  status w ith  age  
w ere  n o t re lated  to  their d iet ( f o r  m o re  details re fer  to  se ct io n  4 .3 ) . C h a n ges  in  serum  
co p p e r  and ca eru lop la sm in  con cen tra tion s  m a y  b e  related  to  the a g e in g  p rocess . 
A n oth er  p o s s ib ility  fo r  h ig h  seru m  co p p e r  in  age  b e tw een  3 0 -3 9  y ea rd  o ld  m a y  b e  
related  to  in crea sed  u se  o f  con tra cep tiv e  p ills  in  this age. A ls o , d e crea sed  serum  
co p p e r  con cen tra tion s  a fter 5 0  years o ld  in  fem a les  m a y  b e  re la ted  to  m en op au sa l 
status. H o w e v e r , further stu d ies are n e e d e d  to  test this h yp oth esis . U n fortu n ate ly , w e  
d id  n ot c o lle c t  in fo rm a tion  a bou t u se  o f  con tra cep tiv e  p ills  and m en op a u sa l status in 
ou r su b jects .
226
R egu la tion  o f  z in c  m e ta b o lism  (a b sorp tion  and e x cre tio n ) ch a n g es  w ith  a ge  (W a stn e y  
et al., 1 9 9 2 ). D e cre a s e d  p la sm a  z in c  w ith  a ge  c o u ld  result fr o m  a d e c lin e  in  the rate o f  
ab sorp tion  a n d /or  an a cce le ra ted  c lea ra n ce  fr o m  the p la sm a  (B a le s  et a l., 1 9 8 6 ). In  ou r 
study, a lth ou gh  seru m  z in c  con cen tra tion s  d ecrea sed  w ith  a ge , th is trend fa iled  to 
reach  statistical s ig n ifica n ce  p artia lly  b e ca u se  o f  sm all sa m p le  s iz e  fo r  each  age  
ca tegory .
T h e  e ffe c ts  o f  a g e  o n  seru m  se len iu m  con cen tra tion  rem ain  co n tro v e rs ia l (G ran d jean  
et al., 1 9 9 2 ; K a fa i and  G a n ji, 2 0 0 3 ; R o b b e re ch t  and D eelstra , 1 9 9 4 ). In  the present 
study, n o  s ig n ifica n t co rre la tion s  b e tw e e n  a ge  and seru m  se len iu m  le v e ls  w e re  
o b serv ed . It has b e e n  rep orted  that a p o s it iv e  corre la tion  ex ists  b e tw e e n  a ge  and G P x  
(E rden -In a l et al., 2 0 0 2 ). W e  fo u n d  a p o s it iv e  corre la tion  in  patients b e tw e e n  age  and 
G P x  activ ity . T h is  m a y  b e  re la ted  to  ce llu la r  co m p e n sa to ry  m ech a n ism s .
Association between dietary intake o f trace element and their serum levels 
W e  h ave n o t fo u n d  a c le a r  lin ear re la tion sh ip  b e tw e e n  d ietary  in take o f  trace  e lem ent 
and their seru m  le v e ls . T h ere  are tw o  p o s s ib le  reason s a) the lik e ly  in tera ction  o f  trace 
e lem ents at the le v e l o f  a b sorp tion  and  m e ta b o lism  (K le v a y , 1 9 7 5 ), b )  seru m  le v e ls  o f  
trace elem ents are d ep en d en t o n  co n d it io n s  su ch  as in fe c t io n  o r  th e  acu te  ph ase 
resp on se , as their transport p ro te in s  in  b lo o d  w o u ld  b e  altered in  th ese  con d ition s . 
Effects o f smoldng on lipid profile
Current and e x -sm o k e rs  h ad  s ig n ifica n tly  h ig h er  fa stin g  tr ig ly ce r id e  than n o n -sm o k e r  
in  hea lth y  su b jects  w e  stu d ied . H o w  cigarette  sm ok in g  lo w e rs  H D L  and in creases 
tr ig ly cer id es  is  n o t en tire ly  c lea r , h o w e v e r  sm o k in g  in creases  lip a se  a ctiv ity  
( l ip o p ro te in  lip ase  and h ep a tic  lip ase ) (B la ch e  et al., 1 9 9 2 ), w h ic h  is  a ssoc ia ted  w ith  
H D L  m e ta b o lism  (F ie v e t  and F ruchart, 19 9 1 ).
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It has b e e n  su g g ested  that sm ok ers  h a v e  m o re  central o b e s ity  than n on -sm ok ers  
(C o lh o u n  and P resco tt-C la rk e , 1 9 9 4 ) and th is is w h at w e  fo u n d  in  ou r  study. S m ok ers 
had  h igh er w a ist and  w a ist /h ip  ratio than n on -sm ok ers  (s e e  a p p en d ix  5 fo r  m o re  
deta ils).
Effects o f smo/dng on trace element status
In  the current study, seru m  con cen tra tion s  o f  z in c , co p p e r , z in c /c o p p e r  ratio, 
ca eru lop la sm in , se len iu m  and G P x  d id  n o t d if fe r  b e tw e e n  current o r  e x -sm o k e r  
su b jects  and  n o n -sm o k e rs . H o w e v e r , s o m e  in vestigators  h a v e  p r e v io u s ly  rep orted  that 
serum  z in c  and c o p p e r  le v e ls  d e crea sed  w ith  in crea sin g  u se  o f  cigarettes , bu t n o  
exp lan ation  w a s  p r o v id e d  (G ra n d jea n  et al., 1 9 9 2 ; K im  et al., 2 0 0 3 ).
It has b e e n  rep orted  that sm o k in g  has n o  e ffe c t  o n  serum  se len iu m  le v e ls  (S w a n so n  et 
al., 1 9 9 0 ; T h u lu vath  and T rig er , 1 9 9 2 ). O n  the oth er hand, oth er research ers c la im e d  
to  fin d  lo w e r  v a lu es  fo r  sm ok ers  (B u k k en s et al., 1 990 ; G ran d jean  et a l., 19 9 2 ). In 
m ost studies the lim ited  in fo rm a tion  o n  the typ e  and n um bers o f  c igarettes  sm o k e d  is 
p ro b a b ly  re sp o n s ib le  fo r  the d iscrep a n cie s  in  literature (R o b b e re ch t  and  D eelstra , 
1994).
Trace elements and lipid metabolism
In o u r  p o p u la tio n  w e  h a v e  sh o w n  that seru m  co p p e r  le v e ls  are s ig n ifica n tly  and 
p o s it iv e ly  rela ted  to  B M I , H D L  ch o le s te ro l, and n e g a tiv e ly  re la ted  to  w a ist/h ip  ratio. 
In a  K u w a iti p o p u la tio n  it has b e e n  rep orted  that seru m  c o p p e r  w a s  p o s it iv e ly  
associa ted  w ith  tota l and L D L  ch o le s te ro l con cen tra tion s  (A d a m  et a l., 2 0 0 1 ). It w as 
a lso  rep orted  that o ccu p a tio n a l e x p osu re  to  c o p p e r  m a y  b e  a ssoc ia ted  w ith  in creased  
serum  L D L  ch o le s te ro l (A d a m  et al., 2 0 0 1 ). N everth e less  severa l o th er studies h a ve  
rep orted  that m ild  d eg rees  o f  c o p p e r  d e f ic ie n c y  in d u ced  b y  d ietary  z in c  e x ce ss  m a y
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lead  to  ra ised  ch o le s te ro l le v e ls  and in crea sed  co ro n a ry  risk  (F ern s et al., 1997 ; 
K le v a y , 1 980 ; K le v a y , 2 0 0 0 ) . C on sisten t w ith  oth er reports (C ig n a re lli et al., 1 9 9 6 ), 
w e  fou n d  a s ig n ifica n t co rre la tion  b e tw e e n  serum  ca eru lop la sm in  and  serum  
tr ig ly cer id es  and ch o le s te ro l.
In  the presen t stu dy , there w a s  n o  s ig n ifica n t co rre la tion  b e tw e e n  seru m  z in c  
con cen tra tion  and c o ro n a ry  risk  fa ctors  (e .g . fastin g  b lo o d  sugar, tota l and H D L  
ch o leste ro l, tr ig ly cer id es , sy s to lic  and d ia s to lic  b lo o d  pressu re , B M I , W H R , and 
serum  C R P  con cen tra tion s). H o w e v e r , T u lly  and co lle a g u e s  h a v e  s h o w n  that serum  
z in c  le v e ls  are p o s it iv e ly  rela ted  to  L D L  ch o le s te ro l con cen tra tion s  in  a fem a le  
p op u la tion  (J ossa  et a l., 1 9 9 1 ). T h e y  p ro p o s e d  that b o th  z in c  and  ch o le s te ro l m a y  b e  
related  to a th ird  fa cto r , su ch  as d ietary  red  m eat intake.
Jossa  et al. (1 9 9 1 )  h a v e  p r e v io u s ly  fo u n d  n o  s ign ifica n t a sso c ia tio n  b e tw e e n  serum  
se len iu m  and co ro n a ry  r isk  fa cto rs  su ch  as tr ig ly cer id es , H D L  ch o le s te ro l, sy sto lic  
and d ia sto lic  b lo o d  pressu re , a g e  and B M I  (J ossa  et al., 1 9 9 1 ). H o w e v e r , th ey  d id  fin d  
a p o s it iv e  and  s ig n ifica n t co rre la tion  b e tw e e n  seru m  se len iu m  and seru m  ch o les te ro l 
(r  =  0 .1 2 ; p  =  0 .0 2 ) , w h erea s  w e  d id  not.
Trace element status in dyslipidaemia
In the current study, s ig n ifica n tly  h ig h er  serum  co p p e r  and se len iu m  le v e ls  and lo w e r  
serum  z in c / c o p p e r  ratio  and G P x  in  d y s lip id a em ic  patients c o m p a re d  w ith  con tro l 
w ere  o b se rv e d . Statin th erapy  ca n n ot ex p la in  the e leva ted  seru m  se len iu m  and co p p e r  
con cen tra tion  in  d y s lip id a e m ic  patients, as w e  fo u n d  that statins d ecrea se  serum  
c o p p e r  and h a v e  n o  e ffe c t  o n  seru m  se len iu m  lev e ls  (s e e  ch apter 9  fo r -m o r e  deta ils). 
D y s lip id a e m ic  patients h ad  s ig n ifica n tly  h igh er d ietary  intake o f  se le n iu m  com p a red  
w ith  con tro ls  (s e e  se c t io n  4 .3  fo r  m o re  deta ils). T h ere fo re , the h ig h e r  seru m  selen iu m
con cen tra tion s  in  d y s lip id a e m ic  patients m a y  b e  related  to  their d ietary  intake. 
H o w e v e r , c o m p a r iso n  b e tw e e n  serum  c o p p e r  lev e ls  and d ieta ry  in take o f  c o p p e r  
rev ea led  that ch a n g es  in  seru m  c o p p e r  le v e ls  are u n lik e ly  to  b e  re la ted  to  their d ietary  
intake o f  c o p p e r  (s e e  ch ap ter  4  fo r  m o re  deta ils).
Trace element status in obesity
C on sisten t w ith  s o m e  p re v io u s  reports, w e  fo u n d  lo w e r  seru m  z in c  le v e ls  (M a rre iro  et 
a l., 2 0 0 2 ; O zata  et a l., 2 0 0 2 ; S in gh  et a l., 1 9 9 8 ; T u n g tron g ch itr  et a l., 2 0 0 3 ) and 
h igh er seru m  c o p p e r  (O m a r  et a l., 2 0 0 1 ; T u n gtron gch itr  et a l., 2 0 0 3 ; Y a k in c i et al., 
1 9 9 7 ) and ca e ru lo p la sm in  con cen tra tion s  (C ig n a re lli et al., 1 9 9 6 ; T u n gtron gch itr  et 
al., 2 0 0 3 ) in  o b e s e  co m p a re d  w ith  n o n -o b e s e  su b jects . H o w e v e r , G jo ra p  et al. (1 9 9 8 ) 
reported  n o  s ig n ifica n t d iffe re n ce s  o f  seru m  z in c  lev e ls  b e tw e e n  o b e s e  and n o n -o b e s e  
su b jects  and Y a k in c i et al. (Y a k in c i et al., 1 9 9 7 ) and T a n e ja  et al. (T a n e ja  et al., 1 9 9 6 ) 
fou n d  that seru m  z in c  le v e ls  in  o b e s e  ch ild ren  w e re  s ig n ifica n tly  h ig h er  than the 
con tro l g rou p  .
It has a lso  b e e n  rep orted  that seru m  se len iu m  con cen tra tion s  are s ig n ifica n tly  lo w e r  in  
o b e s e  su b jects  than n o n -o b e s e  su b je cts  (G jo ru p  et al., 1 9 8 8 ), b u t w e  fo u n d  n o  
s ig n ifica n t d if fe re n ce s  b e tw e e n  o b e s e  and n o n -o b e s e  su b jects  w ith  regard  to  selen ium . 
S im ilar to  O za ta  et a / . ’ s resu lts (O za ta  et al., 2 0 0 2 ), w e  fo u n d  lo w e r  G P x  le v e ls  in  
m a le  o b e s e  versu s n o n -o b e s e  su b jects .
Coronary risk factors and trace element status
In the presen t stu dy , w e  fo u n d  n o  s ig n ifica n t d if fe re n ce s  fo r  trace  e lem en t status 
b e tw een  patients w ith  and w ith ou t either d iabetes m ellitu s , h ig h  b lo o d  pressure, 
h y p ertr ig ly cer id a em ia  o r  in cre a se d  ca lcu la ted  1 0 -yea r c o ro n a ry  risk . H o w e v e r , m ost 
researchers h a v e  b e e n  rep orted  that patients w ith  typ e  II d iabetes  m ellitu s  h a v e  lo w e r  
serum  z in c  and  se len iu m  con cen tra tion s  and h ig h er  seru m  c o p p e r  le v e ls  than patients
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w ith ou t d iabetes  m ellitu s  (K lja i and R u n je , 2 0 0 1 ; N a v a rro -A la rco n  et al., 1 999 ; 
Q u illio t  et a l., 2 0 0 1 ). B y  con trast, n o  s ig n ifica n t d iffe re n ce s  (Z a rg a r  et a l., 2 0 0 2 ) and 
s ig n ifica n tly  h ig h er  (B ra n d a o -N e to  et al., 2 0 0 0 ) p la sm a  z in c  le v e ls  in  ty p e -I  d iabetes  
m ellitu s patients h a v e  b e e n  rep orted . A ls o , im b a la n ce  o f  z in c  and c o p p e r  status has 
b een  h y p oth es ised  as a fa c to r  in  hum an  h yp erten sion  (V iv o l i  et a l., 1 9 9 5 ), and in  
patients w ith  p r im a ry  h y p erten s ion , an in crea sed  z in c  a b sorp tion  fr o m  the a lim entary  
tract w a s  fo u n d  (T u b e k , 2 0 0 1 ).
Association between metabolic syndrome and trace element status 
L ukasiak  et al. (L u k a s ia k  et a l., 1 9 9 8 ) and F a lk ie w icz  et al. (F a lk ie w ic z  et a l., 2 0 0 0 ) 
rep orted  lo w e r  hair z in c  con cen tra tion s  in  patients w ith  m e ta b o lic  sy n d rom e . In the 
p resent stu dy , w e  fo u n d  n o  s ig n ifica n t d iffe re n ce s  in  seru m  z in c  con cen tra tion s  
b e tw een  su b jects  w ith  and  w ith ou t m e ta b o lic  syn d rom e. T h ere  are tw o  p o s s ib le  
reason s fo r  th ese  d iffe re n t fin d in g s ; ( i )  z in c  status w a s  a ssessed  b y  d iffe re n t m ean s -  
hair le v e ls  v  seru m  con cen tra tion , ( i i )  the fin d in g s  m a y  b e  a ffe c te d  b y  d ietary  intake, 
the results o f  w h ic h  w e re  n o t rep orted  b y  F a lk ie w icz  et al. (2 0 0 0 ) . H o w e v e r , in  the 
present study, b o th  d ietary  in take and seru m  le v e ls  o f  z in c  d id  n o t  d if fe r  b e tw e e n  
patients w ith  and w ith ou t m e ta b o lic  sy n d rom e .
C on sisten t w ith  K im  et aids resu lts (K im  et al., 2 0 0 2 ), w e  fo u n d  e lev a ted  serum  
ca eru lop la sm in  con cen tra tion s  in  patients w ith  m e ta b o lic  sy n d ro m e  co m p a re d  w ith  
patients w ith ou t m e ta b o lic  sy n d rom e. S im ila r  to  F ord  et aids resu lts (F o rd  et al., 
2 0 0 3 ), w e  fo u n d  n o  s ig n ifica n t d iffe re n ce s  in  serum  se len iu m  le v e ls  b e tw e e n  patients 
w ith  and w ith ou t m e ta b o lic  sy n d rom e. H o w e v e r , w e  d id  fin d  d ecrea s in g  serum  
se len iu m  le v e ls  w ith  in crea s in g  features o f  m e ta b o lic  sy n d rom e  in d ep en d en t o f  their 
d ietary  intake.
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A c c o r d in g  to  e v id e n ce  gath ered  in  h um an  and exp erim en ta l stu d ies in  rats, an 
im b a la n ce  in  z in c /c o p p e r  m e ta b o lism  w a s  p ro p o s e d  as a risk  fa c to r  fo r  C H D  (K le v a y , 
1 975 ). A c c o r d in g  to  th is h y p o th es is , ex trem e d ietary  co p p e r  d e f ic ie n c y , either a lon e  
o r  in  a ssoc ia tion  w ith  a h ig h  z in c  intake leads to h y p e rch o le s te ro la e m ia  and the 
d e v e lo p m e n t o f  a th erosc leros is  (K le v a y , 1 9 7 5 ). W e  fo u n d  lo w  serum  z in c  
con cen tra tion s  and h ig h  seru m  c o p p e r  con cen tra tion s  in  d y s lip id a e m ic  patients w ith  
estab lished  C H D  c o m p a re d  w ith  patients w ith ou t C H D . T h is  im b a la n ce  in  z in c /c o p p e r  
m eta b o lism  m a y  either con trib u te  to  C H D  risk  o r  b e  a co n s e q u e n ce  o f  an acu te phase 
respon se .
In co n c lu s io n , a s ig n ifica n t d if fe re n ce  in  trace e lem ent p r o f i le  w a s  o b se rv e d  in  
d y s lip id a em ic  patients co m p a re d  w ith  co n tro l su b jects . D iffe r e n c e s  in  serum  co p p e r  
m a y  b e  rela ted  to  a  h e ig h ten ed  state o f  in flam m ation , as s o m e  o f  the in fla m m a tory  
m arkers, su ch  as C R P  and ca eru lop la sm in  (the  m a in  co p p e r  transport p ro te in  in  the 
b lo o d )  are e leva ted  in  the patien t g rou p . B o th  C R P  and ca eru lop la sm in  orig inate  in  
the liver, and their syn th esis is  in creased  in  a cu te-ph ase  resp o n se  (B u rtis  and 
A s h w o o d , 19 9 9 ).
T h e  lo w e r  le v e ls  o f  seru m  G P x  in  o b e s ity  and d y s lip id a em ia  and lo w e r  le v e l o f  serum  
se len iu m  w ith  a ccu m u la tion  features o f  m e ta b o lic  sy n d rom e  m a y  b e  rela ted  to  the 
p resen ce  o f  an a th erosc leros is  p ro n e  state and con seq u en tia l co n su m p tio n  o f  
an tioxidants b y  fre e  ra d ica l in teraction . D ru gs  m a y  a lso  in flu e n ce  seru m  trace e lem ent 
status. In  ou r  recen t study, the e ffe c ts  o f  statin th erapy  o n  serum  trace  e lem en t status 
w ere  eva lu ated  (se e  ch apter 9  fo r  m o re  deta ils). Further studies are n e e d e d  to  evaluate 
the e ffe c ts  o f  o th er dru gs su ch  as fibrate and an ti-hyperten sives o n  trace  elem ent 
status.
Klevay and the zinc/copper hypothesis
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CHAPTER 8
S e r u m  v i t a m i n  E  s t a t u s  i n  c o n d i t i o n s  
r e l a t e d  t o  c o r o n a r y  r i s k  f a c t o r s
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V ita m in  E  is  a  m a jo r  lip id -s o lu b le  an tiox idant in  ce llu la r  m em b ra n es . It has b e e n  
dem on strated  that su p p lem en ta tion  w ith  v ita m in  E  ca n  in h ib it the o x id a t io n  o f  L D L  
(P rin cen  et al., 1 9 9 2 ; R e a v e n  et al., 1 9 9 3 ). A t  least part o f  the b e n e fic ia l e ffe c ts  o f  
v itam in  E  against C H D  m a y  b e  du e to  d ecrea sed  p latelet a b ility  to  aggregate  in  
hum ans (R e a v e n  et a l., 1 9 9 3 ). V ita m in  E  m a y  a lso  h ave  a b e n e fic ia l acu te  e ffe c t  o n  
vascu lar en d oth e lia l fu n ctio n  (V o g e l  et al., 19 9 7 ).
M o s t  o f  the m o re  recen t w o r k  in  an im al m o d e ls  has su p p orted  the h y p o th es is  that 
v itam in  E  su p p lem en ta tion  ca n  p reven t o r  s lo w  the d e v e lo p m e n t o f  a th eroscleros is , 
a lthough  the resu lts o f  early  an im al exp erim en ts w e re  e q u iv o c a l  (S m ith  and 
K u m m e ro w , 1 9 8 9 ; V e r la n g ie r i and B u sh , 1 9 9 2 ). O n  the oth er hand , the results o f  
severa l p ro sp e c t iv e  c lin ica l trials in  h um an  are in con sisten t fo r  the ca rd io p ro te ct iv e  
e ffe c ts  o f  v ita m in  E  (G IS S I , 1 9 9 9 ; R a p o la  et al., 1 9 9 6 ; S teph ens et al., 1 9 9 6 ; Y u s u f  et 
a l., 2 0 0 0 ).
W e  h a v e  in vestiga ted  the e ffe c ts  o f  p h y s io lo g ic a l and p a th o p h y s io lo g ica l con d ition s  
related  to  c o ro n a ry  r isks o n  seru m  v ita m in  E  status.
8.1 Vitamin E in healthy subjects
8.1.1 Physiological variation in vitamin E status
Gender
Seru m  v itam in  E  con cen tra tion s  d id  n o t d if fe r  s ig n ifica n tly  b e tw e e n  h ea lth y  m ales 
(n = 9 5 , 1 4 .0 6 + 0 .4 4 ) and  fem a les  (n = 9 4 , 1 3 .6 9 + 0 .4 4 ) (p > 0 .0 5 , fo r  m o re  deta ils  re fer  to 
app en d ix  4  and se c t io n  4 .1 .1 ) . N o r  d id  seru m  v ita m in  E /  total ch o le s te ro l ratio d iffe r  
s ig n ifica n tly  b e tw e e n  h ea lth y  m a le  (2 .6 3 1 0 .0 7 )  and fem a le  (2 .5 0 + 0 .0 7 )  su b jects  
¥ > 0 .0 5 ) .
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Age
W ith in  the m a le  and  fe m a le  h ea lth y  g rou p s, w h ich  w e re  d iv id e d  in to  6  g rou p s b a sed  
o n  their age  ( f o r  m o re  d eta ils  re fe r  to  s e c t io n  5 .1 .1 ) serum  con cen tra tion s  o f  v itam in  E 
and v ita m in  E /tota l ch o le s te ro l ratio d id  n ot d if fe r  s ig n ifica n tly  w ith  a g e  (p > 0 .0 5 ). 
Physical activity levels (PAL)
In h ea lth y  su b jects , p h y s ica l a ctiv ity  le v e ls  w e re  n o t corre la ted  w ith  seru m  v itam in  E  
con cen tra tion s  (r=  -0 .1 0 , p > 0 .0 5 )  and seru m  v ita m in  E /  total ch o le s te ro l ratio (r=  - 
0 .1 6 , / ;> 0 .0 5 ) .  N o r  w e re  p h y s ica l a ctiv ity  le v e ls  corre la ted  w ith  seru m  v itam in  E  
con cen tra tion s  (r =  - 0 .1 1 , / j> 0 .0 5 )  o r  seru m  v itam in  E / total ch o le s te ro l ratio  (r=  -0 .0 7 , 
p>0 .0 5 ) in  the d y s lip id a e m ic  patients ( fo r  m o re  details re fe r  to  a p p en d ix  6  and section  
5 .1 .1 ).
Association between dietary vitamin E and its serum levels
T h e  w ea k  and s ig n ifica n t a sso c ia tio n  b e tw e e n  d ietary  v itam in  E  and  its seru m  lev e ls  
w e re  o b se rv e d  in  patients ( l -O . lb j /^ O .O S )  and con tro ls  ( r = 0 .1 9 ,/ /= 0 .0 2 ) .
8.1.2 Pathophysiological conditions and their effects on vitamin E status
Smoking
S erum  con cen tra tion s  o f  v ita m in  E  d id  n o t d iffe r  s ig n ifica n tly  b e tw e e n  sm ok ers  (n =  
66 , 1 4 .2 5 + 0 .4 8 ) and  n o n -sm o k e rs  (n = 1 2 3 , 1 3 .6 8 + 0 .4 0 ,$ > 0 .0 5 )  ( f o r  m o r e  deta ils  re fer  
to  ap p en d ix  5 and se c t io n  4 .1 .2 ) . N o r  d id  serum  v itam in  E /tota l ch o le s te ro l ratio d iffe r  
s ig n ifica n tly  b e tw e e n  sm ok ers  (2 .5 8 + 0 .0 7 )  and  n o n -sm o k e rs  (2 .5 6 + 0 .0 7 ,/> > 0 .0 5 ). 
Obesity
Serum  v itam in  E  con cen tra tion s  and v ita m in  E /  total ch o le s te ro l ratio  d id  n o t d if fe r  
s ig n ifica n tly  b e tw e e n  o b e s e  (n = 3 3 ), o v e rw e ig h t (n = 5 8 ), and su b je cts  o f  n orm a l w e ig h t 
(n = 7 8 ) fo r  m a le , fe m a le  and c o m b in e d  m a le  and fem a le  su b jects  (T a b le  8 .1 , fo r  m o re  
details re fe r  to  T a b le  3 .3  and  se c t io n  4 .1 .2 ).
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T a b le  8.1 A s s o c ia t io n  b e tw e e n  B M I  and serum  v itam in  E  status in  h ea lth y  su b jects________
O b e s e  O v e rw e ig h t N orm a l w e ig h t
Males
N u m b er o f  su b je cts  19 36  31
V ita m in  E  1 4 .18  +  0 .9 0  15 .05  +  0 .7 6  1 3 .7 0  +  0 .71
(p g /m L )
V ita m in  E /T C  ratio  2 .5 4  +  0 .1 4  2 .7 2  +  0 .1 0  2 .6 8  +  0 .1 2
(p g /m m o l)
Females
N u m b er  o f  su b jects  15 2 2  47
V ita m in  E  1 3 .0 9  +  0 .9 8  1 4 .62  +  0 .9 6  1 3 .44  +  0 .65
(t ig /m L )
V ita m in  E /T C  ratio 2 .3 2  ±  0 .1 4  2 .5 4  ±  0 .1 3  2 .51  ±  0 .1 2
(p g /m m o l)
Males & Females
N u m b er  o f  su b je cts  3 4  58  77
V ita m in  E  1 3 .72  +  0 .6 6  1 4 .89  +  0 .5 9  1 3 .5 4  +  0 .4 8
(Hg/mL)
V ita m in B /T C  ratio 2 .4 5 1 0 . 1 0  2 .6 5 1 0 . 0 8  2 .5 3  +  0 .0 9
(p g /m m o l)_____________________________________________________________________ ________________________
V a lu es  are e x p ressed  as m ed ia n  and interquartile  range. B e tw e e n  the g rou p s  com p a rison s  
w e re  a ssessed  b y  K ru sk a l-W a llis  as th ey  are n on -n orm a l d istr ibu tion  data.
S u b jects  w ith  B M I  greater than 3 0 , b e tw e e n  25  and 3 0 , and less  than 25  w e re  d e fin e d  as 
o b e se , o v e r  w e ig h t, and n orm a l w e ig h t re sp e c tiv e ly  (B ritish  N u trition  F ou n d a tion  T ask  
F orce , 1 9 9 9 ). T C  =  toa l ch o le s te ro l.
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8.2 Serum vitamin E concentrations in conditions related to CHD
8.2.1 Vitamin E and CHD risk factors
D y s lip id a e m ic  patients h ad  s ig n ifica n tly  h igh er seru m  v itam in  E  con cen tra tion s  in  
m ales ¥ < 0 -0 1 )  and fe m a le s  ( /K O -0 1 ) and in  the co m b in e d  g rou p  ¥ < 0 .0 0 1 )  com p a red  
w ith  con tro ls . H o w e v e r , v ita m in  E /  total ch o les te ro l ratio d id  n o t  d if fe r  b e tw een  
patients and con tro ls  in  m a les , fem a les  and the co m b in e d  g rou p  ¥ > 0 .0 5 ,  T a b le  8 .2 ).
In  gen era l seru m  v ita m in  E  and seru m  v itam in  E / total ch o le s te ro l ratio rem ained  
s ig n ifica n tly  h igh er  in  patients co m p a re d  w ith  con tro ls  fo r  su b g rou p s o f  d y s lip id a em ic  
patients, ev en  fo r  th ose  su b -ca te g o r ie s  w ith ou t the resp ectiv e  c o ro n a ry  r isk  factors. 
S eru m  v itam in  E  le v e ls  d id  n ot d if fe r  b e tw e e n  su b -ca teg or ie s  o f  d y s lip id a em ic  
patients in  m a les , fem a les  and the co m b in e d  g rou p  (p<0.05, T a b le s  8 .3 , and 8 .4 ). 
V ita m in  E / T o ta l ch o le s te ro l ratio  w a s  s ig n ifica n tly  h igh er in  patients w ith  established  
C H D  in  fem a les  and  the c o m b in e d  grou p  ¥ < 0 .0 1 )  co m p a re d  w ith  patients w ith ou t 
estab lish ed  C H D  (p<0.05, T a b le s  8 .3 ). V ita m in  E / T o ta l ch o le s te ro l ratio w as 
s ig n ifica n tly  h igh er in  the c o m b in e d  m a le  and fe m a le  patients w ith  
h y p ertr ig ly cer id a em ia  c o m p a re d  w ith  patients w ith ou t h y p ertr ig ly cer id a em ia  ¥ < 0 -0 5 , 
T a b les  8 .3 , and 8 .4 ).
V ita m in  E / T o ta l ch o le s te ro l ratio  w a s  a lso  s ig n ifica n tly  h ig h er  in  the m a le  su bgroup  
w ith  m e ta b o lic  sy n d ro m e  ¥ < 0 -0 1 )  and c o m b in e d  g rou p  ¥ < 0 -0 5 )  co m p a re d  w ith  
patients w ith ou t m e ta b o lic  sy n d ro m e  ¥ < 0 -0 5 , T a b les  8 .3 , and 8 .4 ).
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Table 8.2 Comparison o f serum vitamin E concentrations between dyslipidaemic patients
and controls
Patients Controls
Males
N u m b er o f  su b je cts  142  6 7
V ita m in  E  16 .53  ±  0 .3 9 * *  1 4 .4 2  ±  0 .53
(p g /m L )
V ita m in  E /T C  ratio 2 .8 2  ±  0 .0 7  2 .7 0  ±  0 .0 8
(p g /m m o l)
Females
N u m b er  o f  su b jects  95  6 8
V ita m in  E  1 6 .1 0  +  0 .4 9 * *  1 3 .7 4  +  0 .5 4
(p g /m L )
V ita m in  E /T C  ratio  2 .6 4  ±  0 .0 9  2 .5 0  ±  0 .0 9
(p g /m m o l)
Males & Females
N u m b er  o f  subj ects  2 3 7  135
V ita m in  E  1 6 .36  ±  0 .3 1 * * *  1 4 .08  ±  0 .38
(H g /m L )
V ita m in  E /T C  ratio  2 .7 5  ±  0 .0 5  2 .6 0  ±  0 .0 6
(p g /m m o l)
V a lu es  are e x p ressed  as M e a n  ±  S E M  o r  m ed ia n  and in terquartile  ran ge. *= /><0 .05 , 
* * = /K 0 .0 1 , * * *= /> < 0 .0 0 1  co m p a r is o n  b e tw een  patients and co n tro ls  b y  u sin g  o n e -w a y  
A N O V A .
T C  =  toa l ch o les te ro l.
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T a b le  8.3  C o m p a r iso n  o f  v ita m in  E  b e tw e e n  d ifferen t su b grou p s  o f  c o m b in e d  m a le  and 
fem a le  d y s lip id a e m ic  patients segm en ted  a cco rd in g  to  tbe  p o s s e s s io n  o f  s p e c if ic
co ro n a ry  risk  fa ctors ._________________________________________________________________________________
Number Vitamin E Vitamin E/total
cholesterol ratio
Group (pg/mL) (pg/mmol)
Established CHD
C H D + 55 1 6 .19  ± 0 .6 3 3 3 .0 2  +  0 .0 1 3* *
C H D - 182 1 6 .4 1 + 0 .3 5 2 .6 7  ±  0 .0 6
Metabolic Syndrome
M S + 142 1 6 .2 7 +  0 .3 9 3 2 .8 5  ±  0 .0 7 3*
M S - 95 1 6 .49  +  0 .5 0 2 .5 9  ±  0 .08
Diabetes Mellitus
D M + 4 2 1 5 .9 4 +  0 .7 5 3 2 .7 5  +  0 .1 3 3
Im paired  G T 21 1 5 .09  +  0 .98 2 .7 1 + 0 .1 8
D M - 174 16.61  +  0 .3 6 2 .7 5  ±  0 .0 6
Obesity
O b e s e + 82 1 5 .7 9 +  0 .5 2 3 2 .7 5  +  0 .1 0 3
O v er  w e ig h t 112 1 6 .4 9  ±  0 .43 2 .7 7  ±  0 .0 7
N orm a l w e ig h t 43 1 7 .09  +  0 .81 2 .7 0  +  0 .1 4
Hypertriglyceridaemia
H ig h  T .G . 176 1 6 .4 4 +  0 .3 6 3 2 .8 2  ±  0 .0 6 3’1
N orm a l T .G . 61 16.11 +  0 .61 2 .5 4  +  0 .1 0
Blood pressure
H ig h  B P 7 6 16.41 ±  0 .5 5 3 2 .7 9  +  0 .0 1 3
M od era te  B P 111 1 6 .0 4  +  0 .43 2 .7 5  ±  0 .08
N orm a l B P 50 16 .99  +  0 .7 0 2 .6 8  +  0 .11
Calculated 10 year 
Coronary Risk
H ig h  > 3 0 % 4 2 1 6 .2 0 +  0 .4 0 3 2 .8 4  ±  0 .1 2 3*
M od era te  2 0 -3 0 % 5 4 1 6 .3 4  +  0 .63 2 .9 7  +  0.11
L o w  < 2 0 % 141 1 6 .4 1 + 0 .7 4 2 .6 4  ±  0 .0 7
Controls 135 14 .08  ±  0 .38 2 .6 0  ±  0 .0 6
V a lu es  are exp ressed  as M e a n  ±  S E M . 3 = p < 0 .0 0 1  co m p a r iso n  b e tw e e n  the g rou p s 
in c lu d in g  patients and co n tro ls , and  * = //< 0 .0 5 , * * = p < 0 .0 1  co m p a r is o n  b e tw e e n  su b ­
ca tegories  o f  the d y s lip id a e m ic  patients b y  u s in g  o n e -w a y  A N O V A .
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T a b le  8 .4  C o m p a r iso n  o f  v ita m in  E  b e tw e e n  d iffe ren t su b g rou p s  o f  separate m a le  and fe n  
d y s lip id a e m ic  patients seg m en ted  a cco rd in g  to  the p o ss e s s io n  o f  s p e c i f ic  co ro n a ry  risk  fa ctors .
M a le s F e m a le s
n V ita m in  E V ita m in  E /to ta l n V ita m in  E V ita m in E /to ta l
c h o le s te r o l  r a t io c h o le s te r o l  r a t io
G r o u p (p g /m L ) (p g /m m o l ) (p g /m L ) (p g /m m o l )
E s ta b lis h e d  C H D
C H D +  37 1 5 .83  +  0 .8 6 2 2 .9 7  ± 0 .1 5 18 16 .9 2  ± 0 .7 5 2 3 .1 2  ±  0 .1 5 2i
C H D - 105 1 6 .78  ± 0 .4 4 2 .7 6  ±  0 .0 8 77 15.91 ± 0 .5 8 2 .5 3  ± 0 .1 0
M e t a b o l ic  S y n d r o m e
M S +  84 1 6 .6 2 +  0 .5 2 2 2 .9 7  ±  0 .0 9  * *  58 1 5 .7 6  ± 0 .5 8 2 2 .6 8  ± 0 . 1 1
M S -  58 1 6 .4 0  ± 0 .6 0 2 .5 9  ±  0 .0 9 37 16 .63  ± 0 . 8 7 2 .5 8  ± 0 . 1 4
D ia b e te s  M e ll itu s
D M +  28 1 5 .6 2  ± 0 . 7 8 2 2 .7 5  ± 0 . 1 5 14 1 6 .5 7  ±  1 .642 2 .7 6  ±  0 .2 5
D M - 114 16 .75  ± 0 .4 5 2 .8 2  ±  0 .08 81 1 6 .5 7  ± 0 . 5 0 2 .6 2  ±  0 .0 9
O b e s ity •
O b e s e +  50 1 6 .1 3 ±  0 .7 2 2 2 .8 3  ± 0 . 1 3 32 1 5 .4 0  ± 0 7 4 2 2 .5 8  ± 0 . 1 5
O b e s e - 92 16 .7 4  ±  0 .4 7 2 .81  ± 0 . 0 8 63 1 6 .4 6  ± 0 . 6 3 2 .6 7  ± 0 . 1 0
H y p e r t r ig ly c e r id a e m ia
H ig h  T .G . 114 1 6 .5 8  ±  0 .45 2 .8 6  ±  0 .08 62 1 6 .1 8  ± 0 . 5 8 2 2 .7 4  ± 0 . 1 1
N o rm a l T .G . 28 16 .31  ± 0 . 7 9 2 .6 3  ± 0 . 1 4 33 1 5 .65  ± 0 . 9 1 2 .4 6  ± 0 . 1 4
B lo o d  p r e s s u r e
H ig h  B P  3 4 1 7 .28  ±  0 .7 6 1 2 .8 7  ± 0 . 1 4 42 1 5 .7 0  ±  0 .7 7 1 2 .7 3  ± 0 . 1 4
M od era te  B P  7 7 1 6 .0 6  ± 0 . 5 3 2 .8 3  ± 0 . 1 0 34 1 6 .0 0  ± 0 . 7 5 2 .5 7  ± 0 . 1 3
N o rm a l B P  31 1 6 .8 8  ± 0 . 9 0 2 .7 4  ± 0 . 1 2 19 1 7 .1 6  ±  1 .16 2 .5 8  ± 0 . 1 9
C a lc u la te d  1 0  y e a r
C o r o n a r y  R is k
H ig h  > 3 0 %  35 1 6 .2 4  ± 0 . 7 8 1 2 .8 0  ± 0 . 1 2 7 1 5 .9 8  ± 2 . 3 1 l 3 .0 5  ± 0 . 4 3
M od era te  38 1 6 .2 7  ±  0 .7 6 3 .0 4  ± 0 . 1 5 17 16 .13  ± 1 . 1 3 2 .7 7  ± 0 . 1 7
2 0 -3 0 %
L o w  < 2 0 %  70 1 6 .7 2  ± 0 . 5 8 2 .7 0  ±  0 .9 6 71 16.11  ± 0 . 5 6 2 .5 7  ± 0 . 1 0
C o n t r o ls  67 1 4 .4 2  ±  0 .5 3 2 .7 0  ±  0 .0 8 68 1 3 .7 4  ± 0 . 5 4 2 .5 0  ±  0 .0 9
V a lu es  are ex p ressed  as M e a n  ±  S E M . l= /> < 0 .0 5 , 2 - /K 0 .0 1 ,  3= /><0 .001  co m p a r iso n  b e tw e e n  
grou ps in c lu d in g  patients and co n tro ls , and * * = /K 0 .0 1  co m p a r is o n  b e tw e e n  su b -ca teg or ie s  o f  
d y s lip id a em ic  patients b y  u s in g  o n e -w a y  A N O V A .
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In control subjects, serum vitamin E concentrations were positively associated with 
BMI (p<0.05), waist/ hip ratio ($<0.01), triglyceride ($<0.05) and total cholesterol 
($<0,001). Vitamin E/ total cholesterol ratio was positively associated with waist/hip 
ratio ($<0,001, Table 9.5). In the patient group, vitamins E concentrations were 
positively associated with HDL ($<0.01), triglyceride ($<0.01) and total cholesterol 
($<0,001). However, vitamin E/  total cholesterol ratio was negatively associated with 
HDL ($<0.05) and total cholesterol (p<0.001, Table 5.5).
8.2.2 Vitamin E and metabolic syndrome
Within the dyslipidaemic group, serum concentrations o f vitamin E and vitamin 
E/total cholesterol ratio did not differ significantly with accumulating of features of 
metabolic syndrome in male and female patients and the combined group ($>0.05, 
Table 8.6).
Relationship between CHD risk factors and serum vitamin E  status
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Table 8.5 Correlations (r) between serum vitamin E concentrations and vitamin 
E/total cholesterol ratio with individual coronary risk factors_________________________
Patients (11=2381 Controls (n=135)
Vitamin E 
(pg/mL)
Vitamin E/ TC 
(pg/mmol)
Vitamin E 
(pg/mL)
Vitamin E/ TC 
(pg/mmol)
Age -0.08 0.07 0.17 -0.08
Fasting blood glucose -0.04 0.03 0.10 -0.03
BMI -0.09 -0.07 0.19* 0.08
Waist: Hip ratio -0.05 0.07 0.28** 0.30***
HDL 0.05 -0.16* 0.14 -0.12
Triglyceride 0.21** 0.09 0.17* 0.03
Total cholesterol 0.25*** -0 39*** 0.50*** -0.13
Systolic BP -0.03 0.05 -0.06 -0.10
Diastolic BP 0.10 0.06 0.05 0.00
CRP 0.02 -0.02 0.08 0.01
Correlations were assessed using Pearson correlation coefficients; *=/K 0.05, **=/><0.01, 
***=/><0.001.
Non-normally distributed data such as serum triglyceride log transformed before using 
the Pearson correction.
Between males and females as well as smokers and non-smokers, serum vitamin E and 
vitamin E/ total cholesterol ratio did not differ in control and patient subjects (p>0.05).
TC =  total cholesterol
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Table 8.6 Comparison o f vitamin E status between dyslipidaemic patients with different features o f t
metabolic syndrome________________________________________________________________________
Number of 0 
Features
Males
1 2 3 4 5
Number of
Subjects 3 15 44 41 34 5
Vitamin E 12.89+1.16 
(pg/mL)
18.00+0.66 15.40+0.80 17.16+0.80 17.00+0.78 15.80+1.7f
Vitamin E /T C  2.49+0.11 
ratio (pg/mmol)
Females
2.77+0.19 2.55+0.12 3.00+0.13 3.00+0.15 2.83+0.46
Number of
Subjects 7 13 17 21 22 15
Vitamin E 17.86+2.36 
(pg/mL)
15.20+1.24 17.63+1.35 16.66+0.91 15.70+0.93 14.14+1. Ii
Vit E /TC  2.62+0.42  
ratio (pg/mmol)
Males &  Females
2.37+0.23 2.82+0.20 2.67+0.17 2.73+0.18 2.48+0.21
Number of
Subjects 10 28 61 62 56 20
V itE  16.37+1.88 
(pg/mL)
16.70+0.87 16.02+0.62 16.99+0.61 16.49+0.60 14.55±0.9(
Vit E /TC 2.58+0.29 
ratio (pg/mmol)
2.59+0.15 2.62+0.10 2.89+0.10 2.89+0.12 2.61+0.19
Values are expressed as Mean ±  SEM. One-way AN O V A  used for comparison between the groups 
with different number of features on metabolic syndrome.
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In order to evaluate the relationship between serum vitamin E concentrations and 
CHD risk factors (in the dyslipidaemic patients), and the effects o f accumulating 
features o f metabolic syndrome on serum vitamin E status, stepwise multiple 
regression analysis was undertaken (for more details refer to section 3.9).
Serum vitamin E
In dyslipidaemic patients, stepwise multiple regression analysis showed that only 
4.4%  o f the variation in serum vitamin E concentrations was attributed to dietary 
vitamin E (p=0.02, +2.5% ), anti-hypertensive treatment (p=0.02, -1 .4% ), and anti­
diabetic agents ¥>0*05, -0.5% ). In the subgroup with metabolic syndrome, 6.7%  of 
the variation in serum vitamin E concentrations could be explained by dietary vitamin 
E ¥ = 0-03, +2% ) and serum triglyceride ¥ = 0.009, +4.7%).
Serum vitamin E/ total cholesterol ratio
In dyslipidaemic patients, stepwise multiple regression analysis show that 9.4%  of the 
variation in serum vitamin E/ total cholesterol ratio was attributed to dietary vitamin E 
¥ =0.01, +3% ), a history o f established CHD ¥ “ 0.005, +2.9% ) and
hypertriglyceridaemia ¥ = 0.01, +2.1% ). Anti-hypertensive treatment ¥ = 0.09, -0.8% ) 
and metabolic syndrome ¥ >0-05, +0.6% ) were not significantly associated. In the 
metabolic syndrome subgroup, 7.9%  of the variation in serum vitamin E/total 
cholesterol ratio could be explained by BMI ¥ =0-02, -3% ), dietary vitamin E 
¥ =0.02, 2.2%) and diastolic blood pressure ¥ =0.03, -2.7%).
8 .3  M u l t i f a c t o r i a l  a n a ly s is  o f  V i t a m i n  E
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A  significant increase in plasma a-tocopherol and cholesterol concentrations with 
age, but not the a-tocopherol: cholesterol ratio has been previously reported 
(Winklhofer-Roob et al., 2003). In the present study, no significant correlation 
between age and either serum vitamin E or serum vitamin E: total cholesterol ratio 
was observed.
Effects of smoking on serum vitamin E status
In the present study, serum vitamin E status did not differ significantly between 
smokers and non-smokers. Relatively minor differences (or even no differences) 
between plasma a - and p-tocopherol levels in passive and active smokers as 
compared to their concentrations in non-smokers have been reported (Sobczak et al., 
2004). This may result from the following reasons: (1) the secondary role played by 
these forms of vitamin E in the elimination o f the free radicals derived from the 
tobacco smoke, (2) the increased regeneration rate of these forms and antioxidative 
mobilization in response to oxidative stress, (3) the association of smoking with 
change of plasma a - and y-tocopherol levels was so slight that any differences in the 
experimental design such as describing smokers based on measuring urine cotinine or 
interviewing would have resulted in different outcomes (Sobczak et al., 2004).
Effects of CHD on serum vitamin E status
Oxidation and the attendant free radical damage may contribute to the pathogenesis of  
diabetes and CHD, but much remains to be learned about the role of antioxidants in 
the prevention of diabetes and CHD. Studies of serum concentrations of antioxidants 
have provided mixed evidence of a benefit o f antioxidants on the risk of diabetes 
(Reunanen et al., 1998; Salonen et al., 1995a). Ford et al (2003) shown that serum
8 .4  D is c u s s io n
E ffects o f age and gender on serum vitamin E  status
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concentrations of antioxidants including vitamin E status was lower in subjects with 
metabolic syndrome than subjects without metabolic syndrome (Ford et al., 2003). 
Non-antioxidant functions of vitamin E
Vitamin E (alpha-tocopherol) has several effects, which are unrelated to its 
antioxidant activity, and possibly reflect specific interactions of alpha-tocopherol with 
enzymes, structural proteins, lipids and transcription factors:
a) Inhibition of protein kinase C, 5-lipoxygenase and phospholipase A2 and 
activates protein phosphatase 2A  and diacylglycerol kinase.
b) Modulation of some genes (e.g. scavenger receptors, alpha-TTP, alpha- 
tropomyosin, matrix metalloproteinase-19 and collagenase).
c) Inhibition of cell proliferation, platelet aggregation and monocyte adhesion 
(Zingg and Azzi, 2004; Munteanu et al., 2004).
Our results showed that serum vitamin E concentrations were higher in the patients 
than the controls. As vitamin E is a major lipid-soluble antioxidant, this is related to 
higher serum cholesterol in patients than controls as shown in lipid-standardised 
values, serum vitamin E/ total cholesterol ratio did not differ between patients and 
controls (Table 3.4). Serum vitamin E/ total cholesterol ratio were higher in subgroups 
of dyslipidaemic patientswith established CHD, metabolic syndrome, 
hypertriglycerides compared with controls and patients without CHD, metabolic 
syndrome and hypertriglycerides. Also, patients with calculated 10-year coronary risk 
greater than 30%  have higher vitamin E/ total cholesterol ratio compared with 
controls and patients with calculated 10-year coronary risk less than 20% .
There are several possible explanations for these findings; a) both cholesterol and 
triglyceride-rich lipoproteins carry vitamin E, but in the cholesterol standardised 
vitamin E values we did not take serum triglycerides into account, b) under reporting
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of antioxidant supplementations taken by patients. This may be particular important in 
the patients group that we have investigated in which there was a high prevalence of 
hypertriglyceidaemia.
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C H A P T E R  9
E f f e c t s  o f  s t a t i n  o n  H s p  a n t i b o d y  
t i t r e s ,  s e r u m  v i t a m i n  E  a n d  t r a c e  
e l e m e n t  s t a t u s  i n  d y s l i p i d a e m i a
2 4 8
Statins or 3-hydroxy-3-methylglutaryl Coenzyme A  (HMG-CoA) reductases are 
effective lipid-lowering agents and widely used in the management o f  coronary risk 
(Aquilani et al., 1999). Several primary and secondary prevention trials have 
demonstrated their efficacy in reducing LDL cholesterol (The Scandinavian 
Simvastatin Survival Study (4S), 1994; Collins et al., 2003), and their utility in 
reducing coronary events (The Scandinavian Simvastatin Survival Study (4S), 1994; 
Collins et al., 2003). However, a debate has ensued as to whether the benefits o f statin 
therapy are entirely due to their cholesterol-lowering properties, or whether other 
'pleiotropic' effects also have a role (Davignon and Laaksonen, 1999; Collins et al.,
2003).
We have investigated the effects of statin therapy on Hsps antibody titres, serum 
vitamin E and trace element status in dyslipidaemic patients.
9.1 Subject recruitment and their demographic characteristics
Twenty patients, who were not originally on a lipid-lowering agent were recruited 
from the Lipid Clinics at the Royal Surrey County Hospital, Guildford. An additional 
14 patients were recruited from the same clinic, as "control" patients. The medication 
o f these latter patients was unaltered for 4 months and the same parameters were 
measured as for the statin group.
The demographic data for the statin groups are shown in table 9.1. They show a 
prevalence of co-morbidity and demographic characteristics typical o f a Lipid Clinic 
population. The patients who were treated with statins had a mean age o f 49.2±3.3 
years, and six o f the patients were women. Four (20%) were diabetic, seven were 
hypertensive, o f whom two were treated with a p-b locker, and two (10%) were
9  E f f e c t s  o f  s t a t in  o n  H s p s  a n t i b o d y  t i t r e s ,  s e r u m  v i t a m i n  E  a n d  t r a c e  e le m e n t
s ta tu s  in  d y s l i p id a e m i a
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current smokers. Treatments for diabetes and hypertension were not changed during 
the study, nor did smoking habit change over this period. Patients with evidence of 
established coronary heart disease and inflammatory disease were excluded from the 
study.
The demographic data for the group o f patients treated with atorvastatin did not differ 
significantly from those treated with simvastatin. The patients treated with 
atorvastatin were younger than patients treated with simvastatin but this failed to 
reach statistical significance. Each patient gave his or her informed written consent to 
participate in the study, which had previously been given approval by the South-West 
Surrey Research Ethics Committee (EC35/02) and The Surrey University’ s Advisory 
Committee on Ethics (AEC/2002/26/SBLS).
Statin Treatment
Patients were assigned to treatment with 10 mg o f either atorvastatin or 
simvastatin as clinically indicated for four months. All other medication 
(aspirin, |3-blockers etc.) remained constant for the duration of the study.
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Table 9.1 Baseline demographic data for groups of patients treated with 
statin
Group
n
Mean age (years)
M:F sex ratio
Smoking Habit 
Current no. (%) 
Former no. (%)
Diabetic no. (% )
Hypertensive no. (% )
Established CHD 
no. (%)
Drug therapy no. (%) 
Calcium channel 
blockers 
Aspirin
p blockers 
ACE inhibitors
Atorvastatin
9
45.3±5.5
7/2
0 (0 )
4(44)
2(22)
4(44)
0 (0 )  
0 (  0)
2(22)
0 (0 )  
0(0 )
Simvastatin 
11
52.3±3.9
7/4
2(18)
3(27)
2(18)
3(27)
0(0 )  
0 ( 0 )
2(18)
2(18)
0 (0 )
Combined
20
49.2+3.3
14/6
2(10)
7(35)
4 (2 0 )
7(35)
0 (0 )  
0(0 )
4(20)
2(10)  
0(0 )
Categorical data were compared by Fisher’ s exact tests. No significant 
differences were found. The mean ages of the groups were compared by 
Student's t-test, and did not differ significantly.
9.2 Baseline biochemistry
As would be expected for patients attending a Lipid Clinic, total- and LDL-cholesterol 
levels were high (Table 9.2). Baseline serum copper, zinc and selenium levels were 
within the reference range for our laboratory, as were serum glutathione peroxidase, 
caeruloplasmin (serum ferrioxidase activity), and serum vitamin E concentrations. 
Baseline Hsp antibody titres were higher in the dyslipidaemic patients than in healthy 
controls, recruited from staff at the University o f Surrey, that we have previously 
reported (Ghayour-Mobarhan et al., 2004). There was a significant (p<0.05) positive 
association between pre-treatment antibody titres to Hsp-60, -65, and -7 0  (Figure 
9.1a-c).
9.3 Effects of the statins on Lipid Profile
Treatment with 10 mg/d of atorvastatin, or simvastatin caused a 27%  and 40%  
reduction in LDL-cholesterol, respectively (/K 0-0 0 1). Statin treatment was also 
associated with a modest effect on triglycerides ¥<0-05). No significant effect was 
seen on HDL-cholesterol (Table 9.2). The lipid profile did not change significantly in 
the control group over the 4-month period (Table 9.2).
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Table 9.2 Fasting Lipid profile and glucose in patients treated with statins
Group 
Mean serum cholesterol 
(mmol/L)
Statin group 
Control group
Median triglyceride 
(mmol/L)
Statin group 
Control group
Mean HDL cholesterol 
(mmol/L)
Statin group 
Control group
Mean LDL cholesterol 
(mmol/L)
Statin group 
Control group
Fasting blood glucose 
(mmol/L)
Statin group 
Control group
Pre-Treatment
7.82 ±  0.43
6.09 + 0.31
1.93 (1.48-3.00) 
1.69 (0.89-2.99)
1.44+0.06  
1.43± 0.06
5.61+ 0.40 
3.83± 0.24
Post-Treatment
6.00 ±  0.47***  
6.15 + 0.29
1.65 (1.3-2.02)* 
1.86(1.00-2.99)
1.40 +  0.07
1.46 +  0.11
3.74+ 0.45***  
3.74+ 0.28
5.68 + 0.18
6.46 ±  0.67
5.77 ±  0.25 
6.24 + 0.64
Values are expressed as mean ±  SEM, or median and interquartile range. 
Comparisons between pre- and post-treatment were assessed by paired t-tests for 
normally distributed data, or by a Wilcoxon test for non-parametric data (*/K0.05, 
***/><0.001).
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Fig 9.1 Relationship between pre-treatment anti-Hsp antibody titres in dyslipidaemic 
patients
a)
Anti-Hsp-60 (Absorbance)
b)
A n ti-H sp-60 (A bsorbance)
c)
A n ti-H sp-65 (A bsorbance)
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Basal serum CRP concentrations were similar to those reported in other studies, and 
as has been previously reported, atorvastatin and simvastatin were both associated 
with a reduction in median serum CRP levels; 50%  and 24% , respectively and 45%  in 
the groups combined (p< 0.05), but not in the control patients (Table 9.3, and Figure 
9.2). These changes are similar to previous reports o f the effects o f these statins on 
CRP levels (Raggatt and Partridge, 2002a; Raggatt and Partridge, 2002c). There was a 
significant, though weak, relationship between total-cholesterol reduction and CRP 
reduction ($<0.05).
9 .4  A n t i - i n f l a m m a t o r y  e f fe c ts  o f  s ta t in s
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Table 9.3 Serum CRP (mg/L) in patients treated with statins
Statin group 1.38(0.54-3.18) 0.76(0.40-2.13)*
Control group 0.86 (0.34-2.92) 1.15 (0.63-6.61)
G r o u p  P r e - T r e a t m e n t  P o s t - T r e a t m e n t
Values are expressed as or median and interquartile range. Comparisons between pre- 
and post-treatment were assessed by a Wilcoxon test, as there are non-parametric data 
(*/><0.05).
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Fig 9.2 Effects o f statin treatment on serum CRP concentrations
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Treatment with statins caused a significant reduction in the median antibody titres to 
Hsp-60 (17.2%), Hsp-65 (15.9%) and Hsp-70 (15.4%), which were not seen in the 
"control" patients (Table 9.4, Figure 9.3a-c). It was unclear whether there was a 
differential effect o f the statins on lowering antibody titres. Although the effects of 
simvastatin were greater at the doses of statin used, the median pre-treatment values 
for Hsp antibody titres were higher in the simvastatin group than in the atorvastatin 
group, though this failed to reach statistical significance ($>0.05).
The reduction in Hsp antibody titres for the combined group o f patients was not 
related to the reduction in CRP. Nor was it related to changes in total- or LDL- 
cholesterol values. However, there were significant positive associations between the 
respective reductions in antibody titres to Hsp-60, -6 5 , and -7 0  (Figure 9.4a-c).
9 .5  E f f e c t s  o f  s ta t in s  o n  a n t i b o d y  t i t r e s  t o  H s p s
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Table 9.4 Plasma Hsp antibody titres (absorbance units) in patients treated with statins
Group 
Anti-Hsp-60
Statin group 
Control group 
Anti-Hsp-65
Statin group 
Control group 
Anti-Hsp-70
Statin group 
Control group
Pre-Treatment
0.29 (0.18-0.44) 
0.25 (0.18-0.32)
0.44 (0.24-0.62) 
0.46 (0.23-0.95)
0.26 (0.19-0.41) 
0.22 (0.18-0.41)
Post-Treatment
0.24 (0.16-0.39)* 
0.26 (0.14-0.35)
0.37 (0.20-0.53)** 
0.39 (0.23-0.82)
0.22 (0.14-0.34)** 
0.22 (0.12-0.43)
Values are expressed as median and interquartile range. Comparisons between pre- 
and post-treatment were assessed by Wilcoxon test, as they are non-parametric data 
(*p<0.05, **p<0.01).
Fig 9.3 Effects of statin treatment on plasma antibody titres to Hsp-60 (a), Hsp-65 (b), 
and Hsp-70 (c) (absorbance units) in dyslipidaemic patients treated with a statin.
a)
b)
c)
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Fig 9.4 Relationship between changes in anti-Hsp antibody titres in dyslipidaemic 
patients treated with a statin, 
a)
c)
r = 0.51
p=0.02
oocro
XIi—0w
XI<,
0  to1
Q.W1iX<
-0.1 -0.05^-Q? f  
*>.04
p^.05
0.06
Ab-Hsp-60 (Absorbance)
0.2
Ab-Hsp-65 (Absorbance)
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Both statins reduced serum copper levels significantly, Atorvastatin by 8.3%, and 
Simvastatin by 9.8%  (Figure 9.5). Although treatment with either statin was 
associated with a reduction in serum zinc concentrations, this only reached 
significance for the group treated with Simvastatin (11%, p< 0.05). For the groups 
combined the serum zinc/ copper ratio was not significantly altered (Table 9.5).
Serum concentrations o f zinc, copper, and zinc/ copper ratio did not significantly 
change over the 4 months period in control patients (Table 9.5).
For the groups combined the serum concentration o f caeruloplasmin were 
significantly reduced ($<0.05, 24% ) but this was not observed in the control patients.
Hence the copper/ caeruloplasmin ratio did not significantly change in either statin or 
control groups (Table 9.5). No significant effects were seen on serum selenium, or 
GPx concentrations in either statin treatment or control groups (Table 9.5).
i
i
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Table 9.5 Trace element parameters in patients treated with statins and control group
Group Statin group Control group
n 20 14
Mean serum copper
concentrations (pmol/L)
Pre-treatment 16.48 + 0.77 17.29 + 0.85
Post-treatment 15.15 +  0.55** 16 .71+ 0 .97
Mean serum caeruloplasmin 
concentrations (g/L)
Pre-treatment 0.17 + 0.02 0.17 ±  0.02
Post-treatment 0.13 ±  0.01* 0.15 ±  0.02
Mean serum copper/ 
caeruloplasmin ratio 
concentrations (pmol/g)
Pre-treatment 111.23 +  8.37 110.92 +  14.14
Post-treatment 120.26 ±  7.06 111.44 ±  13.85
Mean serum zinc 
concentrations (pmol/L)
Pre-treatment 14.83 +  0.48 13.64 +  0.69
Post-treatment 13.62 + 0.35* 12.79 + 0.92
Mean serum zinc/copper 
ratio (pmol/pmol)
Pre-treatment 0.95+0.07 0.80 ±  0.06
Post-treatment 0.93+0.05 0.84 ±  0.06
Mean serum selenium 
concentrations (pmol/L)
Pre-treatment 
Post-treatment 
Mean serum Glutathione 
Peroxidase cone (U/mL) 
Pre-treatment 
Post-treatment 
Median serum CRP 
concentrations (mg/L) 
Pre-treatment 
Post-treatment
1.10 +  0.04
1.07 +  0.03
0.34 ±  0.02 
0.32 ±  0.02
1.38 (0.54-3.18) 
0.76 (0.40-2.13)*
1.09 +  0.08
1.07 +  0.05
0.34 ±  0.03
0.30 ±  0.02
0.86 (0.34-2.92) 
1.15(0.63-6.61)
Values are expressed as mean ±  SEM or median and interquartile range. 
Comparisons between pre- and post-treatment were assessed by paired t-tests for 
normally distributed data, or by a Wilcoxon test for non-parametric data (*p<0.05,
**p<0.01, ***p<0.001).
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Fig 9.5 Effects o f Atorvastatin (a) and Simvastatin (b) on serum copper 
concentrations.
Mean pre- and post treatment serum concentrations are indicated. Paired t-tests were 
used to assess the significance o f changes (see table 9.5).
a)
b)
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Both statins reduced serum vitamin E significantly, atorvastatin by 19.7% (/><0.05), 
and simvastatin by 22%  ($<0.01), and in a group combined by 21%  ($<0,001, Table 
9.6). However, serum vitamin E/ total cholesterol ratio was not significantly altered 
($>0.05) by treatment with either statin (Table 9.6). Serum concentrations of vitamin 
E, and vitamin E/ total cholesterol ratio did not significantly change over the 4 months 
period in the control patients (Table 9.6).
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Table 9.6 Serum vitamin E and vitamin E /  total cholesterol ratio in patients treated 
with statins
Group
Serum vitamin E 
(pg/mL)
Statin group
Control group
Serum vitamin E/ 
total cholesterol ratio 
(pg/mmol)
Statin group
Control group
Pre-Treatment
18.81+1.37
16.62±1.04
2.46+0.16
2.63+0.14
Post-Treatment
14.92+1.26***
16.85+1.30
2.56+0.20
2.70+0.26
Values are expressed Mean + SEM. Comparisons between pre- and post-treatment 
were assessed by paired t-tests (***/?<0.01).
Antibody titres to Hsp-60, -65, and -70 are positively related to the risk of vascular 
disease and cardiovascular endpoints (Raggatt and Partridge, 2002b). The pleiotropic 
effects o f statins appear to include immunomodulation. Statins directly inhibit MHC- 
II expression by macrophages and would thus be expected to inhibit MHC-II- 
mediated T-cell activation (Raggatt and Partridge, 2002b). They also reduce CD40 
expression in vascular cells in vitro and in vivo (Mulhaupt et al., 2003; Wang et al., 
2003a). By reducing CD40 expression and signalling, statins may thereby reduce 
inflammation leading to atherosclerotic plaque stabilization (Mulhaupt et al., 2003).
As far as we are aware this is the first report on the effects o f statins on antibody titres 
to PIsps. However, it has been previously reported that fluvastatin reduces antibody 
titres to oxidised LDL by approximately 20%  (Wang et al., 2003b). The data on the 
effects o f statins on Hsp antigen expression are veiy sparse. Wang et al. (2003) show 
that simvastatin stimulates the expression o f Hsp-27 but not Hsp-90 or Hsp-70 in 
osteoblast via p38 MAP kinase (Wang et al., 2003b). No effects on Hsp-60 have been 
reported.
W e found baseline Hsp antibody titres were higher in the dyslipidaemic patients than 
has previously been reported for healthy controls (Sims et al., 2002) and that 
lOmg/day o f statin treatment reduced antibody titres to Hsp-60, -65, and -7 0 ; 
lowering titres to similar values seen in our healthy control group (Sims et al., 2002).
It has been previously reported that patients with type I diabetes mellitus with 
periodontitis have significantly higher anti-Hsps titres compared with non-diabetic 
controls (Sims et al., 2002). Twenty percent of the patients in our study had type II 
diabetes mellitus, and consistent with these previous studies, the diabetics did have 
higher titres o f all three Hsp antibodies, though this only reached statistical
9 .8  D is c u s s io n
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significance for anti-Hsp-60 (p<0.05), presumably because of the small number of 
diabetic patients.
Effects of statin on the lipid profile and CRP measurements
The effects of the statins on lipid profile were similar to previous clinical trials using 
atoivastatin and simvastatin (Ferns, 2003; Jialal et al., 2001; Oranje et al., 2001) and 
confirm that the patients were compliant with their medication. The effects of the 
statins on serum CRP concentrations were also similar to those previously reported 
for the doses of drug and duration o f treatment used in this study (Ferns, 2003; Jialal 
et al., 2001). Recent studies using atorvastatin in patients with established coronary 
disease have reported a 36%  and 89%  reduction in median serum CRP concentrations 
respectively, but these patients had higher baseline values and the statin was used at 
high dose (Cannon et al., 2004; Nissen et al., 2004).
Relationship between changes in Hsp antibody titres and in other CHD risk factors 
In our study, there was a modest correlation between the changes in total-cholesterol 
and CRP (n= 20, R2=  0.36, /K 0.05). In another study with a larger sample size 
(n=130), a correlation between the changes in LDL-cholesterol and CRP in patients 
treated with atorvastatin (n=63, R2=0.11,p=0.009) has been reported previously (Kent 
et al., 2003). However this was not obseived in patients treated with pravastatin in this 
study (n=67, R2=-0 .003,/;=0 .69), nor was this obseived in the PRINCE study (Albert 
et al., 2001). This indicates that the effects on CRP are not directly related to the 
cholesterol-lowering properties of the statins, and that statins may differ in their 
ability to affect serum CRP concentrations.
The reduction in Hsp antibody titres observed with statin treatment in our study 
cannot be fully explained by the anti-inflammatory properties o f these drugs. There
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was a weak correlation between the reduction in CRP and anti-Hsp-60 (R2=0.41, 
/>=0.034) in the simvastatin group, which was not observed in the atorvastatin group. 
Nor was there an association between CRP reduction and the reduction in the titres to 
the other Hsps.
Effects of statins on Hsp antibody titres
The reduction in Hsp antibody titres observed following statin treatment may be 
related to the other immunomodulatory properties of this class o f drugs, perhaps their 
reported effects on lymphocyte function (Raggatt and Partridge, 2002b; Wan et al., 
2003; Weitz-Schmidt, 2003). W e observed a significant relationship between baseline 
antibody titres to Hsp-60, -65, and -7 0  (see Figure 9.1a-c), and between their 
respective reduction following statin therapy (see Figure 9.4a-c). This may be related 
in part to crossreactivity between the antibodies and different Hsp antigens because 
previous studies found a sequence similarity between Hsp-60 and -7 0 , despite the 
lack of obvious structural resemblance between them (Bonk et al., 1996; Flores and 
Cuezva, 1997).
Statins and antioxidant status
Several studies have shown that statins affect antioxidant status, although the effects 
are complicated and not entirely consistent. Pizzi and colleagues have recently 
reported that treatment with a combination of atorvastatin and ACE inhibitor 
(Ramipril) was associated with a reduction in SOD activity and improved endothelial 
responses (Pizzi et al., 2004). They conclude that this may be due to reduced 
superoxide anion production. Wassmann et al. (2002) have reported that Atorvastatin 
increases the expression o f catalase, but not glutathione peroxidase nor superoxide
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dismutase by vascular smooth muscle cells in vitro (Wassmann et al., 2002). Manuel 
et al. (2003) LDL susceptibility to copper oxidation in patients with type I diabetes 
mellitus (Manuel et al., 2003) whereas Oranje et al. (2001) and have found that 
atorvastatin increases the resistance o f LDL to oxidation in type I diabetes mellitus 
(Oranje et al., 2001).
Twenty percent of the patients in our study had type II diabetes mellitus. Juturu et al.
(1999) have reported that patients with non insulin dependent diabetes mellitus have 
low serum zinc concentrations (Juturu et al., 1999), but our subjects had levels within 
our reference range.
In conclusion, our study demonstrates that statin treatment is associated with a 
reduction in antibody titres to Hsp-60, -65 and -70. This reduction does not appear to 
be fully explained by the anti-inflammatory effects o f the statins, but may be due to 
their other immunomodulatory properties. Also, we have shown that trace element 
status may be affected significantly by treatment with statins at doses used in routine 
practice. These effects may be due in part to the anti-inflammatory properties of the 
statins as statins reduce CRP and caeruloplasmin (the main carrier of copper in the 
blood). However, there also appear to be differential effects for drugs o f the same 
class. These data may be o f some importance in epidemiological studies o f the role o f  
trace element status in coronary risk and other conditions given the widespread use of  
statins.
However, our study group was a small heterogeneous sample o f dyslipidaemic 
patients. It would be important to confirm these findings in a larger sample with 
sufficient power to establish whether factors such as gender, diabetes and smoking 
habit affect the Hsps antibody response, trace element, and vitamin E status to statin 
treatment.
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In the preceding chapters, we have reported several interesting findings in our studies:
1. The diet o f dyslipidaemic patients was different in several respects compared with 
controls, despite them having not been given detailed dietary advice. However, the 
reported dietary intake o f total fat remained higher in patients compared with 
controls. The dyslipidaemic patients were found to have a significantly higher 
dietary intake o f protein ¥ <0.05), starch ¥<0-05), fibre ¥<0-05), total fat 
¥<0.05), selenium ¥ <0.05), zinc ¥ <0.01) and a higher dietary zinc/ copper ratio, 
compared with controls. It may be important for the patients with dyslipidaemia to 
have more individualised dietary advice, especially to reduce their dietary intake 
of total fat and protein.
2. Within the dyslipidaemic group, obesity and metabolic syndrome were both very 
common. Among dyslipidaemic patients those with obesity and metabolic 
syndrome were found to have elevated CRP compared with controls as previously 
reported (Forouhi et al., 2001; Tamakoshi et al., 2003), and that CRP 
concentrations increased incrementally with accumulation features o f metabolic 
syndrome (Lee et al., 2004; Tamakoshi et al., 2003). Similar results reported by 
others have been explained as being due to a systemic inflammatory response 
associated with these conditions possibly due to inflammatory cytokines release 
from adipocytes (Lee et al., 2004). Stepwise multiple regression analysis, using 
the best fitting model showed that obesity approximately explained 13.5% of the 
variation of serum CRP concentrations among the dyslipidaemic patients being 
obesity.
In the healthy controls, serum CRP concentrations were not associated with 
dietary factors. However in the dyslipidaemics, CRP concentrations were
1 0 .  F i n a l  c o n c lu s io n s
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associated positively with dietary cholesterol and negatively with vitamin C. 
Whether a diet low in cholesterol (low meat and dairy products) and high in 
vitamin C (rich in fruit and vegetable) could normalised levels o f CRP n these 
patients would need to be tested in a dietary intervention trial, as causation cannot 
be assumed from our cross-sectional study design.
3. Antibody titres to several heat shock proteins were higher in the dyslipidaemics 
than controls. Elevated antibody titres to Hsps in these patients may be related to a 
heightened state o f immunoactivation associated with atherosclerosis in this 
group, and the strong correlation between antibody titres to Hsp-60, -65, and -70 
(p=0.001) supports this.
Studies have shown that conditions associated with auto immunity, such as 
Rheumatoid arthritis and systemic lupus erythematosus (SLE) are associated with 
increased CHD risks. It is unclear at the present time whether the link between 
auto antibodies and atherosclerosis is a direct aetiological link or whether the 
autoimmune response is as epiphenomenona (El Magadmi et al., 2004; Erb et al.,
2004).
Antibody titres to Hsps were determined in part by dietary factors, including 
vitamin E, vitamin C and total fat and this does not necessarily indicate causality. 
The immune-modulating effects of dietary fat and antioxidants (Bub et al., 2003; 
Stulnig, 2003) and their effects on Hsps in animal models (Andres et al., 2000; 
Khassaf et al., 2003; Lamb and Ferns, 2002) support these findings. However the 
anti-heat shock antibody titres could not be explained by classical risk factors.
The relationship between anti-Hsp titres and infection (Mandal et al., 2004) may 
to some degree explain why our best-fitting models explained a relatively small 
amount of the variation in titres. Antibody titres to specific organism such as
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Chlamydia phenomena or Helicobacter pylori may clarify this. However, recent 
meta-analysis data found no strong relationship between titres to these organisms 
and CHD (Danesh et al., 2002).
4. A  significant difference in trace element profile was observed in dyslipidaemic 
patients compared with control subjects. Differences in serum copper may be 
related to a chronic state o f inflammation. The lower levels o f serum GPx in 
obesity and dyslipidaemia and lower level o f serum selenium with accumulation 
features of metabolic syndrome may be related to the presence o f an 
atherosclerosis prone state and consequential consumption o f antioxidants by free 
radical interaction.
In assessing trace element status the following factors need to be taken into 
account:
• Physiological factors such as age and gender.
• Drugs therapy, for example we found that Statins may influence serum trace 
element concentrations.
• The fact that the estimation of a single parameter o f trace elements status may be
misleading and that the assessment of several parameters may give a better
assessment of trace element status. In the present study, we assessed the dietary 
intake of selenium in addition to measuring serum selenium and GPx. W e found 
higher dietary and serum selenium and lower GPx in patients compared with 
controls. It is clear that without measuring GPx, we may not have been able to 
interpret our findings accurately.
• There is not always a clear linear relationship between dietary intake of trace 
element and their serum levels. There are two possible reasons a) the likely 
interaction o f trace elements at the level o f absorption and metabolism (Klevay,
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1975), b) serum levels o f trace elements are dependent on conditions such as 
infection or the acute phase response, as their transport proteins in blood would be 
altered in these conditions.
5. Serum vitamin E concentrations were higher in the patients than the controls. As 
vitamin E is a major lipid-soluble antioxidant, this is related to the higher serum 
lipid concentrations in patients than controls. Serum vitamin E/ total cholesterol 
differed significantly between patients with and without established CHD, 
metabolic syndrome, and hypertriglyceridaemia. There are several possible 
explanations for these findings; a) both cholesterol and triglyceride-rich 
lipoproteins cany vitamin E, but in the cholesterol standardised vitamin E values 
we did not take serum triglycerides into account, b) under reporting of antioxidant 
supplementations taken by patients. This may be particular important in the 
patients group that we have investigated in which there was a high prevalence of  
hypertriglyceidaemia.
6. Statin treatment was found to affect several measures o f trace element status, 
inflammation and autoimmunity. The effects of treatment with statins at doses 
used in routine practice may be due in part to the anti-inflammatory properties of 
the statins. However, the reduction o f anti-Hsps does not appear to be fully 
explained by the anti-inflammatory effects o f the statins, but may be due to their 
other immunomodulatory properties. These data may be o f some importance in 
epidemiological studies o f the role of trace element status in coronary risk and 
other conditions given the widespread use o f statins. It would be important to 
determine if other lipid lowering drugs, such as the fibrates have similar effects.
275 i
This study was undertaken in two groups o f subjects: patients attending a lipid clinic 
at the Royal Surrey County Hospital, Guildford, UK, and healthy subjects recruited 
from University and Hospital staff, Guildford. The Lipid Clinic population is a highly 
selected population. Patients are often referred because of a strong family history or 
because they react adversely to medication, or have very high lipid values. They are, 
however, a group at high coronary risk. The control group on the other hand reside in 
an area of the U K  with perhaps the lowest risk of CHD, almost entirely Caucasian and 
predominantly middle class.
In using multiple comparisons as we have done here in the present study, false 
positive results may be unavoidable. The use of the Bonferonni correction for multiple 
comparisons in this case might result in a type 2 error, in which potentially important 
relationships are overlooked. W e view the use of these multiple comparison methods 
to some degree to be hypothesis generating, and requiring further confirming studies 
to validate the association we have found. However their interpretations require 
caution.
Our study group was a small heterogeneous sample of dyslipidaemic patients. Also, a 
high proportion o f patients were taking medication in particular statins (75%) and 
fibrates (74%), and the effects o f statins on biochemical marker have been reported 
here. The possible effects o f fibrates on biochemical markers, including inflammatory 
markers, may have confounded some of the results in the present study, as fibrates are 
known to exert pleiotropic, anti-inflammatory effects other than simply lowering 
triglycerides (Chapman, 2003). It would perhaps be important to confirm our findings 
in a larger sample o f patients prior to their drug treatment.
We have attempted to bring together our findings from the various chapters, 
summarising them in figure 10.1.
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The inflammatory nature o f atherosclerosis is well established. In obesity and 
metabolic syndrome, inflammatory process is stimulated activated through the 
systemic release o f cytokines such as IL-6 and TNF-a. These cytokines stimulate the 
liver to synthesis and secrete CRP, caeruloplasmin (the main copper carrier in the 
blood) and selenoproteins.
These cytokines and other CHD risk factors cause endothelial activation and stress. 
The cytotoprotective Hsps are released from these ‘ ’ stressed”  endothelial cells to 
protect them. But the Hsps themselves become denatured. The fact that some of these 
endothelial cells derived Hsps share common epitops with homologous Hsps derived 
from micro-organisme (Chlamydia pneumoniae) increases the risk of an auto immune 
response which is indicated by a rise in anti-Hsps antibodies.
W e have found that dietary factors (fat, vitamins C and E) can modulate antibody 
titres to Hsps.
Our data have attempted to provide an insight into the highly complex interaction 
between some o f the traditional CHD risk factors and some of the potentially novel, 
emerging coronary risk factors. Our work has been confirmed to a UK-based largely 
causation population and the association we have found, may not be substantiated in 
other population in which the dietary habits are different or in which the prevalence of 
the traditional coronary risk factors differs substantially.
The current definition of the metabolic syndrome and obesity is based on findings in a 
USA-based population and work is currently underway in other countries to establish 
more specific race-related definition of these conditions. This may clearly have an 
impact on the interpretation of our findings.
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Figure 10.1 Relationship between coronary risk factors, diet, indices o f serum trace 
element status, antibody titres to Hsps and inflammatory markers
CHD risk factors
CHD =  Coronary heart disease 
ROS = Reactive oxygen species 
NO =  Nitric oxide 
IL-6 =  Interleukin-6 
Hsp =  Heat shock protein 
CRP =  C-reactive protein 
LDL =  Low density lipoprotein 
Ox-LDL =  Oxidised-LDL
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Stand-on BIA machine
Bioelectrical impedance from ‘ ’ foot-to-foot”  was measured using the Tanita-305 
body-fat analyser (Tanita Corp., Tokyo, Japan), which provides measured impedance. 
The required data o f age, sex and height were entered and the subjects stood 011 the 
metal sole plates of the machine wearing light clothes and bare foot.
Hand-held BIA machine
Bioelectrical impedance from hand to hand was measured using the Roman body-fat 
analyser (Bodystat-1500, Bodystat Ltd, Isle o f Men. UK), which provides measured 
impedance. This is a single frequency, lightweight, menu-driven bioelectrical 
analyser. The machine needs input o f age, sex, height and weight, and directly 
displays fat mass as a percentage of total body weight and in kilograms. This machine 
was used just for the comparison study o f devices in the healthy controls.
Automated blood pressure device
DINAMAP compact monitor model TS (CRITIKON 1998 TAMPA. FL 33634). 
Cardiac risk calculator (CRC-91, supralip®160 company)
The calculator needs input of sex, age, cholesterol, HDL, systolic blood pressure, 
smoke, left ventricular hypertrophy, and diabetes and directly displays total points of 
Framingham formula calculation, then 5-years and 10-years CHD risk.
Electrothermal atomic absorption spectrometry
PYE UNICAM  SP9 atomic absorption spectrometry. Manufactured in U K  by Philips 
(Thermo Electron Corporation, Stafford House, Boundary Way, Hemel Hempstead, 
HP2 7GE).
Flame atomic absorption spectroscopy
PYE UNICAM  PU9000 atomic absorption spectrometry. Manufactured in U K  by 
Philips.
ELISA plate reader
iEMS Reader MF, Labsystem, UK.
NUNC™ plate washer
Nalge Nunc International, Denmark.
Multichannel pipette: Finnipipette Digital Mutichannel, 50-300pL, Labsystems, UK.
Appendix-1: Equipment
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Appendix-2: Reagents
• Reverse osmosis/deionised water (RO/DI).
• Ascorbic acid, Sigma Chemical Co, UK.
• Antifoam B, Sigma Chemical Co, UK.
• Triton X-100, Sigma Chemical Co, UK.
• Palladium chloride matrix modifier, Sigma Chemical Co, UK.
Reagent used for the measurement of serum zinc and copper by flame AAS
• Reverse osmosis/deionised water (RO/DI),
• Cupric nitrate standard solution, 15.7 mmol/l (1000 ppm) "spectrosol" BDH 
product No. 14139 2N.
• Zinc nitrate standard solution, 15.3 mmol/l (1000 ppm) "spectrosol" BDH product 
No. 14150 3C.
Reagent used for the measurement of plasma anti-Hsps antibody By ELISA
• Albumin, Bovine (Fraction V , Approx 99%), Sigma Chemical Co, UK.
• Anti-Human Ig G (y-chain specific) peroxide conjugate (antibody raised in Goat) 
Sigma Sigma-Aldrich, INC., USA.
• Chelating Resin (iminodiacetic acid), Sigma Chemical Co, UK.
• Heat shock proteins (i.e. Hsp-60, Hsp-65, and Hsp-70); Human recombinant, 
expressed in Escherichia coli, Buffered aqueous solution. Sigma Chemical Co, 
Poole, Dorset, UK.
• 3M hydrochloric acid (HCL); Sigma Chemical Co, UK.
• Hydrogen Peroxide 30%  (W /W ) Solution; Sigma Chemical Co, UK.
• O-Phenylenediamine Dihydrochloride, 1,2-Benzenediamine (solid); Sigma 
Chemical Co, Poole, Dorset, UK.
• 0.04%  O-phenylenediamine: dissolved 14.7g sodium citrate and 14.2g sodium 
phosphate in 800ml distilled water and bring solution to pH 5.0, then add lOOmg 
of Chelating resin to the solution. For each 500ml of solution, add 0.2g o f O- 
phenylenediamine Dihydrochloride. Finally just before use, add 16 pL H2O2 to 
40mL of each solution used.
• Phosphate Buffered Saline Dulbecco A  (PBS); Oxoid LTD, England.
• PBT solution=500mL distilled water+ 5 tablets PBS+ 5g 1% BSA+ 0.5mL 
Tween-20.
• Polyoxyethyenesorbitan (Tween-20); Sigma Chemical Co, UK.
• SuperBlock®Blocking Buffer in PBS; Pierce & Warriner, Chester, Cheshire, UK.
• Tri-Sodium Citrate; Fisons Scientific Equipment, England.
• Wash buffer; 1 litre distilled water + 1 0  tablets PBS +  0.5mL Tween-20.
R e a g e n t  u s e d  f o r  t h e  m e a s u r e m e n t  o f  s e r u m  s e le n iu m  b y  e l e c t r o d e r m a l  A A S
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Appendix-4: Clinical and biochemical characteristics o f healthy male and female
subjects.
Male Female P-Value
Number 94 95 -
Age (Year) 49.51+1.55 49.14+1.46 0.86
Present Smoker (%) 16% 18% 0.85
Previous Smoker (%) 11% 24% 0.73
Non-smoker (%) 63% 58% 0.55
BMI (Kg/m2) 26.54+0.47 25.45+0.49 0.11
W HR 0.93+0.01 0.82+0.01 <0.001
Fasting blood glucose 
(mmol/L)
5.26+0.05 4.94+0.09 0.003
SBP (mmHg) 127.3+1.8 128.7+2.1 0.60
DBP (mmHg) 78.03+0.94 74.63+1.05 0.02
Triglyceride (mmol/L) 1.24 (0.91-1.64) 1.05 (0.82-1.40) 0.01
HDL (mmol/L) 1.49+0.03 1.80+0.05 <0.001
Total cholesterol 
(mmol/L)
5.40+0.11 5.45+0.10 0.75
T.C/HDL ratio 3.80+0.09 3.19+0.08 <0.001
Values are expressed as median and interquartile range. Between the groups 
comparisons were assessed by one-way A N O V A  for normal distributed data and 
Kruskal-Wallis for non-normal distribution data.
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Appendix-5: Clinical and biochemical characteristics o f smoker and non-smoker
healthy subjects
Smoker Non-smoker P-value
Number 65 124 —
Age (Year) 52.55+1.92 47.63+1.25 0.03
Male/Female 37/28 56/68 0.13
Weight (kg) 76.47+2.17 72.73+1.34 0.13
BMI (Kg/m2) 26.39+0.64 25.80+0.40 0.41
Waist (cm) 93.36+1.86 88.48+1.21 0.02
W HR 0.91+0.01 0.86+0.01 0.003
SBP (mmHg) 129.2+2.3 127.4+1.7 0.53
DBP (mmHg) 76.8+1.2 76.1+0.9 0.64
Fasting blood glucose (mmol/L) 5.08+0.09 5.11+0.07 0.80
Triglyceride (mmol/L) 1.23 (0.96-1.70) 1.10(0.83-1.44) 0.02
HDL (mmol/L) 1.59+0.05 1.68+0.04 0.20
Total cholesterol (mmol/L) 5.53+0.13 5.37+0.09 0.32
T.C/HDL ratio 3.65+0.12 3.40+0.07 0.08
Values are expressed as median and interquartile range. Between the groups 
comparisons were assessed by one-way A N O V A  for normal distributed data and 
Kruskal-Wallis for non-nonnal distribution data.
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Appendix-6: Comparison o f physical activity levels (PAL) between different subgroups
of dyslipidaemic patients segmented according to the possession o f specific coronary risk
factors.
Group
Number PAL
Established CHD
CHD+
CHD-
55
182
1.50+0.07“
1.49+0.03
Metabolic Syndrome
M S+
MS-
142
95
1.45+0.043**
1.54+0.05
Diabetes Mellitus
DM +
Impaired GT 
DM -
42
21
174
1.40+0.063*
1.65+0.09
1.50+0.04
Obesity
Obese+
Over weight 
Normal weight
82
112
43
1.40+0.043**
1.48+0.04
1.66+0.07
Hypertriglyceridaemia
High T.G.
Normal T.G.
176
61
1.43±0.033*
1.65±0.06
Blood pressure
High BP 
Moderate BP 
Normal BP
76
111
50
1.55+0.06“
1.44+0.04
1.53+0.07
Calculated 10-year 
Coronary Risk
High >30%  
Moderate 20-30%  
Low <20%
42
54
141
1.39+0.04
1.45+0.06
1.54+0.04
Controls 135 1.66+0.03
Values are expressed as Mean ±  SEM. PAL differed significantly between all sub­
categories o f patients compared with control subjects (/K0.001), and *=p<0.05 and 
**=p<0.01 shows the comparison between sub-categories of the dyslipidaemic patients. 
Dyslipidaemic patients (1.49 ±  0.03) had a significantly lower PAL compared with 
control subjects (1.66 ±  0 .03 ,/K 0 .001). Within the dyslipidaemic group, PAL decreased 
with accumulating features of the metabolic syndrome (p<0.001).
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DIET AND PHYSICAL ACTIVITY QUESTIONNAIRE
Thank you for agreeing to answer the following questions on your personal history, food intake and physical 
activity levels.
All your answers will be kept completely confidential.
SECTION ONE - PERSONAL HISTORY
1. What is your date of birth?
Day I ~l Month Year
2. How many years have you lived in the Aberdeen area?
Years
3. Where were you born?
Town/Place
County
/
Country
4. What Is the highest level o f education you have completed?
Please tic k  o ne  b o x  o n ly
1. University degree course
l ''
2. Other professional or technical qualification
or diploma after leaving school
3. Secondary School
4. Primary School
□
□
□
□
5. Have you smoked In the last year? 1. Yes
2. NO
□
□
Please do not
write In this
margin.
P
SECTION TWO - PRESENT AND PAST DIETARY INTAKE Please do notwrite in this
margin.
The following questions are mostly about how often each week you usually eat different foods (over the 
last year), or about how often you used to eat different foods when you were younger.
Please answer every question as far as you can, (except those you are told to skip). We cannot use those 
questions that you leave completely blank. If the answer Is “No" or “I donl know", you still need to show 
this on the paper.
We realise that It may be very difficult to remember as far back as your childhood, so we have added a few 
events to help remind you. Please answer all questions as accurately as you can.
How to Answer the Questions
The questions are divided into two different parts - how many times a day you usually eat a food; 
and how many days a week you usually eat a food. Please answer both parts.
Times a day
If you usually eat a portion or a serving of food once a day, ring 1 times a day
If you usually eat a portion or a serving of food 2-3 times a day, ring 2-3 times a day
If you usually eat a portion or a serving of food more than 4 times a day, ring >4 times a day
Number o f days a week
If you usually eat a food every day, that is, 7 days a week, ring 7 days a week 
If you usually eat a food 3 days each week, ring 3 days a week, and so on 
If you usually eat a food about twice a month (fortnightly), ring F. 
if you usually eat a food less than once a month or you never eat It at all, ring R.
The range of >4 times a day to once a day, and the range of 7 days a week to never at all will 
enable you to ring at least one answer on each line.
Please do not leave any blank lines. Remember to circle R if you never eat a food.
Here Is an example o f how it can b e done: ,
Times a day No. of days a week
Food usually eaten once a day, 7 days a week >4 2-3©, ©6 5 4 3 2 1 F R
Food usually eaten once a day, 3 days week >4 2-3© • 7 6 5 4(§)2 1 F R
Food usually eaten 2-3 times a day, 2 days a week >4 0 ) 1 7 6 5 4 3©1 F R
Food usually eaten about once a day, twice a month >4 2-3© 7 6 5 4 3 2 1 © R
Food usually eaten less than once a month or never >4 2-0 1 7 6 5 4 3 2 1 F ©
\
0
SECTION TWO - PRESENT AND PAST DIETARY INTAKE
a)
b) 
C)
d)
e)
f)
g)
h)
i) 
])
Present Intake of Meat and Meat Products
(Including meat used in meat dishes: eg. curries, stews, lasagna)
How many times a day/week do you usually eat a portion or serving of the following:
Times a day No. of days a week
Beef (Including minced beef, beefburgers)
Lamb
Pork, bacon, ham
Chicken, turkey and other poultry
Tinned meat (all types, corned beef etc)
Pork sausages 
Beef Sausages
Meat pies, bradles, pasties, sausage rolls 
Haggis, stovies, mealle pudding & similar meals 
Liver, kidney, heart
>4 2-3 1 7 6 5 4 3 2 1 F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1 F R
>4 2-3 1 7 6 5 4 3 2 1  F R
2. Present Intake of Fish and Fish Products
a) White fish (eg. cod, haddock, hake, plaice, 
fishfingers)
b) Fatty fish (eg. kippers, herrings, pilchards, tuna,
salmon, mackerel, sardines) Include tinned fishI
c) Shell-type fish (including prawns, mussels, 
cockles etc.)
d) Fish cakes, fish pie and other fish dishea
>4 2-3 1 7 6 5 4 3 2 1 F  R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1 F  R
>4 2-3 1 7 6 5 4 3 2 1 F  R
3. Present Intake of Eggs
a) How many eggs (boiled, poached, fried scram bed), 
do you usually eat each week?
(If you do not eat eggs please ring 0)
b) How many eggs In baked dishes (flans, quiches, 
souffles, egg custard) do you usually eat each week? 
(1 average portion = 1 egg).
(If you do not eat eggs please ring 0)
No. of eggs usually eaten each week
>11 8-10 7 6 5 4 3 2 1 0
>11 8-10 7 6 5 4 3 2 1 0
Please do not
write In this
margin.
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4 .1  Present Milk Intake
a) Roughly, how much milk do you usually drink a day In tea or coffee, in milky drinks, as a drink on 
it’s own, or with cereals etc?
Please tick one box only
1. None at all □
2. Half pint or less □
3. Between half and one pint □
4. Between one and two pints □
5. More than two pints □
What kind of milk do you usually use?b)
Please tick one box only
1. Full-fat milk Q
2. Seml-sklmmed milk Q
3. Fully skimmed milk HH
4. Other kinds of milk (eg. condensed, evaporated) I I
Please give type ...............................................
c) Is this milk usually:
Please tick one box only
1. Fresh □
2. Long Life (UHT etc) □
3. Dried □
4.2 Past M ilk Intake
Try to think about your past milk intake. Firstly, when you were a child (by this we mean upto 12
years), and secondly, in early adulthood (by this we mean 20 to 30 years).
Here are a few events which may help you to remember.
Childhood: School milk, school meals, family meals, allergies,
(Upto 12 years) milkman calling, dally routine etc
Early Adulthood: Changes occurring In life - leaving school for work or further
(20 - 30 years) education, moving away from home, getting married etc
Please do not
write In this
margin.
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a) Roughly, how much milk did you used to normally drink a day in tea or coffee, in milky drinks, 
as a drink on It’s own, with cereals etc?
Please tick one box for your childhood (upto 12 years) and one box for your early adulthood 
(20 - 30 years)
Upto 12 years 20 - 30 years
1. None at all □ □
2. Half pint or less □ □
3. Between half and one pint □ □
4. Between one and two pints □ □
5. More than two pints □ □
5.1 Present Intake of Milk Products
How many times a day/week do you usually eat the following milk products:
(Please remember to circle R if never eaten)
a) Yogurt (full-fat plain & fruit)
b) Yogurt (low fat plain & fruit)
c) Cream (half, single, imitation creams 
eg. Elmlea, Tip Top, Dream Topping etc)
d) Full fat cream (double, whipping, clotted)
5.2 Past Intake of Milk Products
How many times a day/week did you used to eat milk products such as yogurt, cream, ice cream, 
custard, btanbmange, milk puddings etc?
Upto 12 years 20-30 years
Times a day No. of days a week Times a day No. of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R >4 2-3 1 7 6 5 4 3 2 1 F  R
Times a day No. of days a week 
>4 2-3 1 76 5 4 3 2 1 F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 76 5 4 3 2  1 F R
>4 2-3 1 7 6 5 4 3 2  1 F R
Please do not
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6 .1  Present Intake of Cheese
How often do you usually eat cheese (eg. with bread, crackers, in sauces, cooked dishes, as a 
topping or on it’s own)?
a) Full fat hard cheese (eg. Cheddar, Cheshire, 
Stilton, Danish Blue,
b) Low fat hard cheese (eg. Edam, reduced 
fat Cheddar)
c) Full fat soft cheese (eg. cream cheese)
d) Low fat soft cheese (Including cottage cheese)
Times a day No. of days a week 
>4 2-3 1 7 6 5 4 3 2 1 F  R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1 F  R
Please do not
write in this
margin.
6 .2  Past Intake of Cheese
How many times a day/week did you used to eat cheese?
Upto 12 years 20 - 30 years
Times a day No. of days a week Times a day No. of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R >4 2-3 1 7 6 5 4 3 2 1 F R
7.1 Present Intake of Vegetables (fresh, frozen, dried & tinned) 
(Please circle R if never eaten)
Times a day No. of days a week
a) Potatoes: boiled, baked, mashed >4 2-3 1 7 6 5 4 3 2 1 F R
b) Potatoes i) Chipped or fried (from shop) >4 2-3 1 7 6 5 4 3 2 1 F R
ii) Chipped or fried (home cooked) >4 2-3 1 7 6 5 4 3 2 1 F R
iii) Oven Chips >4 2-3 1 7 6 5 4 3 2 1 F R
c) Green vegetables (eg. broccoli, spring greens >4 2-3 1 7 6 5 4 3 2 1 F R
cauliflower, brussel sprouts, green beans)
d) Salad type vegetables (eg. cucumber, lettuce, >4 2-3 1
mushroom, radish, avocados)
e) Sweet peppers (green, yellow, red etc) >4 2-3 1
f) Carrots >4 2 - 3 1
g) Parsnips, swedes, turnips, beetroot and other root >4 2-3 1
vegetables
h) Onions (all types) >4 2-3 1
i) Tomatoes (including puree) >4 2 - 3 1
7 6 5 4 3 2 1 F  R
7 6 5 4 3 2 1 F  R
7 6 5 4 3 2 1 F  R
7 6 5 4 3 2 1 F  R
7 6 5 4 3 2 1 F  R
7 6 5 4 3 2 1 F  R
0
7 . 2  Past Intake of Vegetables
How many times a day/week did you used to eat vegetables (Green and Root)?
(Do not include potatoes)
Upto 12 years 20 to 30 years
Times a day No.of days a week Times a day No.of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R >4 2-3 1 7 6 5 4 3 2 1 F  R
8.1 Present Intake of Fruit (fresh & frozen)
a) Number of apples usually eaten each week . □
b) Number of pears usually eaten each week □
c) Number of oranges/grapefruit usually eaten each week □
d) Number of bananas usually eaten each week □
e) Number of other fnilts usually eaten each week
(Please give name and quantity)
Name Quantity Name Quantity
8 . 2  Past Intake of Fruit
How many times a day/week did you used to normally eat fresh fruit?
Upto 12 years 20 to 30 years
Times a day No. of days a week Times a day No. of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R >4 2-3 1 7 6 5 4 3 2 1 F  F
Please do not
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9.1 Present Intake of Bread
a)
b)
How many days a week do you usually eat these different breads? 
(it will say on the packet if it is wholemeal)
No. of days a week
1. White Bread 7 6 5 4 3 2 1 F R
2. Brown Bread 7 6 5 4 3 2 1 F R .
3. Wholemeal Bread 7 6 5 4 3 2 1 F R
4. Bread Roll(s) (Give type) ............................ R
5. Buttery(s) 7 6 5 4 3 2 1 F R
6. Other Types of Bread (Give type) ......... R
Further details on your bread.
How many slices 
or roils a day?
Are the slices thick or medium? 
(Please circle your answer)
1. White Bread □ thick medium
2. Brown Bread □ thick medium
3. Wholemeal Bread □ thick medium
4. Bread Roll(s) □ large medium
5. Buttery(s) □
6.- Other Types of Bread □ thick medium
9.2 Past Intake of Bread
a) How many; times a day/week did you used to eat bread?
Upto 12 years: 20 - 30 years:
Times a day No. of days a week Times a day No. of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R >4 2-3 1 7 6 5 4 3 2 1 F  R
b) What type of bread did you used to normally eat?
Please tick one box for your childhood (upto 12 years) and one box for your early adulthood 
(20 to 30 years)
1. White
2. Brown
3. Wholemeal
4. Other
Upto 12 Years:
□
□
□
□
20 - 30 years:
□
□
□
□
0
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10. Present Intake of Beans, Rice and Pasta
(Please remember to circle R if never eaten)
How many times a day/week do you usually eat:
Times a day No. of days a week
a) Baked beans, butter beans, kidney beans etc, 
lentils, peas, sweet-corn
>4 2-3 1 7 6 5 4 3 2 1 F R
b) Spaghetti and other pasta 
(except pasta in puddings)
Wholemeal 
Not wholemeal
>4 2-3 1 
>4 2-3 1
7 6 5 4 3 2 1 F 
7 6 5 4 3 2 1 F
R
R
c) Rice (except rice In puddings) White
Brown
>4 2-3 1 
>4 2-3 1
7 6 5 4 3 2 1 F 
7 6 5 4 3 2 1 F
R
R
11. Present Intake of Cereals
Times a day No. of days a week
a) Porridge >4 2-3 1 7 6 5 4 3 2 1 F R
b) Bran flakes, sultana bran >4 2-3 1 7 6 5 4 3 2 1 F R
c) All Bran, Wheat Bran >4 2-3 1 7 6 5 4 3 2 1 F R
c) Cornflakes, nutri-graln, special K >4 2-3 1 7 6 5 4 3 2 1 F R
d) Unsweetened muesli, weetabfx, shredded wheat >4 2-3 1 7 6 5 4 3 2 1 F R
e) Coco-pops, crunchy nut cornflakes, frostles, 
ricicles, sugar puffs or similar
>4 2-3 1 7 6 5 4 3 2 1 F R
12. Present Intake of Biscuits
Times a day No. of days a week
a) Plain, semi-sweet, digestive >4 2-3 1 7 6 5 4 3 2 1 F R
b) Sweet, fancy, cream filled >4 2-3 1 7 6 5 4 3 2 1 F R
c) Shortbread >4 2-3 1 7 6 5 4 3 2 1 F R
d) Chocolate coated biscuits >4 2-3 1 7 6 5 4 3 2 1 F R
e) Savoury biscuits, crispbreads & cream crackers >4 2-3 1 7 6 5 4 3 2 1 F R
0 Oatcakes >4 2-3 1 7 6 5 4 3 2 1 F R
Please do not
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margin.
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13. Present Intake of Cakes
(Please remember to circle R If never eaten)
Times of day No. of days a week
a) Plain cakes (eg. madeira, ginger, sponge) >4 2-3 1 7 6 5 4 3 2 1 F R
b) Fruit cakes (all kinds) >4 2-3 1 7 6 5 4 3 2 1 F R
c) Rich cakes (eg. chocolate, cream, cheese) >4 2-3 1 7 6 5 4 3 2 1 F R
d) Pastries and other fancy cakes 
(eg. Danish pastries, small fancies)
>4 2-3 1 7 6 5 4 3 2 1 F R
e) Pancakes and scones (eg plain, treacle, fruit) >4 2-3 1 7 6 5 4 3 2 1 F R
14. Present Intake of Puddings
Times of day No. of days a week
a) Milk-based pudding (eg. rice, semolina, pasta) >4 2-3 1 7 6 5 4 3 2 1 F R
b) Sponge-type pudding (eg. steam, syrup, jam) >4 2-3 1 7 6 5 4 3 2 1 F R
o) Fruit-based pudding (eg. fruit pies, tarts, crumble) >4 2-3 1 7 6 5 4 3 2 1 F R
d) Blancmange, mousse, trifle, meringue >4 2-3 1 7 6 5 4 3 2 1 F R
e) Custard and other sweet sauces (eg chocolate) >4 2-3 1 7 6 5 4 3 2 1 F R
f) Ice cream (all kinds) >4 2-3 1 7 6 5 4 3 2 1 F R
g) Tinned fruit (all kinds) >4 2-3 1 7 6 5 4 3 2 1 F R
h) Dried fruit (eg. prunes, figs, apricots) >4 2-3 1 7 6 5 4 3 2 1 F R
15. Present Intake of Confectionery
Time of day No. of days a week
a) Chocolate bars (eg. mars bar, snickers, bounty, 
dairy milk, galaxy, yorkie)
>4 2-3 1 7 6 5 4 3 2 1 F R
b) Chocolate covered or chocolate centred sweets 
(eg. milk tray and other types)
>4 2-3 1 7 6 5 4 3 2 1 F R
c) Boiled sweets, toffees, fruit gums etc >4 2-3 1 7 6 5 4 3 2 1 F R
Please do no
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16. Present Intake of Other Foods
(Please remember to circle R if never eaten)
Times of day No. of days a week
a) Soups (all kinds, homemade, tinned, packet) >4 2 - 3 1  7 6 5 4 3 2 1 f  r
b) Nuts, nut butter >4 2 - 3 1  7 6 5 4 3 2 1 f  r
(all types - salted and unsalted)
c) Savoury Snacks (eg. potato crisps, >4 2 - 3 1  7 6 5 4 3 2 1 f  r
com chips, prawn crackers)
d) Milk based sauces (eg. bread, cheese, white) >4 2^ 1 7 5 5 4 3 2  1 f  r
e) Bottled sauces, salad cream, mayonnaise >4 2 - 3 1  7 6 5 4 3 2 1 f  r
g) Sweet Spreads (eg.jam, honey, marmalade) >4 2 - 3 1  7 6 5 4 3 2 1 f  r
17. Present Intake of Fats
a) What do you usually eat on bread?
1. EE Butter. Please give brand name ...........................
2 . Q  Full-fat soft margarine. Please give brand name
3. □  Low-fat soft margarine. Please give brand name ............................
4* EH Hard margarine. Please give brand name ............................
b) How do you normally spread the fat?
1. [J  Thinly 2. □  Average 3. [$] Thickly
c) How often do you eat home-fried food (including chips) cooked with:
i
Times a day No. of days a week
1. Lard, dripping or solid vegetable oil? >4 2 - 3 1  7 6 5 4 3 2 1 f  r
Please give brand name and type...................................................................
2. Liquid vegetable oil? >4 2 - 3 1  7 6 5 4 3 2 1 f  r
Please give brand name and type.............. ....................................................
Please do not
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18. Present Intake of Hot and Cold Beverages
a) How many cups of coffee do you have a day?
1. Coffee
2. Decaffeinated Coffee
b) How many teaspoons of sugar do you take in each cup?
c) How many cups of tea do you have a day?
1. Tea
2. Decaffeinated Tea
d) How many teaspoons of sugar do you take in each cup?
| | cups a day 
I | cups a day
| | teaspoons
I I cups a day 
I | cups a day 
| | teaspoons
e)
f)
g)
h)
How often each week do you drink natural 
fruit juice (including tomato juice)?
How often each week do you have coco-cola 
drinks and Ir n Bru?
How often each week do you have other 
fizzy drinks and squashes?
Times a day No. of days a week
>4 2-3 1 7 6 5 4 3 2 1  F R
>4 2-3 1 7 6 5 4 3 2 1 F  R
>4 2-3 1 7 6 5 4 3 2 1  F R
Are these drinks usually: 1. □  Diet 2. □  Non-Diet
Please do no
write in this
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19. A lcoholic Drinks
a) Have you ever taken alcoholic drinks?
1 . □  Yes 2. □  No
If No, go to Question 21
b) Do you take alcoholic drinks at present
1. EH Yes 2. CH No 3. EH Occasionally
If No, go to Question 20
c) Think back carefully over the last seven days. Please write in the table exactly what alcoholic drinks 
you have consumed on each day during the past week. Tiy to remember where and who you were 
with on each day. This may help you to remember what you had to drink.
For each day, write how much you have drunk:
(i) the number of half pints of low alcohol beers etc
(ii) the number of half pints of beer, lager, shandy, cider, stout
(iii) the number of single glasses of whisky, vodka, gin, rum etc
(iv) the number of single glasses of martini, sherry or wine etc
Half pints of 
low-alcohol 
beer etc
Half pints of 
beer, lager, 
stout etc
Single glasses 
of spirits
Single glasses 
of wine etc
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
d) Would you say that last week was fairly typical of what you usually have to drink in one week? 
1. □  Yes 2. EH No
e) If last week was not typical, would you normally drink more or less in a week?
1. EH More 2. EH Less
Now go to Question 21
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20. Non-drinkers
a) How long ago did you give up alcohol? CU Years CU Months ago
b) Why did you give up alcohol?
1. The doctor advised me to
2. Other reasons, please give details ............................... ...................
21.1 Present Intake of Vitamin, Mineral and Food Supplements
a) Are you taking any vitamin, mineral or food supplements at present?
1. □  Yes 2. □  No
b) If Yes, please give the details from the packet (type, brand name and strength) and how often 
you take each one (Frequency).
Type Brand (and strength) Frequency
21.2 Past Intake of Vitamin, Mineral and Food Supplements
a) As a child or in your early adulthood, did you take any vitamin or mineral supplements?
(eg. haliborange, cod liver oil)
Upto 12 years 20 to 30 years
1. C U Yes 2* CU N° 1 . CU Y es 2- CUNo
b) If Yes, please give the type of supplement
Upto 12 years 20 to 30 years
Type Type
0
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22. Present Intake of Salt
How much salt is added to your food on cooking?
a) 1. □  a lot 2. □  a little 3. □  none
How much salt do you add to your food on the plate?
b) 1. □  a lot 2. □  a little 3. □  none
23. Are you on a special diet?
a) No (Please go to Question 25) Q
Slimming diet you decided for yourself Q
Slimming diet prescribed by your doctor Q
Diabetic diet | |
Cholesterol-lowering diet | |
Other ‘medical diet’. Please give details Q j
Vegetarian (person who does not eat red meat, poultry or fish, Q ] 
but does eat milk and milk products)
h) Vegan (person who does not eat any animal products at all) f  '
24. How long have you been on your special diet?
Years Months
25. How many times have you ever been on a weight reducing diet for longer 
than one month?
Times
26. Have you eaten more, less or about the same of the following foods over the 
last 3-4 years?
Eaten More Eaten Less No Change
a) Meat and meat products □ □ □
b) Fish and fish products □ □ □
c) Miik and milk products □ □ □
d) Vegetables □ □ □
e) Fruit □ □ I I
Please do not
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27. Your Household
How many people noimalfy eat in your household?
Number of adults (including yourself) 1 1
Number of children 5 to 16 years I I
Number of children 1 to 4 years.. I \
Number of babies under 1 year old I I
28. How much of the following foods does the whole household use on average a 
week? (including that used in cooking or baking)
If you do not eat any of the foods yourself, please put a cross in the box, but still fill in the family 
amounts. If you live on your own, give the amounts which you yourself eat a week.
(To help, try to think how long a bottle of vegetable oil 
or tub of margarine lasts you).
1. Butter | | lbs | | ozs
2. CH Margarine (all types) | I lbs | | ozs
3. EH Lard and solid vegetable oil | I lbs I | ozs
4* EH Liquid Vegetable Oil [ j lbs | I ozs
or grams
or |___ | grams
or  grams
or ___  grams
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SECTION THREE - PRESENT AND PAST PHYSICAL ACTIVITIES
The following questions are about how often each day or week you usually take physical exercise, 
and about how often you used to normally take physical exercise. Please answer all sections.
Present Physical Activities
1. Do you usually walk and/or cycle during your activities each day? 
(Please tick two boxes if necessary).
1. NO
2. I I Walk Total time walked each day | I Hours I I Minutes
3. I I Cycle Total time cycled each day | | Hours | | Minutes
a) How many hours a day do you do paid work? | | Hours a DAY
b) How many hours a, day do you do housework? | ~~] Hours a DAY
c) How many days a week do you do paid work? | | Days a WEEK
d) How many days a week do you do housework? |_ □  Days a WEEK
3.a) When working (including housework), for how long are you usually physically 
1) Very active, 2) Moderately active and 3) Inactive each day?
Please circle an answer in each section.
To help, try to think how much time you spend on different activities during your working day.
For example, if you do very little strenuous activity, spend one and a half hours walking 
belween shops or offices, and spend most of your time sitting or driving, you would circle: <1 
hours a DAY for very active, 1-2 hours a DAY for moderately active, and 5-6 hours a DAY for inactive.
1) Very active
(For example, hurried walking, heavy housework, going 
up and down stairs, heavy lifting or carrying)
2) Moderately active
(For example, moderate walking, light housework, 
shopping, light lifting or carrying)
3) Inactive
(For example, unhurried walking, light arm movements, 
sitting, standing, driving)
Hours a DAY
<1 1-2 3-4 5-6 7-8 >8
Hours a DAY
<1 1-2 3-4 5-6 7-8 >8
Hours a DAY
<1 1-2 3-4 5-6 7-8 >8
0
Pleaso do not
write In this
margin.
3.b) When working (including housework), how often are you physically active for at 
least 20 minutes during which time you become short of breath and sweat?
1. EH more than 3 times a week
2. EH 2-3 times a week
3. . □  once a week
4. EH less than once a week
4.a) During your non-working time (including going to and from work), for how long are you usually 
physically 1) very active, 2) moderately active and 3) inactive each week? Please answer each 
section.
To help, try to think of how many hours you spend on different activities during 
your non-woiking time.
1) Very active Hours a week
(For example, aerobics, jogging, bicycling, swimming, <1 1-2 3-4 5-6 7-8 >s
hill walking, heavy gardening, competitive sports 
- squash, badminton, tennis, running)
2) Moderately active
(For example, moderate walking, shopping, light 
gardening, taking a shower or bath, getting dressed, 
dancing, golf)
3) Inactive
(For example, sitting, standing, watching TV, listening to 
music, cooking, drinking, eating, visiting pub, piano 
playing, driving). :
(Do not count time In bed).
4.b) During your non-woiking time, how often are you physically active for at least 20 minutes during 
which time you become short of breath and sweat?
1. □ more than 3 times a week
2. □ 2-3 times a week
3. □ once a week
4. □ less than once a week
Hours a DAY
<1 1-2 3-4 5-6 7-8 >8
Hours a DAY
<1 1-2 3-4 5-6 7-8 >8
0
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5. Would you say that over the past year your level ot physical activity has
1. EE Increased 2. HE stayed the same 3. HE decreased
If it has changed, for how many months has it been at its current level?
6 . How many hours a day do you usually spend in bed?
(This includes time reading in bed and also short sleeps during the day)
On work days 
On non-work days
I | Hours
| j Hours
[ I Months
Past Physical Activities
7.a) During ypur childhood (upto 12 years), and in your early adulthood (20 to 30 years), which of the 
following statements would best describe your level of walking each day? Here are a few events to 
help remind you.
Childhood:
(Upto 12 years)
Early Adulthood:
(20 to 30 years)
Try to think about walking to and from school, walking to the 
playing fields, playing with friends, visiting relatives,
Try to think about walking to and from work, walking for pleasure, 
shopping, meeting friends, visiting relatives
Upto 12 years 20 to 30 years
1. None □ □
2. Less than 1 hour a day □ □
3. 1 to 2 hours a day □ □
4. 2 to 3 hours a day □ □
5. Greater than 3 hours a day □ □
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7.b) During your childhood (upto 12 yeans), and In your early adulthood (20 to 30 years), how often were 
you physically active for at least 20 minutes during which time you would become short of breath 
and sweat?
Childhood: Try to think about PE lessons, sports played in and
(Upto 12 years) out of school hours, hobbies etc.
Early Adulthood: Try to think about household jobs, hobbies you took up,
’ (20 to 30 years) and how demanding your job was etc.
Upto 12 years 20 to 30 years
1. More than 3 times a week CU CU
2. to 3 times a week CU CU
3. once a week CH.. CU
4. less than once a week CU CU
Thank you vevy much for taking the time to fill in th is questionnaire, 
tt is  very Important, so please check that you have answered every question,
i
and then return it k i the pre-paid envelope straight away. 
YOUR HELP IS GREATLY APPRECIATED.
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